{"2772":{"id":2772,"qattrid":49,"type":1,"title":"人体最大的器官是？","result":"C","content":"皮肤是覆盖在人体表面上的最大器官，约占成人总体重的16％ ","options":[{"flag":"A","name":"肺"},{"flag":"B","name":"大脑"},{"flag":"C","name":"皮肤"},{"flag":"D","name":" 肠道"}]},"2773":{"id":2773,"qattrid":49,"type":1,"title":"皮肤分为几层？","result":"C","content":"皮肤分为三层，表皮，真皮，皮下（次真皮）","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"2774":{"id":2774,"qattrid":49,"type":1,"title":"外层皮肤形成了________物理表皮屏障。AAA","result":"A","content":"皮肤是机体抵御微生物入侵、物理化学因素损伤和外伤的第一道防线","options":[{"flag":"A","name":"第一道"},{"flag":"B","name":"第二道"},{"flag":"C","name":"第三道"},{"flag":"D","name":" 第四道"}]},"2775":{"id":2775,"qattrid":49,"type":1,"title":"免疫球蛋白也称为_______，由_________组成。","result":"C","content":"免疫球蛋白也称为抗体，由蛋白质组成","options":[{"flag":"A","name":"淋巴细胞，淋巴液"},{"flag":"B","name":"抗原，葡萄糖细胞"},{"flag":"C","name":"抗体，蛋白质"},{"flag":"D","name":" 抗体，红细胞"}]},"2776":{"id":2776,"qattrid":49,"type":1,"title":"抗体是：","result":"C","content":"抗体（antibody,Ab）是免疫系统在抗原刺激下，由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋","options":[{"flag":"A","name":"免疫系统在抗原刺激下，由T淋巴细胞增殖分化成的浆细胞所产生的"},{"flag":"B","name":"免疫系统在抗原刺激下，由T淋巴细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋白"},{"flag":"C","name":"免疫系统在抗原刺激下，由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋白"},{"flag":"D","name":" 免疫系统在抗原刺激下，由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的"}]},"2777":{"id":2777,"qattrid":49,"type":1,"title":"人体皮肤不包括以下哪层？","result":"D","content":"皮肤分为三层，表皮，真皮，皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"2778":{"id":2778,"qattrid":49,"type":1,"title":"斑块型银屑病皮疹基本特点为？","result":"C","content":"皮疹基本特点为境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑","options":[{"flag":"A","name":"境界不清的暗红色斑块或浸润性红斑"},{"flag":"B","name":"境界清楚的暗紫色斑块或浸润性紫斑"},{"flag":"C","name":"境界清楚的暗红色斑块或浸润性红斑"},{"flag":"D","name":" 境界不清的暗紫色斑块或浸润性紫斑"}]},"2779":{"id":2779,"qattrid":49,"type":1,"title":"银屑病皮肤典型症状的出现是由于哪个系统错误信号导致的？","result":"A","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"免疫系统"},{"flag":"B","name":"神经系统"},{"flag":"C","name":"内分泌系统"},{"flag":"D","name":" 血液系统"}]},"2780":{"id":2780,"qattrid":49,"type":2,"title":"以下哪几项属于银屑病的特点：","result":"A,B,C,D","content":"银屑病是一种终身慢性疾病，很可能经历复发和消退。不同个体可能出现不同的斑块类型，严重程度也各不相同，该疾病目前无治愈方案","options":[{"flag":"A","name":"银屑病是一种终身慢性疾病"},{"flag":"B","name":"很可能经历复发和消退"},{"flag":"C","name":"不同个体可能出现不同的斑块类型"},{"flag":"D","name":" 该疾病目前无治愈方案"}]},"2781":{"id":2781,"qattrid":49,"type":2,"title":"银屑病的危害有：","result":"A,B,C,D","content":"银屑病易使患者产生抑郁、焦虑等情感障碍，影响人际交往，增加患者自杀风险","options":[{"flag":"A","name":"产生抑郁"},{"flag":"B","name":"影响人际交往"},{"flag":"C","name":"增加自杀风险"},{"flag":"D","name":" 产生焦虑"}]},"2782":{"id":2782,"qattrid":49,"type":1,"title":"哪一种为最常见的银屑病类型？","result":"C","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":"点滴型"},{"flag":"B","name":"脓疱型"},{"flag":"C","name":"斑块型"},{"flag":"D","name":" 反向型"}]},"2783":{"id":2783,"qattrid":49,"type":1,"title":"银屑病的症状不包括？","result":"B","content":"银屑病可引起疼痛、瘙痒、干燥和皮肤发红等症状","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"湿润"},{"flag":"C","name":"疼痛"},{"flag":"D","name":"鳞屑"}]},"2784":{"id":2784,"qattrid":49,"type":1,"title":"银屑病的典型临床表现是？","result":"B","content":"典型临床表现为鳞屑性红斑或斑块","options":[{"flag":"A","name":"斑点"},{"flag":"B","name":"斑块"},{"flag":"C","name":"红疹"},{"flag":"D","name":" 红点"}]},"2785":{"id":2785,"qattrid":49,"type":1,"title":"在全世界范围内，受银屑病影响的人数高达 _____。","result":"C","content":"银屑病影响全球1.25亿人口","options":[{"flag":"A","name":"9500万"},{"flag":"B","name":"1亿"},{"flag":"C","name":"1.25亿"},{"flag":"D","name":" 1.50亿"}]},"2786":{"id":2786,"qattrid":49,"type":1,"title":"在中国，受银屑病影响的人数预计可达_______以上：","result":"B","content":"中国银屑病患病约在600万以上","options":[{"flag":"A","name":"100万"},{"flag":"B","name":"600万"},{"flag":"C","name":"1200万"},{"flag":"D","name":" 2400万"}]},"2787":{"id":2787,"qattrid":49,"type":1,"title":"银屑病斑块的直径范围是多少？","result":"B","content":"斑块直径范围在一厘米至数厘米","options":[{"flag":"A","name":"数毫米"},{"flag":"B","name":"一至数厘米"},{"flag":"C","name":"10-20厘米"},{"flag":"D","name":" 30-40厘米"}]},"2788":{"id":2788,"qattrid":49,"type":1,"title":"斑块型银屑病皮疹不好发于：","result":"B","content":"银屑病不好发于四肢屈侧","options":[{"flag":"A","name":"四肢伸侧"},{"flag":"B","name":"四肢屈侧"},{"flag":"C","name":"头皮"},{"flag":"D","name":" 背部"}]},"2789":{"id":2789,"qattrid":49,"type":2,"title":"下列关于促进银屑病疾病活动度的因素中，正确的是：","result":"A,B,C,D","content":"以上都有相关研究证实与银屑病疾病活动度有关","options":[{"flag":"A","name":"锂剂"},{"flag":"B","name":"应激"},{"flag":"C","name":"刺青"},{"flag":"D","name":" 肥胖"}]},"2790":{"id":2790,"qattrid":49,"type":2,"title":"表皮层是一种不断分化的结构，主要由哪些细胞组成？ ","result":"C,D","content":"表皮层主要由角质形成细胞和树突状细胞组成","options":[{"flag":"A","name":"肥大细胞"},{"flag":"B","name":"基底细胞"},{"flag":"C","name":"角质形成细胞"},{"flag":"D","name":" 树突状细胞"}]},"2791":{"id":2791,"qattrid":49,"type":2,"title":"银屑病斑块部位通常症状有？ ","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"疼痛感"},{"flag":"C","name":"开裂"},{"flag":"D","name":" 出血"}]},"2792":{"id":2792,"qattrid":49,"type":1,"title":"IL-17家族的哪个成员负责募集中性粒细胞和对细胞外病原体的免疫？","result":"A","content":"IL-17A负责募集中性粒细胞和对细胞外病原体的免疫","options":[{"flag":"A","name":"IL-17A"},{"flag":"B","name":"IL-17B"},{"flag":"C","name":"IL-17C"},{"flag":"D","name":" IL-17E"}]},"2793":{"id":2793,"qattrid":49,"type":1,"title":"已发现，与未患银屑病皮肤疾病的人群相比，银屑病患者的以下哪种疾病发生率显著更高？","result":"A","content":"已发现，与非银屑病皮肤疾病患者相比，银屑病患者的肥胖发生率显著更高","options":[{"flag":"A","name":"肥胖"},{"flag":"B","name":"白化病"},{"flag":"C","name":"甲状腺功能亢进"},{"flag":"D","name":" 甲状腺功能减退"}]},"2794":{"id":2794,"qattrid":49,"type":1,"title":"银屑病最常见的发病季节是？","result":"D","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":"春季"},{"flag":"B","name":"夏季"},{"flag":"C","name":"秋季"},{"flag":"D","name":"冬季"}]},"2795":{"id":2795,"qattrid":49,"type":1,"title":"银屑病发病年龄总体上存在_____。","result":"B","content":"发病年龄总体上存在双峰分布","options":[{"flag":"A","name":"单峰分布"},{"flag":"B","name":"双峰分布"},{"flag":"C","name":"三峰分布"},{"flag":"D","name":" 无特点"}]},"2796":{"id":2796,"qattrid":49,"type":1,"title":"获得性免疫应答可分为两种，分别是由_______介导的_______；以及_______介导的_______。","result":"B","content":"T细胞在细胞介导的免疫中起主要作用。体液免疫，也称为抗体介导的免疫应答，是由B细胞产生的抗体介导的","options":[{"flag":"A","name":"T细胞，体液应答；B细胞，细胞应答。"},{"flag":"B","name":"B细胞，体液应答；T细胞，细胞应答。"},{"flag":"C","name":"淋巴细胞，体液应答；T细胞，细胞应答。"},{"flag":"D","name":" B细胞，体液应答；淋巴细胞，细胞应答。"}]},"2797":{"id":2797,"qattrid":49,"type":1,"title":"下面哪一种细胞不属于淋巴细胞？","result":"B","content":"淋巴细胞包括B细胞、T细胞以及NK细胞。肥大细胞属于嗜碱性粒细胞","options":[{"flag":"A","name":"NK细胞"},{"flag":"B","name":"肥大细胞"},{"flag":"C","name":"B细胞"},{"flag":"D","name":" T细胞"}]},"2798":{"id":2798,"qattrid":49,"type":2,"title":"除了角质层，以下哪些也是属于表皮层？","result":"A,B,C,D","content":"表皮的结构包括五个交错的皮肤细胞层，,由外向内依次是角质层、透明层、颗粒层、棘层以及基底层","options":[{"flag":"A","name":"透明层"},{"flag":"B","name":"颗粒层"},{"flag":"C","name":"棘层"},{"flag":"D","name":" 基底层"}]},"2799":{"id":2799,"qattrid":49,"type":1,"title":"斑块型银屑病约占银屑病的_______：","result":"D","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":"0.3"},{"flag":"B","name":"0.5"},{"flag":"C","name":"0.7"},{"flag":"D","name":"0.9"}]},"2800":{"id":2800,"qattrid":49,"type":2,"title":"银屑病还可能与其他炎性疾病相关，包括：","result":"A,B,D","content":"银屑病还可能与其他炎性疾病相关，包括银屑病关节炎、炎性肠病和冠状动脉疾病","options":[{"flag":"A","name":"银屑病关节炎"},{"flag":"B","name":"炎性肠病"},{"flag":"C","name":"慢性咽炎"},{"flag":"D","name":" 冠状动脉疾病"}]},"2801":{"id":2801,"qattrid":49,"type":1,"title":"根据银屑病患病的地理性差异推断，以下哪个国家患病率最低？","result":"A","content":"总体来说，靠近赤道的群体与较远的群体相比，银屑病患病率较低。亚洲（包括中国、斯里兰卡和台湾地区）所报告的银屑病患病率为世界最低，低于0.5%","options":[{"flag":"A","name":"斯里兰卡"},{"flag":"B","name":"美国"},{"flag":"C","name":"意大利"},{"flag":"D","name":" 法国"}]},"2802":{"id":2802,"qattrid":49,"type":1,"title":"临床表现描述“红色斑块伴较薄银白鳞屑”是指哪一类银屑病类型？","result":"A","content":"斑块型的临床表现为边界清晰，界限分明，红色斑块伴较薄银白鳞屑。点滴型的临床表现为皮肤上分散的小红点。红皮病型的临床表现为皮肤发红，面积扩展至>90%的体表面积（BSA）。脓疱型的临床表现为个体/聚结的无菌脓疱","options":[{"flag":"A","name":"斑块型"},{"flag":"B","name":"点滴型"},{"flag":"C","name":"红皮病型"},{"flag":"D","name":" 脓疱型"}]},"2803":{"id":2803,"qattrid":49,"type":1,"title":"与未患该疾病的患者相比，银屑病患者如果无其他风险因素（如肥胖），面临的糖尿病风险为：","result":"C","content":"与未患该疾病的患者相比，银屑病患者即使无其他风险因素（如肥胖），面临的糖尿病风险也更高","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"正常"},{"flag":"C","name":"更高"},{"flag":"D","name":" 不清楚"}]},"2804":{"id":2804,"qattrid":49,"type":1,"title":"银屑病是一种：","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"皮肤病"},{"flag":"B","name":"精神疾病"},{"flag":"C","name":"关节疾病"},{"flag":"D","name":" 系统性免疫介导疾病"}]},"2805":{"id":2805,"qattrid":49,"type":1,"title":"以下哪项不是银屑病的治疗目的：","result":"B","content":"控制和稳定病情，减缓向全身发展的进程；减轻红斑、鳞屑、斑块增厚等皮损加重的症状；避免复发/诱发加重的因素；减少不良反应；提高生活质量","options":[{"flag":"A","name":"减缓向全身发展的进程"},{"flag":"B","name":"治愈病情"},{"flag":"C","name":"避免复发/诱发加重的因素"},{"flag":"D","name":" 减少不良反应"}]},"2806":{"id":2806,"qattrid":49,"type":1,"title":"（）是银屑病的关键性炎症因子，与角质形成细胞的增殖与活化相关。","result":"B","content":"IL-17A促进角质形成细胞活化和增殖，进一步释放细胞因子，对促炎性疾病周期产生反馈，使炎性反应持续","options":[{"flag":"A","name":"IL-17D"},{"flag":"B","name":"IL-17A"},{"flag":"C","name":"IL-17B"},{"flag":"D","name":" IL-17C"}]},"2807":{"id":2807,"qattrid":49,"type":1,"title":"斑块型银屑病的分期不包括？","result":"A","content":"分为3期，进行期、静止期、退行期","options":[{"flag":"A","name":"复发期"},{"flag":"B","name":"进行期"},{"flag":"C","name":"静止期"},{"flag":"D","name":"退行期"}]},"2808":{"id":2808,"qattrid":49,"type":1,"title":"IL-17A主要由哪个细胞产生？","result":"C","content":"IL-17A主要由Th17细胞产生，其他细胞包括CD8+T细胞、γδT细\r\n胞、NK细胞等也表达IL-17A","options":[{"flag":"A","name":"Th15"},{"flag":"B","name":"Th16"},{"flag":"C","name":"Th17"},{"flag":"D","name":" NK细胞"}]},"2809":{"id":2809,"qattrid":49,"type":2,"title":"以下哪些因素导致银屑病的发病：","result":"A,B,C","content":"银屑病的病因及发病机制尚未完全清楚，病因涉及遗传、免疫、环境等多种因素","options":[{"flag":"A","name":"遗传因素"},{"flag":"B","name":"环境因素"},{"flag":"C","name":"免疫因素"},{"flag":"D","name":" 神经因素"}]},"2810":{"id":2810,"qattrid":49,"type":1,"title":"_____是最常见的导致银屑病加重的药物。","result":"A","content":"β-阻断剂是最常见的导致银屑病加重的药物。β-阻断剂的主要用途是治疗高血压、缺血性心脏病、心率失常和心力衰竭","options":[{"flag":"A","name":"β-阻断剂"},{"flag":"B","name":"锂剂"},{"flag":"C","name":"合成抗疟疾药物（SAD）"},{"flag":"D","name":" 非甾体类抗炎药物（NSAID）"}]},"2811":{"id":2811,"qattrid":49,"type":2,"title":"银屑病患者面临的共病包括：","result":"A,B,C,D","content":"这些共病包括银屑病关节炎、糖尿病、心血管疾病、癌症、精神疾病、其他自身免疫性疾病和代谢综合征","options":[{"flag":"A","name":"银屑病关节炎"},{"flag":"B","name":"糖尿病"},{"flag":"C","name":"心血管疾病"},{"flag":"D","name":" 癌症"}]},"2812":{"id":2812,"qattrid":49,"type":1,"title":"心血管疾病（CV）的不良事件发生风险随着银屑病的加重会？","result":"B","content":"心血管疾病（CV）的不良事件发生风险随银屑病的加重而增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"增加"},{"flag":"C","name":"不受影响"},{"flag":"D","name":" 以上都不对"}]},"2813":{"id":2813,"qattrid":49,"type":1,"title":"代谢综合征，比如糖尿病的发病风险在银屑病患者中有所_______：","result":"B","content":"代谢综合征，比如糖尿病的发病风险在银屑病患者中有所增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"增加"},{"flag":"C","name":"不受影响"},{"flag":"D","name":" 以上都不对"}]},"2814":{"id":2814,"qattrid":49,"type":1,"title":"银屑病与糖尿病之间________病理生理联系。","result":"A","content":"银屑病和糖尿病之间存在病理生理联系，有共同的免疫介导炎症通路","options":[{"flag":"A","name":"存在"},{"flag":"B","name":"不存在"},{"flag":"C","name":"间歇性存在"},{"flag":"D","name":" 以上都不对"}]},"2815":{"id":2815,"qattrid":49,"type":1,"title":"在英国一项基于人群的调查中，___________是心血管疾病死亡的独立危险因素。","result":"C","content":"英国一项基于人群的调查中，重度银屑病是CV死亡的独立危险因素。","options":[{"flag":"A","name":"轻度银屑病"},{"flag":"B","name":"中度银屑病"},{"flag":"C","name":"重度银屑病"},{"flag":"D","name":" 以上都不对"}]},"2816":{"id":2816,"qattrid":49,"type":1,"title":"共病的发病率随着银屑病严重程度的增加而________:","result":"B","content":"共病的发病率随着银屑病严重程度的增加而增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"增加"},{"flag":"C","name":"不受影响"},{"flag":"D","name":" 以上都不对"}]},"2817":{"id":2817,"qattrid":49,"type":1,"title":"I类银屑病占比为多少？","result":"D","content":"超过75%的病例为I类银屑病","options":[{"flag":"A","name":"0.4"},{"flag":"B","name":"0.55"},{"flag":"C","name":"0.65"},{"flag":"D","name":"0.75"}]},"2818":{"id":2818,"qattrid":49,"type":2,"title":"目前确定银屑病的发病时间主要依赖于？","result":"A,C","content":"难以准确确定发病时间。为了识别这些数据而进行的研究通常依赖于患者对病灶出现时间的回忆，或依赖于该疾病主诉在就医时记录于病历的时间","options":[{"flag":"A","name":"患者回忆"},{"flag":"B","name":"医生回忆"},{"flag":"C","name":"病历主诉记录时间"},{"flag":"D","name":" 实验室检查报告时间"}]},"2819":{"id":2819,"qattrid":49,"type":2,"title":"银屑病是一种遗传与环境共同作用诱发的免疫介导的_______：","result":"A,B,C,D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"慢性疾病"},{"flag":"B","name":"复发性疾病"},{"flag":"C","name":"炎症性疾病"},{"flag":"D","name":" 系统性疾病"}]},"2820":{"id":2820,"qattrid":49,"type":1,"title":"重度银屑病患者较早死亡的风险增加_____。","result":"B","content":"重度银屑病患者较早死亡的风险增加50%","options":[{"flag":"A","name":"0.4"},{"flag":"B","name":"0.5"},{"flag":"C","name":"0.6"},{"flag":"D","name":"0.7"}]},"2821":{"id":2821,"qattrid":49,"type":2,"title":"银屑病的特点有哪些：","result":"A,B","content":"银屑病不具有传染性，控制和稳定病情是治疗目的","options":[{"flag":"A","name":"典型临床表现为鳞屑性红斑或斑块"},{"flag":"B","name":"局限或广泛分布"},{"flag":"C","name":"有传染性"},{"flag":"D","name":" 常能治愈"}]},"2822":{"id":2822,"qattrid":49,"type":1,"title":"最常用的表达银屑病严重程度和描述不同治疗有效性的指标是：","result":"A","content":"银屑病面积和严重程度指数（PASI）是最常用的表达银屑病严重程度和描述不同治疗有效性的指标","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"NAPSI"},{"flag":"D","name":" BSA"}]},"2823":{"id":2823,"qattrid":49,"type":1,"title":"银屑病不具有传染性的原因是因为它是一种（ ）疾病：","result":"B","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"遗传性"},{"flag":"B","name":"免疫介导"},{"flag":"C","name":"局部性"},{"flag":"D","name":" 急性"}]},"2824":{"id":2824,"qattrid":49,"type":1,"title":"以下哪一项在斑块型银屑病查体中见不到？","result":"C","content":"束状发是指银屑病患者头皮毛发成束状，类似毛笔，无断发和脱发，查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"等","options":[{"flag":"A","name":"蜡滴现象"},{"flag":"B","name":"薄膜现象"},{"flag":"C","name":"大片出血现象"},{"flag":"D","name":" 束状发"}]},"2825":{"id":2825,"qattrid":49,"type":1,"title":"_______是衡量银屑病治疗改善的金标准：","result":"C","content":"PASI 75是衡量银屑病治疗改善的金标准","options":[{"flag":"A","name":"PASI 100"},{"flag":"B","name":"PASI 85"},{"flag":"C","name":"PASI 75"},{"flag":"D","name":" PASI 65"}]},"2826":{"id":2826,"qattrid":49,"type":1,"title":"_____可能是银屑病和心血管疾病之间的关联因素。","result":"A","content":"慢性炎症可能是银屑病和心血管疾病之间的关联因素","options":[{"flag":"A","name":"慢性炎症"},{"flag":"B","name":"免疫失调"},{"flag":"C","name":"感染"},{"flag":"D","name":" 精神因素"}]},"2827":{"id":2827,"qattrid":49,"type":1,"title":"在皮肤特异性方面，____是临床试验中最广泛用于评估皮肤疾病相关的生活质量指标。。","result":"C","content":"在皮肤特异性方面，皮肤病学生活质量指数（Dermatology Life Quality Index, DLQI）是临床试验中最广泛用于评估皮肤疾病相关的生活质量指标","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"EQ-5D"},{"flag":"C","name":"DLQI"},{"flag":"D","name":" SF-36"}]},"2828":{"id":2828,"qattrid":49,"type":2,"title":"以下哪些身体外伤会导致同形反应Koebner现象？","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"蚊虫叮咬"},{"flag":"B","name":"刺青"},{"flag":"C","name":"割伤"},{"flag":"D","name":" 手术切口"}]},"2829":{"id":2829,"qattrid":49,"type":1,"title":"据粗略统计，有_____的银屑病患者报告存在患有该疾病的亲属：","result":"B","content":"据粗略统计，有30%的银屑病患者报告存在患有该疾病的亲属","options":[{"flag":"A","name":"0.2"},{"flag":"B","name":"0.3"},{"flag":"C","name":"0.4"},{"flag":"D","name":"0.5"}]},"2830":{"id":2830,"qattrid":49,"type":2,"title":"数项研究中，已识别出构成银屑病遗传倾向的关键因素，包括：","result":"A,B,C","content":"据粗略统计，有30%的银屑病患者报告存在患有该疾病的亲属","options":[{"flag":"A","name":"受影响的渊源者的亲属中，银屑病发病率上升"},{"flag":"B","name":"在父母一方或双方受影响的儿童中，银屑病的发病率存在成比例的上升"},{"flag":"C","name":"同卵双胞胎中，其中一个显示该疾病体征时，两者均患银屑病的一致率高"},{"flag":"D","name":" 据粗略统计，有60%的银屑病患者报告存在患有该疾病的亲属"}]},"2831":{"id":2831,"qattrid":49,"type":1,"title":"发生同形反应Koebner现象的前提是：","result":"C","content":"发生Koebner现象的前提是，创伤必须涉及表皮和真皮","options":[{"flag":"A","name":"创伤必须涉及表皮"},{"flag":"B","name":"创伤必须涉及真皮"},{"flag":"C","name":"创伤必须涉及表皮和真皮"},{"flag":"D","name":" 创伤必须涉及表皮、真皮和皮下层"}]},"2832":{"id":2832,"qattrid":49,"type":1,"title":"斑块型银屑病皮疹基本特点为？","result":"B","content":"皮疹基本特点为境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑","options":[{"flag":"A","name":"附红色、紫红色鳞屑"},{"flag":"B","name":"附白色、银白色鳞屑"},{"flag":"C","name":"不附白色、银白色鳞屑"},{"flag":"D","name":" 不附红色、紫红色鳞屑"}]},"2833":{"id":2833,"qattrid":49,"type":1,"title":"银屑病的特征为：","result":"D","content":"银屑病的特征为皮损处炎症，炎症刺激导致","options":[{"flag":"A","name":"局部炎症"},{"flag":"B","name":"全身炎症"},{"flag":"C","name":"黏膜炎症"},{"flag":"D","name":" 皮损处炎症"}]},"2834":{"id":2834,"qattrid":49,"type":1,"title":"银屑病的炎症刺激导致角质形成细胞：","result":"C","content":"银屑病的特征为皮损处炎症，炎症刺激导致角质形成细胞过度增殖","options":[{"flag":"A","name":"增殖降低"},{"flag":"B","name":"增值暂停"},{"flag":"C","name":"过度增殖"},{"flag":"D","name":" 正常增殖"}]},"2835":{"id":2835,"qattrid":49,"type":1,"title":"斑块型银屑病皮损反复发作，多数：","result":"C","content":"多数冬重夏轻","options":[{"flag":"A","name":"春重秋轻"},{"flag":"B","name":"夏重冬轻"},{"flag":"C","name":"冬重夏轻"},{"flag":"D","name":" 全年差别不大"}]},"2836":{"id":2836,"qattrid":49,"type":1,"title":"斑块型银屑病绝大部分银屑病斑块：","result":"D","content":"绝大部分银屑病斑块具有持续性，可存在数年，即不会时常发作又消失，但在某些病例中，病情不稳定，或持续发生变化","options":[{"flag":"A","name":"短期存在"},{"flag":"B","name":"不具有持续性"},{"flag":"C","name":"持续发生变化"},{"flag":"D","name":" 具有持续性"}]},"2837":{"id":2837,"qattrid":49,"type":1,"title":"“同形反应”(Kobner现象)见于斑块型银屑病的：","result":"B","content":"斑块型银屑病进展期可有“同形反应”(Kobner现象)","options":[{"flag":"A","name":"隐匿期"},{"flag":"B","name":"进展期"},{"flag":"C","name":"静息期"},{"flag":"D","name":" 恢复期"}]},"2838":{"id":2838,"qattrid":49,"type":1,"title":"体表面积（BSA）是指采用一只手掌约代表_______的体表面积的近似法：","result":"A","content":"体表面积（BSA）是指采用一只手掌代表1%","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.015"},{"flag":"C","name":"0.02"},{"flag":"D","name":"0.005"}]},"2839":{"id":2839,"qattrid":49,"type":1,"title":"银屑病皮损面积BSA超过多少为重度：","result":"B","content":"银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":"0.05"},{"flag":"B","name":"0.1"},{"flag":"C","name":"0.15"},{"flag":"D","name":"0.18"}]},"2840":{"id":2840,"qattrid":49,"type":1,"title":"银屑病的确定性诊断工具是：","result":"D","content":"西医诊断主要依据皮疹特点（包括皮疹形态、境界和分布等）和病史（包括发病情况、演变及消长规律、伴随症状和治疗反应等），结合既往史和家族史，必要时可借助组织病理和影像学技术明确诊断","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"NAPSI"},{"flag":"D","name":" 以上都不是"}]},"2841":{"id":2841,"qattrid":49,"type":2,"title":"以下哪些评估方法不涉及生活质量问题：","result":"A,B","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，SF-36衡量患者身体和精神健康状态，以描述疾病对生活质量的影响","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"DLQI"},{"flag":"D","name":" SF-36"}]},"2842":{"id":2842,"qattrid":49,"type":1,"title":"下列关于寻常型银屑病的疾病严重度分类描述正确的是","result":"D","content":"以上均正确","options":[{"flag":"A","name":"轻度BSA<3%，DLQI 2~5分，甚少影响患者生活质量"},{"flag":"B","name":"中度BSA 3~10%，DLQI 6~10分，影响患者生活质量"},{"flag":"C","name":"重度BSA>10%，DLQI>10分，极大影响患者生活质量"},{"flag":"D","name":" 以上说法均正确"}]},"2843":{"id":2843,"qattrid":49,"type":1,"title":"寻常型银屑病按中国指南严重程度分为_______种：","result":"B","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":"2"},{"flag":"B","name":"3"},{"flag":"C","name":"4"},{"flag":"D","name":"5"}]},"2844":{"id":2844,"qattrid":49,"type":1,"title":"以下哪种不属于中国指南寻常型银屑病的严重程度类别：","result":"C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"中度"},{"flag":"C","name":"重度"},{"flag":"D","name":" 极重度"}]},"2845":{"id":2845,"qattrid":49,"type":1,"title":"受影响体表面积百分比为多少时，银屑病划分为中度？","result":"C","content":"受影响体表面积百分比为3 - 10%时，银屑病划分为中度","options":[{"flag":"A","name":"低于3%"},{"flag":"B","name":"3 - 5%"},{"flag":"C","name":"3 - 10%"},{"flag":"D","name":" 高于10%"}]},"2846":{"id":2846,"qattrid":49,"type":1,"title":"PASI评分为多少评分范围的量表？","result":"D","content":"银屑病面积和严重度指数(PASI)是将疾病的严重程度和受损面积都纳入评分，范围从0（无疾病）至72（最严重疾病） [45]。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"1-100"},{"flag":"B","name":"0-100"},{"flag":"C","name":"0-75"},{"flag":"D","name":" 0-72"}]},"2847":{"id":2847,"qattrid":49,"type":1,"title":"PASI评分越高，银屑病就：","result":"A","content":"银屑病面积和严重度指数(PASI)是将疾病的严重程度和受损面积都纳入评分，范围从0（无疾病）至72（最严重疾病） [45]。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"严重"},{"flag":"B","name":"轻度"},{"flag":"C","name":"无关系"},{"flag":"D","name":" 以上都不对"}]},"2848":{"id":2848,"qattrid":49,"type":2,"title":"计算PASI时，医师对患者几个单独的身体区域情况进行评价。这些区域为：","result":"A,B,C,D","content":"PASI评分将身体分为头颈部、上肢、躯干、下肢四个部位进行评分","options":[{"flag":"A","name":"头"},{"flag":"B","name":"上肢"},{"flag":"C","name":"躯干"},{"flag":"D","name":" 下肢"}]},"2849":{"id":2849,"qattrid":49,"type":1,"title":"银屑病PASI评分超过多少为中重度：","result":"B","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":"0.05"},{"flag":"B","name":"0.1"},{"flag":"C","name":"0.15"},{"flag":"D","name":"0.18"}]},"2850":{"id":2850,"qattrid":49,"type":1,"title":"以下哪一个DLQI分数的患者生活质量最高？","result":"A","content":"DLQI给出了0-30分的范围。分数越低，代表生活质量更高","options":[{"flag":"A","name":"2"},{"flag":"B","name":"4"},{"flag":"C","name":"6"},{"flag":"D","name":"8"}]},"2851":{"id":2851,"qattrid":49,"type":1,"title":"医师总体评估（PGA）中，0分代表：","result":"A","content":"PGA按0分（清洁）至6分（非常严重）的7分制评分","options":[{"flag":"A","name":"无或已清洁"},{"flag":"B","name":"轻度或无变化"},{"flag":"C","name":"中度至重度"},{"flag":"D","name":" 逐渐加重的严重程度"}]},"2852":{"id":2852,"qattrid":46,"type":1,"title":"拓咨®通用名是：","result":"D","content":"说明书","options":[{"flag":"A","name":"依那西普"},{"flag":"B","name":"环孢素软胶囊"},{"flag":"C","name":"阿达木单抗"},{"flag":"D","name":" 依奇珠单抗"}]},"2853":{"id":2853,"qattrid":50,"type":1,"title":"根据单克隆抗体的来源不同，可分为：","result":"B","content":"根据单克隆抗体的来源不同，可分为鼠源抗体、嵌合体抗体、人源化抗体和人源抗体","options":[{"flag":"A","name":"鼠源抗体、人源化抗体和人源抗体"},{"flag":"B","name":"鼠源抗体、嵌合体抗体、人源化抗体和人源抗体"},{"flag":"C","name":"鼠源抗体、嵌合体抗体、人源化抗体"},{"flag":"D","name":" 嵌合体抗体、人源化抗体和人源抗体"}]},"2854":{"id":2854,"qattrid":50,"type":1,"title":"拓咨®特异性作用于白介素：","result":"D","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"IL-17D"},{"flag":"B","name":"IL-17C"},{"flag":"C","name":"IL-17B"},{"flag":"D","name":" IL-17A"}]},"2855":{"id":2855,"qattrid":50,"type":1,"title":"拓咨®是一种：","result":"C","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"全源化lgG1单克隆抗体"},{"flag":"B","name":"全源化lgG4单克隆抗体"},{"flag":"C","name":"人源化lgG4单克隆抗体"},{"flag":"D","name":" 人源化lgG1单克隆抗体"}]},"2856":{"id":2856,"qattrid":50,"type":1,"title":"由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为：","result":"D","content":"A.由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":"单克隆抗原"},{"flag":"B","name":"抗体"},{"flag":"C","name":"抗原"},{"flag":"D","name":" 单克隆抗体"}]},"2857":{"id":2857,"qattrid":50,"type":1,"title":"关于单克隆抗体，下列说法正确的是：","result":"D","content":"A:由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":"单克隆抗体是针对多种不同抗原表面的抗体"},{"flag":"B","name":"免疫球蛋白lgG1诱导CDC或ADCC能力较差，细胞毒性少"},{"flag":"C","name":"与人源化抗体相比，鼠源抗体免疫原性更低"},{"flag":"D","name":" 抗药性抗体（ADAs）一般会影响单克隆抗体治疗的临床效果"}]},"2858":{"id":2858,"qattrid":46,"type":2,"title":"银屑病常用外用药物包括：","result":"A,B,C,D","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂等。","options":[{"flag":"A","name":"润肤剂"},{"flag":"B","name":"保湿剂"},{"flag":"C","name":"维A酸类"},{"flag":"D","name":" 维生素D3衍生物"}]},"2859":{"id":2859,"qattrid":49,"type":2,"title":"以下哪些是银屑病的治疗方法：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"外用药物治疗"},{"flag":"B","name":"光疗"},{"flag":"C","name":"中医外治法"},{"flag":"D","name":" 生物制剂"}]},"2860":{"id":2860,"qattrid":49,"type":2,"title":"以下哪些是银屑病的治疗原则：","result":"A,B,D","content":"1.正规：强调使用指南推荐的治疗药物/方法；2.安全：以确保安全为首要，尽量避免不良反应；3.个体化：应综合考量患者的病情、需求、耐受性、经济承受能力、既往治疗史和药物不良反应等制定合理的治疗方案","options":[{"flag":"A","name":"强调使用指南推荐的治疗药物/方法"},{"flag":"B","name":"以确保安全为首要"},{"flag":"C","name":"治愈疾病"},{"flag":"D","name":" 尽量避免不良反应"}]},"2861":{"id":2861,"qattrid":49,"type":1,"title":"在银屑病治疗中，外用药物单独用药常用于：","result":"A","content":"外用药物常用于轻度银屑病患者。优点是药物直接作用于皮损，起效快、使用方便、全身不良反应少。缺点是长期使用可出现局部不良反应，皮损泛发者使用不便，患者依从性差异较大","options":[{"flag":"A","name":"轻度银屑病"},{"flag":"B","name":"中度银屑病"},{"flag":"C","name":"重度银屑病"},{"flag":"D","name":" 甲银屑病"}]},"2862":{"id":2862,"qattrid":51,"type":1,"title":"拓咨®试验患者入组标准中，临床诊断严重程度至少为（）才可以参加试验","result":"B","content":"患者入组标准：（1）年龄≥18岁（2）基线之前诊断为慢性斑块型银屑病≥6个月（3）筛查和基线时BSA≥10%（4）临床诊断严重程度至少为中度","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"中度"},{"flag":"C","name":"重度"},{"flag":"D","name":" 无要求"}]},"2863":{"id":2863,"qattrid":49,"type":1,"title":"以下哪项不是银屑病的治疗方法：","result":"D","content":"以上都是除了化疗","options":[{"flag":"A","name":"外用药物治疗"},{"flag":"B","name":"光疗"},{"flag":"C","name":"生物制剂"},{"flag":"D","name":" 化疗"}]},"2864":{"id":2864,"qattrid":47,"type":1,"title":"以下哪一个属于IL-17A拮抗剂：","result":"B","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂","options":[{"flag":"A","name":"乌司奴单抗"},{"flag":"B","name":"司库奇尤单抗"},{"flag":"C","name":"英夫利西单抗"},{"flag":"D","name":" 阿达木单抗"}]},"2865":{"id":2865,"qattrid":47,"type":1,"title":"下列哪项药物的通用名和商品名对应不正确？","result":"C","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂","options":[{"flag":"A","name":"新山地明®环孢素软胶囊"},{"flag":"B","name":"类克®英夫利西单抗"},{"flag":"C","name":"可善挺®依那西普"},{"flag":"D","name":" 喜达诺®乌司奴单抗"}]},"2866":{"id":2866,"qattrid":51,"type":1,"title":"在所有3项UNCOVER III期试验中，0-12周阶段称为（）","result":"A","content":"在所有3项UNCOVER III期试验中，0-12周阶段称为诱导治疗期","options":[{"flag":"A","name":"诱导治疗期"},{"flag":"B","name":"维持治疗期"},{"flag":"C","name":"开始治疗期"},{"flag":"D","name":" 治疗进展期"}]},"2867":{"id":2867,"qattrid":47,"type":1,"title":"乌丝奴单抗的作用机制是（）","result":"A","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂","options":[{"flag":"A","name":"IL-12/23抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":" IL-17A及其受体拮抗剂"}]},"2868":{"id":2868,"qattrid":47,"type":1,"title":"可善挺®的作用机制（）","result":"D","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":" IL-17A及其受体拮抗剂"}]},"2869":{"id":2869,"qattrid":47,"type":1,"title":"下列哪个药物不是生物制剂","result":"A","content":"甲氨蝶呤属于系统性用药，不属于生物制剂","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"类克"},{"flag":"C","name":"益赛普"},{"flag":"D","name":"修美乐"}]},"2870":{"id":2870,"qattrid":50,"type":2,"title":"单克隆抗体具有（）特点","result":"A,B,C,D","content":"单克隆抗体具有结构单一、纯度高、特异性强、少或无血清交叉反应、制备成本低等特点","options":[{"flag":"A","name":"结构单一"},{"flag":"B","name":"纯度高"},{"flag":"C","name":"特异性强"},{"flag":"D","name":"少或无血清交叉反应"}]},"2871":{"id":2871,"qattrid":50,"type":2,"title":"下列叙述正确的是（）","result":"A,B,C,D","content":"以上均正确","options":[{"flag":"A","name":"拓咨®特异性作用于银屑病关键性炎症因子IL-17A"},{"flag":"B","name":"拓咨®使得更多患者达到清洁或几乎清洁疗效"},{"flag":"C","name":"拓咨®安全性良好，与依那西普总体TEAEs发生率相当"},{"flag":"D","name":"对于斑块型银屑病患者，拓咨®皮下注射初始剂量为160mg"}]},"2872":{"id":2872,"qattrid":46,"type":1,"title":"拓咨®在国内目前获批的适应症为：","result":"B","content":"拓咨®在国内目前获批的适应症为斑块型银屑病患","options":[{"flag":"A","name":"糖尿病"},{"flag":"B","name":"斑块性银屑病"},{"flag":"C","name":"成人中重度活动性类风湿关节炎"},{"flag":"D","name":" 活动性强直性脊柱炎"}]},"2873":{"id":2873,"qattrid":46,"type":1,"title":"拓咨®是一种：","result":"C","content":"拓咨®（依奇珠单抗）是皮下注射剂","options":[{"flag":"A","name":"口服片剂"},{"flag":"B","name":"口服胶囊"},{"flag":"C","name":"皮下注射药物"},{"flag":"D","name":" 肌注药物"}]},"2874":{"id":2874,"qattrid":51,"type":1,"title":"拓咨®的目前已进行的主要临床研究叫：","result":"A","content":"拓咨®的目前已进行的主要临床研究叫UNCOVER 和IXORA","options":[{"flag":"A","name":"Uncover；IXORA"},{"flag":"B","name":"PREVENT"},{"flag":"C","name":"Clear"},{"flag":"D","name":" AMAGINE"}]},"2875":{"id":2875,"qattrid":50,"type":1,"title":"单克隆抗体不具有（）特点","result":"B","content":"单克隆抗体具有结构单一、纯度高、特异性强、少或无血清交叉反应、制备成本低等特点","options":[{"flag":"A","name":"结构单一"},{"flag":"B","name":"纯度低"},{"flag":"C","name":"特异性强"},{"flag":"D","name":" 少或无血清交叉反应"}]},"2876":{"id":2876,"qattrid":51,"type":1,"title":"综合临床试验中的诱导治疗期间拓咨®治疗组患者，出现比例最高的不良反应是：","result":"A","content":"综合临床试验中的诱导治疗期间Taltz治疗组患者注射部位反应出现比例为17%，上呼吸道感染13%，恶心2%，皮癣感染2%","options":[{"flag":"A","name":"注射部位反应"},{"flag":"B","name":"上呼吸道感染"},{"flag":"C","name":"恶心"},{"flag":"D","name":" 皮癣感染"}]},"2877":{"id":2877,"qattrid":50,"type":1,"title":"（）的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。","result":"A","content":"lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少","options":[{"flag":"A","name":"lgG4"},{"flag":"B","name":"lgG1"},{"flag":"C","name":"lgG3"},{"flag":"D","name":"lgG2"}]},"2878":{"id":2878,"qattrid":46,"type":1,"title":"依奇珠单抗的亲和力大约是司库奇尤单抗的（）倍。","result":"D","content":"依奇珠单抗的亲和力大约是司库奇尤单抗的100倍","options":[{"flag":"A","name":"10"},{"flag":"B","name":"30"},{"flag":"C","name":"50"},{"flag":"D","name":"100"}]},"2879":{"id":2879,"qattrid":46,"type":1,"title":"拓咨®的半衰期约为：","result":"C","content":"拓咨®的半衰期约为13天","options":[{"flag":"A","name":"6天"},{"flag":"B","name":"10天"},{"flag":"C","name":"13天"},{"flag":"D","name":"18天"}]},"2880":{"id":2880,"qattrid":51,"type":2,"title":"拓咨®开展了针对哪些部位的治疗效果的临床研究？ ","result":"A,B,C,D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"头皮银屑病"},{"flag":"B","name":"掌跖银屑病"},{"flag":"C","name":"指甲银屑病"},{"flag":"D","name":" 生殖器部位"}]},"2881":{"id":2881,"qattrid":47,"type":2,"title":"银屑病先前非生物制剂的系统治疗包括： ","result":"A,B,C","content":"甲氨蝶呤、环孢素、阿维A属于系统性用药，不属于生物制剂，PUVA属于光疗","options":[{"flag":"A","name":"甲氨喋呤"},{"flag":"B","name":"环孢素"},{"flag":"C","name":"阿维A"},{"flag":"D","name":" PUVA"}]},"2882":{"id":2882,"qattrid":47,"type":1,"title":"益赛普®的作用机制是（）","result":"C","content":"益赛普®的作用机制是TNF-α 抑制剂，厂家是三生制药","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":" IL-17A及其受体拮抗剂"}]},"2883":{"id":2883,"qattrid":47,"type":1,"title":"可善挺®的厂家是（）","result":"B","content":"可善挺®的厂家是诺华","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"辉瑞"},{"flag":"D","name":" 强生"}]},"2884":{"id":2884,"qattrid":47,"type":1,"title":"可善挺®适用于什么程度的斑块状银屑病患者","result":"C","content":"可善挺®适用中度至重度的斑块状银屑病患者","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"轻度至中度"},{"flag":"C","name":"中度至重度"},{"flag":"D","name":" 重度"}]},"2885":{"id":2885,"qattrid":47,"type":1,"title":"下列哪个药物是IL-12/23抑制剂","result":"A","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":" 恩利®"}]},"2886":{"id":2886,"qattrid":47,"type":1,"title":"下列哪个药物厂家是艾伯维","result":"B","content":"修美乐/阿达木单抗的厂家是艾伯维","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":" 恩利®"}]},"2887":{"id":2887,"qattrid":47,"type":1,"title":"中国未获批银屑病适应症的药物是（）","result":"D","content":"中国未获批银屑病适应症的药物是恩利®（依那西普）","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":" 恩利®"}]},"2888":{"id":2888,"qattrid":47,"type":1,"title":"修美乐®的作用机制是（）","result":"C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":" IL-17A及其受体拮抗剂"}]},"2889":{"id":2889,"qattrid":47,"type":1,"title":"益赛普®的厂家是（）","result":"A","content":"益赛普®的作用机制是TNF-α 抑制剂，厂家是三生制药TNF-α 抑制剂","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"辉瑞"},{"flag":"D","name":" 强生"}]},"2890":{"id":2890,"qattrid":47,"type":2,"title":"甲氨蝶呤的不良反应有（）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"骨髓抑制"},{"flag":"B","name":"黏膜损伤"},{"flag":"C","name":"胃肠道异常"},{"flag":"D","name":" 肝功能受损"}]},"2891":{"id":2891,"qattrid":47,"type":2,"title":"下列厂家、药物、作用机制对应正确的是","result":"B,C","content":"益赛普®的作用机制是TNF-α 抑制剂，厂家是三生制药；类克的厂家是西安杨森，作用机制是","options":[{"flag":"A","name":"辉瑞 益赛普® 叶酸还原酶抑制剂"},{"flag":"B","name":"诺华 新山地明®选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"艾伯维 修美乐®TNF-α抑制剂"},{"flag":"D","name":" 西安杨森 类克®IL-23抑制剂"}]},"2892":{"id":2892,"qattrid":46,"type":1,"title":"拓咨®注射笔需要几步操作：","result":"B","content":"拓咨®注射笔需要3步操作，简单易用","options":[{"flag":"A","name":"2"},{"flag":"B","name":"3"},{"flag":"C","name":"4"},{"flag":"D","name":"1"}]},"2893":{"id":2893,"qattrid":48,"type":1,"title":"以下哪项不是银屑病的治疗目的：","result":"C","content":"控制和稳定病情，减缓向全身发展的进程；减轻红斑、鳞屑、斑块增厚等皮损加重的症状；避免复发/诱发加重的因素；减少不良反应；提高生活质量；治愈不是","options":[{"flag":"A","name":"减缓向全身发展的进程"},{"flag":"B","name":"避免复发/诱发加重的因素"},{"flag":"C","name":"治愈病情"},{"flag":"D","name":" 减少不良反应"}]},"2894":{"id":2894,"qattrid":48,"type":2,"title":"拓咨®通过多项全球临床研究证实，可有效帮助患者实现：","result":"A,B,D","content":"拓咨®快速起效、全面清除、长期稳定","options":[{"flag":"A","name":"快速起效"},{"flag":"B","name":"全面清除"},{"flag":"C","name":"完全治愈"},{"flag":"D","name":" 长期稳定"}]},"2895":{"id":2895,"qattrid":48,"type":1,"title":"拓咨®的推广关键词是______。","result":"D","content":"拓咨®的推广关键词是净化论","options":[{"flag":"A","name":"净界无忧"},{"flag":"B","name":"净界可达"},{"flag":"C","name":"净无止境"},{"flag":"D","name":" 净化论"}]},"2896":{"id":2896,"qattrid":47,"type":1,"title":"下列哪项不是银屑病常用的外用药物：","result":"D","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂；无抗真菌药","options":[{"flag":"A","name":"糖皮质激素"},{"flag":"B","name":"钙调磷酸酶抑制剂"},{"flag":"C","name":"抗人白介素8单克隆抗体"},{"flag":"D","name":" 抗真菌药"}]},"2897":{"id":2897,"qattrid":51,"type":1,"title":"UNCOVER-J中拓咨®使得更多患者达到清洁或几乎清洁疗效。（）患者达到PASI 75。","result":"D","content":"UNCOVER-J中拓咨®的PASI 75,90,100分别为97%，87%，40%","options":[{"flag":"A","name":"0.57"},{"flag":"B","name":"0.67"},{"flag":"C","name":"0.77"},{"flag":"D","name":"0.97"}]},"2898":{"id":2898,"qattrid":51,"type":1,"title":"UNCOVER-J中拓咨®治疗，（）患者达到PASI 90。","result":"D","content":"UNCOVER-J中拓咨®的PASI 75,90,100分别为97%，87%，40%","options":[{"flag":"A","name":"0.47"},{"flag":"B","name":"0.57"},{"flag":"C","name":"0.67"},{"flag":"D","name":"0.87"}]},"2899":{"id":2899,"qattrid":51,"type":1,"title":"UNCOVER-J中拓咨®治疗，（）患者达到PASI 100。","result":"D","content":"UNCOVER-J中拓咨®的PASI 75,90,100分别为97%，87%，40%","options":[{"flag":"A","name":"0.1"},{"flag":"B","name":"0.2"},{"flag":"C","name":"0.3"},{"flag":"D","name":"0.4"}]},"2900":{"id":2900,"qattrid":51,"type":2,"title":"拓咨®关键性III期临床试验有： ","result":"A,B,D","content":"UNCOVER1,2,3是拓咨®关键性III期临床试验","options":[{"flag":"A","name":"UNCOVER-1"},{"flag":"B","name":"UNCOVER-2"},{"flag":"C","name":"EXPRESS"},{"flag":"D","name":" UNCOVER-3"}]},"2901":{"id":2901,"qattrid":51,"type":2,"title":"参与拓咨®实验的人群中，先前进行过的治疗主要有:","result":"A,B,C","content":"除了放疗，以上都是","options":[{"flag":"A","name":"非生物制剂的系统治疗"},{"flag":"B","name":"生物制剂"},{"flag":"C","name":"光疗"},{"flag":"D","name":" 放疗"}]},"2902":{"id":2902,"qattrid":46,"type":1,"title":"拓咨®第0周推荐剂量是：","result":"C","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":"120mg"},{"flag":"C","name":"160mg"},{"flag":"D","name":" 240mg"}]},"2903":{"id":2903,"qattrid":48,"type":1,"title":"拓咨®的推广的主要关键信息为：","result":"A","content":"拓咨®快速起效、全面清除、长期稳定","options":[{"flag":"A","name":"快速起效，全面清除，长期稳定"},{"flag":"B","name":"快速起效，全面获益"},{"flag":"C","name":"全面清除，完全治愈"},{"flag":"D","name":"安全有效，百分获益"}]},"2904":{"id":2904,"qattrid":51,"type":1,"title":"UNCOVER-2研究显示，拓咨®治疗几周即可见皮损以及瘙痒症状改善","result":"A","content":"UNCOVER-2研究显示，拓咨®治疗1周即可见皮损以及瘙痒症状改善","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"2905":{"id":2905,"qattrid":51,"type":1,"title":"UNCOVER系列研究显示，拓咨®治疗几周PASI平均改善达到54%","result":"B","content":"UNCOVER系列研究显示，拓咨®治疗2周PASI平均改善达到54%","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"2906":{"id":2906,"qattrid":51,"type":1,"title":"下列哪项试验在中重度斑块型银屑病中对拓咨®和喜达诺®治疗进行研究？","result":"C","content":"IXORA-S比较IXE和喜达诺/乌司奴单抗在中重度斑块型银屑病患者中的有效性和安全性","options":[{"flag":"A","name":"UNCOVER-3"},{"flag":"B","name":"IXORA-P"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":"IXORA-R"}]},"2907":{"id":2907,"qattrid":51,"type":1,"title":"对于UNCOVER-3临床试验一直接受依奇珠单抗治疗达4年的患者，达到PASI 100的比例超过（）","result":"C","content":"拓咨® 治疗4年，67%患者实现皮损全面清除（PASI 100）","options":[{"flag":"A","name":"0.7"},{"flag":"B","name":"0.4"},{"flag":"C","name":"0.6"},{"flag":"D","name":"0.5"}]},"2908":{"id":2908,"qattrid":51,"type":1,"title":"综合临床试验中的维持治疗期间拓咨®治疗组患者最常见的治疗相关不良反应是：","result":"B","content":"综合临床试验中的维持治疗期间拓咨®治疗组患者最常见的治疗相关不良反应是上呼吸道感染","options":[{"flag":"A","name":"过敏"},{"flag":"B","name":"上呼吸道感染"},{"flag":"C","name":"口咽炎"},{"flag":"D","name":" 喉炎"}]},"2909":{"id":2909,"qattrid":51,"type":1,"title":"首次发生注射部位不良反应中位时间为（）周。","result":"A","content":"三期试验最常见的注射部位不良反应是轻度至中度不良反应，很少有患者由于注射部位不良反应而停药。首次发生注射部位不良反应中位时间为2周。治疗2周后，注射部位不良反应的发生率下降","options":[{"flag":"A","name":"2"},{"flag":"B","name":"3"},{"flag":"C","name":"4"},{"flag":"D","name":"1"}]},"2910":{"id":2910,"qattrid":46,"type":2,"title":"拓咨®最常见的注射部位反应是： ","result":"A,C","content":"说明书中拓咨®最常见的注射部位反应是红疹和疼痛","options":[{"flag":"A","name":"红疹"},{"flag":"B","name":"出血"},{"flag":"C","name":"疼痛"},{"flag":"D","name":" 大片红斑"}]},"2911":{"id":2911,"qattrid":51,"type":2,"title":"用于评估银屑病活性和记录患者对治疗的临床应答的两种最常用工具为：","result":"A,B","content":"用于评估银屑病活性和记录患者对治疗的临床应答的两种最常用工具为sPGA和PASI","options":[{"flag":"A","name":"sPGA"},{"flag":"B","name":"PASI"},{"flag":"C","name":"VAS"},{"flag":"D","name":" UBA"}]},"2912":{"id":2912,"qattrid":46,"type":1,"title":"以下关于拓咨®的说法不正确的是：","result":"C","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"化学名为依奇珠单抗，礼来公司产品"},{"flag":"B","name":"全球第二个上市的IL-17A抑制剂，第一个IL-17A抑制剂为司库奇尤单抗"},{"flag":"C","name":"诱导治疗期为三个月，第一个月需注射三次，每次1针"},{"flag":"D","name":" 维持治疗期每月注射1次，每次1针"}]},"2913":{"id":2913,"qattrid":46,"type":1,"title":"以下关于拓咨®的注射方法不正确的是：","result":"D","content":"拓咨®的注射前需要解锁","options":[{"flag":"A","name":"只需三步"},{"flag":"B","name":"步骤简单，方便易用，患者可自行在家注射"},{"flag":"C","name":"不要在皮损初注射，且需轮换注射部位，避免始终在同一部位注射"},{"flag":"D","name":" 不需要解锁"}]},"2914":{"id":2914,"qattrid":51,"type":1,"title":"综合临床试验中的诱导治疗期间，拓咨®治疗组患者有多少比例出现注射部位反应？","result":"B","content":"12周内，UNCOVER-1,2,3研究依奇珠单抗Q2W组发生注射部位反应的概率为10.0%","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.1"},{"flag":"C","name":"0.2"},{"flag":"D","name":"0.3"}]},"2915":{"id":2915,"qattrid":51,"type":1,"title":"关于不同部位的银屑病治疗效果，描述错误的是：","result":"D","content":"UNCOVER-3临床试验三年研究结果显示，超过66%的头皮银屑病患者能维持完全清洁的效果；超过60%的掌跖银屑病患者能维持完全清洁的效果；超过62%的指甲银屑病患者能维持完全清洁的效果","options":[{"flag":"A","name":"对于头皮银屑病，拓咨®治疗后能达到清洁或几乎清洁（PSSI 90和PSSI 100）"},{"flag":"B","name":"对于掌跖银屑病，拓咨®治疗后能长期保持清洁效果（PPASI 100）"},{"flag":"C","name":"对于指甲银屑病，拓咨®治疗后NAPSI改善率显著提高"},{"flag":"D","name":" UNCOVER-3临床结果显示，对于累及头皮、掌跖、指甲部位的银屑病患者，不足60%的患者维持清洁或几乎清洁的效果"}]},"2916":{"id":2916,"qattrid":47,"type":1,"title":"以下关于乌司奴单抗不正确的说法是：","result":"B","content":"第一年5次，推荐剂量为45mg皮下注射，4周后及之后每12周给予一次相同剂量","options":[{"flag":"A","name":"商品名为喜达诺，西安杨森公司产品"},{"flag":"B","name":"第一年仅需注射四次"},{"flag":"C","name":"拓咨有头对头临床研究证实疗效优于乌司奴单抗"},{"flag":"D","name":" 临床研究显示乌司奴单抗对炎症性肠病也有很好的效果"}]},"2917":{"id":2917,"qattrid":51,"type":1,"title":"UNCOVER 3项试验评估了2个联合主要终点的基线至第12周的变化，PASI综合评分较基线改善（）百分比的患者比例。","result":"B","content":"PASI 75","options":[{"flag":"A","name":"≥ 90%"},{"flag":"B","name":"≥ 75%"},{"flag":"C","name":"≥ 50%"},{"flag":"D","name":" ≤ 65%"}]},"2918":{"id":2918,"qattrid":51,"type":1,"title":"IXORA-S研究主要研究重点为12周时的：","result":"B","content":"主要研究终点为12周时的PASI 90，依奇珠单抗治疗组达到PASI 90患病比例明显高于乌司奴单抗治疗组","options":[{"flag":"A","name":"PASI 50"},{"flag":"B","name":"PASI 90"},{"flag":"C","name":"PASI 75"},{"flag":"D","name":" PASI 100"}]},"2919":{"id":2919,"qattrid":50,"type":2,"title":"下列说法正确的是：","result":"A,B,C,D","content":"以上均正确","options":[{"flag":"A","name":"拓咨®是一种人源化IgG4单克隆抗体，对白介素-17A（IL-17A）有中和活性"},{"flag":"B","name":"IL-17A、IL-17C和IL-17F在银屑病病灶部位表达升高"},{"flag":"C","name":"IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用"},{"flag":"D","name":"拓咨®选择性结合IL-17A细胞因子，抑制其与IL-17受体相互作用，从而抑制促炎细胞因子和趋化因子释放"}]},"2920":{"id":2920,"qattrid":51,"type":2,"title":"下列关于关键性三期实验入组患者标准正确的是： ","result":"B,C","content":"患者入组标准：（1）年龄≥18岁（2）基线之前诊断为慢性斑块型银屑病≥6个月（3）筛查和基线时BSA≥10%（4）临床诊断严重程度至少为中度sPGA(6分制)≥3(5)银屑病面积和严重程度指数PASI≥12（6）作为光疗或系统治疗的候选者，或两者兼有。之前接受生物制剂治疗的患者中，接受过ETN治疗的患者在UNCOVER-2和UNCOVER-3中被排除在外","options":[{"flag":"A","name":"临床诊断严重程度为重度"},{"flag":"B","name":"筛查和基线时BSA≥10%"},{"flag":"C","name":"年龄≥18岁"},{"flag":"D","name":" 之前接受过ETN治疗的患者"}]},"2921":{"id":2921,"qattrid":51,"type":1,"title":"拓咨®临床试验患者入组标准的基线之前诊断为慢性斑块型银屑病的时间为：","result":"B","content":"患者入组标准：（1）年龄≥18岁（2）基线之前诊断为慢性斑块型银屑病≥6个月","options":[{"flag":"A","name":"≥3个月"},{"flag":"B","name":"≥6个月"},{"flag":"C","name":"≥9个月"},{"flag":"D","name":"≥12个月"}]},"2922":{"id":2922,"qattrid":51,"type":1,"title":"多项研究显示，拓咨®可实现对（）等难治部位皮损的完全清除。","result":"A","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"生殖器、掌跖、头皮和指甲"},{"flag":"B","name":"头皮和指甲"},{"flag":"C","name":"颈部、掌跖、头皮和指甲"},{"flag":"D","name":" 生殖器"}]},"2923":{"id":2923,"qattrid":51,"type":1,"title":"以下哪个不是拓咨®的主要研究名称","result":"A","content":"UNCOVER-J才是","options":[{"flag":"A","name":"IXORA-J"},{"flag":"B","name":"IXORA-P"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":"IXORA-Q"}]},"2924":{"id":2924,"qattrid":51,"type":1,"title":"第0-12周，在UNCOVER1、2和3，安慰剂与拓咨®的严重感染发生率：","result":"C","content":"第0-12周，在UNCOVER1、2和3，安慰剂与拓咨®的严重感染发生率两者无差别，均为0.4%","options":[{"flag":"A","name":"拓咨®高，0.8%"},{"flag":"B","name":"安慰剂高，0.8%"},{"flag":"C","name":"两者无差别，均为0.4%"},{"flag":"D","name":" 两者无差别，均为1.0%"}]},"2925":{"id":2925,"qattrid":51,"type":1,"title":"综合临床试验中的诱导治疗期间拓咨®治疗组患者主要的上呼吸道感染类别是（）","result":"A","content":"鼻咽炎是最常见","options":[{"flag":"A","name":"鼻咽炎"},{"flag":"B","name":"鼻窦炎"},{"flag":"C","name":"咽炎"},{"flag":"D","name":"喉炎"}]},"2926":{"id":2926,"qattrid":51,"type":1,"title":"拓咨®使得更多患者达到清洁或几乎清洁疗效。（）患者达到PASI 75","result":"C","content":"90%以上患者达到PASI 75","options":[{"flag":"A","name":" 4/10"},{"flag":"B","name":" 8/10"},{"flag":"C","name":" 9/10"},{"flag":"D","name":" 7/10"}]},"2927":{"id":2927,"qattrid":51,"type":1,"title":"UNCOVER 2,3 前12周拓咨®主要和__________做头对头研究：","result":"B","content":"临床试验UNCOV\u0002ER-2和UNCOVER-3分为IXE(依奇珠单抗)、ETN（依那西普）和PBO(安慰剂组)， 前12周拓咨®主要和依那西普做头对头研究","options":[{"flag":"A","name":"阿达木单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"乌丝奴单抗"},{"flag":"D","name":" 司库奇尤单抗"}]},"2928":{"id":2928,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 75患者比例为（）","result":"D","content":"均为uncover-2研究结果","options":[{"flag":"A","name":"0.42"},{"flag":"B","name":"0.58"},{"flag":"C","name":"0.72"},{"flag":"D","name":"0.9"}]},"2929":{"id":2929,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 100患者比例为（）","result":"D","content":"均为uncover-2研究结果","options":[{"flag":"A","name":"0.05"},{"flag":"B","name":"0.15"},{"flag":"C","name":"0.25"},{"flag":"D","name":"0.4"}]},"2930":{"id":2930,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，恩利®治疗12周后，达到PASI 75患者比例为（）","result":"A","content":"均为uncover-2研究结果","options":[{"flag":"A","name":"0.42"},{"flag":"B","name":"0.58"},{"flag":"C","name":"0.72"},{"flag":"D","name":"0.9"}]},"2931":{"id":2931,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，恩利®治疗12周后，达到PASI 100患者比例为（）","result":"A","content":"均为uncover-2研究结果","options":[{"flag":"A","name":"0.05"},{"flag":"B","name":"0.15"},{"flag":"C","name":"0.25"},{"flag":"D","name":"0.4"}]},"2932":{"id":2932,"qattrid":51,"type":1,"title":"IXORA-S研究，拓咨®主要和________进行头对头研究。","result":"C","content":"IXORA-S研究，拓咨®主要和喜达诺/乌丝奴单抗进行头对头研究","options":[{"flag":"A","name":"阿达木单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"乌丝奴单抗"},{"flag":"D","name":" 司库奇尤单抗"}]},"2933":{"id":2933,"qattrid":51,"type":1,"title":"以下哪个是拓咨®的亚洲的主要研究名称","result":"D","content":" UNCOVER-J 是拓咨®的亚洲的主要研究名称","options":[{"flag":"A","name":"UNCOVER-1"},{"flag":"B","name":"UNCOVER-2"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":" UNCOVER-J "}]},"2934":{"id":2934,"qattrid":48,"type":1,"title":"2016 WHO 《银屑病全球报告》指出，患者对银屑病治疗存在：","result":"C","content":"2016 WHO 《银屑病全球报告》指出，患者对银屑病治疗存在较高需求","options":[{"flag":"A","name":"基本需求"},{"flag":"B","name":"较低需求"},{"flag":"C","name":"较高需求"},{"flag":"D","name":" 最高需求"}]},"2935":{"id":2935,"qattrid":48,"type":1,"title":"2019年AAD/NPF指南等权威指南提出了_________治疗目标。","result":"C","content":"2019年AAD/NPF指南等权威指南提出了更高治疗目标，提及PASI 90/100","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"相同"},{"flag":"C","name":"更高"},{"flag":"D","name":"以上都不对"}]},"2936":{"id":2936,"qattrid":48,"type":1,"title":"以下哪一项不是当前银屑病患者期待实现的更好的治疗目标：","result":"B","content":"皮损完全清除或几乎完全清除已作为治疗目标，被国际指南广泛接受","options":[{"flag":"A","name":"皮损快速改善"},{"flag":"B","name":"皮损基本清除"},{"flag":"C","name":"皮损全面清除"},{"flag":"D","name":"病情稳定控制"}]},"2937":{"id":2937,"qattrid":50,"type":1,"title":"拓咨®的强效亲和体现在：","result":"C","content":"拓咨®的强效亲和体现在特异性靶向IL-17A","options":[{"flag":"A","name":"特异性靶向IL-23A"},{"flag":"B","name":"非特异性靶向IL-17A"},{"flag":"C","name":"特异性靶向IL-17A"},{"flag":"D","name":" 非特异性靶向IL-23A"}]},"2938":{"id":2938,"qattrid":46,"type":1,"title":"关于拓咨®安全性描述正确的是：","result":"D","content":"拓咨安全性良好，与依那西普总体TEAEs发生率相当。治疗期间最常见的不良反应是注射部位不良反应。TEAEs多为轻至中度，极少导致治疗中断","options":[{"flag":"A","name":"与依那西普相比，拓咨®治疗组TEAEs发生率显著降低"},{"flag":"B","name":"拓咨®的TEAEs多为中重度，常导致治疗中断"},{"flag":"C","name":"最常见导致拓咨®治疗中断的不良反应是念珠菌感染、鼻咽炎、上呼吸道感染"},{"flag":"D","name":"  拓咨®特别关注的不良事件是主要心血管不良事件、克罗恩病、恶性肿瘤等"}]},"2939":{"id":2939,"qattrid":48,"type":1,"title":"拓咨®的主要推广信息中不包括：","result":"D","content":"D不是","options":[{"flag":"A","name":"净化论"},{"flag":"B","name":"银屑病治疗新主张"},{"flag":"C","name":"快速起效，全面清除，长期稳定"},{"flag":"D","name":"银屑病治疗的基础用药"}]},"2940":{"id":2940,"qattrid":49,"type":1,"title":"关于斑块型银屑病，下列哪项描述是错误的","result":"B","content":"发疹前常有咽喉部链球菌感染病史的为点滴状银屑病","options":[{"flag":"A","name":"斑块型银屑病最为常见，约占90%"},{"flag":"B","name":"发疹前常有咽喉部链球菌感染病史"},{"flag":"C","name":"皮损反复发作，多数冬重夏轻"},{"flag":"D","name":" 进展期可有“同形反应"}]},"2941":{"id":2941,"qattrid":49,"type":1,"title":"指甲型银屑病的严重程度评估上，会特定使用到：","result":"C","content":"N=nail指甲，指甲型银屑病的严重程度评估上，会使用到NAPSI(Nail Psoriasis Severity Index)","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"NAPSI"},{"flag":"D","name":" BSA"}]},"2942":{"id":2942,"qattrid":49,"type":1,"title":"以下不是银屑病的治疗方法的是：","result":"C","content":"手术治疗不是","options":[{"flag":"A","name":"局部治疗"},{"flag":"B","name":"物理治疗"},{"flag":"C","name":"手术治疗"},{"flag":"D","name":" 系统治疗"}]},"2943":{"id":2943,"qattrid":47,"type":1,"title":"下列不是外用药物治疗银屑病的优点是：","result":"D","content":"优点是药物直接作用于皮损，起效快、使用方便、全身不良反应少。缺点是长期使用可出现局部不良反应，皮损泛发者使用不便，患者依从性差异较大","options":[{"flag":"A","name":"直接作用于皮损"},{"flag":"B","name":"起效快"},{"flag":"C","name":"使用方便"},{"flag":"D","name":" 局部不良反应少"}]},"2944":{"id":2944,"qattrid":47,"type":1,"title":"银屑病常用外用药物复方制剂不会：","result":"C","content":"复方制剂可提高疗效、减轻副作用，便于患者使用","options":[{"flag":"A","name":"提高疗效"},{"flag":"B","name":"减轻副作用"},{"flag":"C","name":"增加副作用"},{"flag":"D","name":" 便于患者使用"}]},"2945":{"id":2945,"qattrid":47,"type":1,"title":"可善挺®的使用方法：","result":"C","content":"可善挺皮下注射","options":[{"flag":"A","name":"肌肉注射"},{"flag":"B","name":"静脉注射"},{"flag":"C","name":"皮下注射"},{"flag":"D","name":" 口服"}]},"2946":{"id":2946,"qattrid":49,"type":1,"title":"BSA评价指标存在局限性是因为没有将银屑病患者_____的影响纳入评价：","result":"B","content":"BSA评价指标存在局限性，没有将银屑病患者生活质量的影响纳入评价","options":[{"flag":"A","name":"皮损面积"},{"flag":"B","name":"生活质量"},{"flag":"C","name":"严重程度"},{"flag":"D","name":" 以上均不是"}]},"2947":{"id":2947,"qattrid":51,"type":1,"title":"对于UNCOVER-3临床试验一直接受依奇珠单抗治疗的患者（0至60周），至少（）的患者达到sPGA 0/1","result":"C","content":"对于一直接受依奇珠单抗治疗的患者（0至60周），至少73%的患者达到sPGA 0/1","options":[{"flag":"A","name":"0.53"},{"flag":"B","name":"0.63"},{"flag":"C","name":"0.73"},{"flag":"D","name":"0.93"}]},"2948":{"id":2948,"qattrid":51,"type":1,"title":"UNCOVER-3临床试验对于前面安慰剂组，患者会在第（）周时开始接受160mg依奇珠单抗治疗，后每4周80mg给药。","result":"B","content":"12周","options":[{"flag":"A","name":"8"},{"flag":"B","name":"12"},{"flag":"C","name":"16"},{"flag":"D","name":"24"}]},"2949":{"id":2949,"qattrid":51,"type":1,"title":"以下哪一项是拓咨®的关键III期临床试验：","result":"A","content":"UNCOVER1,2.3是拓咨®的关键III期临床试验","options":[{"flag":"A","name":"UNCOVER-3"},{"flag":"B","name":"IXORA-P"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":" IXORA-R"}]},"2950":{"id":2950,"qattrid":51,"type":1,"title":"参加UNCOVER-1，2，3的患者有（）比例接受了既往生物制剂用于治疗银屑病。","result":"C","content":"参加UNCOVER-1，2，3的患者有26%比例接受了既往生物制剂用于治疗银屑病","options":[{"flag":"A","name":"0.06"},{"flag":"B","name":"0.16"},{"flag":"C","name":"0.26"},{"flag":"D","name":"0.46"}]},"2951":{"id":2951,"qattrid":51,"type":1,"title":"UNCOVER系列研究结果显示，拓咨® 治疗2周，_______实现PASI 75：","result":"C","content":"UNCOVER系列研究结果显示，拓咨® 治疗2周，23%实现PASI 75","options":[{"flag":"A","name":"0.03"},{"flag":"B","name":"0.13"},{"flag":"C","name":"0.23"},{"flag":"D","name":"0.33"}]},"2952":{"id":2952,"qattrid":51,"type":1,"title":"Meta分析结果显示，拓咨® 治疗12周，相较于司库奇尤单抗可实现_________皮损清除率：","result":"B","content":"Meta分析结果显示，拓咨® 治疗12周，相较于司库奇尤单抗可实现更高皮损清除率：","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"更高"},{"flag":"C","name":"相同"},{"flag":"D","name":" 结果差异较大"}]},"2953":{"id":2953,"qattrid":46,"type":1,"title":"拓咨®说明书里推荐维持剂量为：","result":"B","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"40mg"},{"flag":"B","name":"80mg"},{"flag":"C","name":"120mg"},{"flag":"D","name":" 160mg"}]},"2954":{"id":2954,"qattrid":46,"type":1,"title":"拓咨®说明书里推荐维持剂量为每____周1次：","result":"C","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"2"},{"flag":"B","name":"3"},{"flag":"C","name":"4"},{"flag":"D","name":"5"}]},"2955":{"id":2955,"qattrid":47,"type":1,"title":"拓咨®每年的注射次数相较于可善挺®：","result":"A","content":"拓咨17次，可善挺32次","options":[{"flag":"A","name":"更少"},{"flag":"B","name":"一样"},{"flag":"C","name":"更多"},{"flag":"D","name":" 个体化因人而异"}]},"2956":{"id":2956,"qattrid":46,"type":1,"title":"拓咨®说明书里推荐诱导剂量为开始后12周内每____周1次：","result":"B","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"2957":{"id":2957,"qattrid":46,"type":2,"title":"拓咨®说明书里关于给药方法正确的是：","result":"A,B,C","content":"需要医护人员指导适当培训","options":[{"flag":"A","name":"皮下注射"},{"flag":"B","name":"轮换注射部位"},{"flag":"C","name":"不得剧烈摇晃"},{"flag":"D","name":"未培训的患者也可以自行注射"}]},"2958":{"id":2958,"qattrid":46,"type":1,"title":"拓咨®说明书里患者对于注射部位反应的程度为","result":"B","content":"说明书内容","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"轻度至中度"},{"flag":"C","name":"中重度"},{"flag":"D","name":"重度"}]},"2959":{"id":2959,"qattrid":51,"type":1,"title":"拓咨®说明书里对于接受治疗长达60周的斑块型银屑病患者，ADA发生率大约为：","result":"B","content":"说明书内容","options":[{"flag":"A","name":"1-8%"},{"flag":"B","name":"9-17%"},{"flag":"C","name":"18-29%"},{"flag":"D","name":"0.3"}]},"2960":{"id":2960,"qattrid":51,"type":1,"title":"拓咨®说明书里对于接受治疗长达60周的斑块型银屑病患者，只有大约_____的患者被确认产生了与低药物浓度和临床应答降低相关的中和抗体。","result":"A","content":"说明书内容","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.02"},{"flag":"C","name":"0.03"},{"flag":"D","name":"0.04"}]},"2961":{"id":2961,"qattrid":51,"type":1,"title":"拓咨®说明书里介绍入组安慰剂对照研究的3866名患者中，_______的患者曾接手过银屑病系统治疗：","result":"D","content":"说明书内容","options":[{"flag":"A","name":"0.34"},{"flag":"B","name":"0.44"},{"flag":"C","name":"0.54"},{"flag":"D","name":"0.64"}]},"2962":{"id":2962,"qattrid":49,"type":2,"title":"银屑病的治疗手段包括：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"局部治疗"},{"flag":"B","name":"系统性治疗"},{"flag":"C","name":"光疗"},{"flag":"D","name":"日间治疗中心"}]},"2963":{"id":2963,"qattrid":46,"type":2,"title":"开具生物制剂处方前的特别注意事项有：","result":"A,B,D","content":"3,4级充血性心力衰竭是开具生物制剂处方前的特别注意事项","options":[{"flag":"A","name":"妊娠"},{"flag":"B","name":"癌症史"},{"flag":"C","name":"1级充血性心力衰竭"},{"flag":"D","name":" 结核感染"}]},"2964":{"id":2964,"qattrid":46,"type":1,"title":"在开始生物制剂之前，患者访谈和体格检查将不会帮助：","result":"D","content":"不能立刻决定","options":[{"flag":"A","name":"排除禁忌症"},{"flag":"B","name":"确定疫苗接种需求和隐患"},{"flag":"C","name":"确定如何管理从先前治疗的过渡"},{"flag":"D","name":" 立刻决定选择哪一种生物制剂"}]},"2965":{"id":2965,"qattrid":46,"type":1,"title":"建议妊娠16周以上、患有银屑病、并接受过生物疗法的母亲，在婴儿_______个月之前不应接种任何活疫苗（比如接种轮状疫苗和卡介苗）：","result":"B","content":"建议妊娠16周以上、患有银屑病、并接受过生物疗法的母亲，在婴儿6个月之前不应接种任何活疫苗（比如接种轮状疫苗和卡介苗）","options":[{"flag":"A","name":"3"},{"flag":"B","name":"6"},{"flag":"C","name":"12"},{"flag":"D","name":"18"}]},"2966":{"id":2966,"qattrid":46,"type":1,"title":"拓咨®治疗前_____筛查乙肝病毒感染（HBV）：","result":"C","content":"拓咨®治疗前需要筛查乙肝病毒感染（HBV）","options":[{"flag":"A","name":"不需要"},{"flag":"B","name":"有条件进行"},{"flag":"C","name":"需要"},{"flag":"D","name":" 以上都不对"}]},"2967":{"id":2967,"qattrid":50,"type":2,"title":"拓咨®是IgG4单抗，具有：","result":"B,C,D","content":"lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少","options":[{"flag":"A","name":"更多细胞毒性"},{"flag":"B","name":"更少细胞毒性"},{"flag":"C","name":"更高亲和力"},{"flag":"D","name":"比可善挺®更少的注射次数"}]},"2968":{"id":2968,"qattrid":49,"type":1,"title":"2019年法国指南明确提出_________可以作为银屑病治疗目标","result":"A","content":"2019年法国指南明确提出PASI 90/100可以作为银屑病治疗目标","options":[{"flag":"A","name":"PASI 90/100"},{"flag":"B","name":"PASI 75/90"},{"flag":"C","name":"PASI 50/75"},{"flag":"D","name":"PASI 75/100"}]},"2969":{"id":2969,"qattrid":51,"type":1,"title":"拓咨®的UNCOVER-1,2都是______年研究：","result":"C","content":"拓咨®的UNCOVER-1,2都是5年研究","options":[{"flag":"A","name":"3"},{"flag":"B","name":"4"},{"flag":"C","name":"5"},{"flag":"D","name":"10"}]},"2970":{"id":2970,"qattrid":51,"type":1,"title":"拓咨®在安全性研究中发现长期治疗，结核再激活的有______例。","result":"A","content":"拓咨®在安全性研究中发现长期治疗，结核再激活的有0例","options":[{"flag":"A","name":"0"},{"flag":"B","name":"1"},{"flag":"C","name":"2"},{"flag":"D","name":"8"}]},"2971":{"id":2971,"qattrid":48,"type":1,"title":"中国银屑病患者接受生物制剂治疗的比例是：","result":"A","content":"中国银屑病患者接受生物制剂治疗的比例是1%","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.05"},{"flag":"C","name":"0.11"},{"flag":"D","name":"0.16"}]},"2972":{"id":2972,"qattrid":49,"type":1,"title":"皮肤是人体第______大器官","result":"A","content":"皮肤是覆盖在人体表面上的最大器官，约占成人总体重的16％ ","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"2973":{"id":2973,"qattrid":49,"type":1,"title":"皮肤分为三层，最外层是？","result":"A","content":"皮肤分为三层，最外层表皮，真皮，最内层皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"2974":{"id":2974,"qattrid":49,"type":1,"title":"表皮是_______保护性外层。","result":"C","content":"表皮是持续再生保护性外层","options":[{"flag":"A","name":"不可再生"},{"flag":"B","name":"间歇性再生"},{"flag":"C","name":"持续再生"},{"flag":"D","name":" 以上都不对"}]},"2975":{"id":2975,"qattrid":49,"type":2,"title":"皮肤可保护机内组织和器官，防止_______损伤。","result":"A,B,C,D","content":"皮肤可保护机内组织和器官，对于防止许多机械性、物理性、化学性刺激，特别对防御生物性侵袭是非常重要的","options":[{"flag":"A","name":"机械性"},{"flag":"B","name":"物理性"},{"flag":"C","name":"化学性"},{"flag":"D","name":" 生物性"}]},"2976":{"id":2976,"qattrid":49,"type":1,"title":"抗体是：","result":"C","content":"抗体是免疫系统在抗原刺激下，由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋白","options":[{"flag":"A","name":"T淋巴细胞增殖分化成的浆细胞所产生的"},{"flag":"B","name":"由T淋巴细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋白"},{"flag":"C","name":"由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的、可与相应抗原发生特异性结合的免疫球蛋白"},{"flag":"D","name":"由B淋巴细胞或记忆B细胞增殖分化成的浆细胞所产生的"}]},"2977":{"id":2977,"qattrid":49,"type":2,"title":"人体皮肤包括以下哪几层？","result":"A,B,C","content":"皮肤分为三层，最外层表皮，真皮，最内层皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"次真皮"},{"flag":"D","name":"脂肪层"}]},"2978":{"id":2978,"qattrid":49,"type":1,"title":"皮肤中的哪种细胞异常增殖与银屑病密切相关？","result":"D","content":"银屑病引 起 角 质 形 成细 胞 过 度 增 殖 ","options":[{"flag":"A","name":"T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"树突状细胞"},{"flag":"D","name":" 角质形成细胞"}]},"2979":{"id":2979,"qattrid":49,"type":1,"title":"银屑病皮肤典型症状的出现主要因为以下哪个系统出现错误信号？","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"血液系统"},{"flag":"B","name":"神经系统"},{"flag":"C","name":"内分泌系统"},{"flag":"D","name":" 免疫系统"}]},"2980":{"id":2980,"qattrid":49,"type":2,"title":"以下哪几项属于皮肤重要的免疫细胞：","result":"A,C,D","content":"角质形成细胞、皮肤树突状细胞和T细胞组成皮肤重要的免疫细胞","options":[{"flag":"A","name":"T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"树突状细胞"},{"flag":"D","name":" 角质形成细胞"}]},"2981":{"id":2981,"qattrid":49,"type":1,"title":"银屑病的危害不包括：","result":"D","content":"银屑病易使患者产生抑郁、焦虑等情感障碍，影响人际交往，增加患者自杀风险及经济负担","options":[{"flag":"A","name":"产生抑郁"},{"flag":"B","name":"影响人际交往"},{"flag":"C","name":"增加自杀风险"},{"flag":"D","name":" 带来较少的社会经济负担"}]},"2982":{"id":2982,"qattrid":49,"type":2,"title":"银屑病类型有以下哪几种？","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"点滴状"},{"flag":"B","name":"脓疱型"},{"flag":"C","name":"斑块型"},{"flag":"D","name":" 红皮病型"}]},"2983":{"id":2983,"qattrid":49,"type":2,"title":"银屑病的症状包括以下哪几种？","result":"A,C,D","content":"银屑病可引起疼痛、瘙痒、干燥和皮肤发红等症状","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"湿润"},{"flag":"C","name":"疼痛"},{"flag":"D","name":"鳞屑"}]},"2984":{"id":2984,"qattrid":49,"type":1,"title":"银屑病发病的性别差异是？","result":"C","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":"男性多"},{"flag":"B","name":"女性多"},{"flag":"C","name":"无性别差异"},{"flag":"D","name":" 以上都不对"}]},"2985":{"id":2985,"qattrid":49,"type":1,"title":"研究数据显示，在年龄不超过 _____岁的人群中，有第一次上升趋势。","result":"B","content":"发病年龄总体上存在双峰分布。研究数据显示，在年龄不超过39岁的人群中，银屑病发病率有上升趋势。在随后的40-49岁发病率下降。而在60-69岁时，又出现一个发病高峰","options":[{"flag":"A","name":"15"},{"flag":"B","name":"39"},{"flag":"C","name":"49"},{"flag":"D","name":"59"}]},"2986":{"id":2986,"qattrid":49,"type":1,"title":"在______，受银屑病影响的人数预计可达600万以上：","result":"B","content":"中国银屑病患病约在600万以上","options":[{"flag":"A","name":"英国"},{"flag":"B","name":"中国"},{"flag":"C","name":"日本"},{"flag":"D","name":" 斯里兰卡"}]},"2987":{"id":2987,"qattrid":49,"type":1,"title":"银屑病斑块确切病因是？","result":"D","content":"银屑病的病因及发病机制尚未完全清楚","options":[{"flag":"A","name":"遗传"},{"flag":"B","name":"免疫"},{"flag":"C","name":"环境"},{"flag":"D","name":" 尚未完全清楚"}]},"2988":{"id":2988,"qattrid":49,"type":2,"title":"斑块型银屑病皮疹好发于：","result":"A,C,D","content":"银屑病不好发于四肢屈侧","options":[{"flag":"A","name":"四肢伸侧"},{"flag":"B","name":"四肢屈侧"},{"flag":"C","name":"头皮"},{"flag":"D","name":" 背部"}]},"2989":{"id":2989,"qattrid":49,"type":1,"title":"下列关于促进银屑病疾病活动度的因素中，不正确的是：","result":"A","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":"温热天气"},{"flag":"B","name":"非甾体类抗炎药"},{"flag":"C","name":"刺青"},{"flag":"D","name":" 肥胖"}]},"2990":{"id":2990,"qattrid":49,"type":1,"title":"Th17产生的细胞因子包括：","result":"A","content":"Th17产生的细胞因子包括：IL-17A、IL-6、IL-21和TNF-α","options":[{"flag":"A","name":"IL-17A、IL-6、IL-21和TNF-α"},{"flag":"B","name":"TGFβ、IL-12、IL-23和IL-4"},{"flag":"C","name":"IFNγ、IL-4、IL-10和IL-13"},{"flag":"D","name":" IL-2、IL-7、IL-15和IFNγ"}]},"2991":{"id":2991,"qattrid":49,"type":2,"title":"银屑病通常症状有？ ","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"外表变化"},{"flag":"C","name":"斑块型相关疼痛"},{"flag":"D","name":" 发红"}]},"2992":{"id":2992,"qattrid":49,"type":1,"title":"银屑病主要以________细胞介导为主？","result":"D","content":"通过以T淋 巴 细 胞 介 导 为主 、多 种 免 疫 细 胞共同参与的免疫反应","options":[{"flag":"A","name":"B淋巴"},{"flag":"B","name":"树突状"},{"flag":"C","name":"角质形成细胞"},{"flag":"D","name":" T淋巴"}]},"2993":{"id":2993,"qattrid":49,"type":1,"title":"已发现，与未患银屑病皮肤疾病的人群相比，银屑病患者的以下哪种疾病发生率显著更高？","result":"A","content":"代谢综合征，比如糖尿病的发病风险在银屑病患者中有所增加","options":[{"flag":"A","name":"代谢综合征"},{"flag":"B","name":"白化病"},{"flag":"C","name":"甲状腺功能亢进"},{"flag":"D","name":" 甲状腺功能减退"}]},"2994":{"id":2994,"qattrid":49,"type":1,"title":"通常情况下，银屑病最不常见的发病季节是？","result":"B","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":"春季"},{"flag":"B","name":"夏季"},{"flag":"C","name":"秋季"},{"flag":"D","name":"冬季"}]},"2995":{"id":2995,"qattrid":49,"type":1,"title":"双峰分布是银屑病发病__________存在的总体特点。","result":"B","content":"发病年龄总体上存在双峰分布","options":[{"flag":"A","name":"性别"},{"flag":"B","name":"年龄"},{"flag":"C","name":"种族"},{"flag":"D","name":" 以上都不对"}]},"2996":{"id":2996,"qattrid":49,"type":1,"title":"IL-17 A 主要由_________产生。","result":"C","content":"IL-17A主要由Th17细胞产生","options":[{"flag":"A","name":"Th15"},{"flag":"B","name":"Th16"},{"flag":"C","name":"Th17"},{"flag":"D","name":" NK细胞"}]},"2997":{"id":2997,"qattrid":49,"type":2,"title":"下面哪几种细胞属于淋巴细胞？","result":"A,C,D","content":"淋巴细胞包括B细胞、T细胞以及NK细胞。肥大细胞属于嗜碱性粒细胞","options":[{"flag":"A","name":"NK细胞"},{"flag":"B","name":"肥大细胞"},{"flag":"C","name":"B细胞"},{"flag":"D","name":" T细胞"}]},"2998":{"id":2998,"qattrid":49,"type":1,"title":"表皮层的最主要细胞类型是？","result":"C","content":"表皮层的最主要细胞类型是角质形成细胞","options":[{"flag":"A","name":"T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"角质形成细胞"},{"flag":"D","name":" 树突状细胞"}]},"2999":{"id":2999,"qattrid":49,"type":1,"title":"约占银屑病的90%的银屑病类型是_______：","result":"C","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":"点滴状"},{"flag":"B","name":"脓疱型"},{"flag":"C","name":"斑块型"},{"flag":"D","name":" 红皮病型"}]},"3000":{"id":3000,"qattrid":49,"type":2,"title":"银屑病对患者生活质量的影响有：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"睡眠"},{"flag":"B","name":"娱乐"},{"flag":"C","name":"两性生活"},{"flag":"D","name":" 工作"}]},"3001":{"id":3001,"qattrid":49,"type":1,"title":"根据流调，银屑病患病的总体可能存在的地理性差异是？","result":"A","content":"总体来说，靠近赤道的群体与较远的群体相比，银屑病患病率较低。亚洲（包括中国、斯里兰卡和台湾地区）所报告的银屑病患病率为世界最低，低于0.5%","options":[{"flag":"A","name":"纬度越高发病率越高"},{"flag":"B","name":"纬度越高发病率越低"},{"flag":"C","name":"无差异"},{"flag":"D","name":" 以上都不对"}]},"3002":{"id":3002,"qattrid":49,"type":1,"title":"斑块型银屑病的皮疹特点是？","result":"B","content":"皮疹基本特点为境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑","options":[{"flag":"A","name":"境界不清的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑"},{"flag":"B","name":"境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑"},{"flag":"C","name":"境界不清的暗红色斑块或浸润性红斑，没有白色、银白色鳞屑"},{"flag":"D","name":" 境界清楚的暗红色斑块或浸润性红斑，没有白色、银白色鳞屑"}]},"3003":{"id":3003,"qattrid":49,"type":1,"title":"与未患该疾病的患者相比，银屑病患者如果无其他风险因素（如肥胖），面临的代谢综合征风险为：","result":"C","content":"代谢综合征，比如糖尿病的发病风险在银屑病患者中有所增加","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"正常"},{"flag":"C","name":"更高"},{"flag":"D","name":" 不清楚"}]},"3004":{"id":3004,"qattrid":49,"type":1,"title":"银屑病是一种：","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"局部性皮肤病"},{"flag":"B","name":"全身性皮肤病"},{"flag":"C","name":"局部性疾病"},{"flag":"D","name":" 系统性疾病"}]},"3005":{"id":3005,"qattrid":48,"type":2,"title":"以下哪几项是银屑病的治疗目的：","result":"A,C,D","content":"控制和稳定病情，减缓向全身发展的进程；减轻红斑、鳞屑、斑块增厚等皮损加重的症状；避免复发/诱发加重的因素；减少不良反应；提高生活质量","options":[{"flag":"A","name":"减缓向全身发展的进程"},{"flag":"B","name":"治愈病情"},{"flag":"C","name":"避免复发/诱发加重的因素"},{"flag":"D","name":" 减少不良反应"}]},"3006":{"id":3006,"qattrid":49,"type":1,"title":"产生_________的T细胞在银屑病患者真皮层中增加。","result":"B","content":"产生IL-17A的T细胞在银屑病患者真皮层中增","options":[{"flag":"A","name":"IL-17D"},{"flag":"B","name":"IL-17A"},{"flag":"C","name":"IL-17B"},{"flag":"D","name":" IL-17C"}]},"3007":{"id":3007,"qattrid":49,"type":2,"title":"斑块型银屑病的分期包括？","result":"B,C,D","content":"分为3期，进行期、静止期、退行期","options":[{"flag":"A","name":"复发期"},{"flag":"B","name":"进行期"},{"flag":"C","name":"静止期"},{"flag":"D","name":"退行期"}]},"3008":{"id":3008,"qattrid":49,"type":2,"title":"IL-17A主要可以由哪些细胞产生？","result":"C,D","content":"IL-17A主要由Th17细胞产生，其他细胞包括CD8+T细胞、γδT细胞、NK细胞等也表达","options":[{"flag":"A","name":"Th15"},{"flag":"B","name":"Th16"},{"flag":"C","name":"Th17"},{"flag":"D","name":" NK细胞"}]},"3009":{"id":3009,"qattrid":49,"type":1,"title":"以下哪个因素目前研究表明不是导致银屑病的发病的主要因素：","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"遗传因素"},{"flag":"B","name":"环境因素"},{"flag":"C","name":"免疫因素"},{"flag":"D","name":" 性别因素"}]},"3010":{"id":3010,"qattrid":49,"type":2,"title":"_____是可以导致银屑病加重的药物。","result":"A,B,C,D","content":"都是","options":[{"flag":"A","name":"β-阻断剂"},{"flag":"B","name":"锂剂"},{"flag":"C","name":"合成抗疟疾药物（SAD）"},{"flag":"D","name":" 非甾体类抗炎药物（NSAID）"}]},"3011":{"id":3011,"qattrid":49,"type":2,"title":"银屑病患者面临的共病包括：","result":"A,B,C,D","content":"都是","options":[{"flag":"A","name":"银屑病关节炎"},{"flag":"B","name":"糖尿病"},{"flag":"C","name":"心血管疾病"},{"flag":"D","name":" 肥胖"}]},"3012":{"id":3012,"qattrid":49,"type":1,"title":"银屑病共病风险随着银屑病的加重会？","result":"B","content":"共病的发病率随着银屑病严重程度的增加而增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"增加"},{"flag":"C","name":"不受影响"},{"flag":"D","name":" 以上都不对"}]},"3013":{"id":3013,"qattrid":49,"type":1,"title":"代谢综合征的发病风险随银屑病的加重而_______：","result":"B","content":"代谢综合征的发生风险随银屑病的加重而增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"增加"},{"flag":"C","name":"不受影响"},{"flag":"D","name":" 以上都不对"}]},"3014":{"id":3014,"qattrid":49,"type":1,"title":"银屑病与心血管疾病之间________病理生理联系。","result":"A","content":"促炎细胞因子不仅在银屑病的发病中发挥着重要作用，还连接着心血管疾病的炎症通路","options":[{"flag":"A","name":"存在"},{"flag":"B","name":"不存在"},{"flag":"C","name":"间歇性存在"},{"flag":"D","name":" 以上都不对"}]},"3015":{"id":3015,"qattrid":49,"type":1,"title":"银屑病关节炎(PsA)是一种与银屑病__________。","result":"C","content":"银屑病关节炎(PsA)是一种与银屑病相关的炎症性关节病","options":[{"flag":"A","name":"相关的风湿性关节病"},{"flag":"B","name":"不相关的炎症性关节病"},{"flag":"C","name":"相关的炎症性关节病"},{"flag":"D","name":" 以上都不对"}]},"3016":{"id":3016,"qattrid":49,"type":1,"title":"银屑病________总体寿命:","result":"A","content":"重度银屑病患者的总体死亡风险增加了50%","options":[{"flag":"A","name":"累及"},{"flag":"B","name":"不累及"},{"flag":"C","name":"无关系"},{"flag":"D","name":" 以上都不对"}]},"3017":{"id":3017,"qattrid":49,"type":1,"title":"重度银屑病患者的总体死亡风险：","result":"C","content":"重度银屑病患者的总体死亡风险增加了50%","options":[{"flag":"A","name":"降低了5%"},{"flag":"B","name":"增加了20%"},{"flag":"C","name":"增加了50%"},{"flag":"D","name":" 无关系"}]},"3018":{"id":3018,"qattrid":49,"type":2,"title":"目前确定银屑病的发病时间不依赖于？","result":"B,D","content":"难以准确确定发病时间。为了识别这些数据而进行的研究通常依赖于患者对病灶出现时间的回忆，或依赖于该疾病主诉在就医时记录于病历的时间","options":[{"flag":"A","name":"患者回忆"},{"flag":"B","name":"医生回忆"},{"flag":"C","name":"病历主诉记录时间"},{"flag":"D","name":" 实验室检查报告时间"}]},"3019":{"id":3019,"qattrid":49,"type":1,"title":"银屑病不是一种遗传与环境共同作用诱发的免疫介导的_______：","result":"A","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":"急性疾病"},{"flag":"B","name":"复发性疾病"},{"flag":"C","name":"炎症性疾病"},{"flag":"D","name":" 系统性疾病"}]},"3020":{"id":3020,"qattrid":49,"type":2,"title":"银屑病严重影响两性关系体现在___________。(多选题)","result":"A,B,C,D","content":"银屑病严重影响两性关系：减少对身体亲密接触的渴望，降低自尊和性自我形象，长期关系中对亲密接触回避","options":[{"flag":"A","name":"减少对身体亲密接触的渴望"},{"flag":"B","name":"降低自尊和性自我形象"},{"flag":"C","name":"部分有性功能障碍"},{"flag":"D","name":" 长期关系中对亲密接触回避"}]},"3021":{"id":3021,"qattrid":49,"type":2,"title":"银屑病的特点没有哪些：","result":"C,D","content":"银屑病不具有传染性，控制和稳定病情是治疗目的","options":[{"flag":"A","name":"典型临床表现为鳞屑性红斑或斑块"},{"flag":"B","name":"局限或广泛分布"},{"flag":"C","name":"有传染性"},{"flag":"D","name":" 常能治愈"}]},"3022":{"id":3022,"qattrid":49,"type":1,"title":"医师总体评估是：","result":"B","content":"医师总体评估（PGA）","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"NAPSI"},{"flag":"D","name":" BSA"}]},"3023":{"id":3023,"qattrid":49,"type":1,"title":"免疫介导的银屑病__________传染性：","result":"B","content":"银屑病不具有传染性，控制和稳定病情是治疗目的","options":[{"flag":"A","name":"有"},{"flag":"B","name":"没有"},{"flag":"C","name":"说不清"},{"flag":"D","name":" 因人而异"}]},"3024":{"id":3024,"qattrid":49,"type":2,"title":"以下哪几项在斑块型银屑病查体中见得到？","result":"A,B,D","content":"查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"、束状发等","options":[{"flag":"A","name":"蜡滴现象"},{"flag":"B","name":"薄膜现象"},{"flag":"C","name":"大片出血现象"},{"flag":"D","name":" 束状发"}]},"3025":{"id":3025,"qattrid":48,"type":1,"title":"_______是目前患者以及最新指南希望达到的治疗目标：","result":"A","content":"PASI 100是目前患者以及最新指南希望达到的治疗目标","options":[{"flag":"A","name":"PASI 100"},{"flag":"B","name":"PASI 80"},{"flag":"C","name":"PASI 75"},{"flag":"D","name":" PASI 50"}]},"3026":{"id":3026,"qattrid":49,"type":1,"title":"_____可能是银屑病和心肌梗死之间的关联因素。","result":"A","content":"促炎细胞因子不仅在银屑病的发病中发挥着重要作用，还连接着心血管疾病的炎症通路","options":[{"flag":"A","name":"慢性炎症"},{"flag":"B","name":"免疫失调"},{"flag":"C","name":"感染"},{"flag":"D","name":" 精神因素"}]},"3027":{"id":3027,"qattrid":49,"type":1,"title":"____________将疾病的严重程度和受损面积纳入评分。","result":"A","content":"银屑病面积和严重度指数(PASI)是将疾病的严重程度和受损面积都纳入评分，范围从0（无疾病）至72（最严重疾病） [45]。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"EQ-5D"},{"flag":"C","name":"DLQI"},{"flag":"D","name":" SF-36"}]},"3028":{"id":3028,"qattrid":49,"type":1,"title":"以下哪些身体外伤会导致同形反应Koebner现象？","result":"D","content":"都是","options":[{"flag":"A","name":"创伤"},{"flag":"B","name":"抓伤"},{"flag":"C","name":"手术切口"},{"flag":"D","name":" 以上都是"}]},"3029":{"id":3029,"qattrid":49,"type":1,"title":"银屑病具有遗传倾向。在双胞胎的研究中，银屑病在同卵双胞胎中患病率：","result":"C","content":"银屑病在同卵双胞胎中患病率为70%，在异卵双胞胎中为20%","options":[{"flag":"A","name":"0.5"},{"flag":"B","name":"0.6"},{"flag":"C","name":"0.7"},{"flag":"D","name":"0.8"}]},"3030":{"id":3030,"qattrid":49,"type":2,"title":"以下关于PASI评分权重因子即每个区域占总皮肤面积的特定百分比正确的是","result":"A,B,C,D","content":"以上都对","options":[{"flag":"A","name":"头颈部占10%"},{"flag":"B","name":"躯干占30%"},{"flag":"C","name":"上肢占20%"},{"flag":"D","name":" 下肢占40%"}]},"3031":{"id":3031,"qattrid":49,"type":2,"title":"银屑病患者可能存在不同的疾病体征和症状，但通常表现为以下一种或多种：","result":"A,B,C,D","content":"以上都对","options":[{"flag":"A","name":"皮肤出现片状红斑，上覆银屑或斑块"},{"flag":"B","name":"小块部位出现鳞屑"},{"flag":"C","name":"皮肤干燥、开裂，可能出血"},{"flag":"D","name":" 指/趾甲增厚、凹陷或纹状突起"}]},"3032":{"id":3032,"qattrid":49,"type":1,"title":"以下哪项是斑块型银屑病皮疹基本特点？","result":"B","content":"皮疹基本特点为境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑","options":[{"flag":"A","name":"附红色、紫红色鳞屑"},{"flag":"B","name":"附白色、银白色鳞屑"},{"flag":"C","name":"不附白色、银白色鳞屑"},{"flag":"D","name":" 不附红色、紫红色鳞屑"}]},"3033":{"id":3033,"qattrid":49,"type":2,"title":"斑块型银屑病的诊断依据为：","result":"A,B,C","content":"多数冬重夏轻","options":[{"flag":"A","name":"皮疹好发于头皮、背部和四肢伸侧"},{"flag":"B","name":"瘙痒是可能出现的临床症状"},{"flag":"C","name":"皮损反复发作"},{"flag":"D","name":" 皮损夏重冬轻"}]},"3034":{"id":3034,"qattrid":49,"type":1,"title":"银屑病的炎症刺激导致淋巴细胞：","result":"B","content":"银屑病的炎症刺激导致淋巴细胞浸润","options":[{"flag":"A","name":"逃离"},{"flag":"B","name":"浸润"},{"flag":"C","name":"无反应"},{"flag":"D","name":" 以上都不对"}]},"3035":{"id":3035,"qattrid":49,"type":1,"title":"斑块型银屑病皮损_______：","result":"D","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":"一过性存在"},{"flag":"B","name":"渐进性消退"},{"flag":"C","name":"随年龄变化"},{"flag":"D","name":" 反复发作"}]},"3036":{"id":3036,"qattrid":49,"type":1,"title":"调查显示，银屑病对患者生活的质量造成的影响与癌症相比______：","result":"C","content":"银屑病对生活质量的影响与其他严重疾病相当，如癌症、高血压、心梗等","options":[{"flag":"A","name":"更高"},{"flag":"B","name":"更低"},{"flag":"C","name":"相当"},{"flag":"D","name":" 说不清"}]},"3037":{"id":3037,"qattrid":49,"type":1,"title":"斑块型银屑病进展期能见到的特定现象是：","result":"D","content":"斑块型银屑病进展期可有“同形反应”(Kobner现象)","options":[{"flag":"A","name":"蜡滴现象"},{"flag":"B","name":"薄膜现象"},{"flag":"C","name":"Auspitz征"},{"flag":"D","name":" 同形反应"}]},"3038":{"id":3038,"qattrid":49,"type":1,"title":"体表面积（BSA）是指采用_______只手掌约代表1%的体表面积的近似法：","result":"B","content":"体表面积（BSA）是指采用一只手掌代表1%体表面积","options":[{"flag":"A","name":"0.5"},{"flag":"B","name":"1"},{"flag":"C","name":"1.5"},{"flag":"D","name":"2"}]},"3039":{"id":3039,"qattrid":49,"type":1,"title":"银屑病皮损面积BSA低于多少为轻度：","result":"C","content":"受影响体表面积百分比低于3%，银屑病划分为轻度","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.02"},{"flag":"C","name":"0.03"},{"flag":"D","name":"0.04"}]},"3040":{"id":3040,"qattrid":49,"type":1,"title":"PASI主要对几个单独身体区域分别评分：","result":"B","content":"PASI评分将身体分为头颈部、上肢、躯干、下肢四个部位进行评分","options":[{"flag":"A","name":"2"},{"flag":"B","name":"4"},{"flag":"C","name":"6"},{"flag":"D","name":"8"}]},"3041":{"id":3041,"qattrid":49,"type":2,"title":"以下哪些评估方法涉及生活质量问题：","result":"C,D","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，在非特异性方面，简表36（SF-36）和EuroQoL 5D（EQ-5D）常用来评估患者整体的生活质量","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"DLQI"},{"flag":"D","name":" EQ-5D"}]},"3042":{"id":3042,"qattrid":49,"type":1,"title":"下列关于寻常型银屑病的疾病严重度分类描述正确的是","result":"C","content":"受影响体表面积百分比低于3%，银屑病划分为轻度，银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":"轻度BSA<5%"},{"flag":"B","name":"中度BSA 5~10%"},{"flag":"C","name":"重度BSA>10%"},{"flag":"D","name":" 以上说法均不正确"}]},"3043":{"id":3043,"qattrid":49,"type":1,"title":"寻常型银屑病按BSA严重程度主要分为_______：","result":"C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":"轻度，中度，中重度，重度"},{"flag":"B","name":"轻度，中度，重度，极重度"},{"flag":"C","name":"轻度，中度，重度"},{"flag":"D","name":" 轻度，重度，危重度"}]},"3044":{"id":3044,"qattrid":49,"type":2,"title":"以下哪几种属于BSA寻常型银屑病的严重程度类别：","result":"A,B,C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"中度"},{"flag":"C","name":"重度"},{"flag":"D","name":" 极重度"}]},"3045":{"id":3045,"qattrid":49,"type":1,"title":"PASI评分为多少分时，银屑病划分为中重度？","result":"B","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":"＞8"},{"flag":"B","name":"＞10"},{"flag":"C","name":"＞12"},{"flag":"D","name":" ＞15"}]},"3046":{"id":3046,"qattrid":49,"type":1,"title":"PASI评分0分时表示：","result":"C","content":"范围从0（无疾病）至72（最严重疾病） 。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"非常严重"},{"flag":"B","name":"轻度"},{"flag":"C","name":"清洁"},{"flag":"D","name":" 严重"}]},"3047":{"id":3047,"qattrid":49,"type":1,"title":"PASI评分按_________评分：","result":"A","content":"从红斑、厚度和鳞屑三个角度对严重程度进行评分（0分=清洁，1-4分随严重程度增加）","options":[{"flag":"A","name":"0-4"},{"flag":"B","name":" 1-4"},{"flag":"C","name":"0-5"},{"flag":"D","name":" 1-5"}]},"3048":{"id":3048,"qattrid":49,"type":2,"title":"计算PASI时，医师对患者几个单独的身体区域情况的________进行评价：","result":"A,B,D","content":"从红斑、厚度和鳞屑三个角度对严重程度进行评分（0分=清洁，1-4分随严重程度增加）","options":[{"flag":"A","name":"红斑"},{"flag":"B","name":"厚度"},{"flag":"C","name":"疼痛"},{"flag":"D","name":" 鳞屑"}]},"3049":{"id":3049,"qattrid":49,"type":1,"title":"银屑病PASI评分多少以下时为轻度：","result":"B","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":"8"},{"flag":"B","name":"10"},{"flag":"C","name":"12"},{"flag":"D","name":"15"}]},"3050":{"id":3050,"qattrid":49,"type":1,"title":"以下哪一个DLQI分数的患者生活质量最低？","result":"D","content":"DLQI给出了0-30分的范围。分数越低，代表生活质量更高","options":[{"flag":"A","name":"2"},{"flag":"B","name":"4"},{"flag":"C","name":"6"},{"flag":"D","name":"8"}]},"3051":{"id":3051,"qattrid":49,"type":1,"title":"医师总体评估（PGA）中，6分代表：","result":"D","content":"PGA按0分（清洁）至6分（非常严重）的7分制评分","options":[{"flag":"A","name":"清洁"},{"flag":"B","name":"轻度或无变化"},{"flag":"C","name":"中度至重度"},{"flag":"D","name":" 非常严重"}]},"3052":{"id":3052,"qattrid":46,"type":2,"title":"拓咨®通用名不是：","result":"A,B,C","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"依那西普"},{"flag":"B","name":"环孢素软胶囊"},{"flag":"C","name":"阿达木单抗"},{"flag":"D","name":" 依奇珠单抗"}]},"3053":{"id":3053,"qattrid":46,"type":1,"title":"拓咨®一年正常治疗注射次数1年次数是：","result":"B","content":"拓咨一年注射17次","options":[{"flag":"A","name":"10"},{"flag":"B","name":"17"},{"flag":"C","name":"27"},{"flag":"D","name":"32"}]},"3054":{"id":3054,"qattrid":50,"type":1,"title":"拓咨®特异性作用于白介素：","result":"A","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"IL-17A"},{"flag":"B","name":"IL-17C"},{"flag":"C","name":"IL-23A"},{"flag":"D","name":" IL-23C"}]},"3055":{"id":3055,"qattrid":50,"type":1,"title":"拓咨®是一种：","result":"C","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"鼠源化lgG1单克隆抗体"},{"flag":"B","name":"鼠源化lgG4单克隆抗体"},{"flag":"C","name":"人源化lgG4单克隆抗体"},{"flag":"D","name":" 人源化lgG1单克隆抗体"}]},"3056":{"id":3056,"qattrid":50,"type":1,"title":"单克隆抗体由单一杂交瘤细胞产生，针对______抗原表位的特异性抗体：","result":"A","content":"A.由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":"单一"},{"flag":"B","name":"两种"},{"flag":"C","name":"多种"},{"flag":"D","name":" 两种相似"}]},"3057":{"id":3057,"qattrid":50,"type":2,"title":"关于单克隆抗体，下列说法不正确的是：","result":"A,B,C","content":"A.由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":"单克隆抗体是针对多种不同抗原表面的抗体"},{"flag":"B","name":"免疫球蛋白lgG1诱导CDC或ADCC能力较差，细胞毒性少"},{"flag":"C","name":"与人源化抗体相比，鼠源抗体免疫原性更低"},{"flag":"D","name":" 抗药性抗体（ADAs）会影响单克隆抗体治疗的临床效果"}]},"3058":{"id":3058,"qattrid":48,"type":1,"title":"银屑病常用外用药物不包括","result":"A","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂等。","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"保湿剂"},{"flag":"C","name":"维A酸类"},{"flag":"D","name":" 维生素D3衍生物"}]},"3059":{"id":3059,"qattrid":48,"type":2,"title":"以下哪些是银屑病的治疗方法：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"糖皮质激素"},{"flag":"B","name":"光疗"},{"flag":"C","name":"中医外治法"},{"flag":"D","name":" 生物制剂"}]},"3060":{"id":3060,"qattrid":46,"type":1,"title":"依奇珠单抗的人类种系序列超过","result":"D","content":"依奇珠单抗是98.2%的人类种系序列(24/1328个非同源氨基酸)","options":[{"flag":"A","name":"0.8"},{"flag":"B","name":"0.88"},{"flag":"C","name":"0.95"},{"flag":"D","name":"0.98"}]},"3061":{"id":3061,"qattrid":50,"type":2,"title":"依奇珠单抗对以下哪些IL-17家族成员没有高亲和性：","result":"B,C,D","content":"依奇珠单抗对人IL-17A (KD=1.8 pM)具有较高的结合亲和力，而对其他IL-17家族成员没有较高的结合亲和力","options":[{"flag":"A","name":"IL-17A"},{"flag":"B","name":"IL-17B"},{"flag":"C","name":"IL-17C"},{"flag":"D","name":" IL-17F"}]},"3062":{"id":3062,"qattrid":46,"type":1,"title":"拓咨®的适应症是：","result":"A","content":"说明书","options":[{"flag":"A","name":"适合全身治疗或光疗的中度至重度斑块型银屑病成人患者"},{"flag":"B","name":"适合局部治疗或光疗的轻度至中度斑块型银屑病成人患者"},{"flag":"C","name":"适合局部治疗或光疗的轻度至中度点滴型银屑病成人患者"},{"flag":"D","name":"适合全身治疗或光疗的中度至重度点滴型银屑病成人患者"}]},"3063":{"id":3063,"qattrid":48,"type":2,"title":"以下哪几项是银屑病的治疗方法：","result":"A,B,C","content":"化疗不是","options":[{"flag":"A","name":"外用药物治疗"},{"flag":"B","name":"光疗"},{"flag":"C","name":"生物制剂"},{"flag":"D","name":" 化疗"}]},"3064":{"id":3064,"qattrid":47,"type":1,"title":"以下哪一个不属于TNF-α拮抗剂：","result":"B","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂","options":[{"flag":"A","name":"益赛普"},{"flag":"B","name":"司库奇尤单抗"},{"flag":"C","name":"英夫利西单抗"},{"flag":"D","name":" 阿达木单抗"}]},"3065":{"id":3065,"qattrid":47,"type":1,"title":"下列哪项药物的通用名和商品名对应不正确？","result":"C","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂","options":[{"flag":"A","name":"恩利®依那西普"},{"flag":"B","name":"类克®英夫利西单抗"},{"flag":"C","name":"可善挺®阿达木单抗"},{"flag":"D","name":" 喜达诺®乌司奴单抗"}]},"3066":{"id":3066,"qattrid":51,"type":1,"title":"在所有3项UNCOVER III期试验中，12周以后阶段称为（）","result":"B","content":"在所有3项UNCOVER III期试验中，12周以后阶段称为维持治疗期","options":[{"flag":"A","name":"诱导治疗期"},{"flag":"B","name":"维持治疗期"},{"flag":"C","name":"开始治疗期"},{"flag":"D","name":"治疗进展期"}]},"3067":{"id":3067,"qattrid":47,"type":1,"title":"益赛普®的作用机制是（）","result":"C","content":"益赛普®的作用机制是TNF-α 抑制剂，厂家是三生制药","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-17A及其受体拮抗剂"}]},"3068":{"id":3068,"qattrid":47,"type":1,"title":"类克®的作用机制是（）","result":"C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-17A及其受体拮抗剂"}]},"3069":{"id":3069,"qattrid":47,"type":1,"title":"下列哪个药物不是生物制剂","result":"A","content":"环孢素是系统性用药，不是生物制剂","options":[{"flag":"A","name":"环孢素"},{"flag":"B","name":"依奇珠单抗"},{"flag":"C","name":"益赛普"},{"flag":"D","name":"修美乐"}]},"3070":{"id":3070,"qattrid":50,"type":1,"title":"单克隆抗体没有（）特点","result":"A","content":"单克隆抗体具有结构单一、纯度高、特异性强、少或无血清交叉反应、制备成本低等特点","options":[{"flag":"A","name":"结构复杂，作用点多"},{"flag":"B","name":"纯度高"},{"flag":"C","name":"特异性强"},{"flag":"D","name":"少或无血清交叉反应"}]},"3071":{"id":3071,"qattrid":46,"type":2,"title":"下列叙述错误的是（）","result":"A,D","content":"依奇珠单抗对人IL-17A (KD=1.8 pM)具有较高的结合亲和力，而对其他IL-17家族成员没有较高的结合亲和力；初始剂量是160mg","options":[{"flag":"A","name":"拓咨®特异性作用于银屑病关键性炎症因子IL-17F"},{"flag":"B","name":"拓咨®使得更多患者达到清洁或几乎清洁疗效"},{"flag":"C","name":"拓咨®安全性良好，与依那西普总体TEAEs发生率相当"},{"flag":"D","name":"对于斑块型银屑病患者，拓咨®皮下注射初始剂量为80mg"}]},"3072":{"id":3072,"qattrid":46,"type":1,"title":"拓咨®在国内目前获批治疗斑块型银屑病的日期为：","result":"D","content":"拓咨®在国内目前获批治疗斑块型银屑病的日期为 2019.08.29","options":[{"flag":"A","name":"2017.05.29"},{"flag":"B","name":"2018.08.29"},{"flag":"C","name":"2019.05.29"},{"flag":"D","name":" 2019.08.29"}]},"3073":{"id":3073,"qattrid":46,"type":2,"title":"拓咨®的使用方式不包括：","result":"A,B,D","content":"拓咨是皮下注射","options":[{"flag":"A","name":"口服片剂"},{"flag":"B","name":"口服胶囊"},{"flag":"C","name":"皮下注射药物"},{"flag":"D","name":" 肌注药物"}]},"3074":{"id":3074,"qattrid":51,"type":2,"title":"拓咨®的目前已进行的主要临床研究叫：","result":"A,C","content":"拓咨®的目前已进行的主要临床研究叫UNCOVER 和IXORA","options":[{"flag":"A","name":"Uncover"},{"flag":"B","name":"REVEAL"},{"flag":"C","name":"IXORA"},{"flag":"D","name":" BECOME"}]},"3075":{"id":3075,"qattrid":50,"type":1,"title":"单克隆抗体不具有（）特点","result":"A","content":"单克隆抗体具有结构单一、纯度高、特异性强、少或无血清交叉反应、制备成本低等特点","options":[{"flag":"A","name":"结构复杂"},{"flag":"B","name":"纯度高"},{"flag":"C","name":"特异性强"},{"flag":"D","name":"少或无血清交叉反应"}]},"3076":{"id":3076,"qattrid":47,"type":1,"title":"以下治疗银屑病获批进入中国时间最早的是：","result":"D","content":" 益赛普是治疗银屑病获批进入中国时间最早","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"依那西普"},{"flag":"D","name":" 益赛普"}]},"3077":{"id":3077,"qattrid":50,"type":2,"title":"一个合格的单抗需要考虑：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"免疫原性"},{"flag":"B","name":"结合抗原能力"},{"flag":"C","name":"结构稳定"},{"flag":"D","name":"半衰期"}]},"3078":{"id":3078,"qattrid":46,"type":1,"title":"拓咨®的亲和力大约是可善挺®的（）倍。","result":"D","content":"依奇珠单抗的亲和力大约是司库奇尤单抗的100倍","options":[{"flag":"A","name":"10"},{"flag":"B","name":"30"},{"flag":"C","name":"50"},{"flag":"D","name":"100"}]},"3079":{"id":3079,"qattrid":50,"type":1,"title":"根据单克隆抗体的来源不同，可分为____类型：","result":"B","content":"根据单克隆抗体的来源不同，可分为4种，鼠源抗体、嵌合体抗体、人源化抗体和人源抗体","options":[{"flag":"A","name":"3"},{"flag":"B","name":"4"},{"flag":"C","name":"5"},{"flag":"D","name":"6"}]},"3080":{"id":3080,"qattrid":51,"type":1,"title":"拓咨®没有开展针对哪个部位的治疗效果的临床研究？","result":"D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"头皮"},{"flag":"B","name":"生殖器"},{"flag":"C","name":"指甲"},{"flag":"D","name":" 口腔"}]},"3081":{"id":3081,"qattrid":47,"type":2,"title":"银屑病先前非生物制剂的治疗包括： ","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"糖皮质激素"},{"flag":"B","name":"环孢素"},{"flag":"C","name":"维A酸"},{"flag":"D","name":"PUVA"}]},"3082":{"id":3082,"qattrid":47,"type":1,"title":"喜达诺®的作用机制是（）","result":"D","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂，厂家是西安杨森","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-12/23拮抗剂"}]},"3083":{"id":3083,"qattrid":47,"type":1,"title":"喜达诺®的厂家是（）","result":"D","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂，厂家是西安杨森","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"辉瑞"},{"flag":"D","name":"西安杨森"}]},"3084":{"id":3084,"qattrid":47,"type":1,"title":"修美乐®适用于什么程度的斑块状银屑病患者","result":"C","content":"修美乐®适用中度至重度的斑块状银屑病患者","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"轻度至中度"},{"flag":"C","name":"中度至重度"},{"flag":"D","name":"仅重度"}]},"3085":{"id":3085,"qattrid":47,"type":2,"title":"下列哪个药物不是IL-12/23抑制剂","result":"B,C,D","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":"恩利®"}]},"3086":{"id":3086,"qattrid":47,"type":1,"title":"下列哪个药物厂家是辉瑞","result":"D","content":"恩利®/依那西普厂家是辉瑞","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":"恩利®"}]},"3087":{"id":3087,"qattrid":47,"type":2,"title":"中国已获批银屑病适应症的药物是（）","result":"A,B,C","content":"中国未获批银屑病适应症的药物是恩利®（依那西普）","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":"恩利®"}]},"3088":{"id":3088,"qattrid":47,"type":1,"title":"类克®的作用机制是（）","result":"C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-17A及其受体拮抗剂"}]},"3089":{"id":3089,"qattrid":47,"type":1,"title":"类克®的厂家是（）","result":"D","content":"类克/英夫利昔单抗的厂家是西安杨森","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"辉瑞"},{"flag":"D","name":"西安杨森"}]},"3090":{"id":3090,"qattrid":47,"type":1,"title":"益赛普®的用法用量是（）","result":"D","content":"益赛普®的用法用量是每次25mg，每周2次","options":[{"flag":"A","name":"每次12.5mg，每周1次"},{"flag":"B","name":"每次12.5mg，每周2次"},{"flag":"C","name":"每次25mg，每周1次"},{"flag":"D","name":"每次25mg，每周2次"}]},"3091":{"id":3091,"qattrid":47,"type":2,"title":"下列厂家、药物、作用机制对应不正确的是","result":"B,C,D","content":"可善挺（司库奇尤单抗）属于IL-17A拮抗剂，类克/英夫利昔单抗的厂家是西安杨森，恩利®/依那西普厂家是辉瑞","options":[{"flag":"A","name":"辉瑞 甲氨蝶呤 叶酸还原酶抑制剂"},{"flag":"B","name":"诺华 可善挺® IL-12/23抑制剂"},{"flag":"C","name":"艾伯维 类克®TNF-α抑制剂"},{"flag":"D","name":"西安杨森 恩利®TNF-α抑制剂"}]},"3092":{"id":3092,"qattrid":46,"type":1,"title":"拓咨®注射笔特点不包括：","result":"B","content":"隐藏针头","options":[{"flag":"A","name":"有专利"},{"flag":"B","name":"开放式针头"},{"flag":"C","name":"简单三步"},{"flag":"D","name":"方便易用"}]},"3093":{"id":3093,"qattrid":48,"type":2,"title":"以下哪项是拓咨®目标患者：","result":"B,C,D","content":"对生物制剂（主要TNF-α）效果不满意的患者；未经生物制剂治疗（包括未经系统治疗或系统治疗失败）","options":[{"flag":"A","name":"对生物制剂（主要TNF-α）效果满意的患者"},{"flag":"B","name":"对生物制剂（主要TNF-α）效果不满意的患者"},{"flag":"C","name":"未经生物制剂治疗（未经系统治疗）"},{"flag":"D","name":" 未经生物制剂治疗（系统治疗失败）"}]},"3094":{"id":3094,"qattrid":48,"type":1,"title":"拓咨®通过多项全球临床研究证实，除了哪一项其他都可有效帮助患者实现","result":"C","content":"拓咨®快速起效、全面清除、长期稳定","options":[{"flag":"A","name":"快速起效"},{"flag":"B","name":"全面清除"},{"flag":"C","name":"完全治愈"},{"flag":"D","name":" 长期稳定"}]},"3095":{"id":3095,"qattrid":49,"type":1,"title":"斑块型银屑病以外的类型约占银屑病所有患者发病率的______。","result":"B","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":"5%以下"},{"flag":"B","name":"10%以下"},{"flag":"C","name":"20%以下"},{"flag":"D","name":" 30%以下"}]},"3096":{"id":3096,"qattrid":48,"type":2,"title":"下列哪几项是常用的外用药物：","result":"A,B,C","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂；无抗真菌药","options":[{"flag":"A","name":"糖皮质激素"},{"flag":"B","name":"维生素D3衍生物"},{"flag":"C","name":"保湿剂"},{"flag":"D","name":" 抗真菌药"}]},"3097":{"id":3097,"qattrid":51,"type":1,"title":"拓咨®治疗_______周即可使近9成患者达到PASI 90。","result":"A","content":"治疗16周，9成患者可达PASI 90，4成患者可达PASI 100","options":[{"flag":"A","name":"16"},{"flag":"B","name":"26"},{"flag":"C","name":"32"},{"flag":"D","name":"40"}]},"3098":{"id":3098,"qattrid":51,"type":1,"title":"拓咨®治疗_____周可使4成患者达到全面清除。","result":"A","content":"治疗16周，9成患者可达PASI 90，4成患者可达PASI 101","options":[{"flag":"A","name":"16"},{"flag":"B","name":"26"},{"flag":"C","name":"32"},{"flag":"D","name":"40"}]},"3099":{"id":3099,"qattrid":51,"type":1,"title":"拓咨®治疗治疗2周，超过______患者即可实现PASI 50。","result":"C","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":"0.3"},{"flag":"B","name":"0.4"},{"flag":"C","name":"0.5"},{"flag":"D","name":"0.7"}]},"3100":{"id":3100,"qattrid":51,"type":1,"title":"拓咨®关键性III期临床试验没有：","result":"C","content":"UNCOVER1,2,3是拓咨®关键性III期临床试验","options":[{"flag":"A","name":"UNCOVER-1"},{"flag":"B","name":"UNCOVER-2"},{"flag":"C","name":"IXORA-P"},{"flag":"D","name":" UNCOVER-3"}]},"3101":{"id":3101,"qattrid":51,"type":1,"title":"参与拓咨®实验的人群中，先前进行过的治疗没有:","result":"D","content":"没有放疗","options":[{"flag":"A","name":"非生物制剂的系统治疗"},{"flag":"B","name":"生物制剂"},{"flag":"C","name":"光疗"},{"flag":"D","name":"放疗"}]},"3102":{"id":3102,"qattrid":46,"type":1,"title":"拓咨®第2周推荐剂量是：","result":"A","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":"120mg"},{"flag":"C","name":"160mg"},{"flag":"D","name":"240mg"}]},"3103":{"id":3103,"qattrid":48,"type":1,"title":"拓咨®的推广的主要关键信息为：","result":"A","content":"拓咨®快速起效、全面清除、长期稳定","options":[{"flag":"A","name":"快速起效，全面清除，长期稳定"},{"flag":"B","name":"快速起效，全面获益，长期稳定"},{"flag":"C","name":"全面清除，完全治愈，短期稳定"},{"flag":"D","name":"安全有效，百分获益，长期稳定"}]},"3104":{"id":3104,"qattrid":51,"type":1,"title":"UNCOVER-2研究显示，拓咨®治疗1周即可见：","result":"C","content":"UNCOVER-2研究显示，拓咨®治疗1周即可见皮损以及瘙痒症状改善","options":[{"flag":"A","name":"仅皮损改善"},{"flag":"B","name":"仅瘙痒改善"},{"flag":"C","name":"皮损以及瘙痒症状改善"},{"flag":"D","name":" 超过1/2患者实现PASI 50"}]},"3105":{"id":3105,"qattrid":51,"type":1,"title":"UNCOVER系列研究显示，拓咨®治疗几周接近1/4患者可实现PASI 75","result":"B","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"3106":{"id":3106,"qattrid":51,"type":1,"title":"下列哪项试验在中重度斑块型银屑病中对拓咨®和喜达诺®治疗进行研究？","result":"C","content":"IXORA-S比较IXE和喜达诺/乌司奴单抗在中重度斑块型银屑病患者中的有效性和安全性","options":[{"flag":"A","name":"UNCOVER-3"},{"flag":"B","name":"IXORA-P"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":"IXORA-R"}]},"3107":{"id":3107,"qattrid":51,"type":1,"title":"对于UNCOVER-3临床试验一直接受依奇珠单抗治疗最长达_____年的患者，达到PASI 100的比例超过60%。","result":"D","content":"拓咨® 治疗4年，67%患者实现皮损全面清除（PASI 100）","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"3108":{"id":3108,"qattrid":51,"type":1,"title":"综合临床试验中拓咨®疗效显著优于：","result":"D","content":"相较于国内已上市的系统用药，均可实现更高的皮损清除率","options":[{"flag":"A","name":"MTX"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"乌丝奴单抗"},{"flag":"D","name":" 以上都是"}]},"3109":{"id":3109,"qattrid":51,"type":1,"title":"拓咨®治疗12周时，超过_____患者实现头皮部位全面清除。","result":"D","content":"75%患者实现头皮部位全面清除","options":[{"flag":"A","name":"0.4"},{"flag":"B","name":"0.5"},{"flag":"C","name":"0.6"},{"flag":"D","name":"0.7"}]},"3110":{"id":3110,"qattrid":51,"type":2,"title":"拓咨®最常见的注射部位反应不包括是： ","result":"B,D","content":"说明书中拓咨®最常见的注射部位反应是红疹和疼痛","options":[{"flag":"A","name":"红疹"},{"flag":"B","name":"出血"},{"flag":"C","name":"疼痛"},{"flag":"D","name":" 大片红斑"}]},"3111":{"id":3111,"qattrid":49,"type":2,"title":"不是用于评估银屑病活性和记录患者对治疗的临床应答的两种最常用工具为：","result":"C,D","content":"用于评估银屑病活性和记录患者对治疗的临床应答的两种最常用工具为sPGA和PASI","options":[{"flag":"A","name":"sPGA"},{"flag":"B","name":"PASI"},{"flag":"C","name":"VAS"},{"flag":"D","name":"UBA"}]},"3112":{"id":3112,"qattrid":46,"type":2,"title":"以下关于拓咨®的说法正确的是：","result":"A,B,D","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"化学名为依奇珠单抗，礼来公司产品"},{"flag":"B","name":"全球第二个上市的IL-17A抑制剂，第一个IL-17A抑制剂为司库奇尤单抗"},{"flag":"C","name":"诱导治疗期为三个月，第一个月需注射三次，每次1针"},{"flag":"D","name":" 维持治疗期每月注射1次，每次1针"}]},"3113":{"id":3113,"qattrid":46,"type":2,"title":"以下关于拓咨®的注射方法正确的是：","result":"A,B,C","content":"拓咨®的注射前需要解锁","options":[{"flag":"A","name":"只需三步"},{"flag":"B","name":"步骤简单，方便易用，患者可自行在家注射"},{"flag":"C","name":"不要在皮损初注射，且需轮换注射部位，避免始终在同一部位注射"},{"flag":"D","name":" 不需要解锁"}]},"3114":{"id":3114,"qattrid":48,"type":1,"title":"当前银屑病治疗现状是中国的治疗目标停留在：","result":"B","content":"中国银屑病治疗目标仍停留在PASI75","options":[{"flag":"A","name":"PASI 50"},{"flag":"B","name":"PASI 75"},{"flag":"C","name":"PASI 90"},{"flag":"D","name":" 以上都不对"}]},"3115":{"id":3115,"qattrid":49,"type":1,"title":"以下PASI对应治疗终点，描述错误的是：","result":"A","content":"PASI 50: 有效","options":[{"flag":"A","name":"PASI 50：无效"},{"flag":"B","name":"PASI 75：控制"},{"flag":"C","name":"PASI 90：接近清除"},{"flag":"D","name":" PASI 100：完全清除"}]},"3116":{"id":3116,"qattrid":48,"type":1,"title":"以下哪一个不是当前中国银屑病治疗现状目标：","result":"B","content":"医生不追求快速起效，因为他们认为银屑病没有不可逆的身体损害","options":[{"flag":"A","name":"控制红斑、鳞屑和单个斑块皮损的厚度"},{"flag":"B","name":"初步快速控制疾病"},{"flag":"C","name":"控制皮损面积"},{"flag":"D","name":" 尽可能避免不良反应"}]},"3117":{"id":3117,"qattrid":48,"type":1,"title":"目前银屑病治疗手段的选择主要是基于_______。","result":"D","content":"目前治疗手段的选择是基于疾病的严重程度，并遵循序贯，联合，替换疗法","options":[{"flag":"A","name":"患者意愿"},{"flag":"B","name":"医院水平"},{"flag":"C","name":"经济因素"},{"flag":"D","name":" 疾病严重程度"}]},"3118":{"id":3118,"qattrid":51,"type":1,"title":"IXORA-S研究12周时的依奇珠单抗较乌丝奴单抗疗效在哪几项更好：","result":"A","content":"均优于","options":[{"flag":"A","name":"以下三项全面占优"},{"flag":"B","name":"PASI 90"},{"flag":"C","name":"PASI 75"},{"flag":"D","name":" PASI 100"}]},"3119":{"id":3119,"qattrid":50,"type":1,"title":"下列说法错误的是：","result":"A","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"拓咨®是一种人源化IgG1单克隆抗体，对白介素-17A（IL-17A）有中和活性"},{"flag":"B","name":"IL-17A、IL-17C和IL-17F在银屑病病灶部位表达升高"},{"flag":"C","name":"IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用"},{"flag":"D","name":"拓咨®选择性结合IL-17A细胞因子，抑制其与IL-17受体相互作用，从而抑制促炎细胞因子和趋化因子释放"}]},"3120":{"id":3120,"qattrid":51,"type":2,"title":"下列关于关键性三期实验入组患者标准错误的是： ","result":"A,D","content":"患者入组标准：（1）年龄≥18岁（2）基线之前诊断为慢性斑块型银屑病≥6个月（3）筛查和基线时BSA≥10%（4）临床诊断严重程度至少为中度sPGA(6分制)≥3(5)银屑病面积和严重程度指数PASI≥12（6）作为光疗或系统治疗的候选者，或两者兼有。之前接受生物制剂治疗的患者中，接受过ETN治疗的患者在UNCOVER-2和UNCOVER-3中被排除在外","options":[{"flag":"A","name":"临床诊断严重程度为重度"},{"flag":"B","name":"筛查和基线时BSA≥10%"},{"flag":"C","name":"年龄≥18岁"},{"flag":"D","name":" 之前接受过依那西普治疗的患者"}]},"3121":{"id":3121,"qattrid":51,"type":2,"title":"拓咨®对以下哪些难治部位的临床试验证明有效：","result":"A,B,C,D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"头皮"},{"flag":"B","name":"掌跖"},{"flag":"C","name":"指甲"},{"flag":"D","name":"生殖器"}]},"3122":{"id":3122,"qattrid":51,"type":1,"title":"多项研究显示，拓咨®可实现对（）等难治部位皮损的完全清除。","result":"A","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"生殖器、掌跖、头皮和指甲"},{"flag":"B","name":"头皮和指甲"},{"flag":"C","name":"颈部、掌跖、头皮和指甲"},{"flag":"D","name":" 生殖器和指甲"}]},"3123":{"id":3123,"qattrid":48,"type":1,"title":"以下哪个是拓咨®的愿景","result":"D","content":" 愿景是成为治疗中度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂","options":[{"flag":"A","name":"成为治疗中度至重度(m/s)斑块型银屑病(PsO)的主要处方生物制剂"},{"flag":"B","name":"成为治疗轻度至重度(m/s)斑块型银屑病(PsO)的主要处方生物制剂"},{"flag":"C","name":"成为治疗轻度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂"},{"flag":"D","name":" 成为治疗中度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂"}]},"3124":{"id":3124,"qattrid":48,"type":1,"title":"以下那一项关键词不属于拓咨®品牌定位：","result":"D","content":"D不在推广定位里","options":[{"flag":"A","name":"更能快速"},{"flag":"B","name":"更能全面"},{"flag":"C","name":"亲密联系"},{"flag":"D","name":" 更加安全"}]},"3125":{"id":3125,"qattrid":48,"type":1,"title":"中国银屑病市场销售额于2018年第三季度已达_____亿人民币","result":"B","content":"中国银屑病市场销售额于2018年第三季度已达5亿人民币","options":[{"flag":"A","name":"1"},{"flag":"B","name":"5"},{"flag":"C","name":"10"},{"flag":"D","name":"20"}]},"3126":{"id":3126,"qattrid":48,"type":1,"title":"以下哪项不是未来十年中国银屑病生物制剂市场预计快速增长的理由","result":"B","content":"2018年生物制剂作为治疗中重度银屑病推荐治疗手段被写入指南","options":[{"flag":"A","name":"患者对疾病和治疗手段的认知与观念被提高"},{"flag":"B","name":"2016年生物制剂作为治疗中重度银屑病推荐治疗手段被写入指南"},{"flag":"C","name":"提高的支付能力，改进的准入和医保报销政策"},{"flag":"D","name":"潜在患者数增加"}]},"3127":{"id":3127,"qattrid":51,"type":1,"title":"UNCOVER 2,3 前12周拓咨®主要和__________做头对头研究：","result":"B","content":"临床试验UNCOV\u0002ER-2和UNCOVER-3分为IXE(依奇珠单抗)、ETN（依那西普）和PBO(安慰剂组)， 前12周拓咨®主要和依那西普做头对头研究","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"恩利®"},{"flag":"C","name":"喜达诺®"},{"flag":"D","name":" 可善挺®"}]},"3128":{"id":3128,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，拓咨®治疗_____周后，达到PASI 75患者比例为90%","result":"C","content":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 75患者比例为90%","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"12"},{"flag":"D","name":"24"}]},"3129":{"id":3129,"qattrid":48,"type":1,"title":"MAT3Q2018显示，易赛普占中国银屑病生物制剂市场份额为：","result":"D","content":"易赛普占中国银屑病生物制剂市场67%份额MAT3Q2018","options":[{"flag":"A","name":"0.27"},{"flag":"B","name":"0.47"},{"flag":"C","name":"0.57"},{"flag":"D","name":"0.67"}]},"3130":{"id":3130,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，依那西普治疗12周后，达到PASI 75患者比例为（）","result":"A","content":"在UNCOVER-2研究中，依那西普治疗12周后，达到PASI 75患者比例为42%","options":[{"flag":"A","name":"0.42"},{"flag":"B","name":"0.58"},{"flag":"C","name":"0.72"},{"flag":"D","name":"0.9"}]},"3131":{"id":3131,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 100患者比例为（）","result":"D","content":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 100患者比例为40%","options":[{"flag":"A","name":"0.05"},{"flag":"B","name":"0.15"},{"flag":"C","name":"0.25"},{"flag":"D","name":"0.4"}]},"3132":{"id":3132,"qattrid":51,"type":1,"title":"以下哪个研究不是拓咨®的临床研究。","result":"B","content":"拓咨的临床研究为UNCOVER和IXORA","options":[{"flag":"A","name":"IXORA-S"},{"flag":"B","name":"REVEAL"},{"flag":"C","name":"IXORA-R"},{"flag":"D","name":" UNCOVER"}]},"3133":{"id":3133,"qattrid":51,"type":1,"title":"UNCOVER-J是拓咨®在________的主要研究名称","result":"C","content":" UNCOVER-J 是拓咨®的亚洲日本的主要研究名称","options":[{"flag":"A","name":"美国"},{"flag":"B","name":"中国"},{"flag":"C","name":"日本"},{"flag":"D","name":" 英国"}]},"3134":{"id":3134,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病在生殖器、掌跖、头皮和指甲等难治部位也可获得:","result":"D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"有效清除（PASI 50）"},{"flag":"B","name":"控制清除（PASI 75）"},{"flag":"C","name":"接近全面清除（PASI 90）"},{"flag":"D","name":" 全面清除（PASI 100）"}]},"3135":{"id":3135,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病4年长期治疗期间，_______特殊不良反应事件发生率。","result":"C","content":"拓咨®治疗银屑病4年长期治疗期间，不增加特殊不良反应事件发生率","options":[{"flag":"A","name":"轻微增加"},{"flag":"B","name":"增加"},{"flag":"C","name":"不增加"},{"flag":"D","name":"降低"}]},"3136":{"id":3136,"qattrid":51,"type":1,"title":"UNCOVER-1,2显示，拓咨®治疗银屑病诱导治疗期获得高皮损清除率的患者，疗效可：","result":"D","content":"疗效持续维持","options":[{"flag":"A","name":"间歇性维持"},{"flag":"B","name":"波动维持"},{"flag":"C","name":"不断增高"},{"flag":"D","name":"持续维持"}]},"3137":{"id":3137,"qattrid":51,"type":1,"title":"在诱导治疗期，拓咨®的相关不良反应比依那西普：","result":"B","content":"在诱导治疗期，拓咨®的相关不良反应与依那西普相似","options":[{"flag":"A","name":"低"},{"flag":"B","name":"相似"},{"flag":"C","name":"高"},{"flag":"D","name":" 显著降低"}]},"3138":{"id":3138,"qattrid":51,"type":2,"title":"关于拓咨®安全性描述错误的是：","result":"A,B,C","content":"拓咨安全性良好，与依那西普总体TEAEs发生率相当。治疗期间最常见的不良反应是注射部位不良反应。TEAEs多为轻至中度，极少导致治疗中断","options":[{"flag":"A","name":"与依那西普相比，拓咨®治疗组TEAEs发生率显著降低"},{"flag":"B","name":"拓咨®的TEAEs多为中重度，常导致治疗中断"},{"flag":"C","name":"最常见导致拓咨®治疗中断的不良反应是念珠菌感染、鼻咽炎、上呼吸道感染"},{"flag":"D","name":"  拓咨®特别关注的不良事件是主要心血管不良事件、克罗恩病、恶性肿瘤等"}]},"3139":{"id":3139,"qattrid":48,"type":2,"title":"拓咨®的主要推广信息中包括：","result":"A,B,C","content":"净界可达不是","options":[{"flag":"A","name":"净化论"},{"flag":"B","name":"银屑病治疗新主张"},{"flag":"C","name":"快速起效，全面清除，长期稳定"},{"flag":"D","name":"净界可达"}]},"3140":{"id":3140,"qattrid":48,"type":1,"title":"关于斑块型银屑病，下列哪项描述是错误的","result":"B","content":"患者的治疗目标高于医生","options":[{"flag":"A","name":"斑块型银屑病最为常见，约占90%"},{"flag":"B","name":"当前中国医生对治疗目标的期待比患者高"},{"flag":"C","name":"皮损反复发作，多数冬重夏轻"},{"flag":"D","name":" 进展期可有“同形反应”"}]},"3141":{"id":3141,"qattrid":51,"type":1,"title":"UNCOVER-1,2,3显示，拓咨®治疗银屑病60周，_____患者发生高效价抗药抗体：","result":"B","content":"UNCOVER-1,2,3显示，拓咨®治疗银屑病60周，1.7%患者发生高效价抗药抗体","options":[{"flag":"A","name":"0.001"},{"flag":"B","name":"0.017"},{"flag":"C","name":"0.051"},{"flag":"D","name":"0.097"}]},"3142":{"id":3142,"qattrid":49,"type":2,"title":"以下是银屑病的治疗方法的是： ","result":"A,B,D","content":"手术治疗不是","options":[{"flag":"A","name":"局部治疗"},{"flag":"B","name":"物理治疗"},{"flag":"C","name":"手术治疗"},{"flag":"D","name":" 系统治疗"}]},"3143":{"id":3143,"qattrid":48,"type":2,"title":"下列是外用药物治疗银屑病的优点是： ","result":"A,B,C","content":"优点是药物直接作用于皮损，起效快、使用方便、全身不良反应少。缺点是长期使用可出现局部不良反应，皮损泛发者使用不便，患者依从性差异较大","options":[{"flag":"A","name":"直接作用于皮损"},{"flag":"B","name":"起效快"},{"flag":"C","name":"使用方便"},{"flag":"D","name":" 局部不良反应少"}]},"3144":{"id":3144,"qattrid":47,"type":2,"title":"银屑病常用生物制剂有：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"司库奇尤单抗"},{"flag":"D","name":" 乌丝奴单抗"}]},"3145":{"id":3145,"qattrid":47,"type":1,"title":"司库奇尤单抗的使用方法：","result":"C","content":"可善挺/司库奇尤单抗皮下注射","options":[{"flag":"A","name":"肌肉注射"},{"flag":"B","name":"静脉注射"},{"flag":"C","name":"皮下注射"},{"flag":"D","name":" 口服"}]},"3146":{"id":3146,"qattrid":49,"type":1,"title":"_________评价指标存在局限性是因为没有将银屑病患者生活质量的影响纳入评价：","result":"B","content":"BSA评价指标存在局限性，没有将银屑病患者生活质量的影响纳入评价","options":[{"flag":"A","name":"DLQI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"SF-36"},{"flag":"D","name":" EQ-5D"}]},"3147":{"id":3147,"qattrid":51,"type":1,"title":"对于UNCOVER-3临床试验一直接受依奇珠单抗治疗的患者（0至60周），至少几成多的患者达到sPGA 0/1","result":"C","content":"对于一直接受依奇珠单抗治疗的患者（0至60周），至少73%的患者达到sPGA 0/1","options":[{"flag":"A","name":"5"},{"flag":"B","name":"6"},{"flag":"C","name":"7"},{"flag":"D","name":"9"}]},"3148":{"id":3148,"qattrid":51,"type":1,"title":"UNCOVER-3临床试验对于前12周安慰剂组，患者会在第12周时开始接受_________mg依奇珠单抗治疗，后每4周1次给药。","result":"B","content":"UNCOVER-3临床试验对于前面安慰剂组，患者会在第12周时开始接受80mg依奇珠单抗治疗，后每4周80mg给药。","options":[{"flag":"A","name":"40"},{"flag":"B","name":"80"},{"flag":"C","name":"160"},{"flag":"D","name":"240"}]},"3149":{"id":3149,"qattrid":51,"type":2,"title":"以下哪几项不是拓咨®的关键III期临床试验：","result":"B,C,D","content":"UNCOVER1,2.3是拓咨®的关键III期临床试验","options":[{"flag":"A","name":"UNCOVER-3"},{"flag":"B","name":"IXORA-P"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":" IXORA-R"}]},"3150":{"id":3150,"qattrid":49,"type":1,"title":"下列关于系统治疗，说法错误的是：","result":"A","content":"甲氨蝶呤对肝肾功能有影响","options":[{"flag":"A","name":"甲氨蝶呤常推荐剂量为5-25mg/周，常有胃肠道反应，对肝肾功能无影响。"},{"flag":"B","name":"甲氨喋呤对各型银屑病均有较好的疗效，对甲病和掌跖部位银屑病也有疗效。"},{"flag":"C","name":"环孢素的毒副作用主要有肾毒性和高血压"},{"flag":"D","name":" 维A酸常用推荐剂量为0.5-1.0mg/kg/d，育龄期妇女、老年、儿童慎用"}]},"3151":{"id":3151,"qattrid":49,"type":1,"title":"下列哪项属于银屑病的系统治疗：","result":"C","content":"环孢素属于系统治疗药物","options":[{"flag":"A","name":"复方卡泊三醇"},{"flag":"B","name":"他扎罗汀"},{"flag":"C","name":"环孢素"},{"flag":"D","name":" PUVA"}]},"3152":{"id":3152,"qattrid":50,"type":1,"title":"下列哪一项是拓咨® (依奇珠单抗)的作用靶点：","result":"C","content":"IL-17A","options":[{"flag":"A","name":"TNF-α"},{"flag":"B","name":"IL-23"},{"flag":"C","name":"IL-17A"},{"flag":"D","name":" IL-17A受体"}]},"3153":{"id":3153,"qattrid":46,"type":1,"title":"关于拓咨®(依奇珠单抗)的用法用量，下列说法正确的是：","result":"D","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"初始剂量80mg，前4周80mg Q1W。维持剂量为80mg Q2W"},{"flag":"B","name":"初始剂量80mg，前4周80mg Q2W。维持剂量为80mg Q4W"},{"flag":"C","name":"初始剂量160mg，前12周 80mg Q1W。维持剂量为80mg Q2W"},{"flag":"D","name":" 初始剂量160mg，前12周 80mg Q2W。维持剂量为80mg Q4W"}]},"3154":{"id":3154,"qattrid":46,"type":1,"title":"拓咨®说明书里规定贮藏的要求是：","result":"D","content":" 拓咨®说明书里规定贮藏的要求是冷藏  2℃~8℃","options":[{"flag":"A","name":"冷冻  -5℃~0℃"},{"flag":"B","name":"冷冻  -3℃~0℃"},{"flag":"C","name":"冷藏  0℃~5℃"},{"flag":"D","name":" 冷藏  2℃~8℃"}]},"3155":{"id":3155,"qattrid":47,"type":1,"title":"拓咨®首月的注射次数相较于可善挺®：","result":"A","content":"拓咨®首月的注射次数相较于可善挺®更少","options":[{"flag":"A","name":"更少"},{"flag":"B","name":"一样"},{"flag":"C","name":"更多"},{"flag":"D","name":" 个体化因人而异"}]},"3156":{"id":3156,"qattrid":46,"type":1,"title":"拓咨®说明书里老年人群清除率与65岁以下患者清除率：","result":"B","content":"拓咨®说明书里老年人群清除率与65岁以下患者清除率相似","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"相似"},{"flag":"C","name":"更高"},{"flag":"D","name":" 个体化因人而异"}]},"3157":{"id":3157,"qattrid":46,"type":1,"title":"拓咨®说明书里关于给药方法不正确的是：","result":"D","content":"需要医护人员指导适当培训","options":[{"flag":"A","name":"皮下注射"},{"flag":"B","name":"轮换注射部位"},{"flag":"C","name":"不得剧烈摇晃"},{"flag":"D","name":"未培训的患者也可以自行注射"}]},"3158":{"id":3158,"qattrid":46,"type":2,"title":"拓咨®说明书介绍其对以下哪些患者有效：","result":"A,B,C,D","content":"说明书内容","options":[{"flag":"A","name":"未经系统治疗"},{"flag":"B","name":"生物制剂经治"},{"flag":"C","name":"抗TNF经治"},{"flag":"D","name":"生物制剂治疗失败"}]},"3159":{"id":3159,"qattrid":46,"type":2,"title":"拓咨®说明书里其与感染发生率有关，主要有以下：","result":"A,B,C","content":"拓咨®在安全性研究中发现长期治疗，结核再激活的有0例","options":[{"flag":"A","name":"上呼吸道感染"},{"flag":"B","name":"结膜炎"},{"flag":"C","name":"口腔念珠菌病"},{"flag":"D","name":" 结核感染"}]},"3160":{"id":3160,"qattrid":46,"type":1,"title":"拓咨®说明书综合分析结果，皮下注射后的平均生物利用度为。","result":"D","content":"拓咨®说明书综合分析结果，皮下注射后的平均生物利用度为54%-90%","options":[{"flag":"A","name":"5%-25%"},{"flag":"B","name":"25%-53%"},{"flag":"C","name":"54%-70%"},{"flag":"D","name":"54%-90%"}]},"3161":{"id":3161,"qattrid":51,"type":1,"title":"拓咨®说明书里介绍接受52周治疗的银屑病关节炎患者，大约多少产生了ADA：","result":"B","content":"11%产生了ADA","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.11"},{"flag":"C","name":"0.21"},{"flag":"D","name":"0.29"}]},"3162":{"id":3162,"qattrid":49,"type":1,"title":"银屑病的治疗手段不包括：","result":"C","content":"激光治疗不是，光疗是","options":[{"flag":"A","name":"局部治疗"},{"flag":"B","name":"系统性治疗"},{"flag":"C","name":"激光治疗"},{"flag":"D","name":" 日间治疗中心"}]},"3163":{"id":3163,"qattrid":46,"type":1,"title":"开具生物制剂处方前的特别注意事项没有：","result":"C","content":"开具生物制剂处方前的特别注意事项：妊娠，癌症史（实体瘤、淋巴组织增生性疾病、血液系统恶性肿瘤），重度感染、慢性感染、TB、HIV、HBV/HCV，3级或4级充血性心力衰竭，炎症性肠病","options":[{"flag":"A","name":"妊娠"},{"flag":"B","name":"癌症史"},{"flag":"C","name":"上呼吸道感染"},{"flag":"D","name":" 结核感染"}]},"3164":{"id":3164,"qattrid":51,"type":1,"title":"拓咨®(依奇珠单抗)起效快，达到PASI 50中位时间为：","result":"A","content":"拓咨®(依奇珠单抗)起效快，达到PASI 50中位时间为2周","options":[{"flag":"A","name":"2周"},{"flag":"B","name":"3周"},{"flag":"C","name":"4周"},{"flag":"D","name":" 5周"}]},"3165":{"id":3165,"qattrid":46,"type":1,"title":"建议妊娠_____周以上、患有银屑病、并接受过生物疗法的母亲，在婴儿6个月之前不应接种任何活疫苗（比如接种轮状疫苗和卡介苗）：","result":"C","content":"建议妊娠16周以上、患有银屑病、并接受过生物疗法的母亲，在婴儿6个月之前不应接种任何活疫苗（比如接种轮状疫苗和卡介苗）","options":[{"flag":"A","name":"2"},{"flag":"B","name":"8"},{"flag":"C","name":"16"},{"flag":"D","name":"30"}]},"3166":{"id":3166,"qattrid":46,"type":1,"title":"拓咨®治疗前_____筛查结核感染：","result":"C","content":"需要进行结核筛查","options":[{"flag":"A","name":"不需要"},{"flag":"B","name":"有条件进行"},{"flag":"C","name":"需要"},{"flag":"D","name":" 以上都不对"}]},"3167":{"id":3167,"qattrid":50,"type":2,"title":"拓咨®是IgG4单抗，不具有：","result":"A,D","content":"lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少；拓咨17次，可善挺32次","options":[{"flag":"A","name":"更多细胞毒性"},{"flag":"B","name":"更少细胞毒性"},{"flag":"C","name":"更高亲和力"},{"flag":"D","name":"比可善挺®更多的注射次数"}]},"3168":{"id":3168,"qattrid":46,"type":1,"title":"拓咨®正常推荐使用下，一年需注射几次：","result":"B","content":"拓咨17次，可善挺32次","options":[{"flag":"A","name":"10"},{"flag":"B","name":"17"},{"flag":"C","name":"28"},{"flag":"D","name":"32"}]},"3169":{"id":3169,"qattrid":47,"type":1,"title":"下列关于TNF抑制剂说法正确的是:","result":"C","content":"恩利® 是TNF受体-lgG融合蛋白，皮下注射","options":[{"flag":"A","name":"修美乐® 是嵌合性单克隆抗体，皮下注射"},{"flag":"B","name":"类克® 是嵌合性单克隆抗体，皮下注射"},{"flag":"C","name":"恩利® 是TNF受体-lgG融合蛋白，皮下注射"},{"flag":"D","name":" 益赛普® 是TNF受体-lgG融合蛋白，静脉输"}]},"3170":{"id":3170,"qattrid":47,"type":1,"title":"下列关于TNF抑制剂疗效和安全性说法正确的是：","result":"D","content":" 修美乐®、类克®、恩利® 主要不良反应都有注射部位不良反应","options":[{"flag":"A","name":"修美乐® 短期治疗16周后，PASI 75应答率超过80%"},{"flag":"B","name":"类克® 短期治疗10周后，PASI 90应答率达到70%"},{"flag":"C","name":"恩利® 短期治疗12周后，PASI 75应答率超过80%"},{"flag":"D","name":" 修美乐®、类克®、恩利® 主要不良反应都有注射部位不良反应"}]},"3171":{"id":3171,"qattrid":48,"type":1,"title":"据调查，中国银屑病患者未接受生物制剂治疗的比例约是：","result":"A","content":"中国银屑病患者接受生物制剂治疗的比例是1%","options":[{"flag":"A","name":"0.99"},{"flag":"B","name":"0.95"},{"flag":"C","name":"0.89"},{"flag":"D","name":"0.85"}]},"3172":{"id":3172,"qattrid":49,"type":1,"title":"皮肤是人体第1大器官，约占成人总体重的：","result":"C","content":"皮肤是覆盖在人体表面上的最大器官，约占成人总体重的16％ ","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.1"},{"flag":"C","name":"0.16"},{"flag":"D","name":"0.32"}]},"3173":{"id":3173,"qattrid":49,"type":1,"title":"皮肤分为三层，最里层是？","result":"C","content":"皮肤分为三层，最外层表皮，真皮，最内层皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"3174":{"id":3174,"qattrid":49,"type":1,"title":"表皮_______免疫功能。","result":"C","content":"表皮具有免疫功能","options":[{"flag":"A","name":" 不具有"},{"flag":"B","name":" 具有最强的"},{"flag":"C","name":" 具有"},{"flag":"D","name":" 以上都不对"}]},"3175":{"id":3175,"qattrid":49,"type":1,"title":"外层皮肤最主要是形成了______表皮屏障","result":"B","content":"外层皮肤最主要是形成了物理表皮屏障","options":[{"flag":"A","name":" 机械"},{"flag":"B","name":" 物理"},{"flag":"C","name":" 化学"},{"flag":"D","name":" 生物"}]},"3176":{"id":3176,"qattrid":49,"type":1,"title":"朗格汉斯细胞具有抗原提呈能力，属于：","result":"C","content":"朗格汉斯细胞具有抗原提呈能力，属于皮肤树突状细胞","options":[{"flag":"A","name":"淋巴B细胞"},{"flag":"B","name":"淋巴T细胞"},{"flag":"C","name":"皮肤树突状细胞"},{"flag":"D","name":"以上都不对"}]},"3177":{"id":3177,"qattrid":49,"type":1,"title":"银屑病是主要发生在_____的系统性疾病：","result":"B","content":"银屑病主要发生在皮肤","options":[{"flag":"A","name":"黏膜"},{"flag":"B","name":"皮肤"},{"flag":"C","name":"肠道"},{"flag":"D","name":"关节"}]},"3178":{"id":3178,"qattrid":49,"type":2,"title":"皮肤中的哪几种细胞参与与银屑病密切相关？（多选题）","result":"A,C,D","content":"角质形成细胞、皮肤树突状细胞和T细胞组成皮肤重要的免疫细胞","options":[{"flag":"A","name":" T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":" 树突状细胞"},{"flag":"D","name":" 角质形成细胞"}]},"3179":{"id":3179,"qattrid":49,"type":1,"title":"银屑病皮肤典型症状的出现主要不是因为以下哪个系统出现错误信号？（多选题）","result":"A,B,C","content":"通过以T淋 巴 细 胞 介 导 为主 、多 种 免 疫 细 胞共同参与的免疫反应","options":[{"flag":"A","name":" 血液系统"},{"flag":"B","name":"神经系统"},{"flag":"C","name":" 内分泌系统"},{"flag":"D","name":" 免疫系统"}]},"3180":{"id":3180,"qattrid":49,"type":1,"title":"以下哪一项不属于参与皮肤重要的免疫细胞：","result":"B","content":"角质形成细胞、皮肤树突状细胞和T细胞组成皮肤重要的免疫细胞","options":[{"flag":"A","name":" T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":" 树突状细胞"},{"flag":"D","name":" 角质形成细胞"}]},"3181":{"id":3181,"qattrid":49,"type":1,"title":"银屑病的危害不包括：（多选题）","result":"C,D","content":"银屑病易使患者产生抑郁、焦虑等情感障碍，影响人际交往，增加患者自杀风险及经济负担","options":[{"flag":"A","name":" 产生抑郁"},{"flag":"B","name":"影响人际交往"},{"flag":"C","name":" 对寿命无影响"},{"flag":"D","name":" 对社会经济负担无影响"}]},"3182":{"id":3182,"qattrid":49,"type":2,"title":"银屑病的诊断分型有以下哪几种？（多选题）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 寻常型点滴状"},{"flag":"B","name":" 局限性脓疱型"},{"flag":"C","name":" 泛发性斑块型"},{"flag":"D","name":" 寻常型斑块型"}]},"3183":{"id":3183,"qattrid":49,"type":1,"title":"银屑病的症状不包括以下哪种？","result":"D","content":"皮肤发红","options":[{"flag":"A","name":"皮肤剥脱"},{"flag":"B","name":"干燥"},{"flag":"C","name":"关节疼痛"},{"flag":"D","name":"皮肤发黑"}]},"3184":{"id":3184,"qattrid":49,"type":1,"title":"银屑病发病______性别差异","result":"C","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":" 有，男性多"},{"flag":"B","name":" 有，女性多"},{"flag":"C","name":" 无性别差异"},{"flag":"D","name":" 以上都不对"}]},"3185":{"id":3185,"qattrid":49,"type":1,"title":"研究数据显示，在年龄_____岁的人群中，有第2次上升趋势。","result":"D","content":"发病年龄总体上存在双峰分布。研究数据显示，在年龄不超过39岁的人群中，银屑病发病率有上升趋势。在随后的40-49岁发病率下降。而在60-69岁时，又出现一个发病高峰","options":[{"flag":"A","name":" 15-25"},{"flag":"B","name":" 39-49"},{"flag":"C","name":" 49-59"},{"flag":"D","name":" 60-69"}]},"3186":{"id":3186,"qattrid":48,"type":1,"title":"在中国，受银屑病影响的人数预计可达600万以上，同时________：","result":"D","content":"在中国，受银屑病影响的人数预计可达600万以上，同时逐年增加","options":[{"flag":"A","name":" 逐年下降"},{"flag":"B","name":" 保持不变"},{"flag":"C","name":" 波动变化"},{"flag":"D","name":" 逐年增加"}]},"3187":{"id":3187,"qattrid":49,"type":1,"title":"银屑病斑块确切发病机制是？","result":"D","content":"银屑病的病因及发病机制尚未完全清楚","options":[{"flag":"A","name":" 遗传"},{"flag":"B","name":" 免疫"},{"flag":"C","name":" 环境"},{"flag":"D","name":" 尚未完全清楚"}]},"3188":{"id":3188,"qattrid":49,"type":2,"title":"斑块型银屑病皮疹好发于（多选题）：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 头皮"},{"flag":"B","name":" 肘部"},{"flag":"C","name":" 膝盖 "},{"flag":"D","name":" 背部"}]},"3189":{"id":3189,"qattrid":49,"type":2,"title":"下列关于促进银屑病疾病活动度的因素中，正确的是：（多选题）","result":"B,C,D","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":" 温热天气"},{"flag":"B","name":" 应激"},{"flag":"C","name":" 外伤"},{"flag":"D","name":" 感染"}]},"3190":{"id":3190,"qattrid":49,"type":1,"title":"Th17产生的细胞因子不包括：","result":"D","content":"Th17产生的细胞因子包括：IL-17A、IL-6、IL-21和TNF-α","options":[{"flag":"A","name":" IL-17A"},{"flag":"B","name":" TNF-α"},{"flag":"C","name":" IL-6"},{"flag":"D","name":" IFNγ"}]},"3191":{"id":3191,"qattrid":49,"type":1,"title":"银屑病通常症状没有？","result":"D","content":"银屑病的症状是紧绷","options":[{"flag":"A","name":" 瘙痒"},{"flag":"B","name":" 干燥"},{"flag":"C","name":" 僵硬"},{"flag":"D","name":" 松弛"}]},"3192":{"id":3192,"qattrid":49,"type":1,"title":" 银屑病发生于_______","result":"D","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":" 儿童"},{"flag":"B","name":" 青少年"},{"flag":"C","name":" 成人"},{"flag":"D","name":" 各年龄段"}]},"3193":{"id":3193,"qattrid":49,"type":1,"title":"已发现，与未患银屑病皮肤疾病的人群相比，银屑病患者的以下哪种疾病发生率显著更高？","result":"A","content":"克罗恩病是银屑病共病之一","options":[{"flag":"A","name":" 克罗恩病 "},{"flag":"B","name":" 白化病 "},{"flag":"C","name":" 甲状腺功能亢进 "},{"flag":"D","name":" 甲状腺功能减退"}]},"3194":{"id":3194,"qattrid":49,"type":1,"title":" 银屑病_______遗传倾向","result":"B","content":"银屑病具有遗传倾向","options":[{"flag":"A","name":"不具有"},{"flag":"B","name":"具有"},{"flag":"C","name":"有时有"},{"flag":"D","name":"说不清"}]},"3195":{"id":3195,"qattrid":49,"type":1,"title":"吸烟_______银屑病的患病风险","result":"C","content":"吸烟会增加银屑病的发病风险","options":[{"flag":"A","name":" 降低"},{"flag":"B","name":" 不改变"},{"flag":"C","name":" 增加"},{"flag":"D","name":" 说不清"}]},"3196":{"id":3196,"qattrid":49,"type":1,"title":"在银屑病中起作用的T细胞有不同类型，其中_________发挥了重要作用。","result":"C","content":"在银屑病中起作用的T细胞有不同类型，其中Th17细胞发挥了重要作用","options":[{"flag":"A","name":" Th15"},{"flag":"B","name":" Th16"},{"flag":"C","name":" Th17"},{"flag":"D","name":" 以上都不对"}]},"3197":{"id":3197,"qattrid":49,"type":2,"title":"下面哪几种细胞属于淋巴细胞？（多选题）","result":"C,D","content":"淋巴细胞包括B细胞、T细胞以及NK细胞","options":[{"flag":"A","name":" 白细胞"},{"flag":"B","name":" 角质形成细胞"},{"flag":"C","name":" B细胞"},{"flag":"D","name":" T细胞"}]},"3198":{"id":3198,"qattrid":49,"type":1,"title":"银屑病发病率在世界各地：","result":"C","content":"银屑病发病率在世界各地有显著差异，与种族、地理、环境等因素有关","options":[{"flag":"A","name":" 无差异"},{"flag":"B","name":" 有一些差异"},{"flag":"C","name":" 有显著差异"},{"flag":"D","name":" 说不清"}]},"3199":{"id":3199,"qattrid":49,"type":1,"title":"约占银屑病的9成以上的银屑病类型是_______：","result":"C","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":" 点滴状"},{"flag":"B","name":" 局限性脓疱型"},{"flag":"C","name":" 斑块型"},{"flag":"D","name":" 红皮病型"}]},"3200":{"id":3200,"qattrid":49,"type":2,"title":"银屑病对患者生活质量的影响有：（多选题）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 心情"},{"flag":"B","name":" 娱乐"},{"flag":"C","name":" 两性生活"},{"flag":"D","name":" 工作"}]},"3201":{"id":3201,"qattrid":49,"type":2,"title":"根据流调，银屑病发病率可能与以下哪些有关？（多选题）","result":"A,B,D","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":" 纬度越高发病率越高"},{"flag":"B","name":" 种族"},{"flag":"C","name":" 性别"},{"flag":"D","name":" 环境"}]},"3202":{"id":3202,"qattrid":49,"type":1,"title":"以下哪项不是斑块型银屑病的皮疹特点？","result":"D","content":"进展期可有同形反应","options":[{"flag":"A","name":" 境界清楚"},{"flag":"B","name":"  暗红色斑块或浸润性红斑"},{"flag":"C","name":"  白色、银白色鳞屑"},{"flag":"D","name":"  静止期可有“同形反应”"}]},"3203":{"id":3203,"qattrid":49,"type":1,"title":"与未患该疾病的患者相比，银屑病患者面临的类风关风险为：","result":"C","content":"共病的发病率随着银屑病严重程度的增加而增加","options":[{"flag":"A","name":" 更低"},{"flag":"B","name":"  正常"},{"flag":"C","name":"  更高"},{"flag":"D","name":"  不清楚"}]},"3204":{"id":3204,"qattrid":49,"type":1,"title":"银屑病是一种：","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":" 单纯性皮肤病"},{"flag":"B","name":"  全身性皮肤病"},{"flag":"C","name":"  急性病"},{"flag":"D","name":"  系统性疾病"}]},"3205":{"id":3205,"qattrid":48,"type":2,"title":"以下哪几项是2018中国指南银屑病的治疗目的：（多选题）","result":"A,C","content":"控制和稳定病情，减缓向全身发展的进程；减轻红斑、鳞屑、斑块增厚等皮损加重的症状；避免复发/诱发加重的因素；减少不良反应；提高生活质量","options":[{"flag":"A","name":" 控制和稳定病情"},{"flag":"B","name":"  治愈病情"},{"flag":"C","name":"  提高生活质量"},{"flag":"D","name":"  完全消除不良反应"}]},"3206":{"id":3206,"qattrid":48,"type":2,"title":"以下哪几项是2018中国指南银屑病的治疗原则：（多选题）","result":"A,B,C","content":"治疗原则是正规、安全、个体化","options":[{"flag":"A","name":" 正规"},{"flag":"B","name":"  安全"},{"flag":"C","name":"  个体化"},{"flag":"D","name":"  系统化"}]},"3207":{"id":3207,"qattrid":49,"type":1,"title":"斑块型银屑病“旧皮损无消退，新皮损不断出现”属于：","result":"B","content":"旧皮损无消退，新皮损不断出现属于进行期","options":[{"flag":"A","name":"复发期"},{"flag":"B","name":" 进行期"},{"flag":"C","name":" 静止期"},{"flag":"D","name":" 退行期"}]},"3208":{"id":3208,"qattrid":49,"type":2,"title":"Th17细胞及相关的细胞因子参与了银屑病的发病，主要有？（多选题）","result":"B,C,D","content":"Th17细胞及相关细胞因子（IL-17A、IL-23、TNF-α）参与了银屑病的炎症反应","options":[{"flag":"A","name":" IL-15"},{"flag":"B","name":"  IL-23"},{"flag":"C","name":"  IL-17A"},{"flag":"D","name":"  TNF-α"}]},"3209":{"id":3209,"qattrid":49,"type":1,"title":"以下哪个因素目前研究表明不是导致银屑病的发病的主要因素：","result":"D","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":" 遗传因素"},{"flag":"B","name":"  环境因素"},{"flag":"C","name":"  免疫因素"},{"flag":"D","name":"  神经因素"}]},"3210":{"id":3210,"qattrid":49,"type":2,"title":"_____是目前发现可以导致银屑病加重的因素。（多选题）","result":"B,C,D","content":"酗酒目前没有研究证实","options":[{"flag":"A","name":" 酗酒"},{"flag":"B","name":"  吸烟"},{"flag":"C","name":"  合成抗疟疾药物（SAD）"},{"flag":"D","name":"  非甾体类抗炎药物（NSAI ）"}]},"3211":{"id":3211,"qattrid":49,"type":1,"title":"银屑病患者面临的共病不包括：","result":"D","content":"慢性咽炎不是共病之一","options":[{"flag":"A","name":" 克罗恩病"},{"flag":"B","name":"  溃疡性结肠炎"},{"flag":"C","name":"  心血管疾病"},{"flag":"D","name":"  慢性咽炎"}]},"3212":{"id":3212,"qattrid":49,"type":1,"title":"银屑病的中风风险随着银屑病的加重会？","result":"B","content":"重度银屑病患者在心血管死亡率、心肌梗死、中风等事件上风险增","options":[{"flag":"A","name":" 减少"},{"flag":"B","name":"  增加"},{"flag":"C","name":"  不受影响"},{"flag":"D","name":"  以上都不对"}]},"3213":{"id":3213,"qattrid":49,"type":2,"title":"银屑病会增加患者的_______风险：（多选题）","result":"A,B,C","content":"不是所有癌症的风险都会增加","options":[{"flag":"A","name":" 抑郁"},{"flag":"B","name":"  焦虑"},{"flag":"C","name":"  自杀"},{"flag":"D","name":"  所有癌症"}]},"3214":{"id":3214,"qattrid":49,"type":1,"title":"银屑病的促炎细胞因子_______心血管疾病的炎症通路。","result":"A","content":"促炎细胞因子不仅在银屑病的发病中发挥着重要作用，还连接着心血管疾病的炎症通路","options":[{"flag":"A","name":" 连接"},{"flag":"B","name":"  不连接"},{"flag":"C","name":"  间歇性连接"},{"flag":"D","name":"  以上都不对"}]},"3215":{"id":3215,"qattrid":49,"type":1,"title":"在银屑病的__________中，心理疾病问题更为明显。","result":"C","content":"在银屑病的年轻患者中，心理疾病问题更为明显","options":[{"flag":"A","name":" 老年患者"},{"flag":"B","name":"  中年患者"},{"flag":"C","name":"  年轻患者"},{"flag":"D","name":"  以上都不对"}]},"3216":{"id":3216,"qattrid":49,"type":1,"title":"一般来说，生物疗法______像传统疗法一样对代谢指标产生不良影响:","result":"B","content":"一般来说，生物疗法不会","options":[{"flag":"A","name":" 会"},{"flag":"B","name":"  不会"},{"flag":"C","name":"  无关系"},{"flag":"D","name":"  以上都不对"}]},"3217":{"id":3217,"qattrid":49,"type":1,"title":"重度银屑病患者对女性患者总体寿命：","result":"D","content":"重度银屑病女性患者总体寿命减少4.4年较未患有银屑病女性","options":[{"flag":"A","name":" 增加了4.4年"},{"flag":"B","name":"  无影响"},{"flag":"C","name":"  减少了1.1年"},{"flag":"D","name":"  减少了4.4年"}]},"3218":{"id":3218,"qattrid":49,"type":2,"title":"目前调查确定银屑病一定会出现的症状有？（多选题）","result":"A,C,D","content":"皮肤发红出现概率为86%，其余为100%","options":[{"flag":"A","name":" 瘙痒"},{"flag":"B","name":"  皮肤发红"},{"flag":"C","name":"  斑块型相关疼痛"},{"flag":"D","name":"  外观变化"}]},"3219":{"id":3219,"qattrid":49,"type":1,"title":"银屑病是一种_________共同作用诱发的免疫介导的系统性疾病：","result":"C","content":"银屑病是一种遗传与环境共同作用诱发的免疫介导的慢性、复发性、炎症性、系统性疾病","options":[{"flag":"A","name":" 性别与地理"},{"flag":"B","name":"  遗传与地理"},{"flag":"C","name":"  遗传与环境"},{"flag":"D","name":"  性别与环境"}]},"3220":{"id":3220,"qattrid":49,"type":1,"title":"银屑病严重影响两性关系不体现在___________。","result":"C","content":"银屑病严重影响两性关系：减少对身体亲密接触的渴望，降低自尊和性自我形象，长期关系中对亲密接触回避","options":[{"flag":"A","name":" 减少对身体亲密接触的渴望"},{"flag":"B","name":"  降低自尊和性自我形象"},{"flag":"C","name":"  不产生性功能障碍"},{"flag":"D","name":"  长期关系中对亲密接触回避"}]},"3221":{"id":3221,"qattrid":49,"type":2,"title":"斑块型银屑病的特点没有哪些（多选题）：","result":"A,C","content":"查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"、束状发等","options":[{"flag":"A","name":" 油滴现象"},{"flag":"B","name":"  薄膜现象"},{"flag":"C","name":"  片状出血现象"},{"flag":"D","name":"  同形反应"}]},"3222":{"id":3222,"qattrid":49,"type":1,"title":"皮肤病生活质量指数是：","result":"C","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，在非特异性方面，简表36（SF-36）和EuroQoL 5D（EQ-5D）常用来评估患者整体的生活质量","options":[{"flag":"A","name":" PSI "},{"flag":"B","name":"  PGA"},{"flag":"C","name":"  DLQI"},{"flag":"D","name":"  BSA"}]},"3223":{"id":3223,"qattrid":49,"type":1,"title":"免疫介导的银屑病没有：","result":"D","content":"银屑病不具有传染性，控制和稳定病情是治疗目的","options":[{"flag":"A","name":" 遗传性"},{"flag":"B","name":"  地理差异"},{"flag":"C","name":"  人种差异"},{"flag":"D","name":"  传染性"}]},"3224":{"id":3224,"qattrid":49,"type":2,"title":"以下哪几项在斑块型银屑病查体中见不到？（多选题）","result":"A,B,C","content":"查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"、束状发等","options":[{"flag":"A","name":" 油滴现象"},{"flag":"B","name":"  厚膜现象"},{"flag":"C","name":"  大片出血现象"},{"flag":"D","name":"  束状发"}]},"3225":{"id":3225,"qattrid":48,"type":2,"title":"PASI100是目前________在现实中希望达到的治疗目标：（多选题）","result":"A,C","content":"PASI 100是目前患者以及最新指南希望达到的治疗目标","options":[{"flag":"A","name":" 患者"},{"flag":"B","name":"  中国银屑病指南"},{"flag":"C","name":"  法国最新指南"},{"flag":"D","name":"  中国医生"}]},"3226":{"id":3226,"qattrid":49,"type":1,"title":"_____可能是银屑病和中风之间的关联因素。","result":"A","content":"促炎细胞因子不仅在银屑病的发病中发挥着重要作用，还连接着心血管疾病的炎症通路","options":[{"flag":"A","name":" 慢性炎症"},{"flag":"B","name":"  免疫失调"},{"flag":"C","name":"  感染"},{"flag":"D","name":"  精神因素"}]},"3227":{"id":3227,"qattrid":49,"type":2,"title":"以下那几项属于PASI评分总计公式内容？（多选题）","result":"A,B,D","content":"PASI总计=严重程度评分×皮损面积评分×权重因子","options":[{"flag":"A","name":" 严重程度评分 "},{"flag":"B","name":"  皮损面积评分"},{"flag":"C","name":"  生活质量评分"},{"flag":"D","name":"  权重因子"}]},"3228":{"id":3228,"qattrid":49,"type":2,"title":"以下哪些身体外伤会导致同形反应Koebner现象？（多选题）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 创伤"},{"flag":"B","name":"  抓伤"},{"flag":"C","name":"  手术切口"},{"flag":"D","name":"  刺青"}]},"3229":{"id":3229,"qattrid":49,"type":1,"title":"银屑病在双胞胎的研究中，银屑病在异卵双胞胎中患病率：","result":"B","content":"在异卵双胞胎中为20%","options":[{"flag":"A","name":"0"},{"flag":"B","name":"0.2"},{"flag":"C","name":"0.5"},{"flag":"D","name":"0.7"}]},"3230":{"id":3230,"qattrid":49,"type":2,"title":"以下关于PASI评分权重因子即每个区域占总皮肤面积的特定百分比错误的是（多选题）","result":"A,B,C","content":"头颈部占10%，躯干占30%，上肢占20%，下肢占40%","options":[{"flag":"A","name":" 头颈部占20%"},{"flag":"B","name":"躯干占40%"},{"flag":"C","name":"  上肢占10%"},{"flag":"D","name":"  下肢占40%"}]},"3231":{"id":3231,"qattrid":49,"type":2,"title":"银屑病患者可能存在不同的疾病体征和症状，但通常表现为以下一种或多种：（多选题）","result":"B,C,D","content":"红斑","options":[{"flag":"A","name":" 皮肤出现片状黑斑，上覆银屑或斑块"},{"flag":"B","name":"小块部位出现鳞屑"},{"flag":"C","name":"  皮肤干燥、开裂，可能出血"},{"flag":"D","name":"  指/趾甲增厚、凹陷或纹状突起"}]},"3232":{"id":3232,"qattrid":49,"type":1,"title":"以下哪项是斑块型银屑病基本特点？","result":"D","content":"皮疹基本特点为境界清楚的暗红色斑块或浸润性红斑，上附白色、银白色鳞屑","options":[{"flag":"A","name":" 附红色、紫红色鳞屑"},{"flag":"B","name":"静止期有同形反应"},{"flag":"C","name":" 查体见油滴现象"},{"flag":"D","name":"  斑块境界清楚"}]},"3233":{"id":3233,"qattrid":49,"type":2,"title":"斑块型银屑病的诊断依据没有（多选题）：","result":"A,D","content":"好发于四肢伸侧，皮损冬重夏轻","options":[{"flag":"A","name":" 皮疹好发于指甲，四肢屈侧"},{"flag":"B","name":"瘙痒是可能出现的临床症状"},{"flag":"C","name":"  皮损反复发作"},{"flag":"D","name":"  皮损夏重冬轻"}]},"3234":{"id":3234,"qattrid":49,"type":1,"title":"以下哪一个不属于银屑病分型：","result":"C","content":"没有片状","options":[{"flag":"A","name":" 红皮病型银屑病"},{"flag":"B","name":"局限性脓疱型"},{"flag":"C","name":"  片状银屑病"},{"flag":"D","name":"  点滴状银屑病"}]},"3235":{"id":3235,"qattrid":49,"type":1,"title":"斑块型银屑病皮损通常不会_______：","result":"C","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":" 有静止期"},{"flag":"B","name":"有退行期"},{"flag":"C","name":"  一过性发作"},{"flag":"D","name":"  反复发作"}]},"3236":{"id":3236,"qattrid":49,"type":1,"title":"调查显示，银屑病对患者生活的质量造成的影响与高血压相比______：","result":"C","content":"银屑病对生活质量的影响与其他严重疾病相当，如癌症、高血压、心梗等","options":[{"flag":"A","name":" 更高"},{"flag":"B","name":"  更低"},{"flag":"C","name":"  相当"},{"flag":"D","name":"  说不清"}]},"3237":{"id":3237,"qattrid":49,"type":1,"title":"据调查，斑块型银屑病的经济负担仅比______低一点，整体与其他相当：","result":"B","content":"据调查，斑块型银屑病的经济负担仅比COPD低一点，整体与其他相当","options":[{"flag":"A","name":" 糖尿病"},{"flag":"B","name":"  COPD"},{"flag":"C","name":"  哮喘"},{"flag":"D","name":"  高血压"}]},"3238":{"id":3238,"qattrid":49,"type":1,"title":"______是指采用1只手掌约代表1%的体表面积的近似法：","result":"B","content":"体表面积（BSA）是指采用一只手掌代表1%体表面积","options":[{"flag":"A","name":" PASI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"  PGA"},{"flag":"D","name":"  EQ-5 "}]},"3239":{"id":3239,"qattrid":49,"type":1,"title":"银屑病皮损面积BSA多少为中度：","result":"C","content":"受影响体表面积百分比低于3%，银屑病划分为轻度，银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":" 1%-3%"},{"flag":"B","name":"  3%-8%"},{"flag":"C","name":"  3%-10%"},{"flag":"D","name":"  8%-12%"}]},"3240":{"id":3240,"qattrid":49,"type":1,"title":"不属于PASI几个单独身体区域评分范畴的是：","result":"A","content":"PASI评分将身体分为头颈部、上肢、躯干、下肢四个部位进行评分","options":[{"flag":"A","name":" 指甲"},{"flag":"B","name":"  头颈"},{"flag":"C","name":"  躯干"},{"flag":"D","name":"  下肢"}]},"3241":{"id":3241,"qattrid":49,"type":2,"title":"以下哪些评估方法涉及生活质量问题：（多选题）","result":"A,C,D","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，在非特异性方面，简表36（SF-36）和EuroQoL 5D（EQ-5D）常用来评估患者整体的生活质量","options":[{"flag":"A","name":" SF-36"},{"flag":"B","name":"SA"},{"flag":"C","name":"  DLQI"},{"flag":"D","name":"  EQ-5 "}]},"3242":{"id":3242,"qattrid":49,"type":1,"title":"2018中国指南关于寻常型银屑病的疾病严重度分类描述正确的是","result":"C","content":"受影响体表面积百分比低于3%，银屑病划分为轻度，银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":" 轻度BSA<5%"},{"flag":"B","name":"  中度 SA 5~10%"},{"flag":"C","name":"  重度BSA>10%"},{"flag":"D","name":"  以上说法均不正确"}]},"3243":{"id":3243,"qattrid":49,"type":1,"title":"2018中国指南寻常型银屑病严重程度主要分为_______：","result":"C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":" 轻度，中度，中重度，重度"},{"flag":"B","name":"  轻度，中度，重度，极重度"},{"flag":"C","name":"  轻度，中度，重度"},{"flag":"D","name":"  轻度，重度，危重度"}]},"3244":{"id":3244,"qattrid":49,"type":2,"title":"2018中国指南寻常型银屑病严重程度主要依据那几项进行分类（多选题）：","result":"A,C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了分类","options":[{"flag":"A","name":" BSA"},{"flag":"B","name":"  PASI"},{"flag":"C","name":"  DLQI"},{"flag":"D","name":"  EQ-5 "}]},"3245":{"id":3245,"qattrid":49,"type":1,"title":"PASI评分为多少分时，银屑病划分为轻度？","result":"C","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":" ≤5"},{"flag":"B","name":"  ≤8"},{"flag":"C","name":"  ≤10"},{"flag":"D","name":"  ≤15"}]},"3246":{"id":3246,"qattrid":49,"type":1,"title":"PASI评分总分为多少时表示最严重疾病：","result":"C","content":"范围从0（无疾病）至72（最严重疾病） 。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"0"},{"flag":"B","name":"52"},{"flag":"C","name":"72"},{"flag":"D","name":"100"}]},"3247":{"id":3247,"qattrid":49,"type":1,"title":"以下PASI评分总分哪一个最严重：","result":"C","content":"范围从0（无疾病）至72（最严重疾病） 。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"0"},{"flag":"B","name":"10"},{"flag":"C","name":"50"},{"flag":"D","name":"80"}]},"3248":{"id":3248,"qattrid":49,"type":1,"title":"计算PASI时，不属于医师对患者几个单独的身体区域情况的进行评价的是：","result":"C","content":"从红斑、厚度和鳞屑三个角度对严重程度进行评分（0分=清洁，1-4分随严重程度增加）","options":[{"flag":"A","name":" 红斑"},{"flag":"B","name":"  厚度"},{"flag":"C","name":"  疼痛"},{"flag":"D","name":"  鳞屑"}]},"3249":{"id":3249,"qattrid":49,"type":2,"title":"以下哪几个银屑病PASI评分为轻度银屑病：（多选题）","result":"A,B","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":"8"},{"flag":"B","name":"10"},{"flag":"C","name":"12"},{"flag":"D","name":"15"}]},"3250":{"id":3250,"qattrid":49,"type":1,"title":"以下哪一个PGA评分制的患者疾病严重程度最重？","result":"B","content":"PGA按0分（清洁）至6分（非常严重）的7分制评分","options":[{"flag":"A","name":"1"},{"flag":"B","name":"4"},{"flag":"C","name":"7"},{"flag":"D","name":"9"}]},"3251":{"id":3251,"qattrid":49,"type":1,"title":"治疗成功是指皮肤症状清洁或几乎清洁的患者比例，对应的sPGA评分为：","result":"A","content":"PGA按0分（清洁）至6分（非常严重）的7分制评分","options":[{"flag":"A","name":" 0/1"},{"flag":"B","name":"  1/2"},{"flag":"C","name":"  0/2"},{"flag":"D","name":"  5/6"}]},"3252":{"id":3252,"qattrid":47,"type":2,"title":"修美乐®通用名不是（多选题）：","result":"A,B,D","content":"修美乐/阿达木单抗","options":[{"flag":"A","name":" 依那西普"},{"flag":"B","name":"  环孢素软胶囊"},{"flag":"C","name":"  阿达木单抗"},{"flag":"D","name":"  依奇珠单抗"}]},"3253":{"id":3253,"qattrid":47,"type":1,"title":"可善挺®一年正常治疗注射1年次数是：","result":"D","content":"可善挺一年注射32次","options":[{"flag":"A","name":"10"},{"flag":"B","name":"17"},{"flag":"C","name":"27"},{"flag":"D","name":"32"}]},"3254":{"id":3254,"qattrid":47,"type":1,"title":"可善挺®特异性作用于白介素：","result":"A","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":" IL-17"},{"flag":"B","name":"  IL-12"},{"flag":"C","name":"  IL-23A"},{"flag":"D","name":"  IL-23C"}]},"3255":{"id":3255,"qattrid":50,"type":2,"title":"拓咨®不是一种：（多选题）","result":"A,B,D","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":" 鼠源化lgG1单克隆抗体"},{"flag":"B","name":"  鼠源化lgG4单克隆抗体"},{"flag":"C","name":"  人源化lgG4单克隆抗体"},{"flag":"D","name":"  人源化lgG1单克隆抗体"}]},"3256":{"id":3256,"qattrid":50,"type":1,"title":"单克隆抗体由单一杂交瘤细胞产生，针对_______表位的特异性抗体：","result":"B","content":"A.由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":" 单一抗体"},{"flag":"B","name":"  单一抗原"},{"flag":"C","name":"  多种抗体"},{"flag":"D","name":"  相似抗原"}]},"3257":{"id":3257,"qattrid":50,"type":2,"title":"关于单克隆抗体，下列说法正确的是（多选题）：","result":"A,C,D","content":"A.由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。B:lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。C:与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":" 单克隆抗体结构单一"},{"flag":"B","name":"  免疫球蛋白lgG1诱导CDC或ADCC能力较差，细胞毒性少"},{"flag":"C","name":"  与鼠源抗体相比，人源化抗体免疫原性更低"},{"flag":"D","name":"  抗药性抗体（A As）会影响单克隆抗体治疗的临床效果"}]},"3258":{"id":3258,"qattrid":48,"type":2,"title":"银屑病常用外用药物不包括（多选题）","result":"A,C","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂等。","options":[{"flag":"A","name":" 甲氨蝶呤"},{"flag":"B","name":"  保湿剂"},{"flag":"C","name":"  环孢素"},{"flag":"D","name":"  维生素 3衍生物"}]},"3259":{"id":3259,"qattrid":48,"type":1,"title":"中国银屑病市场销售额2018年Q3已达","result":"B","content":"中国银屑病市场销售额于2018年第三季度已达5亿人民币","options":[{"flag":"A","name":" 1亿人民币"},{"flag":"B","name":"  5亿人民币"},{"flag":"C","name":"  15亿人民币"},{"flag":"D","name":"  25亿人民币"}]},"3260":{"id":3260,"qattrid":46,"type":1,"title":"依奇珠单抗的鼠源种系序列低于","result":"B","content":"依奇珠单抗是98.2%的人类种系序列(24/1328个非同源氨基酸)","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.02"},{"flag":"C","name":"0.1"},{"flag":"D","name":"0.14"}]},"3261":{"id":3261,"qattrid":49,"type":1,"title":"固有免疫细胞产生IL-17A的调控途径：","result":"C","content":"固有免疫细胞产生的IL-17A可以独立于IL-23而发生，比如γδ-T细胞和iNKT细胞","options":[{"flag":"A","name":" 必须依赖IL-23"},{"flag":"B","name":"  完全独立于IL-23"},{"flag":"C","name":"  可以独立于IL-23"},{"flag":"D","name":"  以上都不对"}]},"3262":{"id":3262,"qattrid":46,"type":2,"title":"不属于拓咨®的适应症内容的是：（多选题）","result":"B,C,D","content":"拓咨®的适应症内容的是适合全身治疗或光疗的中度至重度斑块型银屑病成人患者","options":[{"flag":"A","name":"适合全身治疗或光疗的中度至重度斑块型银屑病成人患者"},{"flag":"B","name":" 适合局部治疗或光疗的轻度至中度斑块型银屑病成人患者"},{"flag":"C","name":"  适合局部治疗或光疗的轻度至中度点滴型银屑病成人患者"},{"flag":"D","name":"  适合全身治疗或光疗的中度至重度点滴型银屑病成人患者"}]},"3263":{"id":3263,"qattrid":49,"type":2,"title":"以下哪几项是银屑病的治疗（多选题）：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 糖皮质激素"},{"flag":"B","name":"  PUVA"},{"flag":"C","name":"  NB-UVB"},{"flag":"D","name":"  依奇珠单抗"}]},"3264":{"id":3264,"qattrid":47,"type":2,"title":"以下哪几个属于TNF-α拮抗剂：（多选题）","result":"A,B,C,D","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":" 益赛普"},{"flag":"B","name":"  依那西普"},{"flag":"C","name":"  英夫利西单抗"},{"flag":"D","name":"  阿达木单抗"}]},"3265":{"id":3265,"qattrid":47,"type":1,"title":"下列哪项药物的通用名和商品名对应不正确？","result":"D","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂，厂家是西安杨森","options":[{"flag":"A","name":" 恩利®依那西普"},{"flag":"B","name":"  类克®英夫利西单抗"},{"flag":"C","name":"  修美乐®阿达木单抗"},{"flag":"D","name":"  喜达诺®司库奇尤单抗"}]},"3266":{"id":3266,"qattrid":47,"type":1,"title":"在银屑病药物的研发历程中，最新的研究药物是（）","result":"C","content":"相较于ABD，依奇珠单抗是最新研究机制药物","options":[{"flag":"A","name":"益赛普"},{"flag":"B","name":" 英夫利西单抗"},{"flag":"C","name":"  依奇珠单抗"},{"flag":"D","name":"  阿达木单抗"}]},"3267":{"id":3267,"qattrid":47,"type":2,"title":"益赛普®的作用机制不是（）（多选题）","result":"A,B,D","content":"益赛普®的作用机制是TNF-α 抑制剂，厂家是三生制药","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":" 选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"  TNF-α 抑制剂"},{"flag":"D","name":"  IL-17A及其受体拮抗剂"}]},"3268":{"id":3268,"qattrid":47,"type":1,"title":"修美乐®的作用机制是（）","result":"C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":" 选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"  TNF-α 抑制剂"},{"flag":"D","name":"  IL-17A及其受体拮抗剂"}]},"3269":{"id":3269,"qattrid":47,"type":2,"title":"下列哪个药物是生物制剂（多选题）","result":"C,D","content":"新山地明、甲氨蝶呤是系统性用药","options":[{"flag":"A","name":"新山地明"},{"flag":"B","name":" 甲氨蝶呤"},{"flag":"C","name":"  益赛普"},{"flag":"D","name":" 修美乐"}]},"3270":{"id":3270,"qattrid":48,"type":1,"title":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它是：","result":"B","content":"AAD-NPF指南时美国指南","options":[{"flag":"A","name":"法国指南"},{"flag":"B","name":" 美国指南"},{"flag":"C","name":" 德国指南"},{"flag":"D","name":" 英国指南"}]},"3271":{"id":3271,"qattrid":48,"type":1,"title":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它的推荐强度是：","result":"C","content":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它的推荐强度是A等级","options":[{"flag":"A","name":"C等级"},{"flag":"B","name":"  B等级"},{"flag":"C","name":"  A等级"},{"flag":"D","name":"  没有等级"}]},"3272":{"id":3272,"qattrid":47,"type":1,"title":"Tremfya的生产厂家是：","result":"C","content":"Tremfya的生产厂家是强生","options":[{"flag":"A","name":" 辉瑞"},{"flag":"B","name":"  诺华"},{"flag":"C","name":"  强生"},{"flag":"D","name":"  艾伯维"}]},"3273":{"id":3273,"qattrid":47,"type":2,"title":"可善挺®的使用方式不包括：（多选题）","result":"A,B,D","content":"可善挺是皮下注射","options":[{"flag":"A","name":" 口服片剂"},{"flag":"B","name":"  口服胶囊"},{"flag":"C","name":"  皮下注射"},{"flag":"D","name":"  肌注"}]},"3274":{"id":3274,"qattrid":51,"type":1,"title":"拓咨®的目前已进行的非关键III期临床主要临床研究叫：","result":"C","content":"拓咨®的目前已进行的非关键III期临床主要临床研究是IXORA","options":[{"flag":"A","name":" Uncover"},{"flag":"B","name":"  REVEAL"},{"flag":"C","name":"  IXORA"},{"flag":"D","name":"  BECOME"}]},"3275":{"id":3275,"qattrid":47,"type":1,"title":"可善挺®的推荐剂量为每次：","result":"D","content":"可善挺®的推荐剂量为每次300mg","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":" 150mg"},{"flag":"C","name":"  250mg"},{"flag":"D","name":"  300mg "}]},"3276":{"id":3276,"qattrid":47,"type":1,"title":"以下治疗银屑病获批进入中国时间日期最近的是：","result":"A","content":"拓咨®在国内目前获批治疗斑块型银屑病的日期为 2019.08.29","options":[{"flag":"A","name":" 依奇珠单抗"},{"flag":"B","name":"  阿达木单抗"},{"flag":"C","name":"  乌司奴单抗"},{"flag":"D","name":"  益赛普"}]},"3277":{"id":3277,"qattrid":47,"type":1,"title":"一个合格的单抗不需要考虑：","result":"D","content":"除了成本考量，其他都是","options":[{"flag":"A","name":"免疫原性"},{"flag":"B","name":" 结合抗原能力"},{"flag":"C","name":"  结构稳定"},{"flag":"D","name":"  价格成本"}]},"3278":{"id":3278,"qattrid":47,"type":1,"title":"可善挺®的亲和力大约是拓咨®的：","result":"D","content":"依奇珠单抗的亲和力大约是司库奇尤单抗的100倍","options":[{"flag":"A","name":" 1/10"},{"flag":"B","name":"  1/30"},{"flag":"C","name":"  1/50"},{"flag":"D","name":"  1/100"}]},"3279":{"id":3279,"qattrid":47,"type":1,"title":"根据单克隆抗体的______不同，可分为包括嵌合性抗体在内的4种类型：","result":"C","content":"根据单克隆抗体的来源不同，可分为4种，鼠源抗体、嵌合体抗体、人源化抗体和人源抗体","options":[{"flag":"A","name":"价格"},{"flag":"B","name":" 厂家"},{"flag":"C","name":"  来源"},{"flag":"D","name":"  结构"}]},"3280":{"id":3280,"qattrid":51,"type":1,"title":"拓咨®没有开展针对哪个难治部位的治疗效果的临床研究？","result":"D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":" 头皮"},{"flag":"B","name":"  生殖器"},{"flag":"C","name":"  指甲"},{"flag":"D","name":"  肠道"}]},"3281":{"id":3281,"qattrid":47,"type":2,"title":"银屑病先前非生物制剂的系统治疗包括： （多选题）","result":"B,C","content":"新山地明/环孢素、甲氨蝶呤是系统性用药","options":[{"flag":"A","name":"益赛普"},{"flag":"B","name":" 环孢素"},{"flag":"C","name":"  甲氨蝶呤"},{"flag":"D","name":"  外用糖皮质激素"}]},"3282":{"id":3282,"qattrid":47,"type":2,"title":"喜达诺®的作用机制不是（）（多选题）","result":"A,B,C","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂，厂家是西安杨森","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":" 选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"  TNF-α 抑制剂"},{"flag":"D","name":"  IL-12/23拮抗剂"}]},"3283":{"id":3283,"qattrid":47,"type":2,"title":"喜达诺®的厂家不是（）（多选题）","result":"A,B,C","content":"喜达诺/乌丝奴单抗的作用机制是IL-12/23抑制剂，厂家是西安杨森","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":" 诺华"},{"flag":"C","name":" 辉瑞"},{"flag":"D","name":"  西安杨森"}]},"3284":{"id":3284,"qattrid":47,"type":1,"title":"司库奇尤单抗适用于什么程度的斑块状银屑病患者","result":"C","content":"可善挺®适用中度至重度的斑块状银屑病患者","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"轻度至中度"},{"flag":"C","name":"  中度至重度"},{"flag":"D","name":"  仅重度"}]},"3285":{"id":3285,"qattrid":47,"type":2,"title":"下列哪个药物不是TNF抑制剂（多选题）","result":"A,D","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"  类克®"},{"flag":"D","name":"  可善挺®"}]},"3286":{"id":3286,"qattrid":47,"type":2,"title":"下列哪个药物厂家是西安杨森（多选题）","result":"A,C","content":"喜达诺/乌丝奴单抗、类克/英夫利昔单抗的厂家是西安杨森","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"  类克®"},{"flag":"D","name":"  恩利®"}]},"3287":{"id":3287,"qattrid":47,"type":2,"title":"中国已获批银屑病适应症的药物是（）（多选题）","result":"A,B,D","content":"中国未获批银屑病适应症的药物是恩利®（依那西普）","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"  依那西普"},{"flag":"D","name":"  拓咨®"}]},"3288":{"id":3288,"qattrid":47,"type":2,"title":"英夫利昔单抗的作用机制不是（）（多选题）","result":"A,B,D","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"  TNF-α 抑制剂"},{"flag":"D","name":"  IL-17A及其受体拮抗剂"}]},"3289":{"id":3289,"qattrid":47,"type":1,"title":"英夫利昔单抗的厂家是（）","result":"D","content":"喜达诺/乌丝奴单抗、类克/英夫利昔单抗的厂家是西安杨森","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":" 辉瑞"},{"flag":"D","name":"  西安杨森"}]},"3290":{"id":3290,"qattrid":47,"type":2,"title":"乌司奴单抗的使用方法不包括（）（多选题）","result":"A,B,D","content":"喜达诺/乌丝奴单抗是皮下注射","options":[{"flag":"A","name":"肌肉注射"},{"flag":"B","name":" 静脉注射"},{"flag":"C","name":"  皮下注射"},{"flag":"D","name":"  口服"}]},"3291":{"id":3291,"qattrid":48,"type":2,"title":"下列关于银屑病的管理，说法错误的是： （多选题）","result":"A,B,D","content":"控制疾病，治疗原则是正规、安全、个体化，生物制剂适用中重度","options":[{"flag":"A","name":" 银屑病的治疗目标是达到皮肤完全清洁，早日治愈 "},{"flag":"B","name":" 银屑病的治疗原则以疗效为首要，强调清洁效果 "},{"flag":"C","name":"  PUVA是指长波紫外线（UVA）联合光敏剂补骨脂素进行治疗 "},{"flag":"D","name":"  对于轻度银屑病患者，适用生物制剂"}]},"3292":{"id":3292,"qattrid":46,"type":2,"title":"拓咨®注射笔特点包括：(多选题）","result":"A,C,D","content":"隐藏针头","options":[{"flag":"A","name":"有专利"},{"flag":"B","name":" 开放式针头"},{"flag":"C","name":"  简单三步"},{"flag":"D","name":"  方便易用"}]},"3293":{"id":3293,"qattrid":46,"type":1,"title":"以下哪项不是拓咨®主要目标患者：","result":"A","content":"对生物制剂（主要TNF-α）效果不满意的患者；未经生物制剂治疗（包括未经系统治疗或系统治疗失败）","options":[{"flag":"A","name":" 对生物制剂（主要TNF-α）效果满意的患者"},{"flag":"B","name":"对生物制剂（主要TNF-α）效果不满意的患者"},{"flag":"C","name":"  未经生物制剂治疗（未经系统治疗）"},{"flag":"D","name":"  未经生物制剂治疗（系统治疗失败）"}]},"3294":{"id":3294,"qattrid":51,"type":1,"title":"拓咨®通过关键头对头研究证实，显著优于：","result":"D","content":"都是","options":[{"flag":"A","name":"MTX"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"  乌司奴单抗"},{"flag":"D","name":"  以上都是"}]},"3295":{"id":3295,"qattrid":48,"type":1,"title":"在WHO研究调查中发现银屑病患者对于______的期望最高。","result":"A","content":"在WHO研究调查中发现银屑病患者对于 快速修复皮肤的期望最高","options":[{"flag":"A","name":" 快速修复皮肤"},{"flag":"B","name":"减少去医院次数"},{"flag":"C","name":"  无瘙痒"},{"flag":"D","name":"  无皮肤烧灼感"}]},"3296":{"id":3296,"qattrid":49,"type":2,"title":"下列哪几项是常用的外用药物：（多选题）","result":"B,C","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂；无抗真菌药","options":[{"flag":"A","name":" PUVA"},{"flag":"B","name":"维生素D3衍生物"},{"flag":"C","name":"  保湿剂"},{"flag":"D","name":"  抗真菌药"}]},"3297":{"id":3297,"qattrid":51,"type":1,"title":"UNCOVER系列研究中拓咨®治疗12周的______优于依那西普。","result":"B","content":"UNCOVER系列研究中拓咨®治疗12周的sPGA0/1优于依那西普","options":[{"flag":"A","name":" BSA"},{"flag":"B","name":"sPGA0/1"},{"flag":"C","name":"  PASI"},{"flag":"D","name":"  不良反应发生率"}]},"3298":{"id":3298,"qattrid":51,"type":1,"title":"拓咨®治疗12周的_______应答率优于依那西普。","result":"D","content":"以上都是","options":[{"flag":"A","name":" PASI 75"},{"flag":"B","name":"PASI 90"},{"flag":"C","name":"  PASI 100"},{"flag":"D","name":"  以上均是"}]},"3299":{"id":3299,"qattrid":51,"type":1,"title":"拓咨®治疗治疗2周，超过______患者即可实现PASI 50。","result":"C","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":" 1/4"},{"flag":"B","name":"43468"},{"flag":"C","name":"  1/2"},{"flag":"D","name":"  以上都不是"}]},"3300":{"id":3300,"qattrid":51,"type":1,"title":"拓咨®uncover系列临床试验没有：","result":"C","content":"没有UNCOVER-P","options":[{"flag":"A","name":" UNCOVER-1"},{"flag":"B","name":"  UNCOVER-2"},{"flag":"C","name":"  UN OVER-P"},{"flag":"D","name":"  UNCOVER-J"}]},"3301":{"id":3301,"qattrid":51,"type":1,"title":"参与拓咨®实验的人群中，先前进行过的治疗没有:","result":"D","content":"没有PUVC","options":[{"flag":"A","name":"非生物制剂的系统治疗"},{"flag":"B","name":" 生物制剂"},{"flag":"C","name":"  PUVA"},{"flag":"D","name":"  PUVC"}]},"3302":{"id":3302,"qattrid":46,"type":1,"title":"拓咨®第4周推荐剂量是：","result":"A","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":" 120mg"},{"flag":"C","name":"  160mg"},{"flag":"D","name":"  240mg"}]},"3303":{"id":3303,"qattrid":48,"type":2,"title":"拓咨®的推广的主要关键信息不是：（多选题）","result":"B,C,D","content":"拓咨®快速起效、全面清除、长期稳定","options":[{"flag":"A","name":"快速起效，全面清除，长期稳定"},{"flag":"B","name":"快速起效，全面获益，长期稳定"},{"flag":"C","name":"   全面清除，完全治愈，终身稳定"},{"flag":"D","name":"   安全有效，百分获益，长期稳定"}]},"3304":{"id":3304,"qattrid":51,"type":1,"title":"研究显示，拓咨®治疗1周后以下说法正确的是：","result":"C","content":"UNCOVER-2研究显示，拓咨®治疗1周即可见皮损以及瘙痒症状改善","options":[{"flag":"A","name":" 仅皮损改善"},{"flag":"B","name":"  仅瘙痒显著改善"},{"flag":"C","name":"  皮损以及瘙痒症状显著改善"},{"flag":"D","name":"  接近1/4患者实现PASI 50"}]},"3305":{"id":3305,"qattrid":51,"type":1,"title":"研究显示，依奇珠单抗治疗几周接近1/4患者可实现PASI 75","result":"B","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"3306":{"id":3306,"qattrid":51,"type":2,"title":"下列哪些试验不是在中重度斑块型银屑病中对拓咨®和喜达诺®治疗进行研究？（多选题）","result":"A,B,D","content":"IXORA-S比较IXE和喜达诺/乌司奴单抗在中重度斑块型银屑病患者中的有效性和安全性","options":[{"flag":"A","name":" UNCOVER-3"},{"flag":"B","name":"  IXORA-P"},{"flag":"C","name":"  IXORA-S"},{"flag":"D","name":"  IXORA-R"}]},"3307":{"id":3307,"qattrid":51,"type":1,"title":"对于UNCOVER-3临床试验一直接受依奇珠单抗治疗最长达4年的患者，达到_______的比例超过60%。","result":"C","content":"拓咨® 治疗4年，67%患者实现皮损全面清除（PASI 100）","options":[{"flag":"A","name":" PASI 75"},{"flag":"B","name":"  PASI 90"},{"flag":"C","name":"  PASI 100"},{"flag":"D","name":"  sPGA 0/1"}]},"3308":{"id":3308,"qattrid":51,"type":1,"title":"头对头研究中治疗12周时拓咨®的______优于乌司奴单抗：","result":"D","content":"都优于","options":[{"flag":"A","name":" PASI 75"},{"flag":"B","name":"  PASI 90"},{"flag":"C","name":"  PASI 100"},{"flag":"D","name":"  以上都是"}]},"3309":{"id":3309,"qattrid":51,"type":1,"title":"拓咨®治疗12周时，超过_____患者实现掌趾部位全面清除。","result":"B","content":"拓咨®治疗12周时，超过50%患者实现掌趾部位全面清除","options":[{"flag":"A","name":"0.4"},{"flag":"B","name":"0.5"},{"flag":"C","name":"0.6"},{"flag":"D","name":"0.7"}]},"3310":{"id":3310,"qattrid":51,"type":2,"title":"以下哪些是修美乐在中国获批的适应症：（多选题）","result":"A,B,C","content":"异位性皮炎不是","options":[{"flag":"A","name":"银屑病"},{"flag":"B","name":" 类风湿关节炎"},{"flag":"C","name":"  强直性脊柱炎"},{"flag":"D","name":"  异位性皮炎"}]},"3311":{"id":3311,"qattrid":51,"type":1,"title":"头对头研究中治疗12周时拓咨®的______优于乌司奴单抗：","result":"B","content":" DLQI (0,1)是生活质量评价指标","options":[{"flag":"A","name":"sPGA"},{"flag":"B","name":" DLQI (0,1)"},{"flag":"C","name":"  BSA"},{"flag":"D","name":"  UBA"}]},"3312":{"id":3312,"qattrid":46,"type":2,"title":"以下关于拓咨®的说法不正确的是：（多选题）","result":"B,D","content":"全球第二个，维持期每次一针","options":[{"flag":"A","name":" 化学名为依奇珠单抗"},{"flag":"B","name":"  全球第一个上市的IL-17A抑制剂"},{"flag":"C","name":"  礼来公司产品"},{"flag":"D","name":"  维持治疗期每月注射1次，每次2针"}]},"3313":{"id":3313,"qattrid":46,"type":2,"title":"以下关于拓咨®的注射方法不正确的是：（多选题）","result":"A,D","content":"只需三步，需要解锁","options":[{"flag":"A","name":" 只需2步"},{"flag":"B","name":"  步骤简单，方便易用，患者可自行在家注射"},{"flag":"C","name":"  不要在皮损初注射，且需轮换注射部位，避免始终在同一部位注射"},{"flag":"D","name":"  不需要解锁"}]},"3314":{"id":3314,"qattrid":48,"type":1,"title":"当前银屑病治疗现状是中国的严重程度分类标准导致治疗方案：","result":"C","content":"严重程度分类标准的不统一导致治疗方案不统一","options":[{"flag":"A","name":" 十分统一"},{"flag":"B","name":"  基本统一"},{"flag":"C","name":"  不统一"},{"flag":"D","name":"  以上都不对"}]},"3315":{"id":3315,"qattrid":49,"type":2,"title":"以下PASI对应治疗终点，描述正确的是：（多选题）","result":"B,C,D","content":"PASI 50 是有效","options":[{"flag":"A","name":" PASI 50：无效"},{"flag":"B","name":"  PASI 75：控制"},{"flag":"C","name":"  PASI 90：接近清除"},{"flag":"D","name":"  PASI 100：完全清除"}]},"3316":{"id":3316,"qattrid":48,"type":1,"title":"以下哪一个是当前中国银屑病治疗现状目标：","result":"A","content":"中国目前治疗目标较国外先进目标偏低","options":[{"flag":"A","name":" 控制红斑、鳞屑和单个斑块皮损的厚度"},{"flag":"B","name":"  初步快速控制疾病"},{"flag":"C","name":"  皮损全部清除"},{"flag":"D","name":"  保持患者长期缓解，避免复发"}]},"3317":{"id":3317,"qattrid":48,"type":1,"title":"目前患者对生物制剂最关注的属性是_______。","result":"B","content":"对生物制剂而言， “有效性” 是最受关注的属性","options":[{"flag":"A","name":" 经济性"},{"flag":"B","name":"  有效性"},{"flag":"C","name":"  依从性"},{"flag":"D","name":"  必要性"}]},"3318":{"id":3318,"qattrid":48,"type":2,"title":"中国生物制剂市场洞察是：（多选题）","result":"A,B,C,D","content":"以上都是中国市场洞察","options":[{"flag":"A","name":" 未被充分开发"},{"flag":"B","name":"  医生目标低于患者"},{"flag":"C","name":"  目前都是自费"},{"flag":"D","name":"  多种产品几乎同时推出"}]},"3319":{"id":3319,"qattrid":50,"type":1,"title":"下列说法正确的是：","result":"C","content":"  IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用","options":[{"flag":"A","name":"拓咨®是一种人源化IgG1单克隆抗体，对白介素-17A（IL-17A）有中和活性"},{"flag":"B","name":" IL-17A、IL-17C和IL-17F在银屑病病灶部位表达降低"},{"flag":"C","name":"  IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用"},{"flag":"D","name":"  拓咨®选择性结合IL-17C细胞因子，抑制其与IL-17受体相互作用，从而抑制促炎细胞因子和趋化因子释放"}]},"3320":{"id":3320,"qattrid":48,"type":1,"title":"中国市场生物制剂份额占一半以上的是","result":"B","content":"易赛普占中国银屑病生物制剂市场67%份额MAT3Q2018","options":[{"flag":"A","name":" MTX"},{"flag":"B","name":"益赛普"},{"flag":"C","name":"  类克"},{"flag":"D","name":"  修美乐"}]},"3321":{"id":3321,"qattrid":51,"type":2,"title":"以下哪些属于银屑病难治部位，需要单独分析的：（多选题）","result":"A,B,C,D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"头皮"},{"flag":"B","name":"掌跖"},{"flag":"C","name":"  指甲"},{"flag":"D","name":"  生殖器"}]},"3322":{"id":3322,"qattrid":51,"type":1,"title":"多项研究显示，拓咨®治疗____周，就可实现对生殖器难治部位皮损的完全清除。","result":"C","content":"12周","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"12"},{"flag":"D","name":"36"}]},"3323":{"id":3323,"qattrid":48,"type":2,"title":"以下哪些不是是拓咨®的愿景（多选题）","result":"A,B,C","content":" 成为治疗中度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂是愿景","options":[{"flag":"A","name":" 成为治疗中度至重度(m/s)斑块型银屑病(PsO)的主要处方生物制剂"},{"flag":"B","name":"成为治疗轻度至重度(m/s)斑块型银屑病(PsO)的主要处方生物制剂"},{"flag":"C","name":"  成为治疗轻度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂"},{"flag":"D","name":"  成为治疗中度至重度(m/s)斑块型银屑病(PsO)的首选处方生物制剂"}]},"3324":{"id":3324,"qattrid":48,"type":2,"title":"以下那几项关键词属于拓咨®品牌定位：（多选题）","result":"A,B,C","content":"D不在推广定位里","options":[{"flag":"A","name":" 更能快速"},{"flag":"B","name":"更能全面"},{"flag":"C","name":"  亲密联系"},{"flag":"D","name":"  更加安全"}]},"3325":{"id":3325,"qattrid":48,"type":1,"title":"中国银屑病口服和生物制剂市场销售额于2018年第三季度已达_____亿人民币","result":"A","content":"2018Q3-1亿RMB，其中50%为生物制剂","options":[{"flag":"A","name":"1"},{"flag":"B","name":"5"},{"flag":"C","name":"10"},{"flag":"D","name":"20"}]},"3326":{"id":3326,"qattrid":48,"type":2,"title":"以下哪几项是未来十年中国银屑病生物制剂市场预计快速增长的理由（多选题）","result":"A,C,D","content":"2018年生物制剂作为治疗中重度银屑病推荐治疗手段被写入指南","options":[{"flag":"A","name":"患者对疾病和治疗手段的认知与观念被提高"},{"flag":"B","name":" 2016年生物制剂作为治疗中重度银屑病推荐治疗手段被写入指南"},{"flag":"C","name":"  提高的支付能力，改进的准入和医保报销政策"},{"flag":"D","name":"  潜在患者数增加"}]},"3327":{"id":3327,"qattrid":51,"type":1,"title":"__________研究前12周拓咨®主要和恩利®做头对头研究：","result":"C","content":"临床试验UNCOV\u0002ER-2和UNCOVER-3分为IXE(依奇珠单抗)、ETN（依那西普）和PBO(安慰剂组)， 前12周拓咨®主要和依那西普做头对头研究","options":[{"flag":"A","name":" CLEAR"},{"flag":"B","name":"IXORA"},{"flag":"C","name":"  UNCOVER"},{"flag":"D","name":"  BECOME"}]},"3328":{"id":3328,"qattrid":48,"type":1,"title":"根据指南，PASI 75现在仍主要是哪个国家的治疗目标","result":"D","content":"中国银屑病治疗目标仍停留在PASI75","options":[{"flag":"A","name":"美国"},{"flag":"B","name":"法国"},{"flag":"C","name":"  欧盟其他发达国家"},{"flag":"D","name":"  中国"}]},"3329":{"id":3329,"qattrid":48,"type":1,"title":"MAT3Q2018显示，占中国银屑病总市场销售额市场份额一半以上的是：","result":"C","content":"局部用药占比54%","options":[{"flag":"A","name":"生物制剂"},{"flag":"B","name":"口服药物"},{"flag":"C","name":"  局部用药"},{"flag":"D","name":"  中成药"}]},"3330":{"id":3330,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，_______治疗12周后，达到PASI 75患者比例为42%","result":"B","content":"在UNCOVER-2研究中，依那西普治疗12周后，达到PASI 75患者比例为42%","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"  乌司奴单抗"},{"flag":"D","name":"  安慰剂"}]},"3331":{"id":3331,"qattrid":51,"type":1,"title":"在UNCOVER-2研究中，_______治疗12周后，达到PASI 100患者比例为40%","result":"A","content":"在UNCOVER-2研究中，拓咨®治疗12周后，达到PASI 100患者比例为40%","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"  乌司奴单抗"},{"flag":"D","name":"  安慰剂"}]},"3332":{"id":3332,"qattrid":51,"type":2,"title":"以下哪个研究是拓咨®的临床研究。（多选题）","result":"A,C,D","content":"拓咨的临床研究为UNCOVER和IXORA","options":[{"flag":"A","name":" IXORA-S"},{"flag":"B","name":"REVEAL"},{"flag":"C","name":"  IXORA-R"},{"flag":"D","name":"  UNCOVER"}]},"3333":{"id":3333,"qattrid":51,"type":1,"title":"UNCOVER-J是依奇珠单抗在________的主要研究名称","result":"C","content":" UNCOVER-J 是拓咨®的亚洲日本的主要研究名称","options":[{"flag":"A","name":" 美国"},{"flag":"B","name":"中国"},{"flag":"C","name":"  日本"},{"flag":"D","name":"  英国"}]},"3334":{"id":3334,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病在生殖器、掌跖、头皮和指甲等难治部位最好可获得:","result":"D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":" 有效清除（PASI 50）"},{"flag":"B","name":" 控制清除（PASI 75）"},{"flag":"C","name":"  接近全面清除（PASI 90）"},{"flag":"D","name":"  全面清除（PASI 100）"}]},"3335":{"id":3335,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病_____年长期治疗期间，_______特殊不良反应事件发生率。","result":"B","content":"拓咨®治疗银屑病4年长期治疗期间，不增加特殊不良反应事件发生率","options":[{"flag":"A","name":"4, 轻微增加"},{"flag":"B","name":" 4, 不增加"},{"flag":"C","name":"  2，不增加"},{"flag":"D","name":"  4，降低"}]},"3336":{"id":3336,"qattrid":51,"type":1,"title":"UNCOVER-1,2显示，拓咨®治疗银屑病诱导治疗期获得______的患者，疗效可持续维持","result":"A","content":"研究结果","options":[{"flag":"A","name":"高皮损清除率"},{"flag":"B","name":" 基本皮损清除率"},{"flag":"C","name":"  高瘙痒清除率"},{"flag":"D","name":"  基本瘙痒清除率"}]},"3337":{"id":3337,"qattrid":51,"type":2,"title":"在诱导治疗期，拓咨®的相关不良反应相较于依那西普错误的是：（多选题）","result":"A,C,D","content":"在诱导治疗期，拓咨®的相关不良反应与依那西普相似","options":[{"flag":"A","name":" 低"},{"flag":"B","name":"  相似"},{"flag":"C","name":"  高"},{"flag":"D","name":"  显著降低"}]},"3338":{"id":3338,"qattrid":51,"type":2,"title":"关于拓咨®安全性描述正确的是：（多选题）","result":"B,D","content":"拓咨安全性良好，与依那西普总体TEAEs发生率相当。治疗期间最常见的不良反应是注射部位不良反应。TEAEs多为轻至中度，极少导致治疗中断","options":[{"flag":"A","name":" 与依那西普相比，拓咨®治疗组TEAEs发生率显著降低"},{"flag":"B","name":"拓咨®的TEAEs多为轻中度，非常少导致治疗中断"},{"flag":"C","name":"   最常见导致拓咨®治疗中断的不良反应是念珠菌感染、鼻咽炎、上呼吸道感染"},{"flag":"D","name":"   拓咨®特别关注的不良事件是主要心血管不良事件、克罗恩病、恶性肿瘤等"}]},"3339":{"id":3339,"qattrid":48,"type":2,"title":"拓咨®的主要推广信息中不包括：（多选题）","result":"B,D","content":"革命性主张，净界可达不是","options":[{"flag":"A","name":" 净化论"},{"flag":"B","name":"  银屑病治疗革命性主张"},{"flag":"C","name":"  快速起效，全面清除，长期稳定"},{"flag":"D","name":"  净界可达"}]},"3340":{"id":3340,"qattrid":49,"type":2,"title":"关于斑块型银屑病，下列哪项描述是正确的（多选题）","result":"C,D","content":"斑块型90%，患者的治疗目标高于医生","options":[{"flag":"A","name":" 斑块型银屑病最为常见，约占80%"},{"flag":"B","name":"  当前中国医生对治疗目标的期待比患者高"},{"flag":"C","name":"  皮损反复发作，多数冬重夏轻"},{"flag":"D","name":"  进展期可有“同形反应”"}]},"3341":{"id":3341,"qattrid":51,"type":1,"title":"UNCOVER-1,2,3显示，拓咨®治疗银屑病60周，1.7%患者发生：","result":"B","content":"UNCOVER-1,2,3显示，拓咨®治疗银屑病60周，1.7%患者发生高效价抗药抗体","options":[{"flag":"A","name":" 低效价抗药抗体"},{"flag":"B","name":"高效价抗药抗体"},{"flag":"C","name":"  中等效价抗药抗体"},{"flag":"D","name":"  极高效价抗药抗体"}]},"3342":{"id":3342,"qattrid":49,"type":2,"title":"以下是银屑病的治疗方法的是： （多选题）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 局部治疗"},{"flag":"B","name":"  物理治疗"},{"flag":"C","name":"  中医治疗"},{"flag":"D","name":"  系统治疗"}]},"3343":{"id":3343,"qattrid":47,"type":2,"title":"下列是甲氨蝶呤治疗银屑病的优点是： （多选题）","result":"A,B","content":"需要定期检测肝肾功能，会产生肝纤维化","options":[{"flag":"A","name":" 对中重度斑块型有较好的疗效"},{"flag":"B","name":"  对掌趾部位也有效"},{"flag":"C","name":"  无需定期检测肝肾功能"},{"flag":"D","name":"  不会产生肝纤维化"}]},"3344":{"id":3344,"qattrid":47,"type":1,"title":"银屑病常用生物制剂没有：","result":"C","content":"他扎罗汀局部用药","options":[{"flag":"A","name":" 依奇珠单抗"},{"flag":"B","name":"  依那西普"},{"flag":"C","name":"  他扎罗汀"},{"flag":"D","name":"  乌丝奴单抗"}]},"3345":{"id":3345,"qattrid":47,"type":1,"title":"环孢素的描述正确的是：","result":"A","content":"环孢素对对各型银屑病均有效","options":[{"flag":"A","name":" 对各型银屑病均有效"},{"flag":"B","name":"  对儿童和青少年患者可以正常使用"},{"flag":"C","name":"  肾毒性小"},{"flag":"D","name":"  无需重点关注高血压"}]},"3346":{"id":3346,"qattrid":49,"type":2,"title":"_________评价指标将银屑病患者生活质量的影响纳入评价：（多选题）","result":"A,C,D","content":"BSA没有","options":[{"flag":"A","name":" DLQI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"  SF-36"},{"flag":"D","name":"  EQ-5 "}]},"3347":{"id":3347,"qattrid":46,"type":1,"title":"拓咨®主要通过什么途径代谢","result":"D","content":"拓咨主要通过细胞代谢","options":[{"flag":"A","name":"肝"},{"flag":"B","name":"肾"},{"flag":"C","name":"  肠道"},{"flag":"D","name":"  细胞代谢"}]},"3348":{"id":3348,"qattrid":51,"type":2,"title":"非头对头试验研究对比不同生物制剂达到PASI 50的中位时间，拓咨®时间比哪几项耗时短：（多选题）","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"司库奇尤单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"  英夫利昔单抗"},{"flag":"D","name":"  乌丝奴单抗"}]},"3349":{"id":3349,"qattrid":51,"type":2,"title":"以下哪几项不是拓咨®的关键III期临床试验：（多选题）","result":"B,C,D","content":"UNCOVER系列是","options":[{"flag":"A","name":" UNCOVER-J"},{"flag":"B","name":"REVEAL"},{"flag":"C","name":"  EXPRESS"},{"flag":"D","name":"  IXORA-R"}]},"3350":{"id":3350,"qattrid":49,"type":1,"title":"下列关于系统治疗，说法正确的是：","result":"A","content":"甲氨蝶呤常推荐剂量为10-25mg/周，最常见的不良反应为骨髓抑制和黏膜损伤","options":[{"flag":"A","name":" 甲氨蝶呤常推荐剂量为10-25mg/周，最常见的不良反应为骨髓抑制和黏膜损伤。"},{"flag":"B","name":"甲氨喋呤对各型银屑病不全都有较好的疗效，对甲病和掌跖部位银屑病无疗效。"},{"flag":"C","name":"  环孢素没有肾毒性和高血压"},{"flag":"D","name":"  维A酸常用推荐剂量为0.5-1.0mg/kg/ ，育龄期妇女、老年、儿童正常使用"}]},"3351":{"id":3351,"qattrid":46,"type":1,"title":"下列关于抗药抗体（ADA），正确的是：","result":"B","content":"  检测方法的敏感度和药物耐受性的不同，导致不同药物之间的ADA发生率的比较并不合理","options":[{"flag":"A","name":" 拓咨诱导治疗期间17%的患者发生高效价的ADA"},{"flag":"B","name":"  检测方法的敏感度和药物耐受性的不同，导致不同药物之间的ADA发生率的比较并不合理"},{"flag":"C","name":"  不影响药物PASI改善率"},{"flag":"D","name":"  在拓咨诱导治疗期间发生低效价或中效价A A的患者，在随后治疗中也产生高效价ADA"}]},"3352":{"id":3352,"qattrid":46,"type":1,"title":"拓咨®自动注射器每一剂的产品规格是：","result":"B","content":"拓咨规格是80mg/ml","options":[{"flag":"A","name":" 40mg/ml"},{"flag":"B","name":"80mg/ml"},{"flag":"C","name":"  120mg/ml"},{"flag":"D","name":"  160mg/ml"}]},"3353":{"id":3353,"qattrid":46,"type":2,"title":"关于拓咨®(依奇珠单抗)的用法用量，下列说法不正确的是：（多选题）","result":"A,B,C","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":" 初始剂量80mg，前4周80mg Q1W。维持剂量为80mg Q2W"},{"flag":"B","name":"初始剂量80mg，前4周80mg Q2W。维持剂量为80mg Q4W"},{"flag":"C","name":"  初始剂量160mg，前12周 80mg Q1W。维持剂量为80mg Q2W"},{"flag":"D","name":"  初始剂量160mg，前12周 80mg Q2W。维持剂量为80mg Q4W"}]},"3354":{"id":3354,"qattrid":46,"type":1,"title":"拓咨®说明书里规定老年患者（≥65岁）：","result":"C","content":"拓咨®说明书里老年人群清除率与65岁以下患者清除率相似","options":[{"flag":"A","name":" 需要减少剂量"},{"flag":"B","name":"  需要增加剂量"},{"flag":"C","name":"  无需调整剂量"},{"flag":"D","name":"  以上都不对"}]},"3355":{"id":3355,"qattrid":47,"type":1,"title":"拓咨®首月的注射次数相较于司库奇尤单抗：","result":"A","content":"拓咨®首月的注射次数相较于可善挺®/司库奇尤单抗更少","options":[{"flag":"A","name":" 更少"},{"flag":"B","name":"  一样"},{"flag":"C","name":"  更多"},{"flag":"D","name":"  个体化因人而异"}]},"3356":{"id":3356,"qattrid":46,"type":1,"title":"拓咨®说明书里对于6-18岁儿童和青少年的使用介绍是：","result":"D","content":"拓咨®说明书里对于6-18岁儿童和青少年的使用介绍是安全性和有效性尚未建立","options":[{"flag":"A","name":" 仅安全性尚未建立"},{"flag":"B","name":"  仅有效性尚未建立"},{"flag":"C","name":"  安全性和有效性都已建立"},{"flag":"D","name":"  安全性和有效性尚未建立"}]},"3357":{"id":3357,"qattrid":46,"type":1,"title":"拓咨®说明书里关于患者可以自行在家注射的介绍是：","result":"C","content":"  需要适当培训后医护人员确定可以","options":[{"flag":"A","name":"无需适当培训"},{"flag":"B","name":" 需要适当培训"},{"flag":"C","name":"  需要适当培训后医护人员确定可以"},{"flag":"D","name":"  需要适当培训后销售人员确定可以"}]},"3358":{"id":3358,"qattrid":46,"type":1,"title":"_______患者由于拓咨®治疗的不良反应而终止治疗","result":"B","content":"非常少的患者由于拓咨®治疗的不良反应而终止治疗","options":[{"flag":"A","name":"没有"},{"flag":"B","name":" 非常少"},{"flag":"C","name":"  较少"},{"flag":"D","name":"  较多"}]},"3359":{"id":3359,"qattrid":46,"type":1,"title":"拓咨®说明书里其与感染发生率有关，但没有：","result":"D","content":"拓咨®在安全性研究中发现长期治疗，结核再激活的有0例","options":[{"flag":"A","name":" 上呼吸道感染"},{"flag":"B","name":"结膜炎"},{"flag":"C","name":"  口腔念珠菌病"},{"flag":"D","name":"  结核感染"}]},"3360":{"id":3360,"qattrid":46,"type":1,"title":"拓咨®说明书综合分析结果，皮下注射后的平均生物利用度最高可达。","result":"D","content":"拓咨®说明书综合分析结果，皮下注射后的平均生物利用度为54%-90%","options":[{"flag":"A","name":"0.5"},{"flag":"B","name":"0.65"},{"flag":"C","name":"0.75"},{"flag":"D","name":"0.9"}]},"3361":{"id":3361,"qattrid":50,"type":1,"title":"拓咨®说明书里介绍依奇珠单抗对以下哪些有抑制作用：","result":"A,B","content":"说明书内容","options":[{"flag":"A","name":" 促炎因子释放 "},{"flag":"B","name":"趋化因子释放"},{"flag":"C","name":"  巨噬细胞释放"},{"flag":"D","name":"  淋巴因子释放"}]},"3362":{"id":3362,"qattrid":49,"type":1,"title":"银屑病的治疗手段不包括：","result":"C","content":"日间治疗中心","options":[{"flag":"A","name":" 局部治疗"},{"flag":"B","name":"系统性治疗"},{"flag":"C","name":"  夜间治疗中心"},{"flag":"D","name":"  改良的Goeckerman"}]},"3363":{"id":3363,"qattrid":46,"type":1,"title":"开具生物制剂处方前的特别注意事项没有：","result":"C","content":"开具生物制剂处方前的特别注意事项：妊娠，癌症史（实体瘤、淋巴组织增生性疾病、血液系统恶性肿瘤），重度感染、慢性感染、TB、HIV、HBV/HCV，3级或4级充血性心力衰竭，炎症性肠病","options":[{"flag":"A","name":" 结核感染"},{"flag":"B","name":"癌症史"},{"flag":"C","name":"  1级高血压"},{"flag":"D","name":"  HBV感染"}]},"3364":{"id":3364,"qattrid":51,"type":1,"title":"拓咨®(依奇珠单抗)起效快，中位时间2周即可达到：","result":"B","content":"拓咨®(依奇珠单抗)起效快，达到PASI 50中位时间为2周","options":[{"flag":"A","name":" PASI 100"},{"flag":"B","name":"PASI 50"},{"flag":"C","name":"  sPGA 0/1"},{"flag":"D","name":"  sPGA 0"}]},"3365":{"id":3365,"qattrid":46,"type":2,"title":"以下哪些患者也要在使用生物制剂前注意（多选题）：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":" 脱髓鞘疾病"},{"flag":"B","name":"严重心力衰竭"},{"flag":"C","name":"  手术"},{"flag":"D","name":"IBD"}]},"3366":{"id":3366,"qattrid":46,"type":1,"title":"活动性结核病与结核感染（状态）的患者______生物制剂治疗：","result":"A","content":"活动性肺结核不推荐","options":[{"flag":"A","name":" 不推荐"},{"flag":"B","name":"有条件推荐"},{"flag":"C","name":"  同样推荐"},{"flag":"D","name":"  视具体情况推荐"}]},"3367":{"id":3367,"qattrid":47,"type":1,"title":"新山地明®是：","result":"C","content":"新山地明是环孢素","options":[{"flag":"A","name":"MTX一种"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"  环孢素"},{"flag":"D","name":"  生物制剂一种"}]},"3368":{"id":3368,"qattrid":46,"type":2,"title":"拓咨®正常推荐使用下，一年需注射次数错误的是：（多选题）","result":"A,C,D","content":"拓咨17次，可善挺32次","options":[{"flag":"A","name":"10"},{"flag":"B","name":"17"},{"flag":"C","name":"28"},{"flag":"D","name":"32"}]},"3369":{"id":3369,"qattrid":47,"type":2,"title":"下列关于TNF抑制剂说法错误的是:（多选题）","result":"A,B,D","content":"恩利® 是TNF受体-lgG融合蛋白，皮下注射","options":[{"flag":"A","name":" 修美乐® 是嵌合性单克隆抗体，皮下注射"},{"flag":"B","name":"类克® 是嵌合性单克隆抗体，皮下注射"},{"flag":"C","name":"  恩利® 是TNF受体-lgG融合蛋白，皮下注射"},{"flag":"D","name":"  益赛普® 是TNF受体-lgG融合蛋白，静脉输"}]},"3370":{"id":3370,"qattrid":47,"type":2,"title":"下列关于TNF抑制剂疗效和安全性说法不正确的是：（多选题）","result":"A,B,C","content":" 修美乐®、类克®、恩利® 主要不良反应都有注射部位不良反应","options":[{"flag":"A","name":" 修美乐® 短期治疗16周后，PASI 75应答率超过90%"},{"flag":"B","name":"类克® 短期治疗10周后，PASI 90应答率达到80%"},{"flag":"C","name":"  恩利® 短期治疗12周后，PASI 75应答率超过80%"},{"flag":"D","name":"  修美乐®、类克®、恩利® 主要不良反应都有注射部位不良反应"}]},"3371":{"id":3371,"qattrid":48,"type":1,"title":"据调查，超过一半的银屑病患者对BSA改善的预期超过：","result":"D","content":"据调查，超过一半的银屑病患者对BSA改善的预期超过90%","options":[{"flag":"A","name":"0.6"},{"flag":"B","name":"0.7"},{"flag":"C","name":"0.8"},{"flag":"D","name":"0.9"}]},"3372":{"id":3372,"qattrid":49,"type":1,"title":"人体第1大器官，约占成人总体重16%的是：","result":"C","content":"皮肤是覆盖在人体表面上的最大器官，约占成人总体重的16％ ","options":[{"flag":"A","name":"血液"},{"flag":"B","name":"肺"},{"flag":"C","name":"皮肤"},{"flag":"D","name":"大脑"}]},"3373":{"id":3373,"qattrid":49,"type":1,"title":"皮肤分为三层，中间层是？","result":"B","content":"皮肤分为三层，最外层表皮，真皮，最内层皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"3374":{"id":3374,"qattrid":49,"type":1,"title":"次真皮又被称为：","result":"C","content":"皮肤分为三层，最外层表皮，真皮，最内层皮下（次真皮）","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"假真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"3375":{"id":3375,"qattrid":49,"type":1,"title":"角质层属于皮肤中的那一层：","result":"A","content":"角质层属于皮肤中的表皮","options":[{"flag":"A","name":"表皮"},{"flag":"B","name":"真皮"},{"flag":"C","name":"皮下"},{"flag":"D","name":"脂肪层"}]},"3376":{"id":3376,"qattrid":49,"type":1,"title":"角质形成细胞活化后能释放：","result":"D","content":"以上都是","options":[{"flag":"A","name":"细胞因子"},{"flag":"B","name":"趋化因子"},{"flag":"C","name":"抗菌肽"},{"flag":"D","name":"以上都是"}]},"3377":{"id":3377,"qattrid":49,"type":1,"title":"银屑病是最主要发生在_____的系统性疾病：","result":"B","content":"银屑病主要发生在皮肤","options":[{"flag":"A","name":"黏膜"},{"flag":"B","name":"皮肤"},{"flag":"C","name":"肠道"},{"flag":"D","name":"关节"}]},"3378":{"id":3378,"qattrid":49,"type":2,"title":"皮肤中的哪几种细胞参与与银屑病的发病机制密切相关？","result":"A,C,D","content":"角质形成细胞、皮肤树突状细胞和T细胞组成皮肤重要的免疫细胞","options":[{"flag":"A","name":"T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"树突状细胞"},{"flag":"D","name":"角质形成细胞"}]},"3379":{"id":3379,"qattrid":49,"type":2,"title":"以下关于银屑病机制描述正确的是？","result":"A,C,D","content":"通过以T淋 巴 细 胞 介 导 为主 、多 种 免 疫 细 胞共同参与的免疫反应","options":[{"flag":"A","name":"尚未完全清楚"},{"flag":"B","name":"B淋巴细胞介导为主"},{"flag":"C","name":"引起角质形成细胞过度增殖"},{"flag":"D","name":"引起软骨细胞炎症发生"}]},"3380":{"id":3380,"qattrid":49,"type":1,"title":"以下哪一项不属于参与皮肤银屑病发病的重要的免疫细胞：","result":"B","content":"角质形成细胞、皮肤树突状细胞和T细胞组成皮肤重要的免疫细胞","options":[{"flag":"A","name":"T细胞"},{"flag":"B","name":"B细胞"},{"flag":"C","name":"树突状细胞"},{"flag":"D","name":"角质形成细胞"}]},"3381":{"id":3381,"qattrid":49,"type":2,"title":"银屑病的危害包括：","result":"A,B,D","content":"银屑病易使患者产生抑郁、焦虑等情感障碍，影响人际交往，增加患者自杀风险及经济负担","options":[{"flag":"A","name":"产生焦虑"},{"flag":"B","name":"影响两性生活"},{"flag":"C","name":"对寿命无影响"},{"flag":"D","name":"与癌症有相当的生活质量影响"}]},"3382":{"id":3382,"qattrid":49,"type":2,"title":"银屑病的诊断分型有以下哪几种？","result":"B,C,D","content":"没有斑片型","options":[{"flag":"A","name":"寻常型斑片状"},{"flag":"B","name":"局限性脓疱型"},{"flag":"C","name":"泛发性斑块型"},{"flag":"D","name":"寻常型斑块型"}]},"3383":{"id":3383,"qattrid":49,"type":1,"title":"银屑病的主要症状有以下哪种？","result":"A","content":"皮肤剥落是症状之一","options":[{"flag":"A","name":"皮肤剥落"},{"flag":"B","name":"湿润"},{"flag":"C","name":"紫色鳞屑"},{"flag":"D","name":"皮肤发黑"}]},"3384":{"id":3384,"qattrid":49,"type":1,"title":"银屑病发病的性别差异是：","result":"C","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":"有，男性多"},{"flag":"B","name":"有，女性多"},{"flag":"C","name":"无性别差异"},{"flag":"D","name":"年轻男性多，老年女性多"}]},"3385":{"id":3385,"qattrid":49,"type":1,"title":"研究数据显示，在年龄60-69岁的人群中，银屑病有第_____次上升趋势。","result":"B","content":"发病年龄总体上存在双峰分布。研究数据显示，在年龄不超过39岁的人群中，银屑病发病率有上升趋势。在随后的40-49岁发病率下降。而在60-69岁时，又出现一个发病高峰","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"3386":{"id":3386,"qattrid":48,"type":2,"title":"在中国，受银屑病影响的人数预计可达600万以上，趋势错误的是________：","result":"A,B,C","content":"在中国，受银屑病影响的人数预计可达600万以上，同时逐年增加","options":[{"flag":"A","name":"逐年下降"},{"flag":"B","name":"保持不变"},{"flag":"C","name":"波动变化"},{"flag":"D","name":"逐年增加"}]},"3387":{"id":3387,"qattrid":49,"type":1,"title":"银屑病斑块确切病因是？","result":"D","content":"银屑病的病因及发病机制尚未完全清楚","options":[{"flag":"A","name":"遗传"},{"flag":"B","name":"免疫"},{"flag":"C","name":"环境"},{"flag":"D","name":"尚未完全清楚"}]},"3388":{"id":3388,"qattrid":49,"type":1,"title":"斑块型银屑病皮疹以下哪个部位最少累及：","result":"D","content":"手部较少累及","options":[{"flag":"A","name":"头皮"},{"flag":"B","name":"肘部"},{"flag":"C","name":"膝盖"},{"flag":"D","name":"手部"}]},"3389":{"id":3389,"qattrid":49,"type":2,"title":"下列关于促进银屑病疾病活动度的因素中，正确的是：","result":"B,C,D","content":"酗酒目前没有研究证实","options":[{"flag":"A","name":"酗酒"},{"flag":"B","name":"心理应激"},{"flag":"C","name":"手术"},{"flag":"D","name":"吸烟"}]},"3390":{"id":3390,"qattrid":49,"type":2,"title":"Th17产生的细胞因子包括：","result":"A,B,C","content":"Th17产生的细胞因子包括：IL-17A、IL-17F、IL-21和TNF-α","options":[{"flag":"A","name":"IL-17A"},{"flag":"B","name":"TNF-α"},{"flag":"C","name":"IL-17F"},{"flag":"D","name":"IFNγ"}]},"3391":{"id":3391,"qattrid":49,"type":1,"title":"银屑病通常以下症状调查中最少出现的是？","result":"C","content":"僵硬/紧度发生率约为52%","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"皮肤剥落"},{"flag":"C","name":"僵硬"},{"flag":"D","name":"斑块型相关疼痛"}]},"3392":{"id":3392,"qattrid":49,"type":1,"title":"超过75%的银屑病病例为_______","result":"A","content":"超过75%的病例为I类银屑病","options":[{"flag":"A","name":"I类"},{"flag":"B","name":"II类"},{"flag":"C","name":"III类"},{"flag":"D","name":"以上都不对"}]},"3393":{"id":3393,"qattrid":49,"type":1,"title":"已发现，与未患银屑病皮肤疾病的人群相比，银屑病患者的以下哪种疾病发生率显著更高？","result":"A","content":"高血脂是银屑病共病之一","options":[{"flag":"A","name":"高血脂"},{"flag":"B","name":"白化病"},{"flag":"C","name":"甲状腺功能亢进"},{"flag":"D","name":"甲状腺功能减退"}]},"3394":{"id":3394,"qattrid":49,"type":1,"title":"通过研究双胞胎发病率发现，银屑病_______遗传倾向","result":"B","content":"银屑病具有遗传倾向","options":[{"flag":"A","name":"不具有"},{"flag":"B","name":"具有"},{"flag":"C","name":"有时有"},{"flag":"D","name":"说不清"}]},"3395":{"id":3395,"qattrid":49,"type":1,"title":"上呼吸道感染_______银屑病的患病风险","result":"C","content":"上感增加银屑病的患病风险","options":[{"flag":"A","name":"降低"},{"flag":"B","name":"不改变"},{"flag":"C","name":"增加"},{"flag":"D","name":"以上都不对"}]},"3396":{"id":3396,"qattrid":49,"type":1,"title":"在银屑病中起作用的T细胞有不同类型，其中_________发挥了重要作用。","result":"C","content":"在银屑病中起作用的T细胞有不同类型，其中Th17细胞发挥了重要作用","options":[{"flag":"A","name":"Th15"},{"flag":"B","name":"Th16"},{"flag":"C","name":"Th17"},{"flag":"D","name":"Th18"}]},"3397":{"id":3397,"qattrid":49,"type":2,"title":"下面哪几种细胞属于淋巴细胞？","result":"A,C,D","content":"淋巴细胞包括B细胞、T细胞以及NK细胞","options":[{"flag":"A","name":"NK细胞"},{"flag":"B","name":"角化细胞"},{"flag":"C","name":"B细胞"},{"flag":"D","name":"T细胞"}]},"3398":{"id":3398,"qattrid":49,"type":1,"title":"低于40岁的个体主要存在的银屑病是：","result":"A","content":"低于40岁的个体中存在I类（或早发）银屑病","options":[{"flag":"A","name":"I类"},{"flag":"B","name":"II类"},{"flag":"C","name":"III类"},{"flag":"D","name":"以上都不对"}]},"3399":{"id":3399,"qattrid":49,"type":2,"title":"哪些银屑病类型占银屑病的发病率不超过1成_______：","result":"A,B,D","content":"斑块型是最常见的类型，约占90%","options":[{"flag":"A","name":"点滴状"},{"flag":"B","name":"局限性脓疱型"},{"flag":"C","name":"斑块型"},{"flag":"D","name":"红皮病型"}]},"3400":{"id":3400,"qattrid":48,"type":2,"title":"银屑病对患者生活质量的影响有：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"行走"},{"flag":"B","name":"睡眠"},{"flag":"C","name":"两性生活"},{"flag":"D","name":"人际关系"}]},"3401":{"id":3401,"qattrid":49,"type":2,"title":"根据流调，银屑病发病率可能与以下哪些有关？","result":"A,B","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":"纬度越高发病率越高"},{"flag":"B","name":"种族"},{"flag":"C","name":"性别"},{"flag":"D","name":"年龄越大，发病率越高"}]},"3402":{"id":3402,"qattrid":49,"type":1,"title":"以下哪项是斑块型银屑病的皮疹特点？","result":"C","content":"查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"、束状发等","options":[{"flag":"A","name":"境界不清"},{"flag":"B","name":"暗黑色斑块或非浸润性红斑"},{"flag":"C","name":"查体见“薄膜现象”"},{"flag":"D","name":"静止期可有“同形反应”"}]},"3403":{"id":3403,"qattrid":49,"type":1,"title":"与未患该疾病的患者相比，银屑病患者面临的自杀风险为：","result":"C","content":"银屑病易使患者产生抑郁、焦虑等情感障碍，影响人际交往，增加患者自杀风险及经济负担","options":[{"flag":"A","name":"更低"},{"flag":"B","name":"正常"},{"flag":"C","name":"更高"},{"flag":"D","name":"不清楚"}]},"3404":{"id":3404,"qattrid":49,"type":1,"title":"以下哪项不是斑块型银屑病的特点：","result":"C","content":"可以全身性分布","options":[{"flag":"A","name":"慢性疾病"},{"flag":"B","name":"发红/增厚/鳞屑"},{"flag":"C","name":"只会局限分布"},{"flag":"D","name":"系统性疾病"}]},"3405":{"id":3405,"qattrid":48,"type":2,"title":"以下哪几项不是2018中国指南银屑病的治疗目的：","result":"B,D","content":"控制和稳定病情，减缓向全身发展的进程；减轻红斑、鳞屑、斑块增厚等皮损加重的症状；避免复发/诱发加重的因素；减少不良反应；提高生活质量","options":[{"flag":"A","name":"控制和稳定病情"},{"flag":"B","name":"治愈病情"},{"flag":"C","name":"减缓向全身发展的进程"},{"flag":"D","name":"完全消除不良反应"}]},"3406":{"id":3406,"qattrid":48,"type":2,"title":"以下哪几项是2018中国指南银屑病的治疗原则：","result":"A,B,C","content":"治疗原则是正规、安全、个体化","options":[{"flag":"A","name":"强调使用指南推荐的治疗药物/方法"},{"flag":"B","name":"以确保安全为首要"},{"flag":"C","name":"个体化"},{"flag":"D","name":"系统化"}]},"3407":{"id":3407,"qattrid":49,"type":1,"title":"斑块型银屑病“皮损缩小或变平，遗留色素减退或色素沉着斑”属于：","result":"D","content":"斑块型银屑病“皮损缩小或变平，遗留色素减退或色素沉着斑”属于退行期","options":[{"flag":"A","name":"复发期"},{"flag":"B","name":"进行期"},{"flag":"C","name":"静止期"},{"flag":"D","name":"退行期"}]},"3408":{"id":3408,"qattrid":49,"type":1,"title":"Th17细胞及相关的细胞因子参与了银屑病的发病，其中没有：","result":"A","content":"Th17细胞及相关细胞因子（IL-17A、IL-23、TNF-α）参与了银屑病的炎症反应","options":[{"flag":"A","name":"IL-15"},{"flag":"B","name":"IL-23"},{"flag":"C","name":"IL-17A"},{"flag":"D","name":"TNF-α"}]},"3409":{"id":3409,"qattrid":49,"type":1,"title":"以下哪个因素目前研究表明不是导致银屑病的发病的主要因素：","result":"D","content":"银屑病可发生于各年龄段，无性别差异","options":[{"flag":"A","name":"遗传因素"},{"flag":"B","name":"环境因素"},{"flag":"C","name":"免疫因素"},{"flag":"D","name":"性别因素"}]},"3410":{"id":3410,"qattrid":49,"type":2,"title":"_____不是目前发现可以导致银屑病加重的因素。","result":"A,C","content":"吸烟和非甾体类抗炎药都是促进疾病活动的因素","options":[{"flag":"A","name":"酗酒"},{"flag":"B","name":"吸烟"},{"flag":"C","name":"感冒口服液"},{"flag":"D","name":"非甾体类抗炎药物（NSAID）"}]},"3411":{"id":3411,"qattrid":49,"type":1,"title":"银屑病患者面临的共病不包括：","result":"D","content":"甲减不是共病之一","options":[{"flag":"A","name":"代谢性疾病"},{"flag":"B","name":"溃疡性结肠炎"},{"flag":"C","name":"肥胖"},{"flag":"D","name":"甲减"}]},"3412":{"id":3412,"qattrid":49,"type":1,"title":"银屑病的共病风险随着银屑病严重程度的加重会？","result":"B","content":"共病的发病率随着银屑病严重程度的增加而增加","options":[{"flag":"A","name":"减少"},{"flag":"B","name":"提高"},{"flag":"C","name":"不受影响"},{"flag":"D","name":"以上都不对"}]},"3413":{"id":3413,"qattrid":49,"type":2,"title":"银屑病作为一种系统性疾病，会增加患者的_______风险：","result":"A,B,C","content":"不是所有癌症的风险都会增加","options":[{"flag":"A","name":"抑郁"},{"flag":"B","name":"焦虑"},{"flag":"C","name":"自杀"},{"flag":"D","name":"所有癌症"}]},"3414":{"id":3414,"qattrid":49,"type":1,"title":"银屑病的促炎细胞因子_______代谢性疾病的炎症通路。","result":"A","content":"促炎细胞因子不仅在银屑病的发病中发挥着重要作用，还连接着心血管疾病的炎症通路","options":[{"flag":"A","name":"连接"},{"flag":"B","name":"不连接"},{"flag":"C","name":"间歇性连接"},{"flag":"D","name":"以上都不对"}]},"3415":{"id":3415,"qattrid":49,"type":1,"title":"在银屑病的年轻患者中，心理疾病问题：","result":"D","content":"在银屑病的年轻患者中，心理疾病问题更为明显","options":[{"flag":"A","name":"更不明显"},{"flag":"B","name":"和其他无差异"},{"flag":"C","name":"因人而异"},{"flag":"D","name":"更为明显"}]},"3416":{"id":3416,"qattrid":48,"type":1,"title":"总的来说，最新研发的生物疗法______像传统疗法一样对代谢指标产生不良影响:","result":"B","content":"一般来说，生物疗法不会","options":[{"flag":"A","name":"会"},{"flag":"B","name":"不会"},{"flag":"C","name":"无关系"},{"flag":"D","name":"以上都不对"}]},"3417":{"id":3417,"qattrid":48,"type":1,"title":"重度银屑病患者对男性患者总体寿命：","result":"D","content":"重度银屑病男性患者总体寿命减少3.5年较未患有银屑病男性","options":[{"flag":"A","name":"增加了3.5年"},{"flag":"B","name":"无影响"},{"flag":"C","name":"减少了1.5年"},{"flag":"D","name":"减少了3.5年"}]},"3418":{"id":3418,"qattrid":49,"type":1,"title":"目前调查确定银屑病不总是会出现的症状是，即以下哪项发生率最低？","result":"B","content":"皮肤发红出现概率为86%，其余为100%","options":[{"flag":"A","name":"瘙痒"},{"flag":"B","name":"皮肤发红"},{"flag":"C","name":"斑块型相关疼痛"},{"flag":"D","name":"外观变化"}]},"3419":{"id":3419,"qattrid":48,"type":1,"title":"银屑病预计影响着全球多少患者：","result":"D","content":"全球预计1.25亿","options":[{"flag":"A","name":"600万"},{"flag":"B","name":"5600万"},{"flag":"C","name":"8600万"},{"flag":"D","name":"1.25亿"}]},"3420":{"id":3420,"qattrid":48,"type":2,"title":"中国很多皮肤科医生目前___________。","result":"A,B,D","content":"医生不追求长期疗效，因为对现有治疗方案长期疗效都不满意","options":[{"flag":"A","name":"不追求完全清除"},{"flag":"B","name":"不追求快速起效"},{"flag":"C","name":"更追求长期疗效"},{"flag":"D","name":"对现有的传统治疗方案不满意"}]},"3421":{"id":3421,"qattrid":48,"type":2,"title":"目前北欧及美国指南和实践认为通过新的药物治疗银屑病能：","result":"A,B,D","content":"追求PASI90/100","options":[{"flag":"A","name":"初步快速控制疾病"},{"flag":"B","name":"皮损几乎全部清除"},{"flag":"C","name":"PASI 75是目标"},{"flag":"D","name":"保持长期缓解，避免复发"}]},"3422":{"id":3422,"qattrid":49,"type":1,"title":"皮肤病生活质量测量工具有：","result":"C","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，在非特异性方面，简表36（SF-36）和EuroQoL 5D（EQ-5D）常用来评估患者整体的生活质量","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"PGA"},{"flag":"C","name":"EQ-5D"},{"flag":"D","name":"BSA"}]},"3423":{"id":3423,"qattrid":49,"type":2,"title":"免疫介导的银屑病有：","result":"A,B,C","content":"没有传染性","options":[{"flag":"A","name":"遗传性"},{"flag":"B","name":"地理差异"},{"flag":"C","name":"人种差异"},{"flag":"D","name":"传染性"}]},"3424":{"id":3424,"qattrid":49,"type":2,"title":"以下哪几项在斑块型银屑病查体中见得到？","result":"B,D","content":"查体见“蜡滴现象”、“薄膜现象”、\"点状出血现象（Auspltz征）\"、束状发等","options":[{"flag":"A","name":"油滴现象"},{"flag":"B","name":"薄膜现象"},{"flag":"C","name":"大片出血现象"},{"flag":"D","name":"束状发"}]},"3425":{"id":3425,"qattrid":49,"type":1,"title":"BSA估计银屑病累及的皮肤表面积占________的百分比:","result":"D","content":"BSA估计银屑病累及的皮肤表面积占总体表面积的百分比","options":[{"flag":"A","name":"上半身表面积"},{"flag":"B","name":"下半身表面积"},{"flag":"C","name":"1只手掌"},{"flag":"D","name":"总体表面积"}]},"3426":{"id":3426,"qattrid":49,"type":1,"title":"sPGA中的5分代表;","result":"D","content":"sPGA中的5分代表特别严重","options":[{"flag":"A","name":"清洁"},{"flag":"B","name":"轻度"},{"flag":"C","name":"显著"},{"flag":"D","name":"特别严重"}]},"3427":{"id":3427,"qattrid":49,"type":1,"title":"以下那项不属于PASI评分总计公式内容？","result":"C","content":"PASI总计=严重程度评分×皮损面积评分×权重因子","options":[{"flag":"A","name":"严重程度评分"},{"flag":"B","name":"皮损面积评分"},{"flag":"C","name":"生活质量评分"},{"flag":"D","name":"权重因子"}]},"3428":{"id":3428,"qattrid":49,"type":1,"title":"外伤会导致的Koebner现象是：","result":"C","content":"外伤会导致的Koebner现象是同形反应","options":[{"flag":"A","name":"油滴现象"},{"flag":"B","name":"薄膜现象"},{"flag":"C","name":"同形反应"},{"flag":"D","name":"束状发"}]},"3429":{"id":3429,"qattrid":49,"type":1,"title":"银屑病在遗传相关的研究中，银屑病在______中患病率为20%：","result":"B","content":"在异卵双胞胎中为20%","options":[{"flag":"A","name":"同卵双胞胎"},{"flag":"B","name":"异卵双胞胎"},{"flag":"C","name":"三胞胎"},{"flag":"D","name":"以上都不对"}]},"3430":{"id":3430,"qattrid":49,"type":1,"title":"医师对银屑病患者头等4个单独的身体区域R、T、S情况进行评价的是：","result":"A","content":"PASI评分将身体分为头颈部、上肢、躯干、下肢四个部位进行评分","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"DLQI"},{"flag":"D","name":"PGA"}]},"3431":{"id":3431,"qattrid":49,"type":2,"title":" 银屑病患者可能存在不同的疾病体征和症状，但通常不会表现为以下一种或多种：","result":"A,C,D","content":"红色，干燥，变厚","options":[{"flag":"A","name":"皮肤出现片状黑斑，上覆银屑或斑块"},{"flag":"B","name":"小块部位出现鳞屑"},{"flag":"C","name":"皮肤湿润渗出，可能出血"},{"flag":"D","name":"指/趾甲变薄"}]},"3432":{"id":3432,"qattrid":51,"type":1,"title":"以下哪项关于UNCOVER-J的描述是错误的？","result":"C","content":"UNCOVER短期是52周","options":[{"flag":"A","name":"关键III期研究"},{"flag":"B","name":"在日本进行"},{"flag":"C","name":"为期16周"},{"flag":"D","name":"16周时PASI 100可达40%"}]},"3433":{"id":3433,"qattrid":51,"type":1,"title":"相较于国内已上市的系统用药，依奇珠单抗的皮损清除率：","result":"A","content":"均更高","options":[{"flag":"A","name":"均更高"},{"flag":"B","name":"部分更高"},{"flag":"C","name":"只比乌丝奴单抗低"},{"flag":"D","name":"只比司库奇尤单抗低"}]},"3434":{"id":3434,"qattrid":51,"type":1,"title":"以下哪一个是乌丝奴单抗的关键临床试验：","result":"B","content":"PHOENIX是乌丝奴单抗的关键临床试验","options":[{"flag":"A","name":"UNCOVER-1"},{"flag":"B","name":"PHOENIX"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":"EXPRESS"}]},"3435":{"id":3435,"qattrid":49,"type":2,"title":"斑块型银屑病皮损通常会_______：","result":"A,B,D","content":"皮损反复发作，多数冬重夏轻","options":[{"flag":"A","name":"有静止期"},{"flag":"B","name":"有退行期"},{"flag":"C","name":"一过性发作"},{"flag":"D","name":"反复发作"}]},"3436":{"id":3436,"qattrid":48,"type":1,"title":"调查显示，银屑病对患者生活的质量造成的影响与COPD相比______：","result":"C","content":"银屑病对生活质量的影响与其他慢性严重疾病相当","options":[{"flag":"A","name":"更高"},{"flag":"B","name":"更低"},{"flag":"C","name":"相当"},{"flag":"D","name":"说不清"}]},"3437":{"id":3437,"qattrid":48,"type":2,"title":"据调查，斑块型银屑病的经济负担整体与以下哪些疾病相当：","result":"A,B,C,D","content":"相当","options":[{"flag":"A","name":"糖尿病"},{"flag":"B","name":"冠脉疾病"},{"flag":"C","name":"哮喘"},{"flag":"D","name":"高血压"}]},"3438":{"id":3438,"qattrid":49,"type":1,"title":"BSA是指采用1只_____约代表_____的体表面积的近似法：","result":"D","content":"体表面积（BSA）是指采用一只手掌代表1%体表面积","options":[{"flag":"A","name":"手臂，2%"},{"flag":"B","name":"手指，0.5%"},{"flag":"C","name":"手掌，2%"},{"flag":"D","name":"手掌，1%"}]},"3439":{"id":3439,"qattrid":49,"type":2,"title":"以下哪一个银屑病皮损面积BSA不是中度：","result":"A,D","content":"受影响体表面积百分比低于3%，银屑病划分为轻度，银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":"0.02"},{"flag":"B","name":"0.03"},{"flag":"C","name":"0.08"},{"flag":"D","name":"0.11"}]},"3440":{"id":3440,"qattrid":49,"type":2,"title":"属于PASI几个单独身体区域评分范畴的是：","result":"B,D","content":"PASI评分将身体分为头颈部、上肢、躯干、下肢四个部位进行评分","options":[{"flag":"A","name":"指甲"},{"flag":"B","name":"头颈"},{"flag":"C","name":"背部"},{"flag":"D","name":"下肢"}]},"3441":{"id":3441,"qattrid":49,"type":2,"title":"以下哪些评估方法涉及生活质量问题：","result":"A,C,D","content":"PASI和PGA均不涉及生活质量问题， 皮肤病生活质量指数（DLQI）是一项皮肤特定生活质量评估工具，在非特异性方面，简表36（SF-36）和EuroQoL 5D（EQ-5D）常用来评估患者整体的生活质量","options":[{"flag":"A","name":"SF-36"},{"flag":"B","name":"PGA"},{"flag":"C","name":"DLQI"},{"flag":"D","name":"EQ-5D"}]},"3442":{"id":3442,"qattrid":49,"type":2,"title":"2018中国指南关于寻常型银屑病的疾病严重度分类描述不正确的是","result":"A,B,D","content":"受影响体表面积百分比低于3%，银屑病划分为轻度，银屑病的严重程度可通过BSA来分类，皮损面积超过10%即为重度","options":[{"flag":"A","name":"轻度BSA<5%"},{"flag":"B","name":"中度BSA 5~10%"},{"flag":"C","name":"重度BSA>10%"},{"flag":"D","name":"极重度BSA＞15%"}]},"3443":{"id":3443,"qattrid":49,"type":1,"title":"严重程度分类标准极为重要，2018中国指南寻常型银屑病严重程度主要分为_______：","result":"C","content":"最新中国银屑病诊疗指南（2018版）根据BSA及生活质量评估，对寻常型银屑病严重程度进行了3分类，轻中重","options":[{"flag":"A","name":"轻度，中度，中重度，重度"},{"flag":"B","name":"轻度，中度，重度，极重度"},{"flag":"C","name":"轻度，中度，重度"},{"flag":"D","name":"轻度，重度，危重度"}]},"3444":{"id":3444,"qattrid":49,"type":1,"title":"2018中国指南寻常型银屑病严重程度中DLQI多少分以上为中重度：","result":"C","content":"6分以上DLQI为中重度","options":[{"flag":"A","name":"3"},{"flag":"B","name":"5"},{"flag":"C","name":"6"},{"flag":"D","name":"10"}]},"3445":{"id":3445,"qattrid":49,"type":1,"title":"PASI评分为10分时，银屑病划分为？","result":"A","content":"PASI>10=中重度，PASI≦10=轻度","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"中度"},{"flag":"C","name":"中重度"},{"flag":"D","name":"重度"}]},"3446":{"id":3446,"qattrid":49,"type":1,"title":"PASI评分总分最高分是：","result":"C","content":"范围从0（无疾病）至72（最严重疾病） 。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"0"},{"flag":"B","name":"52"},{"flag":"C","name":"72"},{"flag":"D","name":"100"}]},"3447":{"id":3447,"qattrid":49,"type":1,"title":"以下PASI评分总分哪一个最严重：","result":"C","content":"范围从0（无疾病）至72（最严重疾病） 。PASI评分越高，银屑病越严重","options":[{"flag":"A","name":"0"},{"flag":"B","name":"50"},{"flag":"C","name":"60"},{"flag":"D","name":"80"}]},"3448":{"id":3448,"qattrid":49,"type":2,"title":"计算PASI时，属于医师对患者几个单独的身体区域情况的进行评价的是","result":"A,B,D","content":"从红斑、厚度和鳞屑三个角度对严重程度进行评分（0分=清洁，1-4分随严重程度增加）","options":[{"flag":"A","name":"红斑"},{"flag":"B","name":"厚度"},{"flag":"C","name":"疼痛"},{"flag":"D","name":"鳞屑"}]},"3449":{"id":3449,"qattrid":49,"type":1,"title":"PASI 75意味着：","result":"D","content":"PASI 75意味着：银屑病面积和严重程度指数评分减少75%","options":[{"flag":"A","name":"银屑病面积和严重程度指数评分减少75分"},{"flag":"B","name":"银屑病面积指数评分减少75%"},{"flag":"C","name":"银屑病严重程度指数评分减少75%"},{"flag":"D","name":"银屑病面积和严重程度指数评分减少75%"}]},"3450":{"id":3450,"qattrid":51,"type":1,"title":"在多数银屑病临床试验中，主要终点指标是：","result":"B","content":"PASI 75在多数银屑病临床试验中是主要终点指标","options":[{"flag":"A","name":"PASI 50"},{"flag":"B","name":"PASI 75"},{"flag":"C","name":"PASI 90"},{"flag":"D","name":"PASI 100"}]},"3451":{"id":3451,"qattrid":51,"type":1,"title":"IXORA-S是拓咨®的重要头对头试验，研究主要终点是12周时的：","result":"C","content":"IXORA-S是拓咨®的重要头对头试验，研究主要终点是12周时的PASI 90","options":[{"flag":"A","name":"PASI 50"},{"flag":"B","name":"PASI 75"},{"flag":"C","name":"PASI 90"},{"flag":"D","name":"PASI 100"}]},"3452":{"id":3452,"qattrid":47,"type":2,"title":"以下在中国获批治疗银屑病的生物制剂有：","result":"A,B,D","content":"恩利®未获批","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"益赛普®"},{"flag":"C","name":"恩利®"},{"flag":"D","name":"可善挺®"}]},"3453":{"id":3453,"qattrid":47,"type":1,"title":"非头对头临床研究对比，拓咨®12周时PASI 90 优于：","result":"D","content":"都优于","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"喜达诺®"},{"flag":"C","name":"可善挺®"},{"flag":"D","name":"以上都是"}]},"3454":{"id":3454,"qattrid":47,"type":2,"title":"特异性作用于白介素IL-17的有：","result":"C,D","content":"特异性作用于白介素IL-17的有可善挺®和拓咨®","options":[{"flag":"A","name":"修美乐®"},{"flag":"B","name":"喜达诺®"},{"flag":"C","name":"可善挺®"},{"flag":"D","name":"拓咨®"}]},"3455":{"id":3455,"qattrid":50,"type":2,"title":"拓咨®不是一种：","result":"A,B,D","content":"拓咨®（依奇珠单抗）是一种人源化lgG4单克隆抗体，具有高亲和力(<3pM)，特异性作用于白介素IL-17A","options":[{"flag":"A","name":"全人源lgG4单克隆抗体"},{"flag":"B","name":"鼠源化lgG4单克隆抗体"},{"flag":"C","name":"人源化lgG4单克隆抗体"},{"flag":"D","name":"人源化lgG1单克隆抗体"}]},"3456":{"id":3456,"qattrid":46,"type":1,"title":"生物制剂可以呈现良好的疗效和安全性，通过：","result":"D","content":"生物制剂可以单独使用活着了联合其他药物使用","options":[{"flag":"A","name":"单独治疗"},{"flag":"B","name":"联合外用药物"},{"flag":"C","name":"联合其他系统药物"},{"flag":"D","name":"以上都是"}]},"3457":{"id":3457,"qattrid":50,"type":2,"title":"关于单克隆抗体，下列说法错误的是","result":"B,D","content":"由单一杂交瘤细胞产生，针对单一抗原表位的特异性抗体，称为单克隆抗体。lgG4的Fc片段诱导CDC或ADCC能力较差，细胞毒性少。与鼠源抗体相比，人源化抗体同源性可达85-90%，减少免疫原性","options":[{"flag":"A","name":"基本结构是由两条完全相同的重链和两条完全相同的轻链通过二硫键连接"},{"flag":"B","name":"免疫球蛋白lgG1诱导CDC或ADCC能力较差，细胞毒性少"},{"flag":"C","name":"分为可变区和恒定区"},{"flag":"D","name":"抗药性抗体（ADAs）不会影响单克隆抗体治疗的临床效果"}]},"3458":{"id":3458,"qattrid":49,"type":2,"title":"银屑病常用外用药物包括","result":"A,B,D","content":"常用外用药物包括润肤剂、保湿剂、维生素D3衍生物、维A酸类、糖皮质激素、钙调磷酸酶抑制剂、抗人白介素8单克隆抗体和焦油制剂等。","options":[{"flag":"A","name":"他扎罗汀"},{"flag":"B","name":"保湿剂"},{"flag":"C","name":"环孢素"},{"flag":"D","name":"维生素D3衍生物"}]},"3459":{"id":3459,"qattrid":48,"type":1,"title":"中国银屑病市场生物制剂销售额2028年预计将达：","result":"C","content":"中国银屑病市场生物制剂销售额2028年预计将达8亿","options":[{"flag":"A","name":"1亿人民币"},{"flag":"B","name":"3亿人民币"},{"flag":"C","name":"8亿人民币"},{"flag":"D","name":"28亿人民币"}]},"3460":{"id":3460,"qattrid":46,"type":1,"title":"依奇珠单抗的人源种系序列高于","result":"C","content":"依奇珠单抗是98.2%的人类种系序列(24/1328个非同源氨基酸)","options":[{"flag":"A","name":"0.78"},{"flag":"B","name":"0.88"},{"flag":"C","name":"0.98"},{"flag":"D","name":"0.998"}]},"3461":{"id":3461,"qattrid":49,"type":2,"title":"固有免疫细胞产生IL-17A的调控途径描述错误的是","result":"A,B,D","content":"固有免疫细胞产生的IL-17A可以独立于IL-23而发生，比如γδ-T细胞和iNKT细胞","options":[{"flag":"A","name":"必须依赖IL-23"},{"flag":"B","name":"完全独立于IL-23"},{"flag":"C","name":"可以独立于IL-23"},{"flag":"D","name":"必须依赖IL-12"}]},"3462":{"id":3462,"qattrid":47,"type":1,"title":"属于可善挺®的适应症内容的是：","result":"A","content":"符合系统治疗或光疗的中度至重度斑块型银屑病成人患者","options":[{"flag":"A","name":"符合系统治疗或光疗的中度至重度斑块型银屑病成人患者"},{"flag":"B","name":"符合局部治疗或光疗的轻度至中度斑块型银屑病成人患者"},{"flag":"C","name":"符合局部治疗或光疗的轻度至中度点滴型银屑病成人患者"},{"flag":"D","name":"符合系统治疗或光疗的中度至重度点滴型银屑病成人患者"}]},"3463":{"id":3463,"qattrid":47,"type":2,"title":"以下哪几项属于银屑病的系统治疗","result":"A,D","content":"光疗不是系统性治疗","options":[{"flag":"A","name":"新山地明"},{"flag":"B","name":"PUVA"},{"flag":"C","name":"NB-UVB"},{"flag":"D","name":"阿维A"}]},"3464":{"id":3464,"qattrid":47,"type":2,"title":"以下哪几个属于TNF-α拮抗剂：","result":"A,B,C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"益赛普"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"英夫利西单抗"},{"flag":"D","name":"乌丝奴单抗"}]},"3465":{"id":3465,"qattrid":47,"type":1,"title":"下列哪项药物的通用名和商品名对应不正确？","result":"B","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"恩利®依那西普"},{"flag":"B","name":"类克®乌丝奴单抗"},{"flag":"C","name":"修美乐®阿达木单抗"},{"flag":"D","name":"可善挺®司库奇尤单抗"}]},"3466":{"id":3466,"qattrid":47,"type":1,"title":"下列在银屑病药物的研发历程中，最新被批准进入中国的研究药物是","result":"C","content":"2019年批准司库奇尤单抗","options":[{"flag":"A","name":"Tremfya®"},{"flag":"B","name":"英夫利西单抗"},{"flag":"C","name":"司库奇尤单抗"},{"flag":"D","name":"阿达木单抗"}]},"3467":{"id":3467,"qattrid":47,"type":1,"title":"恩利®的作用机制不是","result":"A,B,D","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-17A及其受体拮抗剂"}]},"3468":{"id":3468,"qattrid":47,"type":1,"title":"阿达木单抗的作用机制是","result":"C","content":"修美乐/阿达木单抗、益赛普、恩利/依那西普以及类克/英夫利昔单抗是TNF-α 抑制剂","options":[{"flag":"A","name":"叶酸还原酶抑制剂"},{"flag":"B","name":"选择性作用于T淋巴细胞的免疫抑制剂"},{"flag":"C","name":"TNF-α 抑制剂"},{"flag":"D","name":"IL-17A及其受体拮抗剂"}]},"3469":{"id":3469,"qattrid":47,"type":2,"title":"下列哪几个药物是系统性治疗药物","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"环孢素"},{"flag":"B","name":"甲氨蝶呤"},{"flag":"C","name":"益赛普"},{"flag":"D","name":"修美乐"}]},"3470":{"id":3470,"qattrid":48,"type":2,"title":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它不是：","result":"A,C,D","content":"AAD-NPF指南时美国指南","options":[{"flag":"A","name":"国指南"},{"flag":"B","name":"美国指南"},{"flag":"C","name":"德国指南"},{"flag":"D","name":"英国指南"}]},"3471":{"id":3471,"qattrid":48,"type":2,"title":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它的推荐强度不是：","result":"A,B,D","content":"AAD-NPF指南推荐依奇珠单抗作为单药治疗选择，它的推荐强度是A等级","options":[{"flag":"A","name":"C等级"},{"flag":"B","name":"B等级"},{"flag":"C","name":"A等级"},{"flag":"D","name":"没有等级"}]},"3472":{"id":3472,"qattrid":48,"type":1,"title":"新山地明®的生产厂家是：","result":"B","content":"新山地明的厂家是诺华制药","options":[{"flag":"A","name":"辉瑞"},{"flag":"B","name":"诺华"},{"flag":"C","name":"西安杨森"},{"flag":"D","name":"艾伯维"}]},"3473":{"id":3473,"qattrid":47,"type":1,"title":"喜达诺®的使用方式为：","result":"C","content":"喜达诺®的使用方式为皮下注射","options":[{"flag":"A","name":"口服片剂"},{"flag":"B","name":"口服胶囊"},{"flag":"C","name":"皮下注射"},{"flag":"D","name":"肌注"}]},"3474":{"id":3474,"qattrid":47,"type":1,"title":"喜达诺®在中国进行的关键III期临床研究叫：","result":"B","content":"喜达诺®在中国进行的关键III期临床研究叫LOTUS","options":[{"flag":"A","name":"Uncover"},{"flag":"B","name":"LOTUS"},{"flag":"C","name":"IXORA"},{"flag":"D","name":"BECOME"}]},"3475":{"id":3475,"qattrid":47,"type":1,"title":"可善挺®的规格为：","result":"B","content":"可善挺®的规格为：150mg","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":"150mg"},{"flag":"C","name":"250mg"},{"flag":"D","name":"300mg"}]},"3476":{"id":3476,"qattrid":47,"type":1,"title":"以下治疗银屑病获批进入中国时间日期最近的是：","result":"A","content":"拓咨®在国内目前获批治疗斑块型银屑病的日期为 2019.08.29","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"乌司奴单抗"},{"flag":"D","name":"司库奇尤单抗"}]},"3477":{"id":3477,"qattrid":47,"type":1,"title":"第一个治疗银屑病获批进入中国的IL-17抑制剂是：","result":"D","content":"可善挺/司库奇尤单抗是第一个获批进入中国的IL-17抑制剂","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"乌司奴单抗"},{"flag":"D","name":"司库奇尤单抗"}]},"3478":{"id":3478,"qattrid":47,"type":1,"title":"可善挺®的亲和力大约是拓咨®的：","result":"D","content":"依奇珠单抗的亲和力大约是司库奇尤单抗的100倍","options":[{"flag":"A","name":"43475"},{"flag":"B","name":"43495"},{"flag":"C","name":"1/50"},{"flag":"D","name":"1/100"}]},"3479":{"id":3479,"qattrid":50,"type":1,"title":"根据单克隆抗体的来源不同，免疫原性最高的是：","result":"B","content":"鼠源抗体免疫原性最高","options":[{"flag":"A","name":"嵌合体抗体"},{"flag":"B","name":"鼠源抗体"},{"flag":"C","name":"人源化抗体"},{"flag":"D","name":"人源抗体"}]},"3480":{"id":3480,"qattrid":47,"type":1,"title":"_______生物制剂可能诱导抗体产生。","result":"D","content":"几乎所有生物制剂可能诱导抗体产生","options":[{"flag":"A","name":"个别"},{"flag":"B","name":"只有嵌合体"},{"flag":"C","name":"只有鼠源"},{"flag":"D","name":"几乎所有"}]},"3481":{"id":3481,"qattrid":47,"type":2,"title":"银屑病先前非生物制剂的系统治疗包括： ","result":"B,C,D","content":"益赛普是生物制剂","options":[{"flag":"A","name":"益赛普"},{"flag":"B","name":"环孢素"},{"flag":"C","name":"阿维A"},{"flag":"D","name":"MTX"}]},"3482":{"id":3482,"qattrid":51,"type":1,"title":"UNCOVER研究中作为对照组的ETN代表：","result":"C","content":"ETN=依那西普","options":[{"flag":"A","name":"乌丝奴单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"依那西普"},{"flag":"D","name":"益赛普"}]},"3483":{"id":3483,"qattrid":47,"type":2,"title":"修美乐®的厂家不是","result":"A,B,D","content":"修美乐的厂家是艾伯维","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"艾伯维"},{"flag":"D","name":"西安杨森"}]},"3484":{"id":3484,"qattrid":47,"type":1,"title":"乌丝奴单抗适用于什么程度的斑块状银屑病患者","result":"C","content":"喜达诺适用于中度至重度的银屑病患者","options":[{"flag":"A","name":"轻度"},{"flag":"B","name":"轻度至中度"},{"flag":"C","name":"中度至重度"},{"flag":"D","name":"仅重度"}]},"3485":{"id":3485,"qattrid":47,"type":2,"title":"下列哪个药物不是叶酸还原酶抑制剂","result":"A,B,C,D","content":"都不是","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":"可善挺®"}]},"3486":{"id":3486,"qattrid":47,"type":2,"title":"下列哪个药物厂家不是强生","result":"B,D","content":"喜达诺/乌丝奴单抗、类克/英夫利昔单抗的厂家是西安杨森","options":[{"flag":"A","name":"喜达诺®"},{"flag":"B","name":"修美乐®"},{"flag":"C","name":"类克®"},{"flag":"D","name":"恩利®"}]},"3487":{"id":3487,"qattrid":47,"type":2,"title":"中国未获批银屑病适应症的药物是","result":"A,C","content":"AC未获批","options":[{"flag":"A","name":"Tremfya"},{"flag":"B","name":"修美乐"},{"flag":"C","name":"恩利"},{"flag":"D","name":"类克"}]},"3488":{"id":3488,"qattrid":47,"type":2,"title":"关于益赛普®的描述正确的是","result":"B,C","content":"益赛普是最早获批进入中国的银屑病药物，作用机制是IL-23抑制剂","options":[{"flag":"A","name":"最新获批进入中国的银屑病药物"},{"flag":"B","name":"最早获批进入中国的银屑病药物"},{"flag":"C","name":"占中国银屑病生物制剂市场份额第一"},{"flag":"D","name":"作用机制是IL-23抑制剂"}]},"3489":{"id":3489,"qattrid":47,"type":1,"title":"益赛普®的厂家是","result":"A","content":"益赛普厂家是三生国健","options":[{"flag":"A","name":"三生国健"},{"flag":"B","name":"诺华"},{"flag":"C","name":"辉瑞"},{"flag":"D","name":"西安杨森"}]},"3490":{"id":3490,"qattrid":47,"type":1,"title":"下列关于喜达诺®的描述正确的是：","result":"D","content":"喜达诺® 主要不良反应包括鼻咽炎、头痛、上呼吸道感染、感染等症状","options":[{"flag":"A","name":"喜达诺® 只作用于IL-23"},{"flag":"B","name":"喜达诺® 是人源化lgG2单克隆抗体"},{"flag":"C","name":"喜达诺® 45mg皮下注射，每4周给药一次"},{"flag":"D","name":"喜达诺® 主要不良反应包括鼻咽炎、头痛、上呼吸道感染、感染等症状"}]},"3491":{"id":3491,"qattrid":47,"type":1,"title":"下列关于系统治疗药物和生物制剂描述正确的是:","result":"C","content":"可善挺® 和拓咨® 可能会导致炎症性肠病不良反应。","options":[{"flag":"A","name":"甲氨蝶呤用量为30-50mg每周直到出现疗效。"},{"flag":"B","name":"修美乐® 和类克® 没有注射部位不良反应。"},{"flag":"C","name":"可善挺® 和拓咨® 可能会导致炎症性肠病不良反应。"},{"flag":"D","name":"在接受生物制剂治疗前，不需要进行结核检测。"}]},"3492":{"id":3492,"qattrid":46,"type":2,"title":"拓咨®注射笔特点主要有：(多选题）","result":"A,C,D","content":"隐藏式针头","options":[{"flag":"A","name":"有专利"},{"flag":"B","name":"开放式针头"},{"flag":"C","name":"简单三步"},{"flag":"D","name":"方便易用"}]},"3493":{"id":3493,"qattrid":48,"type":1,"title":"以下哪项不是拓咨®主要市场策略：","result":"B","content":"净界无忧不是","options":[{"flag":"A","name":"更能快速全面有效清洁皮肤"},{"flag":"B","name":"净界无忧"},{"flag":"C","name":"能够快速达到更高的清除率，无需承担更多的安全风险"},{"flag":"D","name":"重构治疗目标，在完全、快速、稳定方面是同品类之最"}]},"3494":{"id":3494,"qattrid":51,"type":1,"title":"拓咨®通过关键头对头研究证实，显著优于：","result":"D","content":"都优于","options":[{"flag":"A","name":"甲氨蝶呤"},{"flag":"B","name":"恩利®"},{"flag":"C","name":"喜达诺®"},{"flag":"D","name":"以上都是"}]},"3495":{"id":3495,"qattrid":48,"type":1,"title":"在研究调查中发现一半以上银屑病患者对于皮损（BSA）改善的预期超过：","result":"D","content":"在研究调查中发现一半以上银屑病患者对于皮损（BSA）改善的预期超过90%","options":[{"flag":"A","name":"0.5"},{"flag":"B","name":"0.6"},{"flag":"C","name":"0.7"},{"flag":"D","name":"0.9"}]},"3496":{"id":3496,"qattrid":48,"type":2,"title":"下列哪些是患者对生物制剂近年来持有的态度：","result":"A,B,C","content":"对疗效大多持乐观态度","options":[{"flag":"A","name":"看法更为积极"},{"flag":"B","name":"对疗效大多持乐观态度"},{"flag":"C","name":"一些对安全性存在疑虑"},{"flag":"D","name":"觉得效果不突出"}]},"3497":{"id":3497,"qattrid":51,"type":1,"title":"UNCOVER 3 研究中拓咨®治疗4年, ______以上患者可以维持 PASI 100。","result":"C","content":"UNCOVER 3 研究中拓咨®治疗4年,60%以上患者可以维持 PASI 100。","options":[{"flag":"A","name":"0.3"},{"flag":"B","name":"0.4"},{"flag":"C","name":"0.6"},{"flag":"D","name":"0.9"}]},"3498":{"id":3498,"qattrid":51,"type":1,"title":"拓咨®治疗12周的_______应答率优于恩利®。","result":"D","content":"都优于","options":[{"flag":"A","name":"PASI 75"},{"flag":"B","name":"PASI 90"},{"flag":"C","name":"PASI 100"},{"flag":"D","name":"以上均是"}]},"3499":{"id":3499,"qattrid":51,"type":1,"title":"拓咨®治疗治疗2周，超过______患者即可实现________。","result":"C","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":"1/4，PASI 100"},{"flag":"B","name":"1/4，PASI 90"},{"flag":"C","name":"1/2，PASI 50"},{"flag":"D","name":"1/2，PASI 75"}]},"3500":{"id":3500,"qattrid":51,"type":2,"title":"拓咨®uncover系列临床试验有：","result":"B,D","content":"123，J","options":[{"flag":"A","name":"UNCOVER-S"},{"flag":"B","name":"UNCOVER-2"},{"flag":"C","name":"UNCOVER-P"},{"flag":"D","name":"UNCOVER-J"}]},"3501":{"id":3501,"qattrid":51,"type":2,"title":". 参与拓咨®实验的人群中，先前进行过的治疗有:","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"环孢素"},{"flag":"B","name":"甲氨蝶呤"},{"flag":"C","name":"PUVA"},{"flag":"D","name":"生物制剂"}]},"3502":{"id":3502,"qattrid":46,"type":1,"title":"拓咨®第6周推荐剂量是：","result":"A","content":"对于斑块型银屑病患者，推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"80mg"},{"flag":"B","name":"120mg"},{"flag":"C","name":"160mg"},{"flag":"D","name":"240mg"}]},"3503":{"id":3503,"qattrid":48,"type":2,"title":"拓咨®的推广的信息有：","result":"A,B,C","content":"D不在推广定位里","options":[{"flag":"A","name":"快速起效"},{"flag":"B","name":"肌肤全面净化"},{"flag":"C","name":"重构治疗目标"},{"flag":"D","name":"无任何安全风险"}]},"3504":{"id":3504,"qattrid":51,"type":1,"title":"UNCOVER-J研究显示，拓咨®治疗16周后达到PASI 75的患者为：","result":"C","content":"UNCOVER-J研究显示，拓咨®治疗16周后达到PASI 75的患者为97%","options":[{"flag":"A","name":"0.77"},{"flag":"B","name":"0.87"},{"flag":"C","name":"0.97"},{"flag":"D","name":"0.99"}]},"3505":{"id":3505,"qattrid":51,"type":1,"title":"研究显示，依奇珠单抗治疗最快几周23%的患者可实现PASI 75","result":"B","content":"治疗2周，超过1/2患者即可实现PASI 50，接近1/4患者可实现PASI 75","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"3"},{"flag":"D","name":"4"}]},"3506":{"id":3506,"qattrid":51,"type":2,"title":"下列哪些试验不是在中重度斑块型银屑病中对拓咨®和恩利®治疗进行研究？","result":"C,D","content":"IXORA-S比较IXE和喜达诺/乌司奴单抗在中重度斑块型银屑病患者中的有效性和安全性，J是单臂研究","options":[{"flag":"A","name":"UNCOVER-3"},{"flag":"B","name":"UNCOVER-2"},{"flag":"C","name":"IXORA-S"},{"flag":"D","name":"UNCOVER-J"}]},"3507":{"id":3507,"qattrid":51,"type":2,"title":"对于UNCOVER-J研究，在哪些银屑病患者中观察了拓咨®的疗效：","result":"A,B,C","content":"没有点滴型","options":[{"flag":"A","name":"斑块型"},{"flag":"B","name":"红皮型"},{"flag":"C","name":"泛发性脓疱型"},{"flag":"D","name":"点滴型"}]},"3508":{"id":3508,"qattrid":51,"type":1,"title":"关于UNCOVER-J研究描述错误的是：","result":"D","content":"主要研究终点是12周时PASI 75","options":[{"flag":"A","name":"III期"},{"flag":"B","name":"多中心"},{"flag":"C","name":"单臂"},{"flag":"D","name":"主要研究终点为12周PASI 100应答率"}]},"3509":{"id":3509,"qattrid":51,"type":1,"title":"UNCOVER-3临床试验三年研究结果显示，拓咨®治疗使超过_____患者实现头皮部位维持完全清洁（PPSI=0）。","result":"C","content":"0.66","options":[{"flag":"A","name":"0.36"},{"flag":"B","name":"0.56"},{"flag":"C","name":"0.66"},{"flag":"D","name":"0.96"}]},"3510":{"id":3510,"qattrid":47,"type":1,"title":"以下哪项不是修美乐®在中国获批的适应症：","result":"D","content":"异位性皮炎不是","options":[{"flag":"A","name":"银屑病"},{"flag":"B","name":"类风湿关节炎"},{"flag":"C","name":"强直性脊柱炎"},{"flag":"D","name":"异位性皮炎"}]},"3511":{"id":3511,"qattrid":47,"type":2,"title":".以下哪几项是类克®在中国获批的适应症：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"银屑病"},{"flag":"B","name":"类风湿关节炎"},{"flag":"C","name":"强直性脊柱炎"},{"flag":"D","name":"炎症性肠病"}]},"3512":{"id":3512,"qattrid":47,"type":2,"title":"以下关于可善挺®的说法不正确的是：","result":"A,C","content":"司库奇尤单抗，是诺华","options":[{"flag":"A","name":"化学名为乌丝奴单抗"},{"flag":"B","name":"全球第一个上市的IL-17A抑制剂"},{"flag":"C","name":"三生国健公司产品"},{"flag":"D","name":"推荐剂量为每次300mg"}]},"3513":{"id":3513,"qattrid":47,"type":1,"title":"以下关于可善挺®的使用不正确的是：","result":"A","content":"随后维持该剂量每4周给药一次","options":[{"flag":"A","name":"维持剂量每8周给药一次"},{"flag":"B","name":"规格为1ml：150mg"},{"flag":"C","name":"推荐剂量为每次300mg"},{"flag":"D","name":"皮下注射"}]},"3514":{"id":3514,"qattrid":48,"type":1,"title":"当前银屑病治疗现状是由于分类问题导致治疗方案：","result":"C","content":"严重程度分类标准的不统一导致治疗方案不统一","options":[{"flag":"A","name":"十分统一"},{"flag":"B","name":"基本统一"},{"flag":"C","name":"不统一"},{"flag":"D","name":"以上都不对"}]},"3515":{"id":3515,"qattrid":47,"type":1,"title":"依那西普在中国获批的适应症没有：","result":"C","content":"依那西普在中国获批的适应症没有银屑病","options":[{"flag":"A","name":"类风关"},{"flag":"B","name":"强直性脊柱炎"},{"flag":"C","name":"银屑病"},{"flag":"D","name":"以上均未获批"}]},"3516":{"id":3516,"qattrid":48,"type":1,"title":"为什么PASI 75是中国当前银屑病的治疗目标：","result":"D","content":"以上都是","options":[{"flag":"A","name":"医生不追求完全清除"},{"flag":"B","name":"医生认为皮损早晚会复发"},{"flag":"C","name":"MTX引起的肝损伤带来的安全担忧"},{"flag":"D","name":"以上都是"}]},"3517":{"id":3517,"qattrid":48,"type":2,"title":"目前患者对生物制剂关注的属性有_______。","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"经济性"},{"flag":"B","name":"有效性"},{"flag":"C","name":"依从性"},{"flag":"D","name":"安全性"}]},"3518":{"id":3518,"qattrid":48,"type":1,"title":"中国生物制剂市场洞察没有：","result":"D","content":"0.01","options":[{"flag":"A","name":"未被充分开发"},{"flag":"B","name":"医生目标低于患者"},{"flag":"C","name":"目前都是自费"},{"flag":"D","name":"50%的中国患者接受生物制剂治疗"}]},"3519":{"id":3519,"qattrid":50,"type":2,"title":"下列说法错误的是：","result":"A,B,D","content":"IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用","options":[{"flag":"A","name":"拓咨®是一种人源化IgG1单克隆抗体，对白介素-17A（IL-17A）有中和活性"},{"flag":"B","name":"IL-17A、IL-17C和IL-17F在银屑病病灶部位表达降低"},{"flag":"C","name":"IL-17A在银屑病中起到促角质形成细胞过度增殖和活化作用"},{"flag":"D","name":"拓咨®选择性结合IL-17C细胞因子，抑制其与IL-17受体相互作用，从而抑制促炎细胞因子和趋化因子释放"}]},"3520":{"id":3520,"qattrid":48,"type":1,"title":"中国市场生物制剂份额占60%以上的是","result":"B","content":"易赛普占中国银屑病生物制剂市场67%份额MAT3Q2018","options":[{"flag":"A","name":"MTX"},{"flag":"B","name":"益赛普"},{"flag":"C","name":"类克"},{"flag":"D","name":"修美乐"}]},"3521":{"id":3521,"qattrid":51,"type":2,"title":". 拓咨®对无论是否经过生物制剂治疗的患者均可达高皮损清除率，以下哪些属于UNCOVER-2,3里的经治生物制剂：","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"依那西普"},{"flag":"B","name":"英夫利昔单抗"},{"flag":"C","name":"阿达木单抗"},{"flag":"D","name":"司库奇尤单抗"}]},"3522":{"id":3522,"qattrid":51,"type":1,"title":"多项研究显示，拓咨®治疗____周，就可实现对指甲难治部位皮损的完全清除。","result":"C","content":"12周","options":[{"flag":"A","name":"1"},{"flag":"B","name":"2"},{"flag":"C","name":"12"},{"flag":"D","name":"36"}]},"3523":{"id":3523,"qattrid":51,"type":1,"title":"拓咨®的快速起效体现在多久就可显著改善皮损及瘙痒症状","result":"C","content":"UNCOVER-2研究显示，拓咨®治疗1周即可见皮损以及瘙痒症状改善","options":[{"flag":"A","name":"1天"},{"flag":"B","name":"3天"},{"flag":"C","name":"1周"},{"flag":"D","name":"2周"}]},"3524":{"id":3524,"qattrid":48,"type":1,"title":"以下那项关键词不属于拓咨®品牌定位：","result":"D","content":"不属于","options":[{"flag":"A","name":"更能快速"},{"flag":"B","name":"更能全面"},{"flag":"C","name":"亲密联系"},{"flag":"D","name":"更加安全"}]},"3525":{"id":3525,"qattrid":48,"type":1,"title":"中国银屑病市场销售额5年复合增长率为：","result":"B","content":"中国银屑病市场销售额5年复合增长率为6%","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.06"},{"flag":"C","name":"0.15"},{"flag":"D","name":"0.5"}]},"3526":{"id":3526,"qattrid":48,"type":1,"title":"以下哪项不是未来十年中国银屑病生物制剂市场预计快速增长的理由：","result":"A","content":"患者对疾病和治疗手段的认知与观念被提高","options":[{"flag":"A","name":"患者对疾病和治疗手段的认知与观念没有改变"},{"flag":"B","name":"2018年生物制剂作为治疗中重度银屑病推荐治疗手段被写入指南"},{"flag":"C","name":"提高的支付能力，改进的准入和医保报销政策"},{"flag":"D","name":"潜在患者数增加"}]},"3527":{"id":3527,"qattrid":51,"type":2,"title":"__________研究不是拓咨®和恩利®做头对头研究：","result":"A,B,D","content":"临床试验UNCOVER-2和UNCOVER-3分为IXE(依奇珠单抗)、ETN（依那西普）和PBO(安慰剂组)， 前12周拓咨®主要和依那西普做头对头研究","options":[{"flag":"A","name":"CLEAR"},{"flag":"B","name":"IXORA-S"},{"flag":"C","name":"UNCOVER-2"},{"flag":"D","name":"EXPRESS"}]},"3528":{"id":3528,"qattrid":48,"type":1,"title":"在2014-2018中国银屑病市场销售额中，增速最快的是：","result":"A","content":"生物制剂增长最快","options":[{"flag":"A","name":"生物制剂"},{"flag":"B","name":"口服药物"},{"flag":"C","name":"中成药"},{"flag":"D","name":"局部用药"}]},"3529":{"id":3529,"qattrid":48,"type":2,"title":"MAT3Q2018显示，占中国银屑病总市场销售额市场份额一半以下的是：","result":"A,B,D","content":"局部用药占比54%","options":[{"flag":"A","name":"生物制剂"},{"flag":"B","name":"口服药物"},{"flag":"C","name":"局部用药"},{"flag":"D","name":"中成药"}]},"3530":{"id":3530,"qattrid":51,"type":2,"title":"头对头研究中，根据研究终点设计，拓咨®治疗12周后________优于乌丝奴单抗：","result":"A,B,D","content":"SF-36不是","options":[{"flag":"A","name":"PASI 90"},{"flag":"B","name":"sPGA 0/1"},{"flag":"C","name":"SF-36"},{"flag":"D","name":"DLQI (0,1)"}]},"3531":{"id":3531,"qattrid":51,"type":1,"title":"在IXORA-S研究中，拓咨®治疗12周后，达到PASI 100患者比例为:","result":"D","content":"在IXORA-S研究中，拓咨®治疗12周后，达到PASI 100患者比例为38%","options":[{"flag":"A","name":"0.145"},{"flag":"B","name":"0.18"},{"flag":"C","name":"0.28"},{"flag":"D","name":"0.38"}]},"3532":{"id":3532,"qattrid":47,"type":1,"title":"以下哪个研究是可善挺®的临床研究。","result":"C","content":"可善挺®的临床研究ERASURE","options":[{"flag":"A","name":"IXORA-S"},{"flag":"B","name":"REVEAL"},{"flag":"C","name":"ERASURE"},{"flag":"D","name":"UNCOVER"}]},"3533":{"id":3533,"qattrid":47,"type":1,"title":"依奇珠单抗在亚洲进行的主要研究名称是：","result":"A","content":" UNCOVER-J 是拓咨®的亚洲日本的主要研究名称","options":[{"flag":"A","name":"UNCOVER-J"},{"flag":"B","name":"IXORA-S"},{"flag":"C","name":"UNCOVER-1"},{"flag":"D","name":"REVEAL"}]},"3534":{"id":3534,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病在生殖器、掌跖、头皮和指甲等难治部位12-24周时最高可获得:","result":"D","content":"拓咨® 可实现生殖器、掌跖、头皮和指甲等难治部位皮损完全清除","options":[{"flag":"A","name":"有效清除（PASI 50）"},{"flag":"B","name":"控制清除（PASI 75）"},{"flag":"C","name":"接近全面清除（PASI 90）"},{"flag":"D","name":"全面清除（PASI 100）"}]},"3535":{"id":3535,"qattrid":51,"type":1,"title":"拓咨®治疗银屑病_____年长期治疗期间，_______特殊不良反应事件发生率。","result":"B","content":"拓咨®治疗银屑病4年长期治疗期间，不增加特殊不良反应事件发生率","options":[{"flag":"A","name":"6, 轻微增加"},{"flag":"B","name":"4, 不增加"},{"flag":"C","name":"2，不增加"},{"flag":"D","name":"4，降低"}]},"3536":{"id":3536,"qattrid":51,"type":1,"title":"UNCOVER-1,2显示，拓咨®治疗银屑病诱导治疗期获得高皮损清除率的患者，疗效可：","result":"A","content":"UNCOVER-1,2显示，拓咨®治疗银屑病诱导治疗期获得高皮损清除率的患者，疗效可持续维持","options":[{"flag":"A","name":"持续维持"},{"flag":"B","name":"间歇维持"},{"flag":"C","name":"波动维持"},{"flag":"D","name":"短期继续提高"}]},"3537":{"id":3537,"qattrid":51,"type":1,"title":"在维持治疗期，拓咨®的相关不良反应相较于依那西普正确的是：","result":"B","content":"在诱导治疗期，拓咨®的相关不良反应与依那西普相似","options":[{"flag":"A","name":"低"},{"flag":"B","name":"相似"},{"flag":"C","name":"高"},{"flag":"D","name":"显著降低"}]},"3538":{"id":3538,"qattrid":46,"type":2,"title":"关于拓咨®安全性描述正确的是：","result":"B,D","content":"拓咨安全性良好，与依那西普总体TEAEs发生率相当。治疗期间最常见的不良反应是注射部位不良反应。TEAEs多为轻至中度，极少导致治疗中断","options":[{"flag":"A","name":"与依那西普相比，拓咨®治疗组TEAEs发生率显著降低"},{"flag":"B","name":"拓咨®的维持治疗期最常见的是不良反应鼻咽炎"},{"flag":"C","name":"最常见导致拓咨®治疗中断的不良反应是念珠菌感染、鼻咽炎、上呼吸道感染"},{"flag":"D","name":"拓咨®特别关注的不良事件是主要心血管不良事件、克罗恩病、恶性肿瘤等"}]},"3539":{"id":3539,"qattrid":46,"type":1,"title":"拓咨®的注射部位不良反应导致患者停药的：","result":"B","content":"拓咨®的注射部位不良反应导致患者停药的非常少","options":[{"flag":"A","name":"完全没有"},{"flag":"B","name":"非常少"},{"flag":"C","name":"较少"},{"flag":"D","name":".较多"}]},"3540":{"id":3540,"qattrid":51,"type":1,"title":"UNCOVER研究中导致患者的PASI改善率降低的是","result":"A","content":"UNCOVER研究中导致患者的PASI改善率降低的是仅发生高效价ADA","options":[{"flag":"A","name":"仅发生高效价ADA"},{"flag":"B","name":"发生中高效价ADA"},{"flag":"C","name":"只要出现ADA"},{"flag":"D","name":"以上都不对"}]},"3541":{"id":3541,"qattrid":51,"type":1,"title":"UNCOVER-1,2,3显示，拓咨®治疗银屑病______周，1.7%患者发生：","result":"B","content":"UNCOVER-1,2,3显示，拓咨®治疗银屑病60周，1.7%患者发生高效价抗药抗体","options":[{"flag":"A","name":"52，低效价抗药抗体"},{"flag":"B","name":"60，高效价抗药抗体"},{"flag":"C","name":"52，中等效价抗药抗体"},{"flag":"D","name":"60，中高效价抗药抗体"}]},"3542":{"id":3542,"qattrid":49,"type":2,"title":"银屑病根据患者严重程度不同有多种治疗方式，以下是银屑病的治疗方法的是： ","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"局部治疗"},{"flag":"B","name":"物理治疗"},{"flag":"C","name":"中医治疗"},{"flag":"D","name":"生物制剂治疗"}]},"3543":{"id":3543,"qattrid":47,"type":2,"title":"下列是修美乐®治疗银屑病的主要不良反应是： ","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"鼻咽炎"},{"flag":"B","name":"上呼吸道感染"},{"flag":"C","name":"注射部位反应"},{"flag":"D","name":"骨骼肌肉疼痛"}]},"3544":{"id":3544,"qattrid":47,"type":1,"title":"银屑病常用生物制剂没有：","result":"C","content":"新山地明是环孢素，系统用药非生物制剂","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"依那西普"},{"flag":"C","name":"新山地明"},{"flag":"D","name":"乌丝奴单抗"}]},"3545":{"id":3545,"qattrid":48,"type":1,"title":"新山地明的描述正确的是：","result":"A","content":"环孢素对对各型银屑病均有效","options":[{"flag":"A","name":"对各型银屑病均有效"},{"flag":"B","name":"对儿童和青少年患者可以正常使用"},{"flag":"C","name":"肾毒性小"},{"flag":"D","name":"无需重点关注高血压"}]},"3546":{"id":3546,"qattrid":49,"type":2,"title":"_________评价指标关注银屑病患者生活质量：","result":"A,C,D","content":"BSA没有","options":[{"flag":"A","name":"DLQI"},{"flag":"B","name":"BSA"},{"flag":"C","name":"SF-36"},{"flag":"D","name":"EQ-5D"}]},"3547":{"id":3547,"qattrid":46,"type":1,"title":"拓咨®代谢途径主要是：","result":"D","content":"拓咨主要通过细胞代谢","options":[{"flag":"A","name":"肝"},{"flag":"B","name":"肾"},{"flag":"C","name":"肠道"},{"flag":"D","name":"细胞代谢"}]},"3548":{"id":3548,"qattrid":47,"type":2,"title":"研究对比不同生物制剂达到PASI 50的中位时间，拓咨®时间比哪几项耗时短：","result":"A,B,C,D","content":"都短","options":[{"flag":"A","name":"司库奇尤单抗"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"英夫利昔单抗"},{"flag":"D","name":"乌丝奴单抗"}]},"3549":{"id":3549,"qattrid":51,"type":2,"title":"关于拓咨®注射部位不良反应（ISR），描述正确的是：","result":"A,B,C,D","content":"以上都正确","options":[{"flag":"A","name":"是生物制剂治疗中的一种非常常见的不良反应"},{"flag":"B","name":"通常发生在治疗前2周，之后发生率下降"},{"flag":"C","name":"95%以上的该反应为轻中度"},{"flag":"D","name":"通常不需要接受治疗和采取预防措施"}]},"3550":{"id":3550,"qattrid":48,"type":2,"title":"下列关于系统治疗，说法错误的是：","result":"B,C,D","content":"甲氨蝶呤常推荐剂量为10-25mg/周，最常见的不良反应为骨髓抑制和黏膜损伤","options":[{"flag":"A","name":"甲氨蝶呤常推荐剂量为10-25mg/周，最常见的不良反应为骨髓抑制和黏膜损伤。"},{"flag":"B","name":"甲氨喋呤对各型银屑病不全都有较好的疗效，对甲病和掌跖部位银屑病无疗效。"},{"flag":"C","name":"环孢素没有肾毒性和高血压"},{"flag":"D","name":"维A酸常用推荐剂量为0.5-1.0mg/kg/d，育龄期妇女、老年、儿童正常使用"}]},"3551":{"id":3551,"qattrid":48,"type":2,"title":"下列关于抗药抗体（ADA），错误的是：","result":"A,C","content":"1.7%，影响","options":[{"flag":"A","name":"拓咨诱导治疗期间17%的患者发生高效价的ADA"},{"flag":"B","name":"检测方法的敏感度和药物耐受性的不同，导致不同药物之间的ADA发生率的比较并不合理"},{"flag":"C","name":"完全不影响药物PASI改善率"},{"flag":"D","name":"未发现ADA与治疗相关不良反应的发生存在关联"}]},"3552":{"id":3552,"qattrid":46,"type":2,"title":"拓咨®每一剂的产品规格不是： ","result":"A,C,D","content":"拓咨规格是80mg/ml","options":[{"flag":"A","name":"40mg/ml"},{"flag":"B","name":"80mg/ml"},{"flag":"C","name":"120mg/ml"},{"flag":"D","name":"160mg/ml"}]},"3553":{"id":3553,"qattrid":46,"type":1,"title":"关于拓咨®(依奇珠单抗)的用法用量，下列说法正确的是：","result":"D","content":"推荐剂量为在第0周皮下注射160 mg（80 mg注射两次），之后分别在第2、4、6、8、10和12周各注射80 mg（注射一次），然后维持剂量为80 mg（注射一次）每4周一次","options":[{"flag":"A","name":"初始剂量40mg，前4周80mg Q1W。维持剂量为80mg Q2W"},{"flag":"B","name":"初始剂量80mg，前4周80mg Q2W。维持剂量为80mg Q4W"},{"flag":"C","name":"初始剂量120mg，前12周 80mg Q1W。维持剂量为80mg Q2W"},{"flag":"D","name":"初始剂量160mg，前12周 80mg Q2W。维持剂量为80mg Q4W"}]},"3554":{"id":3554,"qattrid":46,"type":1,"title":"拓咨®说明书里规定≥65岁患者：","result":"C","content":"拓咨®说明书里老年人群清除率与65岁以下患者清除率相似，无需调整剂量","options":[{"flag":"A","name":"需要减少剂量"},{"flag":"B","name":"需要增加剂量"},{"flag":"C","name":"无需调整剂量"},{"flag":"D","name":"以上都不对"}]},"3555":{"id":3555,"qattrid":46,"type":1,"title":"拓咨®说明书里对于注射部位反应的最常见注射反应是：","result":"D","content":"红疹和疼痛最常见","options":[{"flag":"A","name":"红斑和瘙痒"},{"flag":"B","name":"红斑和疼痛"},{"flag":"C","name":"红疹和瘙痒"},{"flag":"D","name":"红疹和疼痛"}]},"3556":{"id":3556,"qattrid":46,"type":1,"title":"拓咨®说明书里对于6岁以下儿童的使用介绍是：","result":"D","content":"6岁以下儿童没有使用本品治疗中重度银屑病经验","options":[{"flag":"A","name":"仅安全性尚未建立"},{"flag":"B","name":"仅有效性尚未建立"},{"flag":"C","name":"安全性和有效性都已建立"},{"flag":"D","name":"没有使用本品治疗中重度银屑病经验"}]},"3557":{"id":3557,"qattrid":46,"type":1,"title":"拓咨®说明书里关于药品贮藏介绍错误的是：","result":"B","content":"冷藏不是冷冻","options":[{"flag":"A","name":"冷藏"},{"flag":"B","name":"冷冻"},{"flag":"C","name":"避免光照"},{"flag":"D","name":"不可摇晃"}]},"3558":{"id":3558,"qattrid":46,"type":1,"title":"拓咨®说明书里介绍其贮藏有效期是：","result":"D","content":"24个月贮藏期","options":[{"flag":"A","name":"6个月"},{"flag":"B","name":"12个月"},{"flag":"C","name":"18个月"},{"flag":"D","name":"24个月"}]},"3559":{"id":3559,"qattrid":46,"type":1,"title":"拓咨®说明书里其与感染发生率有关，但没有：","result":"D","content":"没有HIV感染","options":[{"flag":"A","name":"上呼吸道感染"},{"flag":"B","name":"结膜炎"},{"flag":"C","name":"口腔念珠菌病"},{"flag":"D","name":"HIV感染"}]},"3560":{"id":3560,"qattrid":46,"type":2,"title":"拓咨®说明书介绍其禁忌是：","result":"A,B,C","content":"禁忌没有鼻咽炎","options":[{"flag":"A","name":"对活性成分存在严重超敏反应"},{"flag":"B","name":"对任何辅料存在严重超敏反应"},{"flag":"C","name":"活动性结核病"},{"flag":"D","name":"鼻咽炎"}]},"3561":{"id":3561,"qattrid":46,"type":1,"title":"拓咨®说明书里介绍育龄女性在治疗期间及治疗后至少_____周内，应使用有效避孕措施：","result":"B","content":"10周内避孕","options":[{"flag":"A","name":"1"},{"flag":"B","name":"10"},{"flag":"C","name":"30"},{"flag":"D","name":"40"}]},"3562":{"id":3562,"qattrid":49,"type":1,"title":"用于专门评估生殖器部位银屑病的评分是：","result":"C","content":"GPSS用于生殖器评分","options":[{"flag":"A","name":"PASI"},{"flag":"B","name":"EQ-5D"},{"flag":"C","name":"GPSS"},{"flag":"D","name":"SF-36"}]},"3563":{"id":3563,"qattrid":46,"type":1,"title":"拓咨®说明书里介绍开具处方前的注意事项没有：","result":"C","content":"开具生物制剂处方前的特别注意事项：妊娠，癌症史（实体瘤、淋巴组织增生性疾病、血液系统恶性肿瘤），重度感染、慢性感染、TB、HIV、HBV/HCV，3级或4级充血性心力衰竭，炎症性肠病","options":[{"flag":"A","name":"结核感染"},{"flag":"B","name":"癌症史"},{"flag":"C","name":"1级高血压"},{"flag":"D","name":"克罗恩病"}]},"3564":{"id":3564,"qattrid":51,"type":1,"title":"在拓咨®诱导治疗期间发生低效价或中效价ADA的患者，随后治疗中_______产生高效价ADA","result":"D","content":"说明书内容","options":[{"flag":"A","name":"多数"},{"flag":"B","name":"部分"},{"flag":"C","name":"少数"},{"flag":"D","name":"没有"}]},"3565":{"id":3565,"qattrid":46,"type":2,"title":"以下哪些患者也要在使用依奇珠单抗前注意","result":"A,B,C,D","content":"以上都是","options":[{"flag":"A","name":"脱髓鞘疾病"},{"flag":"B","name":"严重心力衰竭"},{"flag":"C","name":"手术"},{"flag":"D","name":"IBD"}]},"3566":{"id":3566,"qattrid":46,"type":1,"title":"依奇珠单抗的半衰期是：","result":"B","content":"半衰期13天","options":[{"flag":"A","name":"3天"},{"flag":"B","name":"13天"},{"flag":"C","name":"23天"},{"flag":"D","name":"33天"}]},"3567":{"id":3567,"qattrid":47,"type":1,"title":"安佰诺®是：","result":"D","content":"安佰诺®是TNF抑制剂","options":[{"flag":"A","name":"MTX"},{"flag":"B","name":"阿达木单抗"},{"flag":"C","name":"环孢素"},{"flag":"D","name":"TNF抑制剂"}]},"3568":{"id":3568,"qattrid":47,"type":2,"title":"可善挺®正常推荐使用下，一年需注射次数错误的是：","result":"A,B,C","content":"32次","options":[{"flag":"A","name":"10"},{"flag":"B","name":"17"},{"flag":"C","name":"28"},{"flag":"D","name":"32"}]},"3569":{"id":3569,"qattrid":47,"type":2,"title":"下列关于TNF抑制剂说法正确的是:","result":"C,D","content":"恩利® 是TNF受体-lgG融合蛋白，皮下注射；益赛普® 是重组人II型肿瘤坏死因子受体-抗体融合蛋白，皮下注射","options":[{"flag":"A","name":"修美乐® 是嵌合性单克隆抗体，皮下注射"},{"flag":"B","name":"类克® 是嵌合性单克隆抗体，静脉输"},{"flag":"C","name":"恩利® 是TNF受体-lgG融合蛋白，皮下注射"},{"flag":"D","name":"益赛普® 是重组人II型肿瘤坏死因子受体-抗体融合蛋白，皮下注射"}]},"3570":{"id":3570,"qattrid":47,"type":1,"title":"喜达诺®推荐剂量为45mg，对于体重＞100kg的患者，推荐首次剂量是：","result":"C","content":"喜达诺®推荐剂量为45mg，对于体重＞100kg的患者，推荐首次剂量是","options":[{"flag":"A","name":"45mg"},{"flag":"B","name":"60mg"},{"flag":"C","name":"90mg"},{"flag":"D","name":"120mg"}]},"3571":{"id":3571,"qattrid":48,"type":1,"title":"据调查，MAT3Q2018生物制剂在银屑病整体市场销售额中占比约为：","result":"B","content":"据调查，MAT3Q2018生物制剂在银屑病整体市场销售额中占比约为11%","options":[{"flag":"A","name":"0.01"},{"flag":"B","name":"0.11"},{"flag":"C","name":"0.24"},{"flag":"D","name":"0.54"}]},"4575":{"id":4575,"qattrid":51,"type":1,"title":"SGLT2负责(  )葡萄11\n糖重吸收。","result":"C","content":"","options":[{"flag":"A","name":"心脏"},{"flag":"B","name":"肝脏"},{"flag":"C","name":"肾脏"},{"flag":"D","name":"肺脏"}]},"4576":{"id":4576,"qattrid":51,"type":1,"title":"2型糖尿病患者的葡萄糖转运体(  )?\t","result":"A","content":"","options":[{"flag":"A","name":"上调"},{"flag":"B","name":"下降"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4577":{"id":4577,"qattrid":51,"type":1,"title":"2型糖尿病患者的近端小管上皮细胞对葡萄糖的摄取(  )?","result":"A","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"减少"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4578":{"id":4578,"qattrid":51,"type":1,"title":"欧唐静属于哪类降糖药物？","result":"B","content":"","options":[{"flag":"A","name":"DPP4 抑制剂"},{"flag":"B","name":"SGLT2抑制剂"},{"flag":"C","name":"噻唑烷二酮类"},{"flag":"D","name":"α-糖苷酶抑制剂"}]},"4579":{"id":4579,"qattrid":51,"type":1,"title":"欧唐静的通用名为(  )，安达唐的通用名为( )，怡可安的通用名为（）","result":"B","content":"","options":[{"flag":"A","name":"恩格列净，卡格列净，达格列净"},{"flag":"B","name":"恩格列净，达格列净，卡格列净"},{"flag":"C","name":"达格列净，恩格列净，卡格列净"},{"flag":"D","name":"卡格列净，恩格列净，达格列净"}]},"4580":{"id":4580,"qattrid":51,"type":1,"title":"欧唐静在中国上市的规格和剂型是？","result":"C","content":"","options":[{"flag":"A","name":"每片10mg，每盒7片"},{"flag":"B","name":"每片25mg，每盒10片"},{"flag":"C","name":"每片10mg，每盒10片"},{"flag":"D","name":"每片25mg，每盒14片"}]},"4581":{"id":4581,"qattrid":51,"type":1,"title":"欧唐静目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合二甲双胍和磺脲"},{"flag":"D","name":"以上都是"}]},"4582":{"id":4582,"qattrid":51,"type":1,"title":"欧唐静的适应症是？","result":"B","content":"","options":[{"flag":"A","name":"1型糖尿病"},{"flag":"B","name":"2型糖尿病"},{"flag":"C","name":"妊娠糖尿病"},{"flag":"D","name":"以上皆是"}]},"4583":{"id":4583,"qattrid":51,"type":1,"title":"\t(  )是导致2型糖尿病患者死亡的首要原因？","result":"B","content":"","options":[{"flag":"A","name":"恶性肿瘤"},{"flag":"B","name":"心血管疾病"},{"flag":"C","name":" 糖尿病"},{"flag":"D","name":"胃肠道疾病"}]},"4584":{"id":4584,"qattrid":51,"type":1,"title":"糖尿病患者心血管疾病风险约较非糖尿病人群高(  )倍？","result":"A","content":"","options":[{"flag":"A","name":"2-4\t"},{"flag":"B","name":"44053"},{"flag":"C","name":"14-16"},{"flag":"D","name":"20-22"}]},"4585":{"id":4585,"qattrid":51,"type":1,"title":"合并心血管疾病的2型糖尿病患者相比2型糖尿病患者预期寿命(  )？","result":"B","content":"","options":[{"flag":"A","name":"增减"},{"flag":"B","name":"降低"},{"flag":"C","name":"无影响"},{"flag":"D","name":"未知"}]},"4586":{"id":4586,"qattrid":51,"type":1,"title":"2型糖尿病治疗的近期目标是？","result":"D","content":"","options":[{"flag":"A","name":"预防慢性并发症"},{"flag":"B","name":"提高患者生活质量"},{"flag":"C","name":"延长寿命"},{"flag":"D","name":"通过控制高血糖和相关代谢紊乱来消除糖尿病症状和防止出现急性代谢并发症"}]},"4587":{"id":4587,"qattrid":51,"type":1,"title":"(  )引发FDA对降糖药物心血管安全性的关注","result":"B","content":"","options":[{"flag":"A","name":"吡格列酮"},{"flag":"B","name":"罗格列酮"},{"flag":"C","name":"二甲双胍"},{"flag":"D","name":"磺脲"}]},"4588":{"id":4588,"qattrid":51,"type":1,"title":"EMPA-REG OUTCOME有(  )个国家与地区参与？","result":"C","content":"","options":[{"flag":"A","name":"12"},{"flag":"B","name":"22"},{"flag":"C","name":"42"},{"flag":"D","name":"80"}]},"4589":{"id":4589,"qattrid":51,"type":1,"title":"EMPA-REG OUTCOME纳入(  )名患者？","result":"C","content":"","options":[{"flag":"A","name":"1020"},{"flag":"B","name":"3020"},{"flag":"C","name":"7020"},{"flag":"D","name":"10020"}]},"4590":{"id":4590,"qattrid":51,"type":1,"title":"2018年美国心脏协会ACC共识推荐，对于合并ASCVD的T2DM患者，推荐（ ）为2型糖尿病合并心血管疾病的首选SGLT2抑制剂","result":"C","content":"","options":[{"flag":"A","name":"恩格列净、卡格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"恩格列净"},{"flag":"D","name":"达格列净"}]},"4591":{"id":4591,"qattrid":51,"type":1,"title":"安达唐目前在中国上市的规格是？","result":"B","content":"","options":[{"flag":"A","name":"5mg"},{"flag":"B","name":"10mg"},{"flag":"C","name":"25mg"},{"flag":"D","name":"50mg"}]},"4592":{"id":4592,"qattrid":51,"type":1,"title":"安达唐目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合胰岛素"},{"flag":"D","name":"以上都是"}]},"4593":{"id":4593,"qattrid":51,"type":1,"title":"怡可安目前在中国上市的规格是？","result":"C","content":"","options":[{"flag":"A","name":"10mg"},{"flag":"B","name":"30mg"},{"flag":"C","name":"100mg"},{"flag":"D","name":"300mg"}]},"4594":{"id":4594,"qattrid":51,"type":1,"title":"CANVAS 研究显示，卡格列净相比安慰剂（  ）心血管死亡、心肌梗死风险、卒中和全因死亡风险","result":"C","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"降低"},{"flag":"C","name":"不降低"},{"flag":"D","name":"未知"}]},"4595":{"id":4595,"qattrid":46,"type":1,"title":"2型糖尿病并发症中，以下哪个不是大血管并发症？","result":"D","content":"11","options":[{"flag":"A","name":"卒中"},{"flag":"B","name":"心肌梗死"},{"flag":"C","name":"外周动脉疾病"},{"flag":"D","name":"糖尿病肾病"}]},"4596":{"id":4596,"qattrid":46,"type":1,"title":"在中国有多少2型糖尿病患者合并心血管危险因素？","result":"B","content":"22","options":[{"flag":"A","name":"0.49"},{"flag":"B","name":"0.72"},{"flag":"C","name":"0.39"},{"flag":"D","name":"0.35"}]},"4597":{"id":4597,"qattrid":46,"type":1,"title":"大庆研究证实：在中国，有多少糖尿病患者死于心血管疾病？","result":"A","content":"33","options":[{"flag":"A","name":"0.49"},{"flag":"B","name":"0.38"},{"flag":"C","name":"0.39"},{"flag":"D","name":"0.35"}]},"4598":{"id":4598,"qattrid":46,"type":1,"title":"以下哪个不是糖尿病治疗的远期目标？","result":"B","content":"44","options":[{"flag":"A","name":"预防慢性并发症（心血管疾病, 肾病等）"},{"flag":"B","name":"防止出现急性代谢并发症"},{"flag":"C","name":"提高患者生活质量"},{"flag":"D","name":"延长寿命"}]},"4599":{"id":4599,"qattrid":46,"type":1,"title":"以下哪个传统降糖药物在临床研究中看到了心血管获益？","result":"D","content":"55","options":[{"flag":"A","name":"磺脲类"},{"flag":"B","name":"格列奈类"},{"flag":"C","name":"甘精胰岛素"},{"flag":"D","name":"二甲双胍"}]},"4600":{"id":4600,"qattrid":46,"type":1,"title":"以下说法，哪个不正确?","result":"B","content":"66","options":[{"flag":"A","name":"健康人的肾小球每日可滤过~180 g的葡萄糖"},{"flag":"B","name":"2型糖尿病患者的葡萄糖重吸收能力减少"},{"flag":"C","name":"SGLT2i其作用机制是抑制近端肾小管钠－葡萄糖重吸收，促进尿糖排泄，从而降低血糖浓度"},{"flag":"D","name":"恩格列净促进尿糖排泄（大约80g 糖分/每天) ，从而出现渗透性利尿"}]},"4601":{"id":4601,"qattrid":46,"type":1,"title":"下列属于欧唐静降糖机制的是？","result":"D","content":"77","options":[{"flag":"A","name":"近90%经肾小球滤出的葡萄糖由SGLT2重吸收"},{"flag":"B","name":"2型糖尿病患者中，SGLT2的重吸收作用加强"},{"flag":"C","name":"恩格列净抑制SGLT2排出多余的葡萄糖近80g每天"},{"flag":"D","name":"以上都对"}]},"4602":{"id":4602,"qattrid":46,"type":1,"title":"下列哪种药物降糖机制为降低肾脏对葡萄糖的重吸收？","result":"B","content":"88","options":[{"flag":"A","name":".二甲双胍"},{"flag":"B","name":"SGLT2抑制剂"},{"flag":"C","name":"格列奈类"},{"flag":"D","name":"磺脲类"}]},"4603":{"id":4603,"qattrid":46,"type":2,"title":"2019年口服降糖药物中恩格列净全球销量第一，且超越以下哪些降糖药物？","result":"A,B,C,D","content":"","options":[{"flag":"A","name":"达格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"西格列汀"},{"flag":"D","name":"利拉鲁肽"}]},"4604":{"id":4604,"qattrid":46,"type":2,"title":"下列哪些是心血管危险因素：","result":"A,B,C,D,E","content":"","options":[{"flag":"A","name":"年龄"},{"flag":"B","name":"高血压"},{"flag":"C","name":"血脂异常"},{"flag":"D","name":"吸烟"}]},"4605":{"id":4605,"qattrid":47,"type":1,"title":"测试","result":"C","content":"","options":[{"flag":"A","name":"啊"},{"flag":"B","name":"从"},{"flag":"C","name":"的"},{"flag":"D","name":"我"}]},"4607":{"id":4607,"qattrid":0,"type":1,"title":"SGLT2负责(  )葡萄11\n糖重吸收。","result":"C","content":"","options":[{"flag":"A","name":"心脏"},{"flag":"B","name":"肝脏"},{"flag":"C","name":"肾脏"},{"flag":"D","name":"肺脏"}]},"4608":{"id":4608,"qattrid":0,"type":1,"title":"2型糖尿病患者的葡萄糖转运体(  )?\t","result":"A","content":"","options":[{"flag":"A","name":"上调"},{"flag":"B","name":"下降"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4609":{"id":4609,"qattrid":0,"type":1,"title":"2型糖尿病患者的近端小管上皮细胞对葡萄糖的摄取(  )?","result":"A","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"减少"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4610":{"id":4610,"qattrid":0,"type":1,"title":"欧唐静属于哪类降糖药物？","result":"B","content":"","options":[{"flag":"A","name":"DPP4 抑制剂"},{"flag":"B","name":"SGLT2抑制剂"},{"flag":"C","name":"噻唑烷二酮类"},{"flag":"D","name":"α-糖苷酶抑制剂"}]},"4611":{"id":4611,"qattrid":0,"type":1,"title":"欧唐静的通用名为(  )，安达唐的通用名为( )，怡可安的通用名为（）","result":"B","content":"","options":[{"flag":"A","name":"恩格列净，卡格列净，达格列净"},{"flag":"B","name":"恩格列净，达格列净，卡格列净"},{"flag":"C","name":"达格列净，恩格列净，卡格列净"},{"flag":"D","name":"卡格列净，恩格列净，达格列净"}]},"4612":{"id":4612,"qattrid":0,"type":1,"title":"欧唐静在中国上市的规格和剂型是？","result":"C","content":"","options":[{"flag":"A","name":"每片10mg，每盒7片"},{"flag":"B","name":"每片25mg，每盒10片"},{"flag":"C","name":"每片10mg，每盒10片"},{"flag":"D","name":"每片25mg，每盒14片"}]},"4613":{"id":4613,"qattrid":0,"type":1,"title":"欧唐静目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合二甲双胍和磺脲"},{"flag":"D","name":"以上都是"}]},"4614":{"id":4614,"qattrid":0,"type":1,"title":"欧唐静的适应症是？","result":"B","content":"","options":[{"flag":"A","name":"1型糖尿病"},{"flag":"B","name":"2型糖尿病"},{"flag":"C","name":"妊娠糖尿病"},{"flag":"D","name":"以上皆是"}]},"4615":{"id":4615,"qattrid":0,"type":1,"title":"\t(  )是导致2型糖尿病患者死亡的首要原因？","result":"B","content":"","options":[{"flag":"A","name":"恶性肿瘤"},{"flag":"B","name":"心血管疾病"},{"flag":"C","name":" 糖尿病"},{"flag":"D","name":"胃肠道疾病"}]},"4616":{"id":4616,"qattrid":0,"type":1,"title":"糖尿病患者心血管疾病风险约较非糖尿病人群高(  )倍？","result":"A","content":"","options":[{"flag":"A","name":"2-4\t"},{"flag":"B","name":"44053"},{"flag":"C","name":"14-16"},{"flag":"D","name":"20-22"}]},"4617":{"id":4617,"qattrid":0,"type":1,"title":"合并心血管疾病的2型糖尿病患者相比2型糖尿病患者预期寿命(  )？","result":"B","content":"","options":[{"flag":"A","name":"增减"},{"flag":"B","name":"降低"},{"flag":"C","name":"无影响"},{"flag":"D","name":"未知"}]},"4618":{"id":4618,"qattrid":0,"type":1,"title":"2型糖尿病治疗的近期目标是？","result":"D","content":"","options":[{"flag":"A","name":"预防慢性并发症"},{"flag":"B","name":"提高患者生活质量"},{"flag":"C","name":"延长寿命"},{"flag":"D","name":"通过控制高血糖和相关代谢紊乱来消除糖尿病症状和防止出现急性代谢并发症"}]},"4619":{"id":4619,"qattrid":0,"type":1,"title":"(  )引发FDA对降糖药物心血管安全性的关注","result":"B","content":"","options":[{"flag":"A","name":"吡格列酮"},{"flag":"B","name":"罗格列酮"},{"flag":"C","name":"二甲双胍"},{"flag":"D","name":"磺脲"}]},"4620":{"id":4620,"qattrid":0,"type":1,"title":"EMPA-REG OUTCOME有(  )个国家与地区参与？","result":"C","content":"","options":[{"flag":"A","name":"12"},{"flag":"B","name":"22"},{"flag":"C","name":"42"},{"flag":"D","name":"80"}]},"4621":{"id":4621,"qattrid":0,"type":1,"title":"EMPA-REG OUTCOME纳入(  )名患者？","result":"C","content":"","options":[{"flag":"A","name":"1020"},{"flag":"B","name":"3020"},{"flag":"C","name":"7020"},{"flag":"D","name":"10020"}]},"4622":{"id":4622,"qattrid":0,"type":1,"title":"2018年美国心脏协会ACC共识推荐，对于合并ASCVD的T2DM患者，推荐（ ）为2型糖尿病合并心血管疾病的首选SGLT2抑制剂","result":"C","content":"","options":[{"flag":"A","name":"恩格列净、卡格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"恩格列净"},{"flag":"D","name":"达格列净"}]},"4623":{"id":4623,"qattrid":0,"type":1,"title":"安达唐目前在中国上市的规格是？","result":"B","content":"","options":[{"flag":"A","name":"5mg"},{"flag":"B","name":"10mg"},{"flag":"C","name":"25mg"},{"flag":"D","name":"50mg"}]},"4624":{"id":4624,"qattrid":0,"type":1,"title":"安达唐目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合胰岛素"},{"flag":"D","name":"以上都是"}]},"4625":{"id":4625,"qattrid":0,"type":1,"title":"怡可安目前在中国上市的规格是？","result":"C","content":"","options":[{"flag":"A","name":"10mg"},{"flag":"B","name":"30mg"},{"flag":"C","name":"100mg"},{"flag":"D","name":"300mg"}]},"4626":{"id":4626,"qattrid":0,"type":1,"title":"CANVAS 研究显示，卡格列净相比安慰剂（  ）心血管死亡、心肌梗死风险、卒中和全因死亡风险","result":"C","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"降低"},{"flag":"C","name":"不降低"},{"flag":"D","name":"未知"}]},"4627":{"id":4627,"qattrid":0,"type":1,"title":"2型糖尿病并发症中，以下哪个不是大血管并发症？","result":"D","content":"11","options":[{"flag":"A","name":"卒中"},{"flag":"B","name":"心肌梗死"},{"flag":"C","name":"外周动脉疾病"},{"flag":"D","name":"糖尿病肾病"}]},"4628":{"id":4628,"qattrid":0,"type":1,"title":"在中国有多少2型糖尿病患者合并心血管危险因素？","result":"B","content":"22","options":[{"flag":"A","name":"0.49"},{"flag":"B","name":"0.72"},{"flag":"C","name":"0.39"},{"flag":"D","name":"0.35"}]},"4629":{"id":4629,"qattrid":0,"type":1,"title":"大庆研究证实：在中国，有多少糖尿病患者死于心血管疾病？","result":"A","content":"33","options":[{"flag":"A","name":"0.49"},{"flag":"B","name":"0.38"},{"flag":"C","name":"0.39"},{"flag":"D","name":"0.35"}]},"4630":{"id":4630,"qattrid":0,"type":1,"title":"以下哪个不是糖尿病治疗的远期目标？","result":"B","content":"44","options":[{"flag":"A","name":"预防慢性并发症（心血管疾病, 肾病等）"},{"flag":"B","name":"防止出现急性代谢并发症"},{"flag":"C","name":"提高患者生活质量"},{"flag":"D","name":"延长寿命"}]},"4631":{"id":4631,"qattrid":0,"type":1,"title":"以下哪个传统降糖药物在临床研究中看到了心血管获益？","result":"D","content":"55","options":[{"flag":"A","name":"磺脲类"},{"flag":"B","name":"格列奈类"},{"flag":"C","name":"甘精胰岛素"},{"flag":"D","name":"二甲双胍"}]},"4632":{"id":4632,"qattrid":0,"type":1,"title":"以下说法，哪个不正确?","result":"B","content":"66","options":[{"flag":"A","name":"健康人的肾小球每日可滤过~180 g的葡萄糖"},{"flag":"B","name":"2型糖尿病患者的葡萄糖重吸收能力减少"},{"flag":"C","name":"SGLT2i其作用机制是抑制近端肾小管钠－葡萄糖重吸收，促进尿糖排泄，从而降低血糖浓度"},{"flag":"D","name":"恩格列净促进尿糖排泄（大约80g 糖分/每天) ，从而出现渗透性利尿"}]},"4633":{"id":4633,"qattrid":0,"type":1,"title":"下列属于欧唐静降糖机制的是？","result":"D","content":"77","options":[{"flag":"A","name":"近90%经肾小球滤出的葡萄糖由SGLT2重吸收"},{"flag":"B","name":"2型糖尿病患者中，SGLT2的重吸收作用加强"},{"flag":"C","name":"恩格列净抑制SGLT2排出多余的葡萄糖近80g每天"},{"flag":"D","name":"以上都对"}]},"4634":{"id":4634,"qattrid":0,"type":1,"title":"下列哪种药物降糖机制为降低肾脏对葡萄糖的重吸收？","result":"B","content":"88","options":[{"flag":"A","name":".二甲双胍"},{"flag":"B","name":"SGLT2抑制剂"},{"flag":"C","name":"格列奈类"},{"flag":"D","name":"磺脲类"}]},"4635":{"id":4635,"qattrid":0,"type":1,"title":"SGLT2负责(  )葡萄11\n糖重吸收。","result":"C","content":"","options":[{"flag":"A","name":"心脏"},{"flag":"B","name":"肝脏"},{"flag":"C","name":"肾脏"},{"flag":"D","name":"肺脏"}]},"4636":{"id":4636,"qattrid":0,"type":1,"title":"2型糖尿病患者的葡萄糖转运体(  )?\t","result":"A","content":"","options":[{"flag":"A","name":"上调"},{"flag":"B","name":"下降"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4637":{"id":4637,"qattrid":0,"type":1,"title":"2型糖尿病患者的近端小管上皮细胞对葡萄糖的摄取(  )?","result":"A","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"减少"},{"flag":"C","name":"不变"},{"flag":"D","name":"未知"}]},"4638":{"id":4638,"qattrid":0,"type":1,"title":"欧唐静属于哪类降糖药物？","result":"B","content":"","options":[{"flag":"A","name":"DPP4 抑制剂"},{"flag":"B","name":"SGLT2抑制剂"},{"flag":"C","name":"噻唑烷二酮类"},{"flag":"D","name":"α-糖苷酶抑制剂"}]},"4639":{"id":4639,"qattrid":0,"type":1,"title":"欧唐静的通用名为(  )，安达唐的通用名为( )，怡可安的通用名为（）","result":"B","content":"","options":[{"flag":"A","name":"恩格列净，卡格列净，达格列净"},{"flag":"B","name":"恩格列净，达格列净，卡格列净"},{"flag":"C","name":"达格列净，恩格列净，卡格列净"},{"flag":"D","name":"卡格列净，恩格列净，达格列净"}]},"4640":{"id":4640,"qattrid":0,"type":1,"title":"欧唐静在中国上市的规格和剂型是？","result":"C","content":"","options":[{"flag":"A","name":"每片10mg，每盒7片"},{"flag":"B","name":"每片25mg，每盒10片"},{"flag":"C","name":"每片10mg，每盒10片"},{"flag":"D","name":"每片25mg，每盒14片"}]},"4641":{"id":4641,"qattrid":0,"type":1,"title":"欧唐静目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合二甲双胍和磺脲"},{"flag":"D","name":"以上都是"}]},"4642":{"id":4642,"qattrid":0,"type":1,"title":"欧唐静的适应症是？","result":"B","content":"","options":[{"flag":"A","name":"1型糖尿病"},{"flag":"B","name":"2型糖尿病"},{"flag":"C","name":"妊娠糖尿病"},{"flag":"D","name":"以上皆是"}]},"4643":{"id":4643,"qattrid":0,"type":1,"title":"\t(  )是导致2型糖尿病患者死亡的首要原因？","result":"B","content":"","options":[{"flag":"A","name":"恶性肿瘤"},{"flag":"B","name":"心血管疾病"},{"flag":"C","name":" 糖尿病"},{"flag":"D","name":"胃肠道疾病"}]},"4644":{"id":4644,"qattrid":0,"type":1,"title":"糖尿病患者心血管疾病风险约较非糖尿病人群高(  )倍？","result":"A","content":"","options":[{"flag":"A","name":"2-4\t"},{"flag":"B","name":"44053"},{"flag":"C","name":"14-16"},{"flag":"D","name":"20-22"}]},"4645":{"id":4645,"qattrid":0,"type":1,"title":"合并心血管疾病的2型糖尿病患者相比2型糖尿病患者预期寿命(  )？","result":"B","content":"","options":[{"flag":"A","name":"增减"},{"flag":"B","name":"降低"},{"flag":"C","name":"无影响"},{"flag":"D","name":"未知"}]},"4646":{"id":4646,"qattrid":0,"type":1,"title":"2型糖尿病治疗的近期目标是？","result":"D","content":"","options":[{"flag":"A","name":"预防慢性并发症"},{"flag":"B","name":"提高患者生活质量"},{"flag":"C","name":"延长寿命"},{"flag":"D","name":"通过控制高血糖和相关代谢紊乱来消除糖尿病症状和防止出现急性代谢并发症"}]},"4647":{"id":4647,"qattrid":0,"type":1,"title":"(  )引发FDA对降糖药物心血管安全性的关注","result":"B","content":"","options":[{"flag":"A","name":"吡格列酮"},{"flag":"B","name":"罗格列酮"},{"flag":"C","name":"二甲双胍"},{"flag":"D","name":"磺脲"}]},"4648":{"id":4648,"qattrid":0,"type":1,"title":"EMPA-REG OUTCOME有(  )个国家与地区参与？","result":"C","content":"","options":[{"flag":"A","name":"12"},{"flag":"B","name":"22"},{"flag":"C","name":"42"},{"flag":"D","name":"80"}]},"4649":{"id":4649,"qattrid":0,"type":1,"title":"EMPA-REG OUTCOME纳入(  )名患者？","result":"C","content":"","options":[{"flag":"A","name":"1020"},{"flag":"B","name":"3020"},{"flag":"C","name":"7020"},{"flag":"D","name":"10020"}]},"4650":{"id":4650,"qattrid":0,"type":1,"title":"2018年美国心脏协会ACC共识推荐，对于合并ASCVD的T2DM患者，推荐（ ）为2型糖尿病合并心血管疾病的首选SGLT2抑制剂","result":"C","content":"","options":[{"flag":"A","name":"恩格列净、卡格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"恩格列净"},{"flag":"D","name":"达格列净"}]},"4651":{"id":4651,"qattrid":0,"type":1,"title":"安达唐目前在中国上市的规格是？","result":"B","content":"","options":[{"flag":"A","name":"5mg"},{"flag":"B","name":"10mg"},{"flag":"C","name":"25mg"},{"flag":"D","name":"50mg"}]},"4652":{"id":4652,"qattrid":0,"type":1,"title":"安达唐目前在中国大陆地区获批的适应症是？","result":"D","content":"","options":[{"flag":"A","name":"单药治疗"},{"flag":"B","name":"联合二甲双胍"},{"flag":"C","name":"联合胰岛素"},{"flag":"D","name":"以上都是"}]},"4653":{"id":4653,"qattrid":0,"type":1,"title":"怡可安目前在中国上市的规格是？","result":"C","content":"","options":[{"flag":"A","name":"10mg"},{"flag":"B","name":"30mg"},{"flag":"C","name":"100mg"},{"flag":"D","name":"300mg"}]},"4654":{"id":4654,"qattrid":0,"type":1,"title":"CANVAS 研究显示，卡格列净相比安慰剂（  ）心血管死亡、心肌梗死风险、卒中和全因死亡风险","result":"C","content":"","options":[{"flag":"A","name":"增加"},{"flag":"B","name":"降低"},{"flag":"C","name":"不降低"},{"flag":"D","name":"未知"}]},"4655":{"id":4655,"qattrid":0,"type":2,"title":"下列哪项描述不符合希爱力每日一次方案（）","result":"A,B","content":"暂无分析","options":[{"flag":"A","name":"可获得持续稳定的有效血药浓度"},{"flag":"B","name":"0.11"},{"flag":"C","name":""},{"flag":"D","name":""}]},"4657":{"id":4657,"qattrid":0,"type":1,"title":"“经初始治疗效果不佳的患者推荐关节内透明质酸注射、度洛西汀、阿片类药物”出自下列哪个选项。（）","result":"D","content":"暂无分析","options":[{"flag":"A","name":"可获得持续稳定的有效血药浓度"},{"flag":"B","name":"0.11"},{"flag":"C","name":"0.24"},{"flag":"D","name":""}]},"4659":{"id":4659,"qattrid":0,"type":1,"title":"下列哪项描述不符合希爱力每日一次方案（）","result":"C","content":"暂无分析","options":[{"flag":"A","name":""},{"flag":"B","name":""},{"flag":"C","name":""},{"flag":"D","name":""}]},"4660":{"id":4660,"qattrid":0,"type":1,"title":"下列哪项描述不符合希爱力每日一次方案（）","result":"D","content":"暂无分析","options":[{"flag":"A","name":"可获得持续稳定的有效血药浓度"},{"flag":"B","name":"0.11"},{"flag":"C","name":"0.24"},{"flag":"D","name":""}]},"4661":{"id":4661,"qattrid":1,"type":1,"title":"测试","result":"A","content":"","options":[{"flag":"A","name":"啊"},{"flag":"B","name":"从"},{"flag":"C","name":"的"},{"flag":"D","name":"我"}]},"4666":{"id":4666,"qattrid":0,"type":1,"title":"测试","result":"A","content":"","options":[{"flag":"A","name":"啊"},{"flag":"B","name":"从"},{"flag":"C","name":"的"},{"flag":"D","name":"我"}]},"4667":{"id":4667,"qattrid":0,"type":2,"title":"淡粉色发","result":"是的","content":"","options":[{"flag":"A","name":""},{"flag":"B","name":""},{"flag":"C","name":""},{"flag":"D","name":""}]},"4691":{"id":4691,"qattrid":0,"type":1,"title":"test","result":"C","content":"暂无分析","options":[{"flag":"A","name":"zx"},{"flag":"B","name":"请问"},{"flag":"C","name":"问"},{"flag":"D","name":"gdgf"}]},"4692":{"id":4692,"qattrid":0,"type":1,"title":"测试题目","result":"B","content":"暂无分析","options":[{"flag":"A","name":"答案A"},{"flag":"B","name":"答案B正确"},{"flag":"C","name":"答案C"},{"flag":"D","name":"答案D"}]},"4695":{"id":4695,"qattrid":0,"type":2,"title":"2019年口服降糖药物中恩格列净全球销量第一，且超越以下哪些降糖药物？","result":"A,B,C,D","content":"","options":[{"flag":"A","name":"达格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"西格列汀"},{"flag":"D","name":"利拉鲁肽"}]},"4696":{"id":4696,"qattrid":0,"type":2,"title":"下列哪些是心血管危险因素：","result":"A,B,C,D,E","content":"","options":[{"flag":"A","name":"年龄"},{"flag":"B","name":"高血压"},{"flag":"C","name":"血脂异常"},{"flag":"D","name":"吸烟"}]},"4697":{"id":4697,"qattrid":0,"type":1,"title":"大庆研究显示，多少比例的糖尿病患者死于心血管疾病？","result":"C","content":"0.49","options":[{"flag":"A","name":"0.29"},{"flag":"B","name":"0.36"},{"flag":"C","name":"0.49"},{"flag":"D","name":""}]},"4698":{"id":4698,"qattrid":0,"type":1,"title":"ACCORD研究结果显示，CVD风险无显著变化，死亡风险降低","result":"B","content":"错误","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"4699":{"id":4699,"qattrid":0,"type":1,"title":"3B研究显示，多少比例的中国糖尿病患者合并心血管风险因素？","result":"D","content":"","options":[{"flag":"A","name":"0.279"},{"flag":"B","name":"0.3"},{"flag":"C","name":"0.598"},{"flag":"D","name":"0.72"}]},"5300":{"id":5300,"qattrid":46,"type":1,"title":"银屑病大约累及全球多少人口？","result":"B","content":"银屑病约累及全球1.25亿人","options":[{"flag":"A","name":"0.25亿"},{"flag":"B","name":"1.25亿"},{"flag":"C","name":"2.25亿"},{"flag":"D","name":"3.25亿"}]},"5301":{"id":5301,"qattrid":46,"type":1,"title":"下列不属于银屑病临床表现的是_____？","result":"A","content":"银屑病常见临床表现为发红、斑块增厚和鳞屑性斑块，局限或广泛分布","options":[{"flag":"A","name":"仅广泛分布"},{"flag":"B","name":"鳞屑性斑块"},{"flag":"C","name":"发红"},{"flag":"D","name":"斑块增厚"}]},"5302":{"id":5302,"qattrid":46,"type":2,"title":"下列哪些属于导致银屑病的常见因素？","result":"A,C,D","content":"导致银屑病的常见病因有遗传、环境和免疫因素","options":[{"flag":"A","name":"环境因素"},{"flag":"B","name":"遗传因素"},{"flag":"C","name":"心理因素"},{"flag":"D","name":"免疫因素"}]},"5303":{"id":5303,"qattrid":46,"type":2,"title":"银屑病与下列哪些结局相关？","result":"B,C,D","content":"银屑病增加银屑病患者抑郁风险","options":[{"flag":"A","name":"降低抑郁风险"},{"flag":"B","name":"生活质量降低"},{"flag":"C","name":"死亡率升高"},{"flag":"D","name":"共病"}]},"5304":{"id":5304,"qattrid":46,"type":2,"title":"银屑病患病率较高的共病有_____？","result":"A,B,C,D","content":"脂肪性肝病、血脂异常、代谢综合征和高血压是银屑病患病率较高的共病","options":[{"flag":"A","name":"高血压"},{"flag":"B","name":"血脂异常"},{"flag":"C","name":"脂肪性肝病"},{"flag":"D","name":"代谢综合征"}]},"5305":{"id":5305,"qattrid":46,"type":1,"title":"下列关于银屑病治疗目标说法不正确的是_____?","result":"B","content":"2004年前银屑病有效治疗目标为PASI50、2004年为PASI75、2015后为PASI75为PASI90、2017后为PASI100","options":[{"flag":"A","name":"2004年前银屑病有效治疗目标为PASI50"},{"flag":"B","name":"2010年银屑病有效治疗目标为PASI75"},{"flag":"C","name":"2015年银屑病有效治疗目标为PASI90"},{"flag":"D","name":"2017后银屑病有效治疗目标为PASI100"}]},"5306":{"id":5306,"qattrid":46,"type":2,"title":"下列说法正确的是_____?","result":"A,B","content":"实现皮损完全清除的患者，患者生活质量得到更好的改善。银屑病对患者生活质量的影响与其他严重疾病相当。银屑病患者通常有比皮肤科医生更高的治疗期望和目标。对于获得PASI75的银屑病患者，仍有明显的皮损残留","options":[{"flag":"A","name":"皮损完全清除提高银屑病患者生活质量"},{"flag":"B","name":"银屑病对患者生活质量的影响与其他严重疾病相当"},{"flag":"C","name":"银屑病患者和皮肤科医生具有相同的治疗期望和目标"},{"flag":"D","name":"实现得PASI75的银屑病患者，皮损残留不再明显"}]},"5307":{"id":5307,"qattrid":46,"type":1,"title":"目前有_____银屑病患者对当前治疗不满意?","result":"C","content":"目前有50%-75%的银屑病患者对他们当前的治疗不满意","options":[{"flag":"A","name":"0%-25%"},{"flag":"B","name":"25%-50%"},{"flag":"C","name":"50%-75%"},{"flag":"D","name":"75%-100%"}]},"5308":{"id":5308,"qattrid":46,"type":1,"title":"目前有_____银屑病患者的治疗依从性不佳？","result":"D","content":"目前有27%-97%的银屑病患者的治疗依从性不佳","options":[{"flag":"A","name":"27%-77%"},{"flag":"B","name":"47%-77%"},{"flag":"C","name":"47%-97%"},{"flag":"D","name":"27%-97%"}]},"5309":{"id":5309,"qattrid":46,"type":2,"title":"中重度银屑病患者认为高度重要的治疗需求有_____?","result":"A,B,C,D","content":"中重度银屑病患者认为高度重要的治疗需求有皮损完全清除(94%)。维持皮损清除2-3年(94%)。对指/趾甲、头皮、生殖器、手掌和足底有效(92%)。快速起效(90%)和副作用小(83%)","options":[{"flag":"A","name":"皮损完全清除"},{"flag":"B","name":"维持皮损清除2-3年"},{"flag":"C","name":"对指/趾甲、头皮、生殖器、手掌和足底有效"},{"flag":"D","name":"快速起效、副作用小"}]},"5310":{"id":5310,"qattrid":46,"type":1,"title":"中重度银屑病患者期望获得PASI50和PASI100的平均天数分别为_____?","result":"D","content":"中重度银屑病患者期望获得PASI50和PASI100的平均天数分别为16天和34天","options":[{"flag":"A","name":"8天和17天"},{"flag":"B","name":"8天和24天"},{"flag":"C","name":"16天和24天"},{"flag":"D","name":"16天和34天"}]},"5311":{"id":5311,"qattrid":46,"type":1,"title":"下列说法不正确的是_____？","result":"A","content":"拓咨®治疗2周有63%的银屑病患者实现PASI50","options":[{"flag":"A","name":"拓咨治疗2周有43%的银屑病患者实现PASI50"},{"flag":"B","name":"拓咨治疗2周有63%的银屑病患者实现PASI50"},{"flag":"C","name":"皮损完全清除或几乎完全清除可使患者回归正常生活"},{"flag":"D","name":"生物制剂的早期应答有助于实现长期皮损清除的目标"}]},"5312":{"id":5312,"qattrid":46,"type":1,"title":"一项MAPP调查结果表明，约有_____患者仍未获得生物制剂治疗?","result":"D","content":"一项MAPP调查结果表明，约有90%左右的银屑病患者仍未获得生物制剂治疗","options":[{"flag":"A","name":"0.6"},{"flag":"B","name":"0.7"},{"flag":"C","name":"0.8"},{"flag":"D","name":"0.9"}]},"5313":{"id":5313,"qattrid":46,"type":1,"title":"拓咨®治疗12周实现绝对值PASI≤2的患者百分比为_____?","result":"C","content":"拓咨®治疗12周实现绝对值PASI≤2的患者百分比为71.6%","options":[{"flag":"A","name":"0.516"},{"flag":"B","name":"0.616"},{"flag":"C","name":"0.716"},{"flag":"D","name":"0.816"}]},"5314":{"id":5314,"qattrid":46,"type":2,"title":"下列关于银屑病治疗说法正确的是_____?","result":"A,C,D","content":"银屑病是一种慢性、复发性疾病，需要长期治疗","options":[{"flag":"A","name":"治疗指南建议医生了解银屑病患者的想法和偏好"},{"flag":"B","name":"银屑病不需要长期治疗"},{"flag":"C","name":"患者满意度佳可提高患者治疗依从性"},{"flag":"D","name":"医患共同决策与更好的患者满意度相关"}]},"5315":{"id":5315,"qattrid":46,"type":2,"title":"下列说法正确的是_____?","result":"A,B,D","content":"早期应答率是后续获得持久的高PASI缓解率的重要影响因素","options":[{"flag":"A","name":"2016年WHO《银屑病全球报告》中，94.2%的银屑病患者希望皮损快速清除"},{"flag":"B","name":"一项对美国中重度银屑病患者治疗期望的网络调查结果显示，银屑病患者期望达到PASI50和PASI75的的平均天数为16天和34天"},{"flag":"C","name":"早期应答率与后续获得持久的高PASI缓解率无关"},{"flag":"D","name":"在使用依奇珠单抗治疗时，第2周获得PASI50的患者更容易在后续52周内获得PASI90或PASI100"}]},"5316":{"id":5316,"qattrid":46,"type":1,"title":"根据不同的作用机制来划分，目前在我国上市的生物制剂有______类?","result":"B","content":"目前在我国上市的生物制剂有4类，包括TNF-α抑制剂、IL-12/23抑制剂、IL-17抑制剂、IL-23抑制剂","options":[{"flag":"A","name":"3类"},{"flag":"B","name":"4类"},{"flag":"C","name":"5类"},{"flag":"D","name":"6类"}]},"5317":{"id":5317,"qattrid":46,"type":1,"title":"目前在我国上市的治疗银屑病的生物制剂有______种(根据药物通用名来看)?","result":"A","content":"目前在我国上市的生物制剂有9种，TNF-α抑制剂(依那西普、英夫利西单抗、阿达木单抗)、IL-12/23抑制剂(乌司奴单抗)、IL-17抑制剂(司库奇尤单抗、依奇珠单抗)、IL-23抑制剂(古塞奇尤单抗)","options":[{"flag":"A","name":"7种"},{"flag":"B","name":"8种"},{"flag":"C","name":"9种"},{"flag":"D","name":"10种"}]},"5318":{"id":5318,"qattrid":46,"type":1,"title":"拓咨®达到PASI50的平均时间为______?","result":"B","content":"拓咨®达到PASI50的平均时间为1.9周","options":[{"flag":"A","name":"1周"},{"flag":"B","name":"1.9周"},{"flag":"C","name":"2.5周"},{"flag":"D","name":"3.6周"}]},"5319":{"id":5319,"qattrid":46,"type":2,"title":"关于IL-17/IL-23轴的描述，下列说法正确的是_____?","result":"A,B,C,D","content":"Th17细胞能分泌多种细胞因子(IL-17A、IL-21,GM-CSF,IL-22,IL-17F,CCL20)。IL-17A可由不同的细胞分泌(如NKT细胞、NK细胞、中性粒细胞、肥大细胞、γδT细胞等)。IL-23可由不同的细胞(树突状细胞、角质形成细胞、巨噬细胞)分泌。","options":[{"flag":"A","name":"Th17细胞可分泌IL-17A、IL-21、GM-CSF"},{"flag":"B","name":"Th17细胞可分泌IL-22、IL-17F、CCL20"},{"flag":"C","name":"IL-17A可由不同的细胞分泌，如：NKT细胞、NK细胞、中性粒细胞、肥大细胞、γδT细胞等"},{"flag":"D","name":"IL-23可由树突状细胞、角质形成细胞和巨噬细胞分泌"}]},"5320":{"id":5320,"qattrid":46,"type":2,"title":"关于IL-17/IL-23轴的作用机制，下列说法正确的是_____?","result":"B,C,D","content":"IL-17/IL-23轴实际存在复杂的反馈回路。IL-23刺激Th17细胞分泌IL-17A。IL-17A促进角质形成细胞释放促炎细胞因子、表皮重构、产生银屑病斑块","options":[{"flag":"A","name":"IL-17/IL-23轴仅存在单向的层级关系"},{"flag":"B","name":"IL-17/IL-23轴实际存在复杂的反馈回路"},{"flag":"C","name":"IL-23刺激Th17细胞分泌IL-17A"},{"flag":"D","name":"IL-17A促进角质形成细胞释放促炎细胞因子、表皮重构、产生银屑病斑块"}]},"5321":{"id":5321,"qattrid":46,"type":2,"title":"拓咨®靶向IL-17A，能快速降低______水平?","result":"A,B,C,D","content":"拓咨®靶向IL-17A，能快速降低IL-23/p19、IL-23/p40、IL-17A、IL-17F水平","options":[{"flag":"A","name":"IL-23/p19"},{"flag":"B","name":"IL-17A"},{"flag":"C","name":"IL-17F"},{"flag":"D","name":"IL-23/p40"}]},"5322":{"id":5322,"qattrid":46,"type":1,"title":"在IXORA-R研究中，拓咨®和古塞奇尤单抗治疗12周实现PASI100的患者比例分别为_____?","result":"D","content":"在IXORA-R研究中，拓咨®和古塞奇尤单抗治疗12周实现PASI100的患者比例分别为25%和41%。","options":[{"flag":"A","name":"15%和35%"},{"flag":"B","name":"15%和41%"},{"flag":"C","name":"25%和35%"},{"flag":"D","name":"25%和41%"}]},"5323":{"id":5323,"qattrid":46,"type":2,"title":"在IXORA-R研究中，在第_____周，拓咨和古塞奇尤单抗分别有_____和_____实现_____改善?","result":"A,B,C,D","content":"在第1周分别有28%和9%实现PASI50,第2周分别有23%和5%实现PASI75，第4周分别有21%和8%实现PASI90，第8周分别有58%和36%实现PASI90，第12周分别有42%和25%实现sPGA(0)","options":[{"flag":"A","name":"1，28%和9%，PASI50"},{"flag":"B","name":"2，23%和5%，PASI75"},{"flag":"C","name":"4，21%和8%，PASI90"},{"flag":"D","name":"12，42%和25%，sPGA(0)"}]},"5324":{"id":5324,"qattrid":46,"type":1,"title":"在IXORA-R研究中，治疗第1周，拓咨和古塞奇尤单抗的PASI自基线改善的中位百分比分别为_____?","result":"D","content":"在IXORA-R研究中，治疗第1周，拓咨和古塞奇尤单抗的PASI自基线改善的中位百分比分别为34%和17%","options":[{"flag":"A","name":"26%和17%"},{"flag":"B","name":"37%和14%"},{"flag":"C","name":"28%和14%"},{"flag":"D","name":"34%和17%"}]},"5325":{"id":5325,"qattrid":46,"type":2,"title":"在IXORA-R研究中，拓咨®可快速_____?","result":"A,B,C,D","content":"在IXORA-R研究中，拓咨®可使更多的银屑病患者快速达到皮损完全清除或几乎完全清除，可更快改善银屑病患者病情情况，可更快缓解皮肤瘙痒症状，可快速改善患者生活质量","options":[{"flag":"A","name":"达到皮损完全清除或几乎完全清除"},{"flag":"B","name":"改善银屑病患者病情情况"},{"flag":"C","name":"缓解皮肤瘙痒症状"},{"flag":"D","name":"改善患者生活质量"}]},"5326":{"id":5326,"qattrid":46,"type":1,"title":"在IXORA-R研究中，拓咨®和古塞奇尤单抗在治疗过程中的不良反应发生率分别为_____?","result":"A","content":"在IXORA-R研究中，拓咨®和古塞奇尤单抗在治疗过程中的不良反应发生率分别为55%和56%","options":[{"flag":"A","name":"55%和56%"},{"flag":"B","name":"66%和65%"},{"flag":"C","name":"44%和45%"},{"flag":"D","name":"44%和65%"}]},"5327":{"id":5327,"qattrid":46,"type":1,"title":"在我国已上市的生物制剂中，使用_____和_____治疗4周和8周，其PASI75和PASI90的应答率更高？","result":"D","content":"在我国已上市的生物制剂中，在第4周和第8周，使用拓咨®治疗的患者，其PASI75和PASI90的应答率更高","options":[{"flag":"A","name":"Brodalumab、拓咨"},{"flag":"B","name":"司库奇尤单抗，拓咨"},{"flag":"C","name":"拓咨，司库奇尤单抗"},{"flag":"D","name":"拓咨、拓咨"}]},"5328":{"id":5328,"qattrid":46,"type":1,"title":"在一项荟萃分析中，拓咨®治疗10-16周和44-60周实现PASI100的患者比例分别为_____?","result":"B","content":"在一项荟萃分析中，拓咨®治疗10-16周和44-60周实现PASI100的患者百分比分别为39.5%和54.3%","options":[{"flag":"A","name":"23.5%和44.3%"},{"flag":"B","name":"39.5%和54.3%"},{"flag":"C","name":"45.3%和55.6%"},{"flag":"D","name":"52.6%和55.6%"}]},"5329":{"id":5329,"qattrid":46,"type":1,"title":"在UNCOVER1,2研究中，拓咨治疗5年实现PASI75/90/100的患者比例分别为_____(观察值)?","result":"A","content":"在UNCOVER1,2研究中，拓咨治疗5年实现PASI75/90/100的患者比例分别为97.7%、86.4%和57.6%","options":[{"flag":"A","name":"97.7%、86.4%和57.6%"},{"flag":"B","name":"86.3%、74.6%和46.7%"},{"flag":"C","name":"78.6%、63.9%和55.2%"},{"flag":"D","name":"79.1%、63.9%和45.0%"}]},"5330":{"id":5330,"qattrid":46,"type":2,"title":"下列关于银屑病和银屑病患者治疗期待的描述，正确的是_____?","result":"B,C,D","content":"患者想了解长期治疗(≥1年)的可行性","options":[{"flag":"A","name":"患者想了解长期治疗(≥1个月)的可行性"},{"flag":"B","name":"初期应答患者想了解他们接受治疗后疗效能维持多久"},{"flag":"C","name":"有报道，银屑病患者经过0.8-3.9年治疗，最终对生物治疗失去应答的比例为20-32%"},{"flag":"D","name":"银屑病是一种慢性疾病"}]},"5331":{"id":5331,"qattrid":46,"type":1,"title":"银屑病皮损复发部位常位于_____?","result":"D","content":"银屑病皮损复发部位常位于原皮损消退区域","options":[{"flag":"A","name":"掌趾"},{"flag":"B","name":"头皮"},{"flag":"C","name":"指甲"},{"flag":"D","name":"原皮损消退区域"}]},"5332":{"id":5332,"qattrid":46,"type":1,"title":"在银屑病复发中具有关键作用的细胞是______，具有______特点?","result":"C","content":"在银屑病复发中具有关键作用的细胞是皮肤组织常驻记忆性T细胞，具有在外周组织中长期存活和低迁移的特点","options":[{"flag":"A","name":"皮肤组织常驻记忆性T细胞，具有在外周组织中短期存活和低迁移的特点"},{"flag":"B","name":"皮肤组织常驻记忆性T细胞，具有在外周组织中短期存活和高迁移的特点"},{"flag":"C","name":"皮肤组织常驻记忆性T细胞，具有在外周组织中长期存活和低迁移的特点"},{"flag":"D","name":"皮肤组织常驻记忆性T细胞，具有在外周组织中长期存活和高迁移的特点"}]},"5333":{"id":5333,"qattrid":46,"type":1,"title":"在使用IL-17单抗对斑块状银屑病治疗后，原消退皮损表皮中仍具有分泌______的CD8T细胞和分泌______的相关T细胞?","result":"A","content":"在使用IL-17单抗对斑块状银屑病治疗后，原消退皮损表皮中仍均在具有分泌IL-17的CD8T细胞及分泌IL-23受体的相关T细胞","options":[{"flag":"A","name":"IL-17、IL-23受体"},{"flag":"B","name":"IL-17、IL-17受体"},{"flag":"C","name":"IL-23、IL-17受体"},{"flag":"D","name":"IL-23、IL-23受体"}]},"5334":{"id":5334,"qattrid":46,"type":2,"title":"下列关于银屑病复发机制的描述，正确的是_____?","result":"A,B,C","content":"皮损部位的朗格汉斯细胞刺激下能够分泌IL-23，激活皮肤组织常驻记忆性T细胞","options":[{"flag":"A","name":"具有活性的T细胞能长期驻留在银屑病皮损部位，在刺激下可迅速激活，介导炎症再次发生"},{"flag":"B","name":"在长期治疗下仍能够刺激细胞分泌IL-17A，导致角质形成细胞增殖"},{"flag":"C","name":"皮损部位的朗格汉斯细胞刺激下能够分泌IL-23，激活皮肤组织常驻记忆性T细胞"},{"flag":"D","name":"皮损部位的朗格汉斯细胞刺激下能够分泌IL-17，激活皮肤组织常驻记忆性T细胞"}]},"5335":{"id":5335,"qattrid":46,"type":2,"title":"2019美国ADD/NPF中关于停药后重新开始生物制剂治疗的建议，正确的是_____?","result":"A,B,D","content":"如果患者正处于复发或自上次给药以来已经超过3至4个半衰期，考虑在重新开始用药时采用负荷剂量","options":[{"flag":"A","name":"根据疾病的严重程度和停药时间，再治疗时可能有必要采用负荷剂量"},{"flag":"B","name":"如果患者正处于复发或自上次给药以来已经超过3至4个半衰期，考虑在重新开始用药时采用负荷剂量"},{"flag":"C","name":"如果患者正处于复发或自上次给药以来已经超过1-3个半衰期，考虑在重新开始用药时采用负荷剂量"},{"flag":"D","name":"停药后再治疗可能会导致一小部分患者无法重新获得以前的稳定血药水平"}]},"5336":{"id":5336,"qattrid":46,"type":2,"title":"在2019年中国银屑病生物制剂治疗专家共识中，下列描述正确的是______?","result":"A,B,C","content":"长期维持治疗对患者生活质量的改善优于间断治疗","options":[{"flag":"A","name":"银屑病是反复发作性疾病"},{"flag":"B","name":"多数生物制剂的治疗方案有诱导治疗和维持治疗两个阶段"},{"flag":"C","name":"长期维持治疗对患者生活质量的改善优于间断治疗"},{"flag":"D","name":"间断治疗对患者生活质量的改善优于长期维持治疗"}]},"5337":{"id":5337,"qattrid":46,"type":2,"title":"停药和再治疗研究设计和分析方法的主要差异包括_____?","result":"A,B,C,D","content":"停药和再治疗研究设计和分析方法的主要差异包括再随机的应答标准、复发标准、再治疗方案和再次重新获得应答的定义","options":[{"flag":"A","name":"再随机的应答标准"},{"flag":"B","name":"复发标准"},{"flag":"C","name":"再治疗方案"},{"flag":"D","name":"再次重新获得应答的定义"}]},"5338":{"id":5338,"qattrid":46,"type":1,"title":"下列关于UNCOVER-1,2研究，描述错误的是_____?","result":"D","content":"患者从丧失sPGA(0,1)应答至达到复发标准(sPGA≥3)的中位时间约为5个月","options":[{"flag":"A","name":"在经过12周依奇珠单抗Q2W治疗后停药随访的患者中，83%患者在停药60周内复发，17%患者未复发"},{"flag":"B","name":"无论治疗中是否出现抗药抗体，再治疗重获PASI应答无差异"},{"flag":"C","name":"患者从丧失sPGA(0,1)应答至达到复发标准(sPGA≥3)的中位时间约为5个月"},{"flag":"D","name":"患者从丧失sPGA(0,1)应答至达到复发标准(sPGA≥3)的中位时间约为3个月"}]},"5339":{"id":5339,"qattrid":46,"type":1,"title":"依奇珠单抗Q2W治疗12周停药后，出现复发再接受依奇珠单抗Q4W治疗，重新获得PASI75的中位时间为_____?","result":"B","content":"依奇珠单抗Q2W治疗12周停药后，出现复发再接受依奇珠单抗Q4W治疗，重新获得PASI75的中位时间为1个月","options":[{"flag":"A","name":"约0.5个月"},{"flag":"B","name":"约1个月"},{"flag":"C","name":"约1.5个月"},{"flag":"D","name":"约2个月"}]},"5340":{"id":5340,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，拓咨持续治疗60周，实现PASI75/90/100的患者比例分别为______?","result":"B","content":"在UNCOVER-1,2研究中，拓咨持续治疗60周，实现PASI75/90/100的患者比例分别为90%、80.5%、58.8%","options":[{"flag":"A","name":"90%、70.5%、58.8%"},{"flag":"B","name":"90%、80.5%、58.8%"},{"flag":"C","name":"80%、70.5%、51.9%"},{"flag":"D","name":"80%、70.5%、46.3%"}]},"5341":{"id":5341,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，拓咨持续治疗60周，______的患者实现sPGA(0,1)","result":"B","content":"在UNCOVER-1,2研究中，拓咨持续治疗60周，81.9%的患者实现sPGA(0,1)","options":[{"flag":"A","name":"0.759"},{"flag":"B","name":"0.819"},{"flag":"C","name":"0.869"},{"flag":"D","name":"0.912"}]},"5342":{"id":5342,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，拓咨停药在治疗后重新获得PASI75/90/100的患者比例分别为______?","result":"A","content":"在UNCOVER-1,2研究中，拓咨停药在治疗后重新获得PASI75/90/100的患者比例分别为87%、63%和32%","options":[{"flag":"A","name":"87%、63%和32%"},{"flag":"B","name":"80%、57%和48%"},{"flag":"C","name":"80%、63%和48%"},{"flag":"D","name":"75%、58%和35%"}]},"5343":{"id":5343,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，拓咨停药在治疗后重新获得sPGA(0,1)的患者比例分别为______?","result":"C","content":"在UNCOVER-1,2研究中，拓咨停药在治疗后71%的银屑病患者重新获得sPGA(0,1)","options":[{"flag":"A","name":"0.57"},{"flag":"B","name":"0.63"},{"flag":"C","name":"0.71"},{"flag":"D","name":"0.82"}]},"5344":{"id":5344,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，拓咨停药在治疗后重新获得sPGA(0)的患者比例分别为______?","result":"C","content":"在UNCOVER-1,2研究中，拓咨停药在治疗后35%的银屑病患者重新获得sPGA(0)","options":[{"flag":"A","name":"0.25"},{"flag":"B","name":"0.29"},{"flag":"C","name":"0.35"},{"flag":"D","name":"0.46"}]},"5345":{"id":5345,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗的基本信息，描述错误的是____？","result":"D","content":"本品为澄清至乳光，无色至微黄色至微棕色溶液，若出现颗粒或溶液混浊和/或明显棕色，则不应使用","options":[{"flag":"A","name":"用于治疗适合系统治疗或光疗的中重度斑块型银屑病成人患者"},{"flag":"B","name":"规格80mg/mL，每盒1支，采用自动注射器注射"},{"flag":"C","name":"依奇珠单抗的自动注射器仅供一次性使用"},{"flag":"D","name":"本品为澄清至乳光，无色至微黄色至微棕色溶液，若出现颗粒或溶液混浊和/或明显棕色，静置后可以使用"}]},"5346":{"id":5346,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗的贮藏保存，描述错误的是____？","result":"A","content":"依奇珠单抗需在冷藏条件下(2℃~8℃)储存，存放在原包装中以避免光照，不可冷冻或摇晃本品","options":[{"flag":"A","name":"依奇珠单抗储存温度不宜过高，最高放在冰箱冷冻保存"},{"flag":"B","name":"依奇珠单抗1mL溶液装于I型透明玻璃注射器中"},{"flag":"C","name":"注射器封装于一次性使用的单剂量自动注射器中"},{"flag":"D","name":"保质期24个月"}]},"5347":{"id":5347,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗给药剂量，描述错误的是_____?","result":"C","content":"≥65岁的老年患者使用依奇珠单抗不需要调整剂量","options":[{"flag":"A","name":"首次用药160mg(80mg注射两次)"},{"flag":"B","name":"在首次用药后第2、4、6、8、10和12周各注射80mg(注射一次)，然后每四周给药1次"},{"flag":"C","name":"对≥65岁的老年患者调整给药剂量"},{"flag":"D","name":"本品尚未在肾脏或肝脏损害的患者中开展研究"}]},"5348":{"id":5348,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗给药方法，描述错误的是_____?","result":"C","content":"如果可能，应避免将银屑病受累皮肤作为注射部位","options":[{"flag":"A","name":"皮下注射给药"},{"flag":"B","name":"应轮换使用注射部位"},{"flag":"C","name":"将银屑病受累皮肤作为注射部位疗效更好"},{"flag":"D","name":"不得剧烈摇晃溶液/自动注射器"}]},"5349":{"id":5349,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗注射部位不良反应描述错误的是_____?","result":"D","content":"与体重≥60kg受试者相比，体重<60kg的受试者中注射部位反应更常见","options":[{"flag":"A","name":"注射部位反应是报告频率最高的药物不良反应之一"},{"flag":"B","name":"最常见的注射部位反应是红疹和疼痛"},{"flag":"C","name":"主要为轻度至中度"},{"flag":"D","name":"体重≥60kg的受试者比体重<60kg的受试者的注射部位反应更常见"}]},"5350":{"id":5350,"qattrid":46,"type":2,"title":"下列关于依奇珠单抗感染相关不良反应描述正确的是_____?","result":"B,C,D","content":"大多数感染不良反应为轻中度","options":[{"flag":"A","name":"大多数感染不良反应为中重度"},{"flag":"B","name":"对伴有重要临床意义感染的患者，需慎用依奇珠单抗"},{"flag":"C","name":"潜伏性结核病患者开始使用依奇珠单抗前应先考虑进行抗结核治疗"},{"flag":"D","name":"活动性结核病(TB)患者不得使用依奇珠单抗"}]},"5351":{"id":5351,"qattrid":46,"type":2,"title":"下列关于依奇珠单抗血小板减少和中性粒细胞减少不良反应的描述正确的是_____?","result":"A,B,D","content":"血小板减少是偶见不良事件","options":[{"flag":"A","name":"血小板减少可能是持续的、波动的或一过性的"},{"flag":"B","name":"血小板减少是常见不良事件"},{"flag":"C","name":"中性粒细胞减少水平可能是持续的、波动的或一过性"},{"flag":"D","name":"通常情况下中性粒细胞减少不需要停用依奇珠单抗"}]},"5352":{"id":5352,"qattrid":46,"type":1,"title":"在推荐剂量给药方案下，使用依奇珠单抗治疗斑块型银屑病患者60周的研究结果描述，错误的是_____?","result":"D","content":"免疫原性与治疗中出现的不良事件的关联尚未明确","options":[{"flag":"A","name":"约9%-17%的患者产生了抗药物抗体"},{"flag":"B","name":"大多数为低滴度并且与临床应答降低无关"},{"flag":"C","name":"大约1％的依奇珠单抗治疗患者被确认产生了与低药物浓度和临床应答降低相关的中和抗体"},{"flag":"D","name":"免疫原性增加治疗过程中出现的不良事件"}]},"5353":{"id":5353,"qattrid":46,"type":2,"title":"下列关于依奇珠单抗超敏反应不良反应描述正确的是_____?","result":"A,C,D","content":"速发性过敏反应属于罕见不良反应","options":[{"flag":"A","name":"临床报告的严重超敏反应包括某些速发过敏反应、血管性水肿、荨麻疹"},{"flag":"B","name":"速发性过敏反应属于偶见不良反应"},{"flag":"C","name":"临床报告的严重超敏反应包括较少见的迟发(注射后10-14天)严重超敏反应，包括广泛性荨麻疹、呼吸困难和高抗体滴度"},{"flag":"D","name":"如果发生严重超敏反应，应立即停止使用依奇珠单抗并开始适当的治疗"}]},"5354":{"id":5354,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗其他不良反应描述错误的是_____?","result":"C","content":"依奇珠单抗对灭活疫苗应答相关数据不足","options":[{"flag":"A","name":"目前已有克罗恩病和溃疡性结肠炎新发或恶化的病例报告"},{"flag":"B","name":"炎症性肠病(包括克罗恩病和溃疡性结肠炎)患者应谨慎使用依奇珠单抗，并应密切接受监测"},{"flag":"C","name":"依奇珠单抗可以和灭活疫苗一起使用"},{"flag":"D","name":"依奇珠单抗不应与活疫苗一起使用"}]},"5355":{"id":5355,"qattrid":46,"type":2,"title":"下列关于依奇珠单抗吸收描述正确的是_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"银屑病患者在5mg-160mg范围内单次皮下注射依奇珠单抗后，在4-7天内达到平均峰浓度"},{"flag":"B","name":"160mg起始剂量后，80mgQ2W给药方案在第8周达到稳态"},{"flag":"C","name":"第12周从80mgQ2W给药方案转换为80mgQ4W给药方案后，约10周后达到稳态"},{"flag":"D","name":"皮下注射依奇珠单抗后的平均生物利用度为54％至90％"}]},"5356":{"id":5356,"qattrid":46,"type":2,"title":"下列关于依奇珠单抗其他药代动力学特征描述错误的是_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"依奇珠单抗是一种单克隆抗体，预计通过与内源性免疫球蛋白相同的分解代谢途径降解为小肽和氨基酸"},{"flag":"B","name":"在斑块型银屑病患者中的平均消除半衰期为13天"},{"flag":"C","name":"在5mg至160mg剂量范围内皮下注射后，依奇珠单抗的暴露水平（AUC）与剂量成比例增加"},{"flag":"D","name":"老年患者与65岁以下患者的清除率相似"}]},"5357":{"id":5357,"qattrid":46,"type":1,"title":"下列关于依奇珠单抗药理作用描述正确的是_____?","result":"A","content":"依奇珠单抗是一种人源化的IgG4单克隆抗体","options":[{"flag":"A","name":"依奇珠单抗是一种全人源的IgG4单克隆抗体"},{"flag":"B","name":"依奇珠单抗与IL-17A发生特异性结合并抑制IL-17A与IL-17受体的相互作用"},{"flag":"C","name":"IL-17A是一种参与正常炎症及免疫应答的天然细胞因子"},{"flag":"D","name":"依奇珠单抗对促炎细胞因子与趋化因子的释放都具有抑制作用"}]},"5358":{"id":5358,"qattrid":46,"type":2,"title":"依奇珠单抗十分常见(≥10%)的药物不良反应有_____?","result":"B,C","content":"依奇珠单抗十分常见(≥10%)的药物不良反应有注射部位反应和上呼吸道感染(其中鼻咽炎最为常见)，荨麻疹和血管性水肿属于偶见不良反应","options":[{"flag":"A","name":"荨麻疹"},{"flag":"B","name":"上呼吸道感染"},{"flag":"C","name":"注射部位反应"},{"flag":"D","name":"血管性水肿"}]},"5359":{"id":5359,"qattrid":46,"type":2,"title":"依奇珠单抗常见(≥1%)的药物不良反应有_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"癣"},{"flag":"B","name":"单纯疱疹(皮肤粘膜)"},{"flag":"C","name":"口咽痛"},{"flag":"D","name":"恶心"}]},"5360":{"id":5360,"qattrid":46,"type":2,"title":"\t下列关于银屑病治疗目标，描述正确的是____?","result":"A,B,D","content":"2015年后IL-17A抑制剂的出现，有望在大多数银屑病患者中实现PASI90甚至更好","options":[{"flag":"A","name":"在2004年前的传统系统治疗阶段(如甲氨蝶呤)，将PASI50作为具有临床意义的皮损改善"},{"flag":"B","name":"2004年TNF-α抑制剂的出现，将PASI75作为具有临床意义的皮损改善"},{"flag":"C","name":"2015年后IL-17A抑制剂的出现，有望在大多数银屑病患者中实现PASI75甚至更好"},{"flag":"D","name":"2015年后IL-17A抑制剂的出现，有望在大多数银屑病患者中实现PASI90甚至更好"}]},"5361":{"id":5361,"qattrid":46,"type":1,"title":"\t下列关于银屑病指南对银屑病治疗目标的描述错误的是____?","result":"C","content":"2019年AAD/NPF应用生物制剂治疗银屑病指南建议将PASI100作为治疗目标","options":[{"flag":"A","name":"2017年国家银屑病基金会斑块型银屑病治疗指南，指出将BSA≤1%作为治疗目标"},{"flag":"B","name":"2017年英国皮肤科医师协会(BAD)银屑病生物治疗指南，指出将PGA(0,1)作为银屑病治疗目标"},{"flag":"C","name":"2019年AAD/NPF应用生物制剂治疗银屑病指南建议将PASI90作为治疗目标"},{"flag":"D","name":"2019年法国成人中重度银屑病的系统治疗指南建议将PASI≥90;PGA0-1作为治疗目标"}]},"5362":{"id":5362,"qattrid":46,"type":1,"title":"\t在2016年WHO《全球银屑病报告》中，关于银屑病患者对治疗目标下列描述错误的是____?","result":"D","content":"90%的患者期望治疗效果有保证","options":[{"flag":"A","name":"94%的患者期待皮损快速改善"},{"flag":"B","name":"93%的患者期待皮损全面清除"},{"flag":"C","name":"83%的患者期望病情稳定控制"},{"flag":"D","name":"70%的患者期望治疗效果有保证"}]},"5363":{"id":5363,"qattrid":46,"type":1,"title":"下列关于拓咨3条推广keymessage，描述错误的是____?","result":"B","content":"全面清除：治疗16周后，患者有望实现皮损全面清除","options":[{"flag":"A","name":"快速起效：治疗1周即可实现皮损和瘙痒症状快速改善"},{"flag":"B","name":"全面清除：治疗12周后，患者有望实现皮损全面清除"},{"flag":"C","name":"全面清除：治疗16周后，患者有望实现皮损全面清除"},{"flag":"D","name":"安全稳定：可稳定维持4年有效皮损清除"}]},"5364":{"id":5364,"qattrid":46,"type":2,"title":"下列关于药物亲和力描述正确的是_____?","result":"A,C","content":"KD值越低，亲和力越高；司库奇尤单抗对IL-17A的KD为100-200pM","options":[{"flag":"A","name":"KD值越低，亲和力越高"},{"flag":"B","name":"KD值越低，亲和力越低"},{"flag":"C","name":"拓咨对IL-17A的KD为1.8pM"},{"flag":"D","name":"司库奇尤单抗对IL-17A的KD为150-200pM"}]},"5365":{"id":5365,"qattrid":46,"type":2,"title":"下列关于拓咨“快速起效”的推广信息，描述正确的是_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"在UNCOVER-2研究中，拓咨治疗1周PASI自基线改善30%"},{"flag":"B","name":"在UNCOVER-2研究中，拓咨治疗1周，37%的患者自基线瘙痒NRS评分≥4"},{"flag":"C","name":"在UNCOVER系列研究中，拓咨治疗2周PASI自基线平均改善54%"},{"flag":"D","name":"在UNCOVER系列研究中，拓咨治2周23%的患者实现PASI75"}]},"5366":{"id":5366,"qattrid":46,"type":1,"title":"下列关于UNCOVER-J的研究结果描述正确的是_____?","result":"D","content":"拓咨治疗16周，87%的患者实现PASI90，40%的患者实现PASI100","options":[{"flag":"A","name":"拓咨治疗12周，87%的患者实现PASI90"},{"flag":"B","name":"拓咨治疗12周，40%的患者实现PASI100"},{"flag":"C","name":"拓咨治疗16周，79%的患者实现PASI90"},{"flag":"D","name":"拓咨治疗16周，40%的患者实现PASI100"}]},"5367":{"id":5367,"qattrid":46,"type":2,"title":"在IXORA-Q和UNCOVER汇总分析中，下列关于拓咨治疗难治部位银屑病12周的研究结果，正确的是_____?","result":"B,C,D","content":"75%的头皮银屑病患者实现PSSI100","options":[{"flag":"A","name":"67%的头皮银屑病患者实现PSSI100"},{"flag":"B","name":"56%的生殖器银屑病患者实现sPGA-G0"},{"flag":"C","name":"49%的甲银屑病患者实现NAPSI0"},{"flag":"D","name":"52%的掌趾银屑病患者实现PPASI100"}]},"5368":{"id":5368,"qattrid":46,"type":1,"title":"一项荟萃分析间接比较了拓咨和司库奇尤单抗治疗银屑病的疗效，下列描述正确的是_____?","result":"A","content":"从治疗第2周到第12周，拓咨实现PASI90和PASI100的患者比例均高于司库奇尤单抗；拓咨实现PASI100的患者比例高出司库奇尤单抗13.1%","options":[{"flag":"A","name":"治疗12周，拓咨实现PASI90的患者比例高出司库奇尤单抗11.2%"},{"flag":"B","name":"拓咨实现PASI100的患者比例高出司库奇尤单抗17.1%"},{"flag":"C","name":"从治疗第0周到第12周，拓咨实现PASI90和PASI100的患者比例均高于司库奇尤单抗"},{"flag":"D","name":"从治疗第4周到第12周，拓咨实现PASI90和PASI100的患者比例均高于司库奇尤单抗"}]},"5369":{"id":5369,"qattrid":46,"type":1,"title":"下列关于IXORA-Z的研究结果，描述正确的是_____?","result":"D","content":"拓咨治疗24周实现PASI100的患者比例高于甲氨蝶呤，41%vs.13%","options":[{"flag":"A","name":"拓咨治疗16周实现PASI90的患者比例高于甲氨蝶呤，67%vs39%"},{"flag":"B","name":"拓咨治疗16周实现PASI100的患者比例高于甲氨蝶呤，41%vs.13%"},{"flag":"C","name":"拓咨治疗24周实现PASI90的患者比例高于甲氨蝶呤，67%vs39%"},{"flag":"D","name":"拓咨治疗24周实现PASI100的患者比例高于甲氨蝶呤，41%vs.13%"}]},"5370":{"id":5370,"qattrid":46,"type":1,"title":"下列关于UNCOVER-2的研究结果，描述正确的是_____?","result":"A","content":"拓咨治疗12周实现PASI100的患者比例高于依那西普，40%vs.5%","options":[{"flag":"A","name":"拓咨治疗12周实现PASI90的患者比例高于依那西普，71%VS.19%"},{"flag":"B","name":"拓咨治疗12周实现PASI100的患者比例高于依那西普，35%vs.5%"},{"flag":"C","name":"拓咨治疗16周实现PASI90的患者比例高于依那西普，71%VS.19%"},{"flag":"D","name":"拓咨治疗16周实现PASI100的患者比例高于依那西普，40%vs.5%"}]},"5371":{"id":5371,"qattrid":46,"type":1,"title":"下列关于IXORA-S的研究结果，描述正确的是_____?","result":"C","content":"拓咨治疗12周实现PASI100的患者比例高于乌司奴单抗，36%vs.14%","options":[{"flag":"A","name":"拓咨治疗16周实现PASI90的患者比例高于乌司奴单抗，73%VS.42%"},{"flag":"B","name":"拓咨治疗16周实现PASI100的患者比例高于乌司奴单抗，36%vs.14%"},{"flag":"C","name":"拓咨治疗12周实现PASI90的患者比例高于乌司奴单抗，73%VS.42%"},{"flag":"D","name":"拓咨治疗12周实现PASI100的患者比例高于乌司奴单抗，41%vs.14%"}]},"5372":{"id":5372,"qattrid":46,"type":1,"title":"下列关于UNCOVER-3的研究结果，描述正确的是_____?","result":"A","content":"拓咨治疗4年，88%的患者实现PASI90；拓咨治疗4年，67%的患者实现PASI100","options":[{"flag":"A","name":"拓咨治疗4年，98%的患者实现PASI75"},{"flag":"B","name":"拓咨治疗4年，80%的患者实现PASI90"},{"flag":"C","name":"拓咨治疗5年，80%的患者实现PASI90"},{"flag":"D","name":"拓咨治疗5年，41%的患者实现PASI100"}]},"5373":{"id":5373,"qattrid":46,"type":1,"title":"下列关于拓咨安全性方面的描述，错误的是_____?","result":"B","content":"一项纳入11项研究的安全性汇总分析表明，拓咨治疗期间，未见结核再激活","options":[{"flag":"A","name":"一项纳入13项研究的安全性汇总分析表明，拓咨治疗4年，严重感染、念珠菌感染、炎症性肠病和恶性肿瘤的发生率趋于稳定"},{"flag":"B","name":"一项纳入11项研究的安全性汇总分析表明，拓咨治疗期间，少数患者发生结核再激活"},{"flag":"C","name":"拓咨主要通过细胞内分解代谢，预计肾脏对原型拓咨消除很低且并非主要途径"},{"flag":"D","name":"拓咨主要通过细胞内分解代谢，预计肝功能损伤不会影响拓咨的清除"}]},"5374":{"id":5374,"qattrid":46,"type":2,"title":"下列关于拓咨的使用描述正确的是_____?","result":"A,B,C","content":"根据处方剂量治疗1年，拓咨需要注射17针，显著低于司库奇尤单抗的32针","options":[{"flag":"A","name":"第一步拧下底盖"},{"flag":"B","name":"第二步旋转解锁"},{"flag":"C","name":"第3步按压注射"},{"flag":"D","name":"根据处方剂量治疗1年，拓咨需要注射17针，显著低于司库奇尤单抗的34针"}]},"5375":{"id":5375,"qattrid":46,"type":2,"title":"下列关于IL-17在银屑病发病机制中的作用，描述正确的是_____?","result":"A,B,C,D","content":"IL-17A是银屑病发病机制中关键性的致病因子，是Th17细胞的主要效应因子；IL-17A刺激角质形成细胞产生趋化因子、细胞因子、抗菌肽等促炎介质，维持和放大导致银屑病的炎症性反应；IL-17A激活角质形成细胞，促进表皮增生，形成银屑病斑块","options":[{"flag":"A","name":"IL-17A是银屑病发病机制中关键的致病因子"},{"flag":"B","name":"IL-17A是Th17细胞的主要效应因子"},{"flag":"C","name":"IL-17A刺激角质形成细胞产生趋化因子、细胞因子、抗菌肽等促炎介质，维持和放大导致银屑病的炎症性反应"},{"flag":"D","name":"IL-17A激活角质形成细胞，促进表皮增生，形成银屑病斑块"}]},"5376":{"id":5376,"qattrid":46,"type":2,"title":"下列_____可以分泌IL-17A?","result":"A,B,C,D","content":"中性粒细胞、肥大细胞、γδT细胞和CD8+T细胞等细胞可以分泌IL-17A","options":[{"flag":"A","name":"中性粒细胞"},{"flag":"B","name":"肥大细胞"},{"flag":"C","name":"γδT细胞"},{"flag":"D","name":"CD8+T细胞"}]},"5377":{"id":5377,"qattrid":46,"type":1,"title":"下列关于IL-12/23依赖途径和非依赖途径的描述错误的是_____?","result":"C","content":"IL-17A抑制剂可同时抑制IL-23依赖途径和非依赖途径产生的IL-17A","options":[{"flag":"A","name":"银屑病的炎症通路主要有两条，IL-23依赖途径和IL-23非依赖途径"},{"flag":"B","name":"IL-12/23抑制剂仅能抑制IL-23依赖途径产生的IL-17A"},{"flag":"C","name":"IL-17A抑制剂仅能抑制IL-23非依赖途径"},{"flag":"D","name":"IL-17A抑制剂可同时抑制IL-23依赖途径和非依赖途径产生的IL-17A"}]},"5378":{"id":5378,"qattrid":46,"type":2,"title":"下列关于银屑病发病机制的描述错误的是_____?","result":"A,B","content":"在IL-23非依赖途径中，γδT细胞、中性粒细胞和肥大细胞等细胞在多种刺激下分泌产生IL-17A；在IL-23依赖途径中，树突状细胞被激活，产生的IL-23促进Th17细胞分化并生成银屑病炎症的关键效应因子IL-17A","options":[{"flag":"A","name":"在IL-23依赖途径中，γδT细胞等细胞在多种刺激下分泌产生IL-17A"},{"flag":"B","name":"在IL-23非依赖途径中，树突状细胞被激活，产生的IL-23促进Th17细胞分化并生成银屑病炎症的关键效应因子IL-17A"},{"flag":"C","name":"激活的角质形成细胞等进一步产生趋化因子、细胞因子，募集炎性细胞，维持和放大银屑病的炎症性反应，升高β-防御素2水平，刺激浆细胞样树突状细胞，导致皮肤反复损伤"},{"flag":"D","name":"IL-17A作用于角质形成细胞等后，可通过反馈通路激活IL-23，形成一个环路"}]},"5379":{"id":5379,"qattrid":46,"type":1,"title":"下列描述错误的是_____?","result":"D","content":"古塞奇尤单抗是全人源IgG1单克隆抗体","options":[{"flag":"A","name":"拓咨是人源化IgG4单克隆抗体"},{"flag":"B","name":"司库奇尤单抗是全人源IgG1单克隆抗体"},{"flag":"C","name":"乌司奴单抗是全人源IgG1单克隆抗体"},{"flag":"D","name":"古塞奇尤单抗是全人源IgG4单克隆抗体"}]},"5380":{"id":5380,"qattrid":46,"type":1,"title":"下列关于不同IgG单抗，描述错误的是_____?","result":"A","content":"拓咨通过基因工程对IgG4铰链区进行改造，以增加其稳固性，大大减少半抗体的产生","options":[{"flag":"A","name":"拓咨通过基因工程对IgG4铰链区进行改造，以降低其稳固性，大大减少半抗体的产生"},{"flag":"B","name":"IgG4具有低补体亲和力，不能诱导补体介导的细胞毒性等作用"},{"flag":"C","name":"IgG4引起炎症应答的能力微弱，具有一定抗炎活性"},{"flag":"D","name":"IgG1与补体结合，具有抗体依赖的细胞介导的细胞毒性作用"}]},"5381":{"id":5381,"qattrid":46,"type":2,"title":"下列关于人源化和全人源抗体，描述错误的是_____?","result":"C,D","content":"拓咨的人源DNA序列占比达98.2%，人源化抗体命名后缀为-zumab，全人源抗体命名后缀为-umab","options":[{"flag":"A","name":"全人源抗体的DNA序列完全来自人源(100%)"},{"flag":"B","name":"人源化抗体的大部分DNA序列来自人源，但CDR区域来自鼠源DNA序列"},{"flag":"C","name":"拓咨的人源DNA序列占比达96.2%"},{"flag":"D","name":"人源化抗体命名后缀为-umab，全人源抗体命名后缀为-zumab"}]},"5382":{"id":5382,"qattrid":46,"type":2,"title":"下列关于拓咨的描述，正确的是_____?","result":"A,C,D","content":"拓咨的半衰期为13天","options":[{"flag":"A","name":"拓咨与IL-17A结合并抑制其与IL-17A受体反应"},{"flag":"B","name":"拓咨的半衰期为21天"},{"flag":"C","name":"拓咨对IL-17A的亲和力比司库奇优单抗高"},{"flag":"D","name":"拓咨的药物解离常数为1.8pM"}]},"5383":{"id":5383,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，拓咨治疗16周，有_____的患者实现皮损全面清除?","result":"B","content":"在UNCOVER-J研究中，拓咨治疗16周，40%的患者实现皮损全面清除","options":[{"flag":"A","name":"0.35"},{"flag":"B","name":"0.4"},{"flag":"C","name":"0.45"},{"flag":"D","name":"0.5"}]},"5384":{"id":5384,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，拓咨治疗16周，有_____的患者实现PASI75?","result":"D","content":"在UNCOVER-J研究中，拓咨治疗16周，97%的患者实现PASI75","options":[{"flag":"A","name":"0.76"},{"flag":"B","name":"0.82"},{"flag":"C","name":"0.89"},{"flag":"D","name":"0.97"}]},"5385":{"id":5385,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，拓咨治疗16周，有_____的患者实现PASI90?","result":"C","content":"在UNCOVER-J研究中，拓咨治疗16周，87%的患者实现PASI90","options":[{"flag":"A","name":"0.7"},{"flag":"B","name":"0.79"},{"flag":"C","name":"0.87"},{"flag":"D","name":"0.95"}]},"5386":{"id":5386,"qattrid":46,"type":1,"title":"在UNCOVER-3研究中，拓咨治疗4年，实现PASI100的患者比例为_____?","result":"C","content":"在UNCOVER-3研究中，拓咨治疗4年，76%的患者实现PASI100","options":[{"flag":"A","name":"0.41"},{"flag":"B","name":"0.53"},{"flag":"C","name":"0.67"},{"flag":"D","name":"0.76"}]},"5387":{"id":5387,"qattrid":46,"type":1,"title":"在2016WHO《银屑病全球报告》中，_____的患者希望皮损快速改善?","result":"A","content":"在2016WHO《银屑病全球报告》中，94%的患者希望皮损快速改善","options":[{"flag":"A","name":"0.94"},{"flag":"B","name":"0.89"},{"flag":"C","name":"0.81"},{"flag":"D","name":"0.79"}]},"5388":{"id":5388,"qattrid":46,"type":1,"title":"在2016WHO《银屑病全球报告》中，_____的患者希望皮损全面清除?","result":"B","content":"在2016WHO《银屑病全球报告》中，93%的患者希望皮损全面清除","options":[{"flag":"A","name":"0.97"},{"flag":"B","name":"0.93"},{"flag":"C","name":"0.86"},{"flag":"D","name":"0.8"}]},"5389":{"id":5389,"qattrid":46,"type":1,"title":"在2016WHO《银屑病全球报告》中，_____的患者希望皮损病情稳定控制?","result":"B","content":"在2016WHO《银屑病全球报告》中，83%的患者希望皮损病情稳定控制","options":[{"flag":"A","name":"0.92"},{"flag":"B","name":"0.83"},{"flag":"C","name":"0.71"},{"flag":"D","name":"0.65"}]},"5390":{"id":5390,"qattrid":46,"type":1,"title":"下列关于银屑病共病的描述，错误的是______?","result":"D","content":"银屑病患者伴有抑郁、焦虑和自杀的风险显著增加，年轻患者的抑郁、焦虑和自杀风险最大","options":[{"flag":"A","name":"银屑病患者的2型糖尿病、血脂异常、动脉性高血压、肥胖发生率均显著高于无银屑病人群"},{"flag":"B","name":"银屑病常见共病有血脂异常、高血压、脂肪性肝病和代谢综合征等"},{"flag":"C","name":"银屑病共病可导致患者预期寿命缩短"},{"flag":"D","name":"银屑病患者伴有抑郁、焦虑和自杀的风险显著增加，老年患者的抑郁、焦虑和自杀风险最大"}]},"5391":{"id":5391,"qattrid":46,"type":1,"title":"下列关于银屑病对生活质量的影响，描述正确的是_____?","result":"C","content":"78%的轻度银屑病患者的生活质量几乎没有影响；51%的中度银屑病患者的生活质量受到中重度影响；银屑病对生活质量的影响与其他严重性疾病(如慢性充血性心力衰竭)相当","options":[{"flag":"A","name":"90%的轻度银屑病患者的生活质量几乎没有影响"},{"flag":"B","name":"32%的中度银屑病患者的生活质量受到中重度影响"},{"flag":"C","name":"60%的重度银屑病患者的生活质量受到中重度影响"},{"flag":"D","name":"银屑病对生活质量的影响不及其他严重性疾病(如慢性充血性心力衰竭)"}]},"5392":{"id":5392,"qattrid":46,"type":1,"title":"下列关于银屑病危害，描述错误的是______?","result":"B","content":"重度银屑病患者的总体死亡风险增加50%","options":[{"flag":"A","name":"重度银屑病患者的总体死亡风险增加50%"},{"flag":"B","name":"重度银屑病患者的总体死亡风险增加80%"},{"flag":"C","name":"重度银屑病女性患者较未患有银屑病的女性，总体寿命减少4.4年"},{"flag":"D","name":"重度银屑病女性患者较未患有银屑病的女性，总体寿命减少3.5年"}]},"5393":{"id":5393,"qattrid":46,"type":2,"title":"下列关于银屑病的发生率，描述正确的是_____?","result":"A,B","content":"一项超过12,000例患者的全国性调研报告显示中国银屑病患者的男女比例为1.23:1；我国银屑病发生率为0.47%，约653万银屑病患者","options":[{"flag":"A","name":"银屑病常见受累部位依次为头皮、背部、四肢伸侧"},{"flag":"B","name":"最常见的银屑病是寻常型银屑病，其中斑块状银屑病最常见"},{"flag":"C","name":"男女比例为1.73:1"},{"flag":"D","name":"我国银屑病发生率为0.47%，约653万银屑病患者"}]},"5394":{"id":5394,"qattrid":46,"type":1,"title":"下列关于银屑病治疗现状，描述错误的是_____?","result":"C","content":"一项日本的中重度银屑病患者调查显示，患者将皮损完全清除作为治疗目标的比例远高于其配对医生(17.9%vs.8.7%)","options":[{"flag":"A","name":"2016年WHO《全球银屑病报告》显示超90%%的患者希望皮损快速清除和皮损全面清除"},{"flag":"B","name":"一项北欧国家的调查显示，62%患者治疗不满意的原因是皮损没有达到完全清除"},{"flag":"C","name":"一项日本的中重度银屑病患者调查显示，患者将皮损完全清除作为治疗目标的比例远高于其配对医生(17.9%vs.8.7%)"},{"flag":"D","name":"皮损完全清除(PASI100)患者生活质量显著高于PASI90患者"}]},"5395":{"id":5395,"qattrid":46,"type":2,"title":"下列哪些指南将皮损几乎完全清除或皮损清除作为银屑病治疗目标？","result":"A,C,D","content":"2012年德国《S3寻常型银屑病治疗指南更新》提出目前临床研究将PASI75作为银屑病的治疗目标","options":[{"flag":"A","name":"2017BAD银屑病生物治疗指南"},{"flag":"B","name":"2012年德国S3寻常型银屑病治疗指南更新"},{"flag":"C","name":"2019中国银屑病生物治疗专家共识"},{"flag":"D","name":"2019法国指南：成人中-重度银屑病的系统治疗"}]},"5396":{"id":5396,"qattrid":46,"type":2,"title":"下列关于2019AAD／NPF：应用生物制剂治疗银屑病指南对IL-17A抑制剂的推荐，正确的是_____?","result":"A,B,C","content":"推荐160mg起始，80mg每两周一次，治疗至第12周；第12周后推荐80mg每4周一次","options":[{"flag":"A","name":"推荐治疗成人中重度斑块型银屑病Ⅰ-Ⅱ(A)"},{"flag":"B","name":"推荐治疗斑块型银屑病累及头颈(包括头皮)，Ⅰ-Ⅱ(B)"},{"flag":"C","name":"推荐治疗斑块型银屑病累及指(趾)甲Ⅰ-Ⅱ(B)"},{"flag":"D","name":"推荐160mg起始，而后使用80mg每两周一次"}]},"5397":{"id":5397,"qattrid":46,"type":1,"title":"下列关于拓咨的描述错误的是______?","result":"A","content":"拓咨抑制IL-17A与其受体之间的相互作用，中和IL-17A同源二聚体和IL-17A/F异二聚体","options":[{"flag":"A","name":"拓咨抑制IL-17A受体，中和IL-17A同源二聚体和IL-17A/F异二聚体"},{"flag":"B","name":"拓咨抑制IL-17A可减少角质形成细胞增殖、炎症蛋白表达、免疫细胞浸润真皮和表皮层"},{"flag":"C","name":"PsO给药方案是首次160mg皮下注射,继而80mg每2周一次给药，持续12周，此后为80mg每4周一次给药"},{"flag":"D","name":"将IgG4的绞链区从丝氨酸突变成脯氨酸,结构更加稳定,防止半抗体的形成和异常配对"}]},"5398":{"id":5398,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，下列说法错误的是______?","result":"B","content":"共纳入78例中重度斑块型银屑病患者","options":[{"flag":"A","name":"治疗16周分别有97%、87%和40%的患者实现PASI75/90/100"},{"flag":"B","name":"共纳入178例中重度斑块型银屑病患者"},{"flag":"C","name":"该研究纳入日本人群"},{"flag":"D","name":"治疗总时长为52周"}]},"5399":{"id":5399,"qattrid":46,"type":2,"title":"下列关于拓咨产品描述及使用，说法错误的是______?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"拓咨注射笔是以患者为中心研发的，超过1000名患者参与研发"},{"flag":"B","name":"拓咨的使用步骤共3步，第一步拧开底盖、第二步旋转解锁、第三步按压注射"},{"flag":"C","name":"拓咨注射笔的结构由注射按钮、锁环、锁定/解锁符号、隐藏针头、透明喇叭形底座、药物、可拧开的底盖组成"},{"flag":"D","name":"按处方推荐剂量，拓咨一年需要注射17剂"}]},"5400":{"id":5400,"qattrid":46,"type":2,"title":"银屑病可由下列______因素引起？","result":"A,B,C,D","content":"银屑病可由免疫、遗传、感染、精神、肥胖、烟酒等因素引起","options":[{"flag":"A","name":"免疫"},{"flag":"B","name":"遗传"},{"flag":"C","name":"感染"},{"flag":"D","name":"精神、肥胖、烟酒"}]},"5401":{"id":5401,"qattrid":46,"type":2,"title":"下列关于银屑病机制，描述正确的是______?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"银屑病由多种炎症细胞和细胞因子参与"},{"flag":"B","name":"IL-17A是银屑病发病机制中关键性的致病因子"},{"flag":"C","name":"IL-17A是Th17细胞的主要效应因子"},{"flag":"D","name":"IL-17A刺激角质形成细胞产生趋化因子、细胞因子、抗菌肽等促炎介质，维持和放大导致银屑病的炎症性反应"}]},"5402":{"id":5402,"qattrid":46,"type":2,"title":"IL-17A与其受体结合，激活内皮细胞、成纤维细胞、巨噬细胞等细胞释放一系列炎症因子，导致______?","result":"A,B,D","content":"IL-17A与其受体结合，激活内皮细胞、成纤维细胞、巨噬细胞等细胞释放一系列炎症因子，导致炎症扩大、血管活化、角质形成细胞过度增生","options":[{"flag":"A","name":"炎症扩大"},{"flag":"B","name":"血管活化"},{"flag":"C","name":"血管抑制"},{"flag":"D","name":"角质形成细胞过度增生"}]},"5403":{"id":5403,"qattrid":46,"type":1,"title":"IL-17A在银屑病皮损部位的表达______?产生IL-17A的T细胞在银屑病真皮层中______?","result":"A","content":"IL-17A在银屑病皮损部位的表达增加，产生IL-17A的T细胞在银屑病真皮层中增加","options":[{"flag":"A","name":"增加，增加"},{"flag":"B","name":"增加，减少"},{"flag":"C","name":"减少，增加"},{"flag":"D","name":"减少，减少"}]},"5404":{"id":5404,"qattrid":46,"type":1,"title":"IL-12/23抑制剂和IL-17A抑制剂分别可以抑制______产生的IL-17A?","result":"D","content":"IL-12/23抑制剂和IL-17A抑制剂分别可以抑制IL-23依赖途径，IL-23依赖途径和IL-23非依赖途径产生的IL-17A","options":[{"flag":"A","name":"IL-23依赖途径，IL-23非依赖途径"},{"flag":"B","name":"IL-23非依赖途径，IL-23依赖途径"},{"flag":"C","name":"IL-23依赖途径和IL-23非依赖途径，IL-23依赖途径"},{"flag":"D","name":"IL-23依赖途径，IL-23依赖途径和IL-23非依赖途径"}]},"5405":{"id":5405,"qattrid":46,"type":2,"title":"下列关于IgG抗体4种亚型在宿主中的生物功能描述，正确的是_____?","result":"A,B,C,D","content":"IgG1和IgG3主要结合蛋白质抗原，IgG2结合糖类抗原，IgG4则响应慢性刺激并且具有抗炎的活性","options":[{"flag":"A","name":"IgG1主要结合蛋白质抗原"},{"flag":"B","name":"IgG3主要结合蛋白质抗原"},{"flag":"C","name":"IgG2结合糖类抗原"},{"flag":"D","name":"IgG4则响应慢性刺激并且具有抗炎的活性"}]},"5406":{"id":5406,"qattrid":46,"type":1,"title":"下列关于IgG抗体4种亚型在触发效应功能的能力排序，正确的是______?","result":"C","content":"下列关于IgG抗体4种亚型在触发效应功能的能力排序，正确的是IgG1>IgG3>IgG4>IgG2","options":[{"flag":"A","name":"IgG1>IgG3>IgG2>IgG4"},{"flag":"B","name":"IgG1>IgG2>IgG3>IgG4"},{"flag":"C","name":"IgG1>IgG3>IgG4>IgG2"},{"flag":"D","name":"IgG1>IgG2>IgG4>IgG3"}]},"5407":{"id":5407,"qattrid":46,"type":1,"title":"与IgG1相比，IgG4______补体，具有______ADCC效应?","result":"A","content":"与IgG1相比，IgG4不激活补体，具有低ADCC效应","options":[{"flag":"A","name":"不激活，低"},{"flag":"B","name":"不激活，高"},{"flag":"C","name":"激活，低"},{"flag":"D","name":"激活，高"}]},"5408":{"id":5408,"qattrid":46,"type":1,"title":"拓咨治疗12周高滴度的自身抗体发生率为______?低滴度______药物长期疗效?","result":"B","content":"拓咨治疗12周高滴度的自身抗体发生率为1.5%，低滴度不影响药物长期疗效?","options":[{"flag":"A","name":"1.7%，影响"},{"flag":"B","name":"1.7%，不影响"},{"flag":"C","name":"2.6%，影响"},{"flag":"D","name":"2.6%，不影响"}]},"5409":{"id":5409,"qattrid":46,"type":2,"title":"下列关于拓咨治疗银屑病的疗效和组织学表现的描述，正确的是______?","result":"A,B,C","content":"在UNCOVER-1,2研究中，拓咨治疗5年，约60%实现PASI100","options":[{"flag":"A","name":"拓咨靶向IL-17A，可通过反馈环路降低IL-23亚基水平"},{"flag":"B","name":"拓咨可降低炎症相关基因表达，逆转银屑病的症状表型"},{"flag":"C","name":"拓咨中和IL-17A，抑制角质形成细胞的增殖和分化，降低炎症细胞浸润和角质形成细胞释放的炎性细胞因子水平"},{"flag":"D","name":"在UNCOVER-1,2研究中，拓咨治疗5年，约50%实现PASI100"}]},"5410":{"id":5410,"qattrid":46,"type":2,"title":"拓咨推广的keymessage是_____?","result":"A,C,D","content":"拓咨推广的keymessage是快速起效、完全清除、长期稳定","options":[{"flag":"A","name":"长期稳定"},{"flag":"B","name":"安全性良好"},{"flag":"C","name":"快速起效"},{"flag":"D","name":"完全清除"}]},"5411":{"id":5411,"qattrid":46,"type":2,"title":"在UNCOVE-1,2,3研究中，关于拓咨治疗银屑病的疗效，下列说法正确的是_____?","result":"A,B","content":"在UNCOVE-1,2,3研究中，治疗12周，分别有89.7%、69.9%、37.6%的患者实现PASI75/PASI90/PASI100","options":[{"flag":"A","name":"治疗12周，37.6%的患者实现PASI100"},{"flag":"B","name":"治疗12周，69.9%的患者实现PASI90"},{"flag":"C","name":"治疗16周，78.6%的患者实现PASI90"},{"flag":"D","name":"治疗16周，89.7%的患者实现PASI75"}]},"5412":{"id":5412,"qattrid":46,"type":1,"title":"在UNCOVER-3研究中，拓咨治疗156周，_____的患者实现PASI75(观察值)?","result":"D","content":"在UNCOVER-3研究中，治疗156周，94%患者实现PASI75(观察值)","options":[{"flag":"A","name":"0.64"},{"flag":"B","name":"0.79"},{"flag":"C","name":"0.87"},{"flag":"D","name":"0.94"}]},"5413":{"id":5413,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，拓咨治疗16周，分别有_____的患者实现PASI75/90/100?","result":"A","content":"在UNCOVER-J研究中，治疗16周分别有97%、87%、40%的患者实现PASI75/90/100","options":[{"flag":"A","name":"97%、87%、40%"},{"flag":"B","name":"92%、76%、35%"},{"flag":"C","name":"87%、76%、40%"},{"flag":"D","name":"87%、76%、35%"}]},"5414":{"id":5414,"qattrid":46,"type":1,"title":"在UNCOVER-2研究中，治疗1周，拓咨Q2W组和依那西普组PASI自基线平均改善分别为_____，瘙痒NRS自基线改善≥4的患者比例分别为______？","result":"A","content":"在UNCOVER-2研究中，治疗1周，拓咨Q2W组vs.依那西普组PASI自基线平均改善的患者比例为30%vs.8%，瘙痒NRS自基线改善≥4的患者比例为37%vs.11%","options":[{"flag":"A","name":"30%和8%，37%和11%"},{"flag":"B","name":"37%和11%，30%和8%"},{"flag":"C","name":"45%和12%，52%和16%"},{"flag":"D","name":"52%和16%，45%和12%"}]},"5415":{"id":5415,"qattrid":46,"type":1,"title":"在UNCOVER-1,2,3研究中，治疗2周，拓咨Q2W组和依那西普组PASI自基线平均改善分别为_____；在UNCOVER-3研究中，拓咨Q2W组和依那西普组实现PASI75的患者比例分别为______？","result":"B","content":"在UNCOVER-1,2,3研究中，治疗2周，拓咨Q2W组vs.依那西普组PASI自基线平均改善的患者比例为54%vs.23%；在UNCOVER-3研究中，拓咨Q2W组vs.依那西普组实现PASI75的患者比例为23%vs.2%？","options":[{"flag":"A","name":"23%和2%，54%和23%"},{"flag":"B","name":"54%和23%，23%和2%"},{"flag":"C","name":"37%和5%，69%和33%"},{"flag":"D","name":"69%和33%，37%和5%"}]},"5416":{"id":5416,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，拓咨Q2W达到PASI50和PASI75的中位时间分别为______?","result":"C","content":"在UNCOVER-2,3研究中，拓咨Q2W达到PASI50和PASI75的中位时间分别为2.1周和4.3周","options":[{"flag":"A","name":"1和2.8周"},{"flag":"B","name":"1.6周和3.5周"},{"flag":"C","name":"2.1周和4.3周"},{"flag":"D","name":"2.7周和5.8周"}]},"5417":{"id":5417,"qattrid":46,"type":1,"title":"在UNCOVER-1,2,3研究中，治疗12周，拓咨Q2W组和依那西普组实现PASI100的患者比例分别为_____？","result":"B","content":"在UNCOVER-1,2,3研究中，治疗12周，拓咨Q2W组vs.依那西普组实现PASI100的患者比例为38%vs.6%","options":[{"flag":"A","name":"29%和3%"},{"flag":"B","name":"38%和6%"},{"flag":"C","name":"45%和12%"},{"flag":"D","name":"49%和15%"}]},"5418":{"id":5418,"qattrid":46,"type":1,"title":"在IXORA-S研究中，治疗12周，拓咨Q2W组和乌司奴单抗组实现PASI100的患者比例分别为_____？","result":"C","content":"在IXORA-S研究中，治疗12周，拓咨Q2W组vs.乌司奴单抗组实现PASI100的患者比例为36%vs.15%","options":[{"flag":"A","name":"30%和15%"},{"flag":"B","name":"30%和21%"},{"flag":"C","name":"36%和15%"},{"flag":"D","name":"36%和21%"}]},"5419":{"id":5419,"qattrid":46,"type":2,"title":"在UNCOVER-2,3研究中，拓咨用于有生物制剂既往史的患者治疗12周，实现PASI75患者比例为______?","result":"D","content":"在UNCOVER-2,3研究中，拓咨用于有生物制剂既往史的患者，治疗12周，实现PASI75的患者比例为92%","options":[{"flag":"A","name":"0.63"},{"flag":"B","name":"0.76"},{"flag":"C","name":"0.89"},{"flag":"D","name":"0.92"}]},"5420":{"id":5420,"qattrid":46,"type":2,"title":"在UNCOVER-2,3研究中，拓咨用于无生物制剂既往史的患者治疗12周，实现PASI75/90/100的患者比例为_____?","result":"C","content":"在UNCOVER-2,3研究中，拓咨用于无生物制剂既往史的患者，治疗12周，实现PASI75的患者比例为88%","options":[{"flag":"A","name":"0.65"},{"flag":"B","name":"0.79"},{"flag":"C","name":"0.88"},{"flag":"D","name":"0.97"}]},"5421":{"id":5421,"qattrid":46,"type":1,"title":"在一项荟萃分析中，拓咨治疗12周实现PASI90/100的患者比例比司库奇尤单抗高______？","result":"C","content":"在一项荟萃分析中，拓咨治疗12周实现PASI90/100的患者比例比司库奇尤单抗高11.2%和13.1%","options":[{"flag":"A","name":"6.2%和9.8%"},{"flag":"B","name":"8.6%和11.3%"},{"flag":"C","name":"11.2%和13.1%"},{"flag":"D","name":"13.6%和15.2%"}]},"5422":{"id":5422,"qattrid":46,"type":2,"title":"下列关于拓咨治疗难治部位银屑病的疗效数据，正确的是______?","result":"A,B,C,D","content":"拓咨治疗12周，75%的患者实现头皮部位全面清除；治疗12周52%的患者实现掌趾部位全面清除；治疗12周，56%的患者实现生殖器部位全面清除；治疗24周，49%的患者实现指甲部位全面清除","options":[{"flag":"A","name":"治疗12周，75%的患者实现头皮部位全面清除"},{"flag":"B","name":"治疗24周，49%的患者实现指甲部位全面清除"},{"flag":"C","name":"治疗12周，56%的患者实现生殖器部位全面清除"},{"flag":"D","name":"治疗12周52%的患者实现掌趾部位全面清除"}]},"5423":{"id":5423,"qattrid":46,"type":1,"title":"在UNCOVER-3研究中，拓咨治疗4年，______的患者实现PASI100？","result":"A","content":"在UNCOVER-3研究中，拓咨治疗4年，67%的患者实现PASI100","options":[{"flag":"A","name":"0.67"},{"flag":"B","name":"0.77"},{"flag":"C","name":"0.87"},{"flag":"D","name":"0.97"}]},"5424":{"id":5424,"qattrid":46,"type":1,"title":"在两项对比分析研究中，拓咨治疗360天和720天的药物维持率分别为_____?","result":"B","content":"在两项对比分析研究中，拓咨治疗360天和720天的药物维持率分别为55%和39%","options":[{"flag":"A","name":"42%和29%"},{"flag":"B","name":"55%和39%"},{"flag":"C","name":"67%和45%"},{"flag":"D","name":"73%和50%"}]},"5425":{"id":5425,"qattrid":46,"type":2,"title":"下列关于真实世界数据，说法正确的是_____?","result":"A,B,C,D","content":"真实世界数据反映了现实世界中治疗药物的临床疗效；减少了传统临床研究的限制；为临床选择使用新药及新设备提供客观的对比依据；可充分了解指南与实践的差距，为指南的制定与规范提供参考，同时平衡临床疗效和成本效益","options":[{"flag":"A","name":"反映了现实世界中治疗药物的临床疗效"},{"flag":"B","name":"减少了传统临床研究的限制"},{"flag":"C","name":"为临床选择使用新药及新设备提供客观的对比依据"},{"flag":"D","name":"可充分了解指南与实践的差距，为指南的制定与规范提供参考，同时平衡临床疗效和成本效益"}]},"5426":{"id":5426,"qattrid":46,"type":1,"title":"下列关于真实世界数据和临床研究数据的研究人群，说法正确的是_____?","result":"B","content":"真实世界数据纳入现实环境下多样性人群，纳入排除标准相对严格；临床研究数据纳入理想环境下相对单一的人群，纳入排除标准多而严格","options":[{"flag":"A","name":"临床研究数据纳入理想环境下相对单一的人群，纳入排除标准少而严格"},{"flag":"B","name":"临床研究数据纳入理想环境下相对单一的人群，纳入排除标准多而严格"},{"flag":"C","name":"真实世界数据纳入现实环境下多样性人群，纳入排除标准相对宽松"},{"flag":"D","name":"真实世界数据纳入现实环境下多样性人群，纳入排除标准相对宽松"}]},"5427":{"id":5427,"qattrid":46,"type":2,"title":"下列关于真实世界数据和临床研究数据的用途，说法正确的是_____?","result":"A,C","content":"真实世界数据通常用于上市后的临床医疗/宏观决策；临床研究数据通常为药物上市前的管理决策","options":[{"flag":"A","name":"临床研究数据通常为药物上市前的管理决策"},{"flag":"B","name":"临床研究数据通常用于上市后的临床医疗/宏观决策"},{"flag":"C","name":"真实世界数据通常用于上市后的临床医疗/宏观决策"},{"flag":"D","name":"真实世界数据通常为药物上市前的管理决策"}]},"5428":{"id":5428,"qattrid":46,"type":1,"title":"下列关于真实世界数据和临床研究数据的数据特点，说法正确的是_____?","result":"D","content":"真实世界数据的研究一般为实效性随机对照试验或观察性研究；临床研究数据一般为传统的大样本、多中心随机对照研究","options":[{"flag":"A","name":"真实世界数据的研究一般为传统的大样本、多中心随机对照研究"},{"flag":"B","name":"真实世界数据的研究一般为传统大样本、随机对照试验或观察性研究"},{"flag":"C","name":"临床研究数据一般为实效性随机对照试验或观察性研究"},{"flag":"D","name":"临床研究数据一般为传统的大样本、多中心随机对照研究"}]},"5429":{"id":5429,"qattrid":46,"type":2,"title":"下列关于真实世界数据和临床研究数据的研究干预措施，说法正确的是_____?","result":"B,D","content":"真实世界研究可调整方案；临床研究方案固定并有严格的设定","options":[{"flag":"A","name":"真实世界研究方案固定并有严格的设定"},{"flag":"B","name":"真实世界研究方案可调整"},{"flag":"C","name":"临床研究方案可调整"},{"flag":"D","name":"临床研究方案固定并有严格的设定"}]},"5430":{"id":5430,"qattrid":46,"type":2,"title":"下列关于真实世界数据和临床研究数据的相关研究，说法正确的是_____?","result":"A,D","content":"真实世界数据多为实效性随机对照试验或观察性研究，临床研究数据多为传统的大样本、多中心随机对照研究","options":[{"flag":"A","name":"真实世界数据多为实效性随机对照试验或观察性研究"},{"flag":"B","name":"真实世界数据多为传统的大样本、多中心随机对照研究"},{"flag":"C","name":"临床研究数据多为实效性随机对照试验或\n观察性研究"},{"flag":"D","name":"临床研究数据多为传统的大样本、多中心随机对照研究"}]},"5431":{"id":5431,"qattrid":46,"type":2,"title":"拓咨在真实世界中治疗银屑病的用药方案为_______?","result":"C,D","content":"拓咨在真实世界中的用药方案和中国说明书一致；诱导治疗期：第0周160mg皮下注射(80mg，注射2次)，随后第2，4，6，8，10和12周分别注射80mg；维持治疗期：注射拓咨80mg每4周一次","options":[{"flag":"A","name":"在诱导治疗和维持治疗期均使用拓咨80mg每4周一次"},{"flag":"B","name":"在诱导治疗和维持治疗期均使用拓咨80mg每2周一次"},{"flag":"C","name":"诱导治疗期：第0周160mg皮下注射(80mg，注射2次)，随后第2，4，6，8，10和12周分别注射80mg"},{"flag":"D","name":"维持治疗期：注射拓咨80mg每4周一次"}]},"5432":{"id":5432,"qattrid":46,"type":1,"title":"在一项真实世界研究(N=100)中，拓咨治疗12-16周，有______银屑病患者实现PASI75?","result":"A","content":"在一项真实世界研究(N=100)中，拓咨治疗12-16周有87.5%银屑病患者实现PASI75","options":[{"flag":"A","name":"0.875"},{"flag":"B","name":"0.796"},{"flag":"C","name":"0.653"},{"flag":"D","name":"0.557"}]},"5433":{"id":5433,"qattrid":46,"type":1,"title":"在一项真实世界研究(N=100)中，拓咨治疗24周，有______银屑病患者实现PASI90?","result":"B","content":"在一项真实世界研究(N=100)中，拓咨治疗24周，有58.4%银屑病患者实现PASI90","options":[{"flag":"A","name":"0.471"},{"flag":"B","name":"0.584"},{"flag":"C","name":"0.667"},{"flag":"D","name":"0.79"}]},"5434":{"id":5434,"qattrid":46,"type":1,"title":"在一项真实世界研究(N=100)中，拓咨治疗52周，有______银屑病患者实现PASI100?","result":"C","content":"在一项真实世界研究(N=100)中，拓咨治疗52周，有41.5%银屑病患者实现PASI100","options":[{"flag":"A","name":"0.55"},{"flag":"B","name":"0.48"},{"flag":"C","name":"0.415"},{"flag":"D","name":"0.35"}]},"5435":{"id":5435,"qattrid":46,"type":1,"title":"一项真实世界研究(N=100)，关于随访治疗期间的安全性描述错误的是______?","result":"C","content":"有26%的患者发生任何不良事件","options":[{"flag":"A","name":"依奇珠单抗在治疗中未出现新的或意外的不良事件"},{"flag":"B","name":"在随访期间，依奇珠单抗治疗未发现之前的共病恶化(如慢性病毒感染、精神疾病或心血管疾病)"},{"flag":"C","name":"有45%的患者发生任何不良事件"},{"flag":"D","name":"注射部位反应是最常见的不良事件"}]},"5436":{"id":5436,"qattrid":46,"type":1,"title":"在一项真实世界研究(N=47)中，拓咨治疗12周分别有_____的银屑病患者实现PASI90/100?","result":"D","content":"在一项真实世界研究(N=47)中，拓咨治疗12周分别有76%和55%的银屑病患者实现PASI90/100","options":[{"flag":"A","name":"97%和68%"},{"flag":"B","name":"88%和62%"},{"flag":"C","name":"82%和58%"},{"flag":"D","name":"76%和55%"}]},"5437":{"id":5437,"qattrid":46,"type":1,"title":"在一项回顾性队列研究研究(N=22)中，拓咨治疗银屑病700天的药物留存率为_____?","result":"B","content":"在一项回顾性队列研究研究(N=22)中，拓咨治疗银屑病700天的药物留存率为63.6%","options":[{"flag":"A","name":"0.783"},{"flag":"B","name":"0.636"},{"flag":"C","name":"0.569"},{"flag":"D","name":"0.472"}]},"5438":{"id":5438,"qattrid":46,"type":1,"title":"在一项回顾性队列研究研究(N=22)中，拓咨治疗银屑病的平均使用天数为_____?","result":"C","content":"在一项回顾性队列研究研究(N=22)中，拓咨治疗银屑病的平均使用天数为379天","options":[{"flag":"A","name":"348天"},{"flag":"B","name":"365天%"},{"flag":"C","name":"379天"},{"flag":"D","name":"397天"}]},"5439":{"id":5439,"qattrid":46,"type":2,"title":"在一项来自丹麦的回顾性研究中，依奇珠单抗和司库奇优单抗治疗52周的停药率分别为_____和______?","result":"A,C","content":"在一项来自丹麦的回顾性研究中，依奇珠单抗和司库奇优单抗治疗52周的停药率分别为12.9%和15.8%","options":[{"flag":"A","name":"0.129"},{"flag":"B","name":"0.135"},{"flag":"C","name":"0.158"},{"flag":"D","name":"0.163"}]},"5440":{"id":5440,"qattrid":46,"type":2,"title":"下列关于银屑病的描述正确的是_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"银屑病是不可治愈性疾病，常罹患终身"},{"flag":"B","name":"银屑病对患者生活质量的影响与2型糖尿病等严重疾病相当"},{"flag":"C","name":"银屑病患者常合并高血压、心肌梗塞、慢性肺阻塞等共病"},{"flag":"D","name":"长期使用生物制剂维持治疗可以维持高缓解率，避免疾病复发"}]},"5441":{"id":5441,"qattrid":46,"type":1,"title":"在UNCOVER-3研究中，使用拓咨治疗4年，有_____的银屑病患者实现PASI100？","result":"C","content":"在UNCOVER-3研究中，使用拓咨治疗4年，有67%的银屑病患者实现PASI100","options":[{"flag":"A","name":"0.41"},{"flag":"B","name":"0.58"},{"flag":"C","name":"0.67"},{"flag":"D","name":"0.73"}]},"5442":{"id":5442,"qattrid":46,"type":1,"title":"在UNCOVER-3研究中，使用拓咨治疗4年，有_____的银屑病患者因疗效不佳脱落？","result":"C","content":"在UNCOVER-3研究中，使用拓咨治疗4年，有2.9的银屑病患者因疗效不佳脱落","options":[{"flag":"A","name":"0.009"},{"flag":"B","name":"0.019"},{"flag":"C","name":"0.029"},{"flag":"D","name":"0.039"}]},"5443":{"id":5443,"qattrid":46,"type":2,"title":"下列关于UNCOVER-3研究的描述，正确的是_____?","result":"A,C,D","content":"初始使用安慰剂或依那西普的患者，换用拓咨后同样能改善瘙痒","options":[{"flag":"A","name":"拓咨在维持治疗期持续改善银屑病患者瘙痒症状"},{"flag":"B","name":"初始使用安慰剂换用拓咨后不能改善瘙痒"},{"flag":"C","name":"初始使用安慰剂或依那西普的患者，换用拓咨后同样能改善瘙痒"},{"flag":"D","name":"拓咨可实现累及头皮、掌趾、指甲银屑病的全面清除"}]},"5444":{"id":5444,"qattrid":46,"type":1,"title":"在IXORA-Q研究中，使用拓咨治疗生殖器部位银屑病52周，有_____的患者实现sPGA(0,1)？","result":"C","content":"在IXORA-Q研究中，使用拓咨治疗生殖器部位银屑病52周，有75%的患者实现sPGA(0,1)","options":[{"flag":"A","name":"0.58"},{"flag":"B","name":"0.62"},{"flag":"C","name":"0.75"},{"flag":"D","name":"0.89"}]},"5445":{"id":5445,"qattrid":46,"type":2,"title":"在UNCOVER-1,2,3研究中，关于拓咨注射部位反应不良事件的描述正确的是_____?","result":"A,C,D","content":"注射部位反应主要发生在开始治疗后的2周内，随后发生率减少","options":[{"flag":"A","name":"仅0.7%的患者发生重度注射部位反应"},{"flag":"B","name":"注射部位反应主要发生在开始治疗后的4周内，随后发生率减少"},{"flag":"C","name":"拓咨Q2W的注射部位反应发生率与依那西普相似，16.8%vs.16.4%"},{"flag":"D","name":"最常见的注射部位反应中非特异性反应占9.5%、红斑占3.1%、疼痛占1.7%"}]},"5446":{"id":5446,"qattrid":46,"type":1,"title":"在UNCOVER-1,2,3研究中，有_____的患者发生高滴度抗体？","result":"B","content":"在UNCOVER-1,2,3研究中，有1.7%的患者发生高滴度抗体","options":[{"flag":"A","name":"0.007"},{"flag":"B","name":"0.017"},{"flag":"C","name":"0.027"},{"flag":"D","name":"0.037"}]},"5447":{"id":5447,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，银屑病患者复发后重新使用拓咨，达到PASI75的中位时间为_____?","result":"D","content":"在UNCOVER-1,2研究中，银屑病患者复发后重新使用拓咨，达到PASI75的中位时间为4周","options":[{"flag":"A","name":"1周"},{"flag":"B","name":"2周"},{"flag":"C","name":"3周"},{"flag":"D","name":"4周"}]},"5448":{"id":5448,"qattrid":46,"type":1,"title":"在UNCOVER-1,2研究中，银屑病患者复发后重新使用拓咨，有______的患者重新获得PASI75?","result":"A","content":"在UNCOVER-1,2研究中，银屑病患者复发后重新使用拓咨，有87%的患者重新获得PASI75","options":[{"flag":"A","name":"0.87"},{"flag":"B","name":"0.76"},{"flag":"C","name":"0.68"},{"flag":"D","name":"0.53"}]},"5449":{"id":5449,"qattrid":46,"type":2,"title":"一项研究对比了依奇珠单抗和司库奇优单治疗52周的药物留存率，下列描述正确的是_____?","result":"A,C","content":"在经生物制剂治疗的患者中，拓咨的药物留存率比司库奇尤单抗更高；在未经生物制剂治疗的患者中，拓咨的药物留存率比司库奇尤单抗更高","options":[{"flag":"A","name":"在经生物制剂治疗的患者中，拓咨的药物留存率比司库奇尤单抗更高"},{"flag":"B","name":"在经生物制剂治疗的患者中，司库奇尤单抗的药物留存率比拓咨更高"},{"flag":"C","name":"在未经生物制剂治疗的患者中，拓咨的药物留存率比司库奇尤单抗更高"},{"flag":"D","name":"在未经生物制剂治疗的患者中，司库奇尤单抗的药物留存率比拓咨更高"}]},"5450":{"id":5450,"qattrid":46,"type":1,"title":"在UNCOVER-2研究中，拓咨和依那西普治疗12周实现PASI100的患者比例分别为_____?","result":"A","content":"在UNCOVER-2研究中，拓咨和依那西普治疗12周实现PASI100的患者比例分别为41%和5%","options":[{"flag":"A","name":"41%和5%"},{"flag":"B","name":"39%和10%"},{"flag":"C","name":"35%和12%"},{"flag":"D","name":"30%和7%"}]},"5451":{"id":5451,"qattrid":46,"type":1,"title":"在IXORA-S研究中，拓咨和乌司奴单抗治疗12周实现PASI100的患者比例分别为_____?","result":"C","content":"在IXORA-S研究中，拓咨和乌司奴单抗治疗12周实现PASI100的患者比例分别为36%和15%","options":[{"flag":"A","name":"49%和25%"},{"flag":"B","name":"45%和21%"},{"flag":"C","name":"36%和15%"},{"flag":"D","name":"30%和15%"}]},"5452":{"id":5452,"qattrid":46,"type":1,"title":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗4周实现PASI90的患者比例分别为_____?","result":"C","content":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗4周实现PASI90的患者比例分别为21%和8%","options":[{"flag":"A","name":"35%和17%"},{"flag":"B","name":"29%和12%"},{"flag":"C","name":"21%和8%"},{"flag":"D","name":"16%和5%"}]},"5453":{"id":5453,"qattrid":46,"type":1,"title":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗12周实现PASI100的患者比例分别为_____?","result":"B","content":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗12周实现PASI100的患者比例分别为41%和25%","options":[{"flag":"A","name":"41%和25%"},{"flag":"B","name":"41%和25%"},{"flag":"C","name":"41%和25%"},{"flag":"D","name":"41%和25%"}]},"5454":{"id":5454,"qattrid":46,"type":1,"title":"在2017年EADV的poster研究中，使用拓咨和乌司奴单抗治疗12周，分别有______的患者实现头皮部位全面清除?","result":"B","content":"在2017年EADV的poster研究中，使用拓咨和乌司奴单抗治疗12周，分别有75%和49%的患者实现头皮部位全面清除","options":[{"flag":"A","name":"64%和42%"},{"flag":"B","name":"75%和49%"},{"flag":"C","name":"82%和58%"},{"flag":"D","name":"89%和65%"}]},"5455":{"id":5455,"qattrid":46,"type":2,"title":"在2018年EADV的poster研究中，使用拓咨和乌司奴单抗治疗24周，分别有______和______的患者实现指甲部位全面清除?","result":"A,D","content":"在2018年EADV的poster研究中，使用拓咨和乌司奴单抗治疗24周，分别有49%和22%的患者实现指甲部位全面清除","options":[{"flag":"A","name":"0.49"},{"flag":"B","name":"0.56"},{"flag":"C","name":"0.32"},{"flag":"D","name":"0.22"}]},"5456":{"id":5456,"qattrid":46,"type":2,"title":"在IXORA-Q研究中，使用拓咨和安慰剂治疗12周，分别有______的患者实现生殖器部位全面清除?","result":"B,D","content":"在IXORA-Q研究中，使用拓咨和安慰剂治疗12周，分别有56%和5%的患者实现生殖器部位全面清除?","options":[{"flag":"A","name":"0.65"},{"flag":"B","name":"0.56"},{"flag":"C","name":"0.12"},{"flag":"D","name":"0.05"}]},"5457":{"id":5457,"qattrid":46,"type":2,"title":"在UNCOVER-1,2,3研究中，使用拓咨和依那西普治疗12周，分别有______的患者实现掌趾部位全面清除?","result":"B,D","content":"在UNCOVER-1,2,3研究中，使用拓咨和依那西普治疗12周，分别有52%和32%的患者实现掌趾部位全面清除","options":[{"flag":"A","name":"0.64"},{"flag":"B","name":"0.52"},{"flag":"C","name":"0.45"},{"flag":"D","name":"0.32"}]},"5458":{"id":5458,"qattrid":46,"type":1,"title":"在UNCOVER-J研究中，使用拓咨治疗16周，有_____的患者实现PASI100?","result":"C","content":"在UNCOVER-J研究中，使用拓咨治疗16周，有40%的患者实现PASI100","options":[{"flag":"A","name":"0.3"},{"flag":"B","name":"0.35"},{"flag":"C","name":"0.4"},{"flag":"D","name":"0.45"}]},"5459":{"id":5459,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，使用拓咨治疗12周，有_____的患者实现绝对值PASI≤2?","result":"B","content":"在UNCOVER-2,3研究中，使用拓咨治疗12周，有71.6%的患者实现绝对值PASI≤2","options":[{"flag":"A","name":"0.826"},{"flag":"B","name":"0.716"},{"flag":"C","name":"0.653"},{"flag":"D","name":"0.579"}]},"5460":{"id":5460,"qattrid":46,"type":2,"title":"快速起效对银屑病患者的临床意义有_____?","result":"A,B,D","content":"银屑病患者期待达到PASI75的中位时间为34天","options":[{"flag":"A","name":"快速清除皮损有助于最大程度提高患者满意度和治疗依从性"},{"flag":"B","name":"早期应答率是后续获得持久的高PASI缓解率的重要影响因素"},{"flag":"C","name":"银屑病患者期待达到PASI75的中位时间为17天"},{"flag":"D","name":"在2016年WHO《全球银屑病报告》中快速清除皮损是银屑病患者的首要需求"}]},"5461":{"id":5461,"qattrid":46,"type":1,"title":"在UNCOVER-1,2,3研究中，使用拓咨治疗_____周，可见PASI自基线平均改善33%？","result":"A","content":"在UNCOVER-1,2,3研究中，使用拓咨治疗1周，可见PASI自基线平均改善33%","options":[{"flag":"A","name":"1周"},{"flag":"B","name":"2周"},{"flag":"C","name":"3周"},{"flag":"D","name":"4周"}]},"5462":{"id":5462,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，使用拓咨治疗1周，可见_____的患者瘙痒NRS评分自基线改善≥4？","result":"B","content":"在UNCOVER-2,3研究中，使用拓咨治疗1周，可见41%的患者瘙痒NRS评分自基线改善≥4","options":[{"flag":"A","name":"0.56"},{"flag":"B","name":"0.41"},{"flag":"C","name":"0.35"},{"flag":"D","name":"0.29"}]},"5463":{"id":5463,"qattrid":46,"type":2,"title":"在UNCOVER-1,2,3研究中，使用拓咨治疗2周，可见PASI自基线改善_____?_____的患者实现PASI75?","result":"A,C","content":"在UNCOVER-1,2,3研究中，使用拓咨治疗2周，可见PASI自基线改善54%，23%的患者实现PASI75","options":[{"flag":"A","name":"0.54"},{"flag":"B","name":"0.45"},{"flag":"C","name":"0.23"},{"flag":"D","name":"0.35"}]},"5464":{"id":5464,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，使用拓咨治疗_____起，其PASI90/100应答率高于依那西普？","result":"B","content":"在UNCOVER-2,3研究中，使用拓咨治疗2周起，其PASI90/100应答率高于依那西普","options":[{"flag":"A","name":"1周"},{"flag":"B","name":"2周"},{"flag":"C","name":"3周"},{"flag":"D","name":"4周"}]},"5465":{"id":5465,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，使用拓咨和依那西普治疗2周，分别有_____的患者实现DLQI0/1?","result":"A","content":"在UNCOVER-2,3研究中，使用拓咨和依那西普治疗2周，分别有21%和11%的患者实现DLQI0/1","options":[{"flag":"A","name":"21%和11%"},{"flag":"B","name":"32%和18%"},{"flag":"C","name":"42%和24%"},{"flag":"D","name":"48%和32%"}]},"5466":{"id":5466,"qattrid":46,"type":1,"title":"在IXORA-S研究中，使用拓咨和乌司奴单抗治疗2周，分别有_____的患者实现DLQI0/1?","result":"D","content":"在IXORA-S研究中，使用拓咨和乌司奴单抗治疗2周，分别有29%和10%的患者实现DLQI0/1","options":[{"flag":"A","name":"56%和32%"},{"flag":"B","name":"46%和28%"},{"flag":"C","name":"37%和16%"},{"flag":"D","name":"29%和10%"}]},"5467":{"id":5467,"qattrid":46,"type":1,"title":"在UNCOVER-2,3研究中，拓咨达到PASI50的中位时间约为_____？","result":"C","content":"在UNCOVER-2,3研究中，拓咨达到PASI50的中位时间约为2周","options":[{"flag":"A","name":"4周"},{"flag":"B","name":"3周"},{"flag":"C","name":"2周"},{"flag":"D","name":"1周"}]},"5468":{"id":5468,"qattrid":46,"type":1,"title":"在IXORA-R研究中，使用拓咨和古塞奇尤单抗治疗1周，分别有_____的患者实现PASI50？","result":"C","content":"在IXORA-R研究中，使用拓咨和古塞奇尤单抗治疗1周，分别有27.5%和93%的患者实现PASI50","options":[{"flag":"A","name":"18%和76%"},{"flag":"B","name":"23%和83%"},{"flag":"C","name":"27.5%和93%"},{"flag":"D","name":"35.2%和97%"}]},"5469":{"id":5469,"qattrid":46,"type":1,"title":"在IXORA-R研究中，使用拓咨和古塞奇尤单抗治疗2周，分别有_____的患者实现PASI75？","result":"D","content":"在IXORA-R研究中，使用拓咨和古塞奇尤单抗治疗2周，分别有23%和5%的患者实现PASI75","options":[{"flag":"A","name":"49%和28%"},{"flag":"B","name":"39%和16%"},{"flag":"C","name":"35%和12%"},{"flag":"D","name":"23%和5%"}]},"5470":{"id":5470,"qattrid":46,"type":1,"title":"下列关于银屑病的疾病认识，错误的是____?","result":"D","content":"2012年一项MAPP调查显示，超过50%的中重度银屑病患者的生活质量受到中度影响(DLQI≥6)","options":[{"flag":"A","name":"银屑病的发生涉及多种炎症细胞和细胞因子"},{"flag":"B","name":"银屑病是第一个把管理皮肤病变及相关疾病同时作为治疗目标的皮肤炎症性疾病"},{"flag":"C","name":"随着病情加重，患者生活质量受到的影响越大"},{"flag":"D","name":"2012年一项MAPP调查显示，超过70%的中重度银屑病患者的生活质量受到中度影响(DLQI≥6)"}]},"5471":{"id":5471,"qattrid":46,"type":1,"title":"下列关于2016年WHO《全球银屑病报告》中的患者需求描述，错误的是_____?","result":"B","content":"76%的患者期待减轻皮肤瘙痒","options":[{"flag":"A","name":"快速清除皮损为患者首要治疗需求"},{"flag":"B","name":"60%的患者期待减轻皮肤瘙痒"},{"flag":"C","name":"病情得到有效控制为患者第3大治疗需求"},{"flag":"D","name":"全面清除皮损为患者第2大治疗需求"}]},"5472":{"id":5472,"qattrid":46,"type":1,"title":"下列关于皮损完全清除的治疗目标，描述错误的是_____?","result":"A","content":"在亚洲人群中，皮损全面清除仍位居银屑病患者治疗需求第1位","options":[{"flag":"A","name":"在亚洲人群中，皮损全面清除仍位居银屑病患者治疗需求第2位"},{"flag":"B","name":"皮损完全清除能进一步显著提高患者生活质量"},{"flag":"C","name":"2019年《中国银屑病生物治疗专家共识》建议以PASI100或PASI90,PGA0/1作为达到满意疗效的指标"},{"flag":"D","name":"2019年法国《成人中重度银屑病的系统治疗指南》建议将PASI90和PASI100绝对值PASI≤3;DLQI0,1作为银屑病治疗目标"}]},"5473":{"id":5473,"qattrid":46,"type":2,"title":"关于银屑病治疗通路的探索，下列描述正确的是_____?","result":"A,B,C,D","content":"1980年以前发现银屑病患者存在角质形成细胞过度增殖；2003年发现IL-23刺激T细胞产生IL-17A；2005年发现Th17细胞系；2008年在银屑病患者皮肤中发现IL-17A+T细胞；2010年IL-17A抑制剂理念形成","options":[{"flag":"A","name":"1980年以前发现银屑病患者存在角质形成细胞过度增殖"},{"flag":"B","name":"2003年发现IL-23刺激T细胞产生IL-17A；2005年发现Th17细胞系"},{"flag":"C","name":"2008年在银屑病患者皮肤中发现IL-17A+T细胞"},{"flag":"D","name":"2010年IL-17A抑制剂理念形成"}]},"5474":{"id":5474,"qattrid":46,"type":2,"title":"下列关于银屑病的作用机制，描述正确的是_____?","result":"A,B,C,D","content":"——","options":[{"flag":"A","name":"银屑病是由T细胞(Th1/Th17)和DC细胞介导的免疫性皮肤病"},{"flag":"B","name":"目前认为，银屑病发病机制的中心环节是IL-23诱导Th17细胞增殖分化，并分泌产生IL17等细胞因子"},{"flag":"C","name":"TNF/NF-κB信号通路与IL-17、角化细胞和DC细胞交互作用，引起炎症的级联放大"},{"flag":"D","name":"IL-23/IL-17轴在银屑病发病机制中发挥重要作用"}]},"5475":{"id":5475,"qattrid":46,"type":2,"title":"下列属于促炎细胞因子的是_____?","result":"A,B,C,D","content":"TNF-α、IL-12、IL-23和IL-17属于促炎细胞因子","options":[{"flag":"A","name":"TNF-α"},{"flag":"B","name":"IL-12"},{"flag":"C","name":"IL-23"},{"flag":"D","name":"IL-17"}]},"5476":{"id":5476,"qattrid":46,"type":1,"title":"下列关于生物制剂上市时间，描述错误的是_____?","result":"C","content":"特诺雅2017年在美国上市，2019年在中国上市","options":[{"flag":"A","name":"拓咨2016年在美国上市，2019年在中国上市"},{"flag":"B","name":"可善挺2015年在美国上市，2019年在中国上市"},{"flag":"C","name":"特诺雅2017年在美国上市，2020年在中国上市"},{"flag":"D","name":"阿达木单抗2008年在美国上市，2016年在中国上市"}]},"5477":{"id":5477,"qattrid":46,"type":1,"title":"在UNCOVER-2研究中，拓咨和依那西普治疗12周实现PASI75(主要研究终点)的患者比例分别为_____?","result":"A","content":"在UNCOVER-2研究中，拓咨和依那西普治疗12周实现PASI75(主要研究终点)的患者比例分别为90%42%","options":[{"flag":"A","name":"90%和42%"},{"flag":"B","name":"83%和39%"},{"flag":"C","name":"76%和32%"},{"flag":"D","name":"65%和29%"}]},"5478":{"id":5478,"qattrid":46,"type":1,"title":"在IXORA-S研究中，拓咨和依那西普治疗12周实现PASI90(主要研究终点)的患者比例分别为_____?","result":"C","content":"在IXORA-S研究中，拓咨和依那西普治疗12周实现PASI90(主要研究终点)的患者比例分别为73%和42%","options":[{"flag":"A","name":"89%和56%"},{"flag":"B","name":"79%和49%"},{"flag":"C","name":"73%和42%"},{"flag":"D","name":"68%和35%"}]},"5479":{"id":5479,"qattrid":46,"type":1,"title":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗12周实现PASI100(主要研究终点)的患者比例分别为_____?","result":"B","content":"在IXORA-R研究中，拓咨和古塞奇尤单抗治疗12周实现PASI100(主要研究终点)的患者比例分别为41%和25%","options":[{"flag":"A","name":"35%和18%"},{"flag":"B","name":"41%和25%"},{"flag":"C","name":"45%和32%"},{"flag":"D","name":"56%和37%"}]},"5480":{"id":5480,"qattrid":46,"type":1,"title":"在2016年WHO发布的《银屑病全球报告》中，患者的第一治疗需求是______？","result":"D","content":"在2016年WHO发布的《银屑病全球报告》中，患者的第一治疗需求是快速修复皮肤","options":[{"flag":"A","name":"治疗效果有保证"},{"flag":"B","name":"治愈所有皮损"},{"flag":"C","name":"正常生活"},{"flag":"D","name":"快速修复皮肤"}]},"5481":{"id":5481,"qattrid":46,"type":1,"title":"UCOVER1,2,3汇总分析研究比较了拓咨与______治疗银屑病的疗效？两种药物治疗2周的平均PASI改善是______？","result":"A","content":"UCOVER1,2,3汇总分析研究比较了拓咨和依那西普治疗银屑病的疗效，拓咨和依那西普治疗2周的平均PASI改善分别为54%和23%","options":[{"flag":"A","name":"拓咨vs.依那西普，\n54%vs.23%"},{"flag":"B","name":"拓咨vs.依那西普，\n46%vs.23%"},{"flag":"C","name":"拓咨vs.阿达木单抗，54%vs.23%"},{"flag":"D","name":"拓咨vs.阿达木单抗，46%vs.23%"}]},"5482":{"id":5482,"qattrid":46,"type":1,"title":"IXORA-S研究比较了拓咨与______治疗银屑病的疗效？两种药物治疗2周实现PASI75的患者比例分别为______？","result":"C","content":"IXORA-S研究比较了拓咨与乌司奴单抗治疗银屑病的疗效，拓咨和乌司奴单抗治疗2周分别有16.2%和1.8%的患者实现PASI75","options":[{"flag":"A","name":"拓咨vs.古塞奇尤单抗，14.2%vs.1.8%"},{"flag":"B","name":"拓咨vs.乌司奴单抗，14.2%vs.1.8%"},{"flag":"C","name":"拓咨vs.乌司奴单抗，16.2%vs.1.8%"},{"flag":"D","name":"拓咨vs.古塞奇尤单抗，23%vs.5%"}]},"5483":{"id":5483,"qattrid":46,"type":1,"title":"IXORA-R研究比较了拓咨与______治疗银屑病的疗效？两种药物治疗1周实现PASI50的患者比例分别为______？","result":"B","content":"IXORA-R研究比较了拓咨与古塞奇尤单抗治疗银屑病的疗效，拓咨和古塞奇尤单抗治疗1周分别有23%和5%的患者实现PASI50","options":[{"flag":"A","name":"拓咨vs.乌司奴单抗，13%vs.5%"},{"flag":"B","name":"拓咨vs.古塞奇尤单抗，23%vs.5%"},{"flag":"C","name":"拓咨vs.古塞奇尤单抗，13%vs.5%"},{"flag":"D","name":"拓咨vs.乌司奴单抗，23%vs.5%"}]},"5484":{"id":5484,"qattrid":46,"type":1,"title":"在中国已上市的生物制剂中起效最快的药物是______？","result":"B","content":"在中国已上市的生物制剂中起效最快的药物是依奇珠单抗","options":[{"flag":"A","name":"Brodalumab"},{"flag":"B","name":"依奇珠单抗"},{"flag":"C","name":"阿达木单抗"},{"flag":"D","name":"司库奇尤单抗"}]},"5485":{"id":5485,"qattrid":46,"type":1,"title":"据2016年WHO《银屑病全球报告》显示，_____的患者期待皮损快速清除?","result":"D","content":"据2016年WHO《银屑病全球报告》显示，94.2%的患者期待皮损快速清除","options":[{"flag":"A","name":"超过60%"},{"flag":"B","name":"超过70%"},{"flag":"C","name":"超过80%"},{"flag":"D","name":"超过90%"}]},"5486":{"id":5486,"qattrid":46,"type":1,"title":"一项关于美国中重度银屑病患者的治疗期望网络调查显示，银屑病患者希望达到PASI50和PASI100的时间分别为_____?","result":"B","content":"一项关于美国中重度银屑病患者的治疗期望网络调查显示，银屑病患者希望2周左右达到PASI50，34天达到PASI100","options":[{"flag":"A","name":"1周左右和34天"},{"flag":"B","name":"2周左右和34天"},{"flag":"C","name":"1周左右和14天"},{"flag":"D","name":"2周左右和14天"}]},"5487":{"id":5487,"qattrid":46,"type":2,"title":"快速起效给银屑病患者带来的临床获益有_____?","result":"A,B,C","content":"快速起效有助于长期维持高缓解率、有助于延缓银屑病的复发、对急性和重度银屑病患者疾病的控制非常重要","options":[{"flag":"A","name":"有助于长期维持高缓解率"},{"flag":"B","name":"有助于延缓银屑病的复发"},{"flag":"C","name":"对急性和重度银屑病患者疾病的控制非常重要"},{"flag":"D","name":"有助于短期维持高缓解率"}]},"5488":{"id":5488,"qattrid":46,"type":1,"title":"拓咨达到PASI自基线改善50%所需要的时间为_____?25%使用拓咨的患者达到PASI75的时间为_____?","result":"A","content":"拓咨用药1.9周达到PASI自基线改善50%，25%使用拓咨的患者2.4周达到PASI75","options":[{"flag":"A","name":"1.9周、2.4周"},{"flag":"B","name":"1.9周、3.4周"},{"flag":"C","name":"2.9周、2.4周"},{"flag":"D","name":"2.9周、3.4周"}]},"5489":{"id":5489,"qattrid":46,"type":1,"title":"在UNCOVER1,2,3研究的汇总分析中，拓咨治疗2周的平均PASI改善为_____?_____的患者实现PASI75？","result":"A","content":"在UNCOVER1,2,3研究的汇总分析中，拓咨治疗2周的平均PASI改善为54%，23%的患者实现PASI75","options":[{"flag":"A","name":"54%、23%"},{"flag":"B","name":"34%、23%"},{"flag":"C","name":"34%、13%"},{"flag":"D","name":"54%、13%"}]},"5490":{"id":5490,"qattrid":46,"type":2,"title":"一项贝叶斯分析了11种生物制剂治疗银屑病的疗效，在治疗2周、4周和8周时，_____起效速度更快？","result":"C,D","content":"在这项贝叶斯分析中，在治疗2周、4周和8周时，brodalumab和依奇珠单抗的起效速度更快","options":[{"flag":"A","name":"risankizumab"},{"flag":"B","name":"tildrakizumab"},{"flag":"C","name":"brodalumab"},{"flag":"D","name":"依奇珠单抗"}]},"5491":{"id":5491,"qattrid":46,"type":1,"title":"一项贝叶斯分析了11种生物制剂治疗银屑病的疗效，在治疗2周、4周和8周时，在我国已上市的生物制剂中，_____实现PASI75/90/100的应答率最高？","result":"D","content":"在这项贝叶斯分析中，在治疗2周、4周和8周时，依奇珠单抗实现PASI75/90/100的应答率最高","options":[{"flag":"A","name":"司库奇尤单抗"},{"flag":"B","name":"brodalumab"},{"flag":"C","name":"古塞奇尤单抗"},{"flag":"D","name":"依奇珠单抗"}]},"5492":{"id":5492,"qattrid":46,"type":2,"title":"一项贝叶斯分析了11种生物制剂治疗银屑病的疗效，治疗12周，下列哪些生物制剂的DLQI(0,1)的患者比例更高？","result":"A,C,D","content":"在这项贝叶斯分析中，在治疗2周、4周和8周时，治疗12周，依奇珠单抗、司库奇尤单抗和brodalumab实现DLQI(0,1)的患者比例更高","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"risankizumab"},{"flag":"C","name":"司库奇尤单抗"},{"flag":"D","name":"brodalumab"}]},"5493":{"id":5493,"qattrid":46,"type":1,"title":"基于贝叶斯分析，治疗银屑病12周相对治疗效果(概率)最好的生物制剂是_____?","result":"A","content":"在这项贝叶斯分析中，治疗银屑病12周相对治疗效果(概率)最好的生物制剂是依奇珠单抗","options":[{"flag":"A","name":"依奇珠单抗"},{"flag":"B","name":"司库奇尤单抗"},{"flag":"C","name":"brodalumab"},{"flag":"D","name":"risankizumab"}]},"5494":{"id":5494,"qattrid":46,"type":1,"title":"基于频率论和贝叶斯分析，治疗银屑病12周实现PASI90患者比例最高的生物制剂是？","result":"C","content":"在这项贝叶斯分析中，治疗银屑病12周实现PASI90患者比例最高的生物制剂是依奇珠单抗","options":[{"flag":"A","name":"brodalumab"},{"flag":"B","name":"司库奇尤单抗"},{"flag":"C","name":"依奇珠单抗"},{"flag":"D","name":"risankizumab"}]},"5495":{"id":5495,"qattrid":46,"type":1,"title":"治疗银屑病的关键靶点是_____?","result":"A","content":"IL-17A是治疗银屑病的关键靶点","options":[{"flag":"A","name":"IL-17A"},{"flag":"B","name":"IL-17B"},{"flag":"C","name":"IL-17C"},{"flag":"D","name":"IL-17D"}]},"5496":{"id":5496,"qattrid":46,"type":2,"title":"导致IL-17A水平异常升高的免疫细胞有_____?","result":"A,B,C,D","content":"自然杀伤细胞、Tc17细胞、γδT细胞和Th17细胞会导致IL-17A水平异常升高","options":[{"flag":"A","name":"自然杀伤细胞"},{"flag":"B","name":"Tc17细胞"},{"flag":"C","name":"γδT细胞"},{"flag":"D","name":"Th17细胞"}]},"5497":{"id":5497,"qattrid":46,"type":2,"title":"异常高水平的IL-17A会_____?","result":"B,C,D","content":"异常高水平的IL-17A会导致角质形成细胞过度增殖，激活其他免疫细胞并使中性粒细胞进入皮肤，导致鳞屑性银屑病斑块，产生红斑、瘙痒症状","options":[{"flag":"A","name":"导致角质形成细胞增殖速度降低"},{"flag":"B","name":"导致角质形成细胞过度增殖"},{"flag":"C","name":"激活其他免疫细胞并使中性粒细胞进入皮肤"},{"flag":"D","name":"导致鳞屑性银屑病斑块，产生红斑、瘙痒症状"}]},"5498":{"id":5498,"qattrid":46,"type":1,"title":"下列对拓咨的描述正确的是_____？","result":"D","content":"拓咨是人源化IgG4单克隆抗体，具有高亲和力和高特异性","options":[{"flag":"A","name":"全人源IgG4单克隆抗体，具有高亲和力和高特异性"},{"flag":"B","name":"全人源IgG4单克隆抗体，具有高亲和力和低特异性"},{"flag":"C","name":"人源化IgG4单克隆抗体，具有高亲和力和低特异性"},{"flag":"D","name":"人源化IgG4单克隆抗体，具有高亲和力和高特异性"}]},"5499":{"id":5499,"qattrid":46,"type":1,"title":"下列关于拓咨作用机制的描述正确的是_____?","result":"C","content":"拓咨与IL-17A结合，抑制IL-17A与其受体结合，抑制下游促炎作用","options":[{"flag":"A","name":"与IL-17A受体结合，抑制下游促炎作用"},{"flag":"B","name":"与IL-17A受体结合，抑制上游促炎作用"},{"flag":"C","name":"与IL-17A结合，抑制IL-17A与其受体结合，抑制下游促炎作用"},{"flag":"D","name":"与IL-17A结合，抑制IL-17A与其受体结合，抑制上游促炎作用"}]},"5515":{"id":5515,"qattrid":0,"type":2,"title":"2019年口服降糖药物中恩格列净全球销量第一，且超越以下哪些降糖药物？","result":"A,B,C,D","content":"","options":[{"flag":"A","name":"达格列净"},{"flag":"B","name":"卡格列净"},{"flag":"C","name":"西格列汀"},{"flag":"D","name":"利拉鲁肽"}]},"5516":{"id":5516,"qattrid":1,"type":2,"title":"下列哪些是心血管危险因素：","result":"A,B,C","content":"","options":[{"flag":"A","name":"年龄"},{"flag":"B","name":"高血压"},{"flag":"C","name":"血脂异常"},{"flag":"D","name":"吸烟"}]},"5517":{"id":5517,"qattrid":0,"type":1,"title":"大庆研究显示，多少比例的糖尿病患者死于心血管疾病？","result":"C","content":"0.49","options":[{"flag":"A","name":"0.29"},{"flag":"B","name":"0.36"},{"flag":"C","name":"0.49"},{"flag":"D","name":""}]},"5518":{"id":5518,"qattrid":0,"type":1,"title":"ACCORD研究结果显示，CVD风险无显著变化，死亡风险降低","result":"B","content":"错误","options":[{"flag":"A","name":"正确"},{"flag":"B","name":"错误"},{"flag":"C","name":""},{"flag":"D","name":""}]},"5519":{"id":5519,"qattrid":0,"type":1,"title":"3B研究显示，多少比例的中国糖尿病患者合并心血管风险因素？","result":"D","content":"","options":[{"flag":"A","name":"0.279"},{"flag":"B","name":"0.3"},{"flag":"C","name":"0.598"},{"flag":"D","name":"0.72"}]}}